Fungicidal azocyclic amides

ABSTRACT

Disclosed are compounds of Formulae 1, 1A, 1B and 1C including all geometric and stereoisomers, N-oxides, and salts thereof, 
                         
wherein
         R 1 , R 2 , R 4a1 , R 4a2 , A, A a , G, M, W, Z 1 , Z 3 , X, J, J 1  and n are as defined in the disclosure.
 
Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

FIELD OF THE INVENTION

This invention relates to certain carboxamides, their N-oxides, saltsand compositions, and methods of their use as fungicides.

BACKGROUND OF THE INVENTION

The control of plant diseases caused by fungal plant pathogens isextremely important in achieving high crop efficiency. Plant diseasedamage to ornamental, vegetable, field, cereal, and fruit crops cancause significant reduction in productivity and thereby result inincreased costs to the consumer. Many products are commerciallyavailable for these purposes, but the need continues for new compoundswhich are more effective, less costly, less toxic, environmentally saferor have different sites of action.

World Patent Publication WO 05/003128 discloses thiazolylpiperidinederivatives of Formula i as MTP (Microsomal Triglyceride transferProtein) inhibitors.

wherein

-   -   A is a radical selected from the radicals a1 and a2 below

-   -   and R¹, R², R^(2′), R³, R⁴ and R⁵ are as defined in the        disclosure.

World Patent Publication WO 04/058751 discloses piperidinyl-thiazolecarboxamide derivatives for altering vascular tone.

SUMMARY OF THE INVENTION

This invention relates to compounds of Formula 1 including all geometricand stereoisomers, N-oxides, and salts thereof, agriculturalcompositions containing them and their use as fungicides:

wherein

-   -   R¹ is an optionally substituted phenyl, naphthalenyl or 5- or        6-membered heteroaromatic ring;    -   A is CHR¹⁵ or NR¹⁶;    -   R¹⁵ is H, halogen, cyano, hydroxy, —CHO, C₁-C₄ alkyl, C₂-C₄        alkenyl, C₂-C₄ alkynyl, C₁-C₄ haloalkyl, C₂-C₄ haloalkenyl,        C₂-C₄ haloalkynyl, C₂-C₄ alkoxyalkyl, C₂-C₄ alkylthioalkyl,        C₂-C₄ alkylsulfinylalkyl, C₂-C₄ alkylsulfonylalkyl, C₂-C₄        alkylcarbonyl, C₂-C₄ haloalkylcarbonyl, C₂-C₅ alkoxycarbonyl,        C₃-C₅ alkoxycarbonylalkyl, C₂-C₅ alkylaminocarbonyl, C₃-C₅        dialkylaminocarbonyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄        alkylthio, C₁-C₄ haloalkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        haloalkylsulfinyl, C₁-C₄ alkylsulfonyl or C₁-C₄        haloalkylsulfonyl;    -   R¹⁶ is H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄        haloalkyl, C₂-C₄ haloalkenyl, C₂-C₄ haloalkynyl, C₂-C₄        alkoxyalkyl, C₂-C₄ alkylthioalkyl, C₂-C₄ alkylsulfinylalkyl,        C₂-C₄ alkylsulfonylalkyl, C₂-C₄ alkylcarbonyl, C₂-C₄        haloalkylcarbonyl, C₂-C₅ alkoxycarbonyl, C₃-C₅        alkoxycarbonylalkyl, C₂-C₅ alkylaminocarbonyl, C₃-C₅        dialkylaminocarbonyl, C₁-C₄ alkylsulfonyl or C₁-C₄        haloalkylsulfonyl;    -   W is O or S;    -   X is a radical selected from

-   -   wherein the bond of X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸ or X⁹ which        is identified with “t” is connected to the carbon atom        identified with “q” of Formula 1, the bond which is identified        with “u” is connected to the carbon atom identified with “r” of        Formula 1, and the bond which is identified with “v” is        connected to G;    -   each R² is independently C₁-C₄ alkyl, C₂-C₄ alkenyl, C₁-C₄        haloalkyl, C₁-C₄ alkoxy, halogen, cyano or hydroxy; or    -   two R² are taken together as C₁-C₄ alkylene or C₂-C₄ alkenylene        to form a bridged bicyclic or fused bicyclic ring system; or    -   two R² attached to adjacent ring carbon atoms joined by a double        bond are taken together as —CH═CH—CH═CH— optionally substituted        with 1 to 3 substituents selected from C₁-C₄ alkyl, C₁-C₄        haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, halogen, hydroxy,        amino, cyano and nitro;    -   G is an optionally substituted 5-membered heteroaromatic ring or        5-membered saturated or partially saturated heterocyclic ring;    -   J is a 5-, 6- or 7-membered ring, a 8- to 11-membered bicyclic        ring system or a 7- to 11-membered spirocyclic ring system, each        ring or ring system containing ring members selected from carbon        and optionally 1 to 4 heteroatoms selected from up to 2 O, up to        2 S and up to 4 N, and optionally including 1 to 3 ring members        selected from the group consisting of C(═O), C(═S), S(O), S(O)₂        and SiR¹⁷R¹⁸, each ring or ring system optionally substituted        with 1 to 5 substituents independently selected from R⁵;    -   each R⁵ is independently H, halogen, cyano, hydroxy, amino,        nitro, —CHO, —C(═O)OH, —C(═O)NH₂, —NR²⁵R²⁶, C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl,        C₂-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl,        C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₆-C₁₄        cycloalkylcycloalkyl, C₄-C₁₀ halocycloalkylalkyl, C₅-C₁₀        alkylcycloalkylalkyl, C₃-C₈ cycloalkenyl, C₃-C₈        halocycloalkenyl, C₂-C₆ alkoxyalkyl, C₄-C₁₀ cycloalkoxyalkyl,        C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆ alkylthioalkyl, C₂-C₆        alkylsulfinylalkyl, C₂-C₆ alkylsulfonylalkyl, C₂-C₆        alkylaminoalkyl, C₃-C₈ dialkylaminoalkyl, C₂-C₆        haloalkylaminoalkyl, C₄-C₁₀ cycloalkylaminoalkyl, C₂-C₆        alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₄-C₈        cycloalkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₄-C₈        cycloalkoxycarbonyl, C₅-C₁₀ cycloalkylalkoxycarbonyl, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₄-C₈        cycloalkylaminocarbonyl, C₂-C₆ haloalkoxyalkyl, C₁-C₆        hydroxyalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy,        C₃-C₈ halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy, C₂-C₆        alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆        haloalkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy,        C₂-C₆ haloalkylcarbonyloxy, C₄-C₈ cycloalkylcarbonyloxy, C₃-C₆        alkylcarbonylalkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈        cycloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl,        C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈        cycloalkylsulfonyl, C₃-C₁₀ trialkylsilyl, C₁-C₆        alkylsulfonylamino, C₁-C₆ haloalkylsulfonylamino or —Z²Q;    -   each R²⁵ is independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈        cycloalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆        alkoxycarbonyl or C₂-C₆ haloalkoxycarbonyl;    -   each R²⁶ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈        cycloalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆        alkoxycarbonyl, C₂-C₆ haloalkoxycarbonyl or —Z⁴Q;    -   each R¹⁷ and R¹⁸ is independently C₁-C₅ alkyl, C₂-C₅ alkenyl,        C₂-C₅ alkynyl, C₃-C₅ cycloalkyl, C₃-C₆ halocycloalkyl, C₄-C₁₀        cycloalkylalkyl, C₄-C₇ alkylcycloalkyl, C₅-C₇        alkylcycloalkylalkyl, C₁-C₅ haloalkyl, C₁-C₅ alkoxy or C₁-C₅        haloalkoxy;    -   each Q is independently phenyl, benzyl, naphthalenyl, a 5- or        6-membered heteroaromatic ring or an 8- to 11-membered        heteroaromatic bicyclic ring system, each optionally substituted        with 1 to 5 substituents independently selected from R⁷ on        carbon atom ring members and R¹² on nitrogen atom ring members;        or    -   each Q is independently a 3- to 7-membered nonaromatic        carbocyclic ring, a 5-, 6- or 7-membered nonaromatic        heterocyclic ring or an 8- to 11-membered nonaromatic bicyclic        ring system, each optionally including ring members selected        from the group consisting of C(═O), C(═S), S(O), S(O)₂ and        SiR¹⁷R¹⁸, and optionally substituted with 1 to 5 substituents        independently selected from R⁷ on carbon atom ring members and        R¹² on nitrogen atom ring members;    -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl; or    -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to        form an optionally substituted 5- to 7-membered ring containing        ring members selected from carbon and optionally 1 to 3        heteroatoms selected from up to 1 O, up to 1 S and up to 1 N and        optionally including 1 to 3 ring members selected from the group        consisting of C(═O), C(═S), S(O), S(O), and SiR¹⁷R¹⁸;    -   each R¹² is independently H, C₁-C₃ alkyl, C₂-C₃ alkylcarbonyl,        C₁-C₃ alkoxy or C₂-C₃ alkoxycarbonyl;    -   each Z¹ and Z² is independently a direct bond, O, C(═O),        S(O)_(m), CHR²⁰ or NR²¹;    -   each Z⁴ is independently O, C(═O), S(O)_(m) or CHR²⁰;    -   each R²⁰ is independently H, C₁-C₄ alkyl or C₁-C₄ haloalkyl;    -   each R²¹ is independently H, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈        cycloalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆        alkoxycarbonyl or C₂-C₆ haloalkoxycarbonyl;    -   each m is independently 0, 1 or 2; and    -   n is 0, 1 or 2;        provided that:    -   (a) when R¹ is unsubstituted thienyl, X is X¹ and the ring        containing X is saturated, G is an unsubstituted thiazole ring        connected at its 2-position to X and at its 4-position to Z¹ in        Formula 1, A is CHR¹⁵, R¹⁵ is H, and J is an isoxazole ring        connected at its 4-position to Z¹ and substituted at its        5-position with methyl and at its 3-position with        meta-substituted phenyl, then Z¹ is O, C(═O), S(O)_(m), CHR²⁰ or        NR²¹.

More particularly, this invention pertains to compounds of Formula 1including all geometric and stereoisomers, N-oxides, and salts thereof;provided that (b) when A is NR¹⁶, X is X¹ or X², Z¹ is a direct bond,and J is phenyl, then J is substituted with at least one R⁵ other thanH, F, Cl, CN, OCH₃, CF₃ and CH₃, and (c) when A is CHR¹⁵, R¹⁵ is H, W isO, X is X¹, n is 0, G is a thiazole ring connected at its 2-position toX, and at its 4-position to Z¹ in Formula 1, and bonded at its5-position to H, F, Cl or Br, Z¹ is a direct bond, and R¹ is

then when J is a substituted phenyl or substituted pyrimidin-4-yl, it issubstituted with at least one R⁵ other than H, SCF₃, OCF₃, C(CH₃)₃,S(O)₂CF₃, OCH₃, CF₃, Br, cyclopropyl, 1-methylcyclopropyl, OH or CF₂CH₃,and when J is a 2,3-dihydro-1H-inden-4-yl or5,6,7,8-tetrahydronaphthalen-2-yl, it is substituted with at least oneR⁵ other than H, CH₃ or C(CH₃)₃.

This invention also relates to a compound of Formula 1A

wherein

-   -   each R^(4a1) and R^(4a2) is independently C₁-C₃ alkyl, C₂-C₃        alkenyl, C₂-C₃ alkynyl, cyclopropyl, C₁-C₃ haloalkyl, C₂-C₃        haloalkenyl, C₂-C₃ haloalkynyl, halocyclopropyl, halogen, cyano,        nitro, C₁-C₂ alkoxy, C₁-C₂ haloalkoxy, C₁-C₂ alkylthio, C₁-C₂        haloalkylthio, C₂-C₃ alkoxyalkyl, C₂-C₃ alkylcarbonyl, C₂-C₃        alkoxycarbonyl, C₂-C₃ alkylaminocarbonyl or C₃-C₄        dialkylaminocarbonyl;    -   A^(a) is H, CH₂CO₂H, CH₂CO₂R³⁰ or CH₂C(═O)Cl; and    -   R³⁰ is C₁-C₃ alkyl.

This invention also relates to a compound of Formula 1B

wherein

-   -   each R^(4a1) and R^(4a2) is independently C₁-C₃ alkyl, C₂-C₃        alkenyl, C₂-C₃ alkynyl, cyclopropyl, C₁-C₃ haloalkyl, C₂-C₃        haloalkenyl, C₂-C₃ haloalkynyl, halocyclopropyl, halogen, cyano,        nitro, C₁-C₂ alkoxy, C₁-C₂ haloalkoxy, C₁-C₂ alkylthio, C₁-C₂        haloalkylthio, C₂-C₃ alkoxyalkyl, C₂-C₃ alkylcarbonyl, C₂-C₃        alkoxycarbonyl, C₂-C₃ alkylaminocarbonyl or C₃-C₄        dialkylaminocarbonyl; and    -   Z³ is CN or C(═S)NH₂.

This invention further relates to a compound of Formula 1C

wherein

-   -   M is C₁-C₃ alkyl, C₁-C₃ haloalkyl, hydroxy, C₁-C₄ alkoxy, C₁-C₂        haloalkoxy, C₁-C₄ alkylamino, C₂-C₈ dialkylamino, 1-piperidinyl,        1-pyrrolidinyl or 4-morpholinyl; and    -   J¹ is J-29-1 through J-29-58 depicted in Exhibit A as described        below.

More particularly, this invention pertains to compounds of Formulae 1A,1B and 1C, including all geometric and stereoisomers, an N-oxide or saltthereof (except that the compounds of Formula 1C of this invention arelimited to those stereoisomer embodiments depicted for J¹ in the Summaryof Invention above).

This invention also relates to a fungicidal composition comprising afungicidally effective amount of a compound of Formula 1 and at leastone additional component selected from the group consisting ofsurfactants, solid diluents and liquid diluents.

This invention also relates to a fungicidal composition comprising amixture of a compound of Formula 1 (including all geometric andstereoisomers, N-oxides, and salts thereof) and at least one otherfungicide (e.g., at least one other fungicide having a different site ofaction).

This invention further relates to a method for controlling plantdiseases caused by fungal plant pathogens comprising applying to theplant or portion thereof, or to the plant seed, a fungicidally effectiveamount of Formula 1 (including all geometric and stereoisomers,N-oxides, and salts thereof) (e.g., as a composition described herein).

This invention additionally relates to fungicidal compositions andmethods of controlling plant diseases as described above, except thatproviso (a) is removed from the definition of the scope of Formula 1.

DETAILS OF THE INVENTION

As used herein, the terms “comprises,” “comprising,” “includes,”“including,” “has.” “having” or any other variation thereof, areintended to cover a non-exclusive inclusion. For example, a composition,process, method, article, or apparatus that comprises a list of elementsis not necessarily limited to only those elements but may include otherelements not expressly listed or inherent to such composition, process,method, article, or apparatus. Further, unless expressly stated to thecontrary, “or” refers to an inclusive or and not to an exclusive or. Forexample, a condition A or B is satisfied by any one of the following: Ais true (or present) and B is false (or not present), A is false (or notpresent) and B is true (or present), and Both A and B are true (orpresent).

Also, use of “a” or “an” are employed to describe elements andcomponents of the invention. This is done merely for convenience and togive a general sense of the invention. This description should be readto include one or at least one and the singular also includes the pluralunless it is obvious that it is meant otherwise.

As referred to in the present disclosure and claims, “plant” includesmembers of Kingdom Plantae, particularly seed plants (Spermatopsida), atall life stages, including young plants (e.g., germinating seedsdeveloping into seedlings) and mature, reproductive stages (e.g., plantsproducing flowers and seeds). Portions of plants include geotropicmembers typically growing beneath of the surface of the growing medium(e.g., soil), such as roots, tubers, bulbs and corms, and also membersgrowing above the growing medium, such as foliage (including stems andleaves), flowers, fruits and seeds.

In the above recitations, the term “alkyl”, used either alone or incompound words such as “alkylthio” or “haloalkyl” includesstraight-chain or branched alkyl, such as, methyl, ethyl, n-propyl,i-propyl, or the different butyl, pentyl or hexyl isomers. “Alkenyl”includes straight-chain or branched alkenes such as ethenyl, 1-propenyl,2-propenyl, and the different butenyl, pentenyl and hexenyl isomers.“Alkenyl” also includes polyenes such as 1,2-propadienyl and2,4-hexadienyl. “Alkynyl” includes straight-chain or branched alkynessuch as ethynyl, 1-propynyl, 2-propynyl and the different butynyl,pentynyl and hexynyl isomers. “Alkynyl” can also include moietiescomprised of multiple triple bonds such as 2,5-hexadiynyl. “Alkylene”denotes a straight-chain or branched alkanediyl. Examples of “alkylene”include CH₂, CH₂CH₂, CH(CH₃), CH₂CH₂CH₂, CH₂CH(CH₃) and the differentbutylene isomers. “Alkenylene” denotes a straight-chain or branchedalkenediyl containing one olefinic bond. Examples of“alkenylene” includeCH═CH, CH₂CH═CH, CH═C(CH₃), CH₂CH═CH and CH₂CH═CHCH₂. “Alkoxy” includes,for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and thedifferent butoxy, pentoxy and hexyloxy isomers. “Alkoxyalkyl” denotesalkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH₃OCH₂,CH₃OCH₂CH₂, CH₃CH₂OCH₂, CH₃CH₂CH₂CH₂OCH₂ and CH₃CH₂OCH₂CH₂. “Alkylthio”includes branched or straight-chain alkylthio moieties such asmethylthio, ethylthio, and the different propylthio, butylthio,pentylthio and hexylthio isomers. “Alkylsulfinyl” includes bothenantiomers of an alkylsulfinyl group. Examples of “alkylsulfinyl”include CH₃S(O), CH₃CH₂S(O), CH₃CH₂CH₂S(O), (CH₃)₂CHS(O) and thedifferent butylsulfinyl, pentylsulfinyl and hexylsulfinyl isomers.Examples of “alkylsulfonyl” include CH₃S(O)₂, CH₃CH₂S(O)₂,CH₃CH₂CH₂S(O)₂, (CH₃)₂CHS(O)₂ and the different butylsulfonyl,pentylsulfonyl and hexylsulfonyl isomers. Examples of “alkylcarbonyl”include C(O)CH₃, C(O)CH₂CH₂CH₃ and C(O)CH(CH₃)₂. Examples of“alkoxycarbonyl” include CH₃OC(═O), CH₃CH₂OC(═O), CH₃CH₂CH₂OC(═O),(CH₃)₂CHOC(═O) and the different butoxy- or pentoxycarbonyl isomers.Examples of “alkylaminocarbonyl” include CH₃NHC(═O)—, CH₃CH₂NHC(═O)—,CH₃CH₂CH₂NHC(═O)—, (CH₃)₂CHNHC(═O)— and the different butylamino- orpentylaminocarbonyl isomers. Examples of “dialkylaminocarbonyl” include(CH₃)₂NC(═O)—, (CH₃CH₂)₂NC(═O)—, CH₃CH₂(CH₃)NC(═O)—,(CH₃)₂CHN(CH₃)C(═O)— and CH₃CH₂CH₂(CH₃)NC(═O)—. “Alkylamino”,“dialkylamino” and the like, are defined analogously to the aboveexamples. “Trialkylsilyl” includes 3 branched and/or straight-chainalkyl radicals attached to and linked through a silicon atom, such astrimethylsilyl, triethylsilyl and tert-butyldimethylsilyl. “Cycloalkyl”includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, andcyclohexyl. Examples of “cycloalkylalkyl” include cyclopropylmethyl,cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chainor branched alkyl groups. “Alkylcycloalkyl” denotes alkyl substitutionon a cycloalkyl moiety. Examples include 4-methylcyclohexyl and3-ethylcyclopentyl.

Unless otherwise indicated, a “ring” or “ring system” as a component ofFormula 1 (e.g., substituent J and Q) is carbocyclic or heterocyclic.The term “ring system” denotes two or more connected rings. The term“spirocyclic ring system” denotes a ring system consisting of two ringsconnected at a single atom (so the rings have a single atom incommonality). Illustrative of a J¹ moiety that is a spirocyclic ringsystem is J-29-28 depicted in the definition of Formula 1C. The term“bicyclic ring system” denotes a ring system consisting of two ringssharing two or more common atoms. In a “fused bicyclic ring system” thecommon atoms are adjacent, and therefore the rings share two adjacentatoms and bond connecting them. In a “bridged bicyclic ring system” thecommon atoms are not adjacent (i.e. there is no bond between thebridgehead atoms). A “bridged bicyclic ring system” is conceptuallyformed by bonding a segment of one or more atoms to nonadjacent ringmembers of a ring.

A ring, a bicyclic ring system or spirocyclic ring system can be part ofan extended ring system containing more than two rings whereinsubstituents on the ring, bicyclic ring system or spirocyclic are takentogether to form the additional rings, which may be in bicyclic and/orspirocyclic relationships with other rings in the extended ring system.For example, the particular J¹ moiety J-29-26 depicted in the definitionof Formula 1C consists of a dihydro isoxazoline ring having one R⁵substituent as Z²Q, which is a cyclobutyl ring substituted with twomethyl groups as R⁷ and also one R⁷ group taken together with another R⁵substituent on the dihydro isoxazoline ring as —CH₂CH₂— to form theadditional six-membered ring component in the ring system.

The term “ring member” refers to an atom (e.g., C, O, N or S) or othermoiety (e.g., C(═O), C(═S), S(O) or S(O)₂) forming the backbone of aring or ring system. The term “carbocyclic ring” denotes a ring whereinthe atoms forming the ring backbone are selected only from carbon. Theterm “carbocyclic ring system” denotes two or more fused rings whereinthe atoms forming the backbone of the rings are selected only fromcarbon. The term “heterocyclic ring” denotes a ring wherein at least oneof the atoms forming the ring backbone is other than carbon. The term“heterocyclic ring system” denotes two or more fused rings wherein atleast one of the atoms forming the backbone of the rings is other thancarbon. “Aromatic” indicates that each of ring atoms is essentially inthe same plane and has a p-orbital perpendicular to the ring plane, andin which (4n+2) π electrons, where n is a positive integer, areassociated with the ring to comply with Hückel's rule. The term“heteroaromatic ring” refers to a heterocyclic ring that is aromatic.The term “saturated heterocyclic ring” denotes a heterocyclic ringcontaining only single bonds between ring members. The term “partiallysaturated heterocyclic ring” denotes a heterocyclic ring containing atleast one double bond but which is not aromatic.

The dotted line in Formula 1 and in other rings depicted in the presentdescription (e.g., J-44, J-45, J-48 and J-49 in Exhibit 3) representsthat the bond indicated can be a single bond or double bond. Unlessotherwise indicated, heterocyclic rings and ring systems are attached tothe remainder of Formula 1 through any available carbon or nitrogen byreplacement of a hydrogen on said carbon or nitrogen, and allsubstituents on the heterocyclic rings and ring systems are attachedthrough any available carbon or nitrogen by replacement of a hydrogen onsaid carbon or nitrogen.

As already described, J is a 5-, 6- or 7-membered ring, a 8- to11-membered bicyclic ring system or a 7- to 11-membered spirocyclic ringsystem, each ring or ring system containing ring members selected fromcarbon and optionally 1 to 4 heteroatoms selected from up to 2 O, up to2 S and up to 4 N, and optionally including 1 to 3 ring members selectedfrom the group consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸,each ring or ring system optionally substituted with 1 to 5 substituentsindependently selected from R⁵. As the heteroatoms are optional, 0 to 4heteroatoms may be present. In this description the heteroatoms selectedfrom up to 2 S are atoms and not the moieties S(O) or S(O)₂. Theheteroatoms selected from up to 4 N may be oxidized as N-oxides, becausethe present invention also relates to N-oxide derivatives of thecompounds of Formula 1. Therefore the optional 1 to 3 ring membersselected from the group consisting of C(═O), C(═S), S(O), S(O)₂ andSiR¹⁷R¹⁸ are in addition to the optional 1 to 4 heteroatoms selectedfrom up to 2 O, up to 2 S and up to 4 N. Of note is when the totalnumber of unoxidized sulfur atoms (i.e. S) and oxidized sulfur moieties(i.e. S(O) and S(O)₂) does not exceed 2, so that at most two ringmembers selected from S, S(O) and S(O)₂ are present in the ring or ringsystem. When none of the optional heteroatoms and none of the optionalring members selected from S(O), S(O)₂ and SiR¹⁷R¹⁸ are present, thering or ring system is carbocyclic. The R⁵ substituents may be attachedto carbon atom ring members and to nitrogen atom ring members having anavailable point of attachment. The carbon-based ring members C(═O) andC(═S) do not have available points of attachment. Furthermore inSiR¹⁷R¹⁸ ring members, the substituents R¹⁷ and R¹⁸ are otherwiseseparately defined, and these ring members cannot be further substitutedwith R⁵. As the R⁵ substituents are optional, 0 to 5 substituents may bepresent, limited by the number of available points of attachment.

Similarly, R⁵ and R⁷ may be taken together with the atoms linking R⁵ andR⁷ to form an optionally substituted 5- to 7-membered ring containingring members selected from carbon and optionally 1 to 3 heteroatomsselected from up to 1 O, up to 1 S and up to 1 N and optionallyincluding 1 to 3 ring members selected from the group consisting ofC(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸. As the heteroatoms are optional,0 to 3 heteroatoms may be present. In this description the heteroatomselected from up to 1 S is an atom and not the moieties S(O) or S(O)₂.The heteroatom selected from up to 1 N may be oxidized as an N-oxide,because the present invention also relates to N-oxide derivatives of thecompounds of Formula 1. Therefore the optional 1 to 3 ring membersselected from the group consisting of C(═O), C(═S), S(O), S(O)₂ andSiR¹⁷R¹⁸ are in addition to the optional 1 to 3 heteroatoms selectedfrom up to 1 O, up to 1 S and up to 1 N. Of note is when the totalnumber of unoxidized sulfur atoms (i.e. S) and oxidized sulfur moieties(i.e. S(O) and S(O)₂) does not exceed 1, so that at most one ring memberselected from S, S(O) and S(O)₂ is present in the ring. When none of theoptional heteroatoms and none of the optional ring members selected fromS(O), S(O)₂ and SiR¹⁷R¹⁸ are present, the ring is carbocyclic. The 5- to7-membered ring is optionally substituted. The substituents on the atomslinking R⁵ and R⁷ are described in the definition of the componentslinking R⁵ and R⁷. For example, when linking component Z² is CHR²⁰, thesubstituent R²⁰ is defined to be H, C₁-C₄ alkyl or C₁-C₄ haloalkyl.Regarding optional substituents attached to the portion of the ringconsisting of R⁵ and R⁷ taken together, an optional substituent is anon-hydrogen substituent that does not extinguish fungicidal activity.Optional substituents may be attached to carbon atom ring members and tonitrogen atom ring members having an available point of attachment. Thecarbon-based ring members C(═O) and C(═S) do not have available pointsof attachment. Furthermore in SiR¹⁷R¹⁸ ring members, the substituentsR¹⁷ and R¹⁸ are otherwise separately defined, and these ring memberscannot be further substituted.

The term “halogen”, either alone or in compound words such as“haloalkyl”, includes fluorine, chlorine, bromine or iodine.Furthermore, when used in compound words such as “haloalkyl”, said alkylmay be partially or fully substituted with halogen atoms which may bethe same or different. Examples of “haloalkyl” include F₃C, ClCH₂,CF₃CH₂ and CF₃CCl₂. The terms “haloalkenyl”, “haloalkynyl”,“halocycloalkyl”, “haloalkoxy”, “haloalkylthio”, and the like, aredefined analogously to the term “haloalkyl”. Examples of “haloalkenyl”include (Cl)₂C═CHCH₂ and CF₃CH₂CH═CHCH₂. Examples of “haloalkynyl”include HC≡CCHCl, CF₃C≡C, CCl₃C≡C and FCH₂C≡CCH₂. Examples of“haloalkoxy” include CF₃O, CCl₃CH₂O, HCF₂CH₂CH₂O and CF₃CH₂O. Examplesof “haloalkylthio” include CCl₃S, CF₃S, CCl₃CH₂S and ClCH₂CH₂CH₂S.Examples of “haloalkylsulfinyl” include CF₃S(O), CCl₃S(O), CF₃CH₂S(O)and CF₃CF₂S(O). Examples of “haloalkylsulfonyl” include CF₃S(O)₂,CCl₃S(O)₂, CF₃CH₂S(O)₂ and CF₃CF₂S(O)₂.

The total number of carbon atoms in a substituent group is indicated bythe “C_(i)-C_(j)” prefix where i and j are numbers from 1 to 10. Forexample, C₁-C₄ alkylsulfonyl designates methylsulfonyl throughbutylsulfonyl; C₂ alkoxyalkyl designates CH₃OCH₂; C₃ alkoxyalkyldesignates, for example, CH₃CH(OCH₃), CH₃OCH₂CH₂ or CH₃CH₂OCH₂; and C₄alkoxyalkyl designates the various isomers of an alkyl group substitutedwith an alkoxy group containing a total of four carbon atoms, examplesincluding CH₃CH₂CH₂OCH₂ and CH₃CH₂OCH₂CH₂.

When a compound is substituted with a substituent bearing a subscriptthat indicates the number of said substituents can vary, then when thenumber of said substituents is greater than 1, said substituents areindependently selected from the group of defined substituents.Furthermore when a range is indicated (e.g., i-j substituents), then thenumber of substituents may be selected from the integers between i and jinclusive. When a group (e.g., J) contains a substituent (e.g., R⁵)which can be hydrogen, then when this substituent is taken as hydrogen,it is recognized that this is equivalent to said group beingunsubstituted. When a variable group is shown to be optionally attachedto a position, for example (R²)_(n) wherein n may be 0, or as a furtherexample (R⁴)_(k) wherein k may be 0 in Exhibit 1, then hydrogen may beat the position even if not recited in the definition of the variablegroup (e.g., R² and R⁴). When a position on a group is said to be “notsubstituted” or “unsubstituted”, then hydrogen atoms are attached totake up any free valency. The term “optionally substituted” inconnection with groups listed for R¹, R², R⁵, R⁷, G, J and Q refers togroups that are unsubstituted or have at least 1 non-hydrogensubstituent. Unless otherwise indicated, these groups may be substitutedwith as many optional substituents as can be accommodated by replacing ahydrogen atom with a non-hydrogen substituent on any available carbon ornitrogen atom. Commonly, the number of optional substituents (whenpresent) ranges from 1 to 3. When a range specified for the number ofsubstituents (e.g., x being an integer from 0 to 5 in Exhibit 3) exceedsthe number of positions available for substituents on a ring (e.g., 2positions available for (R⁵)_(x) on J-1 in Exhibit 3), the actual higherend of the range is recognized to be the number of available positions.The term “optionally substituted” means that the number of substituentscan be zero. For example, the phrase “optionally substituted with up to2 substituents selected from R³ on carbon ring members and selected fromR¹¹ on nitrogen ring members” means that 0, 1 or 2 substituents can bepresent (if number of potential connection points allows), and thus thenumber of R³ and R¹¹ substituents can be zero. Similarly, the phrase“optionally substituted with 1 to 5 substituents” means that 0, 1, 2, 3,4 or 5 substituents can be present if the number of available connectionpoints allows. The term “unsubstituted” in connection with a group suchas a ring or ring system means the group does not have any substituentsother than its one or more attachments to the remainder of Formula 1.The term “meta-substituted phenyl” means a phenyl ring substituted witha non-hydrogen substituent at a meta position relative to attachment ofthe phenyl ring to the remainder of Formula 1.

As noted above, R¹ is an optionally substituted phenyl, naphthalenyl or5- or 6-membered heteroaromatic ring; G is an optionally substituted5-membered heteroaromatic ring or 5-membered saturated or partiallysaturated heterocyclic ring; and R⁵ and R⁷ may be taken together withthe atoms linking R⁵ and R⁷ to form an optionally substituted 5- to7-membered ring containing ring members selected from carbon andoptionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and upto 1 N and optionally including 1 to 3 ring members selected from thegroup consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸. The term“substituted” in connection with the definitions of R¹, G, R⁵ and R⁷refers to groups that have at least one non-hydrogen substituent thatdoes not extinguish fungicidal activity. Since these groups areoptionally substituted, they need not have any non-hydrogensubstituents. As these groups are “optionally substituted” without thenumber of substituents indicated, these groups may be substituted withas many optional substituents as can be accommodated by replacing ahydrogen atom with a non-hydrogen substituent on any available carbon ornitrogen atom.

Naming of substituents in the present disclosure uses recognizedterminology providing conciseness in precisely conveying to thoseskilled in the art the chemical structure. For sake of conciseness,locant descriptors may be omitted; “pyrazol-1-yl” means“1H-pyrazol-1-yl” according to the Chemical Abstracts system ofnomenclature. The term “pyridyl” is synonymous with “pyridinyl”. Theorder of listing substituents may be different from the ChemicalAbstracts system if the difference does not affect the meaning.

Compounds of this invention can exist as one or more stereoisomers. Thevarious stereoisomers include enantiomers, diastereomers, atropisomersand geometric isomers. One skilled in the art will appreciate that onestereoisomer may be more active and/or may exhibit beneficial effectswhen enriched relative to the other stereoisomer(s) or when separatedfrom the other stereoisomer(s). Additionally, the skilled artisan knowshow to separate, enrich, and/or to selectively prepare saidstereoisomers. The compounds of the invention may be present as amixture of stereoisomers, individual stereoisomers, or as an opticallyactive form. For example, when J is J-29 (see Exhibit 3) bonded at the3-position to the remainder of Formula 1 and J-29 has one R⁵ substituentother than H at the 5-position, then Formula 1 possesses a chiral centerat the carbon atom to which R⁵ is bonded. The two enantiomers aredepicted as Formula 1′ and Formula 1″ with the chiral center identifiedwith an asterisk (*).

This invention comprises racemic mixtures, for example, equal amounts ofthe enantiomers of Formulae 1′ and 1″. In addition, this inventionincludes compounds that are enriched compared to the racemic mixture inan enantiomer of Formula 1. Also included are the essentially pureenantiomers of compounds of Formula 1, for example, Formula 1′ andFormula 1″.

When enantiomerically enriched, one enantiomer is present in greateramounts than the other, and the extent of enrichment can be defined byan expression of enantiomeric excess (“ee”), which is defined as(2x−1)·100%, where x is the mole fraction of the dominant enantiomer inthe mixture (e.g., an ee of 20% corresponds to a 60:40 ratio ofenantiomers).

Preferably the compositions of this invention have at least a 50%enantiomeric excess; more preferably at least a 75% enantiomeric excess;still more preferably at least a 90% enantiomeric excess; and the mostpreferably at least a 94% enantiomeric excess of the more active isomer.Of particular note are enantiomerically pure embodiments of the moreactive isomer.

Compounds of Formula 1 can comprise additional chiral centers. Forexample, substituents and other molecular constituents such as R⁴, R⁵,R⁷, G, J, Q and X¹ through X⁹ may themselves contain chiral centers.This invention comprises racemic mixtures as well as enriched andessentially pure stereoconfigurations at these additional chiralcenters.

Compounds of this invention can exist as one or more conformationalisomers due to restricted rotation about the amide bond (e.g., C(W)—N)in Formula 1. This invention comprises mixtures of conformationalisomers. In addition, this invention includes compounds that areenriched in one conformer relative to others.

Some of the unsaturated rings and ring systems depicted in Exhibits 1,2, 3 and 4 can have an arrangement of single and double bonds betweenring members different from that depicted. Such differing arrangementsof bonds for a particular arrangement of ring atoms correspond todifferent tautomers. For these unsaturated rings and ring systems, theparticular tautomer depicted is to be considered representative of allthe tautomers possible for the arrangement of ring atoms shown. Thetables listing particular compounds incorporating the ring and ringsystems depicted in the Exhibits may involve a tautomer different fromthe tautomer depicted in the Exhibits.

The compounds of the invention include N-oxide derivatives. One skilledin the art will appreciate that not all nitrogen-containing heterocyclescan form N-oxides since the nitrogen requires an available lone pair ofelectrons for oxidation to the oxide; one skilled in the art willrecognize those nitrogen containing heterocycles which can formN-oxides. One skilled in the art will also recognize that tertiaryamines can form N-oxides. Synthetic methods for the preparation ofN-oxides of heterocycles and tertiary amines are very well known by oneskilled in the art including the oxidation of heterocycles and tertiaryamines with peroxy acids such as peracetic and m-chloroperbenzoic acid(MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butylhydroperoxide, sodium perborate, and dioxiranes such asdimethyldioxirane. These methods for the preparation of N-oxides havebeen extensively described and reviewed in the literature, see forexample: T. L. Gilchrist in Comprehensive Organic Synthesis, vol. 7, pp748-750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik inComprehensive Heterocyclic Chemistry, vol. 3, pp 18-20, A. J. Boultonand A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keenein Advances in Heterocyclic Chemistry, vol. 43, pp 149-161, A. R.Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in Advancesin Heterocyclic Chemistry, vol. 9, pp 285-291, A. R. Katritzky and A. J.Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G.Werstiuk in Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, A.R. Katritzky and A. J. Boulton, Eds., Academic Press.

The present compounds of Formula 1 can be in the form of agriculturallysuitable salts. One skilled in the art recognizes that because in theenvironment and under physiological conditions salts of chemicalcompounds are in equilibrium with their corresponding nonsalt forms,salts share the biological utility of the nonsalt forms. Thus a widevariety of salts of the compounds of Formula 1 are useful for control ofplant diseases caused by fungal plant pathogens (i.e. are agriculturallysuitable). The salts of the compounds of Formula 1 include acid-additionsalts with inorganic or organic acids such as hydrobromic, hydrochloric,nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic,malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic orvaleric acids. When a compound of Formula 1 contains an acidic moietysuch as a carboxylic acid or phenol, salts also include those formedwith organic or inorganic bases such as pyridine, triethylamine orammonia, or amides, hydrides, hydroxides or carbonates of sodium,potassium, lithium, calcium, magnesium or barium. Accordingly, thepresent invention comprises compounds selected from Formulae 1, 1A, 1Band 1C, N-oxides and salts thereof.

Embodiments of the present invention include:

Embodiment 1

A compound of Formula 1 wherein A is CHR¹⁵.

Embodiment 1a

A compound of Embodiment 1 wherein R¹⁵ is H, halogen, cyano, hydroxy,—CHO, C₁-C₄ alkyl, C₁-C₄ haloalkyl or C₂-C₅ alkoxycarbonyl.

Embodiment 1b

A compound of Embodiment 1a wherein R¹⁵ is H, cyano, hydroxy, methyl ormethoxycarbonyl.

Embodiment 1c

A compound of Embodiment 1b wherein R¹⁵ is H.

Embodiment 2

A compound of Formula 1 wherein A is NR¹⁶.

Embodiment 2a

A compound of Embodiment 2 wherein R¹⁶ is H, C₁-C₄ alkyl, C₁-C₄haloalkyl, C₂-C₄ alkylcarbonyl, C₂-C₄ haloalkylcarbonyl or C₂-C₄alkoxycarbonyl.

Embodiment 2b

A compound of Embodiment 2a wherein R¹⁶ is H, methyl, methylcarbonyl ormethoxycarbonyl.

Embodiment 2c

A compound of Embodiment 2b wherein R¹⁶ is H.

Embodiment 3

A compound of Formula 1 wherein W is O.

Embodiment 4

A compound of Formula 1 wherein W is S.

Embodiment 5

A compound of Formula 1 wherein each R² is independently C₁-C₂ alkyl,C₁-C₂ haloalkyl, C₁-C₂ alkoxy, halogen, cyano or hydroxy.

Embodiment 5a

A compound of Embodiment 5 wherein each R² is independently methyl,methoxy, cyano or hydroxy.

Embodiment 5b

A compound of Embodiment 5a wherein each R² is methyl.

Embodiment 6

A compound of Formula 1 wherein n is 0 or 1.

Embodiment 7

A compound of Embodiment 6 wherein n is 0.

Embodiment 7a

A compound of Embodiment 6 wherein n is 1.

Embodiment 8

A compound of Formula 1 wherein X is X¹, X² or X³.

Embodiment 9

A compound of Embodiment 8 wherein X is X¹ or X².

Embodiment 10

A compound of Embodiment 9 wherein X is X¹.

Embodiment 11

A compound of Formula 1 wherein the ring comprising X is saturated (i.e.contains only single bonds).

Embodiment 12

A compound of Formula 1 wherein R¹ is a phenyl or 5- or 6-memberedheteroaromatic ring optionally substituted with substituents that do notlink together to make R¹ a fused ring system.

Embodiment 12a

A compound of Embodiment 12 wherein R¹ is a phenyl or 5- or 6-memberedheteroaromatic ring optionally substituted with 1-3 substituentsindependently selected from R^(4a) on carbon ring members and R^(4b) onnitrogen ring members;

-   -   each R^(4a) is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl; and    -   each R^(4b) is independently C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆        alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ haloalkyl, C₃-C₆ haloalkenyl,        C₃-C₆ haloalkynyl, C₃-C₆ halocycloalkyl or C₂-C₄ alkoxyalkyl.

Embodiment 12b

A compound of Embodiment 12a wherein R¹ is a phenyl or 5- or 6-memberedheteroaromatic ring optionally substituted with 1-2 substituentsindependently selected from R^(4a) on carbon ring members and R^(4b) onnitrogen ring members.

Embodiment 13

A compound of Embodiment 12b wherein R¹ is one of U-1 through U-50depicted in Exhibit 1;

wherein

-   -   when R⁴ is attached to a carbon ring member, said R⁴ is selected        from R^(4a), and when R⁴ is attached to a nitrogen ring member        (e.g., in U-4, U-11 through U-15, U-24 through U-26, U-31 or        U-35), said R⁴ is selected from R^(4b); and    -   k is 0, 1 or 2.

Embodiment 14

A compound of Embodiment 13 wherein R¹ is selected from U-1 through U-5,U-8, U-11, U-13, U-15, U-20 through U-28, U-31, U-36 through U-39 andU-50.

Embodiment 15

A compound of Embodiment 14 wherein R¹ is selected from U-1 through U-3,U-5, U-8, U-11, U-13, U-20, U-22, U-23, U-25 through U-28, U-36 throughU-39 and U-50.

Embodiment 16

A compound of Embodiment 15 wherein R¹ is selected from U-1 through U-3,U-11, U-13, U-20, U-22, U-23, U-36 through U-39 and U-50.

Embodiment 17

A compound of Embodiment 16 wherein R¹ is U-1 or U-50.

Embodiment 18

A compound of Embodiment 17 wherein R¹ is U-1.

Embodiment 19

A compound of Embodiment 17 wherein R¹ is U-50.

Embodiment 20

A compound of any one of Embodiments 12 and 13 wherein each R^(4a) isindependently C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, cyclopropyl,C₁-C₃ haloalkyl, C₂-C₃ haloalkenyl, C₂-C₃ haloalkynyl, halocyclopropyl,halogen, cyano, nitro, C₁-C₂ alkoxy, C₁-C₂ haloalkoxy, C₁-C₂ alkylthio,C₁-C₂ haloalkylthio, C₁-C₃ alkoxyalkyl, C₂-C₃ alkylcarbonyl, C₂-C₃alkoxycarbonyl, C₂-C₃ alkylaminocarbonyl or C₃-C₄ dialkylaminocarbonyl.

Embodiment 21

A compound of Embodiment 20 wherein each R^(4a) is independently C₁-C₃alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, cyclopropyl, C₁-C₃ haloalkyl, C₂-C₃haloalkenyl, C₁-C₃ haloalkynyl, halocyclopropyl, halogen, cyano, nitro,C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.

Embodiment 22

A compound of Embodiment 21 wherein each R^(4a) is independentlyhalogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.

Embodiment 23

A compound of Embodiment 21 wherein each R^(4a) is independentlyhalogen, C₁-C₂, alkyl, C₁-C₂ haloalkyl or C₁-C₂ alkoxy.

Embodiment 24

A compound of Embodiment 23 wherein each R^(4a) is independently C₁-C₂alkyl, trifluoromethyl, Cl, Br, I or methoxy.

Embodiment 25

A compound of Embodiment 24 wherein each R^(4a) is independently C₁-C₂alkyl, trifluoromethyl, Cl or Br.

Embodiment 26

A compound of any one of Embodiments 12 and 13 wherein each R^(4b) isindependently C₁-C₃ alkyl, C₃ alkenyl (e.g., allyl), C₃ alkynyl (e.g.,propargyl), cyclopropyl, C₁-C₃ haloalkyl, C₃ haloalkenyl, C₃haloalkynyl, halocyclopropyl or C₂-C₃ alkoxyalkyl.

Embodiment 27

A compound of Embodiment 26 wherein each R^(4b) is independently C₁-C₃alkyl, C₃ alkenyl, C₃ alkynyl, cyclopropyl, C₁-C₃ haloalkyl, C₃haloalkenyl or halocyclopropyl.

Embodiment 28

A compound of Embodiment 27 wherein each R^(4b) is independently C₁-C₂alkyl or C₁-C₂ haloalkyl.

Embodiment 29

A compound of Embodiment 28 wherein each R^(4b) is independently C₁-C₂alkyl or trifluoromethyl.

Embodiment 30

A compound of Embodiment 29 wherein each R^(4b) is independently C₁-C₂alkyl.

Embodiment 31

A compound of Embodiment 13 wherein k is 1 or 2 and at least one R⁴ isCl.

Embodiment 32

A compound of Embodiment 13 wherein k is 1 or 2 and at least one R⁴ isBr.

Embodiment 33

A compound of Embodiment 13 wherein k is 1 or 2 and at least one R⁴ ismethyl.

Embodiment 34

A compound of Embodiment 13 wherein k is 1 or 2 and at least one R⁴ isethyl.

Embodiment 35

A compound of Embodiment 13 wherein k is 1 or 2 and at least one R⁴ istrifluoromethyl.

Embodiment 36

A compound of Embodiment 13 wherein k is 1 or 2 and at least one R⁴ ismethoxy.

Embodiment 37

A compound of Embodiment 18 wherein k is 1 and R⁴ is connected to the 3-or 5-position of U-1.

Embodiment 38

A compound of Embodiment 18 wherein k is 2 and one R⁴ is connected tothe 3-position and the other R⁴ is connected to the 5-position of U-1.

Embodiment 39

A compound of Embodiment 19 wherein k is 1 and R⁴ is connected to the 2-or 3-position of U-50.

Embodiment 40

A compound of Embodiment 19 wherein k is 2 and one R⁴ is connected tothe 2-position and the other R⁴ is connected to the 5-position of U-50.

Embodiment 41

A compound of Formula 1 wherein G is a 5-membered heteroaromatic ring or5-membered saturated or partially saturated heterocyclic ring, each ringoptionally substituted with up to 2 substituents selected from R³ oncarbon ring members and selected from R¹¹ on nitrogen ring members;

-   -   each R³ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or        halogen; and    -   each R¹¹ is independently C₁-C₃ alkyl.

Embodiment 42

A compound of Embodiment 41 wherein G is one of G-1 through G-59depicted in Exhibit 2;

-   -   wherein the bond projecting to the left is bonded to X, and the        bond projecting to the right is bonded to Z¹; each R^(3a) is        independently selected from H or R³; and R^(11a) is selected        from H and R¹¹;

provided that:

-   -   when G is G-6, G-16 or G-42, and each R^(3a) is other than H,        then R^(11a) is H;    -   when G is G-25 or G-31, then at least one R^(3a) is H; and    -   when G is one of G-31 through G-35, then Z¹ is a direct bond or        CHR²⁰.

Embodiment 43

A compound of Embodiment 42 wherein G is selected from G-1 through G-3,G-7, G-8, G-10, G-11, G-14, G-15, G-23, G-24, G-26 through G-28, G-30,G-36 through G-38 and G-49 through G-55.

Embodiment 44

A compound of Embodiment 43 wherein G is selected from G-1, G-2, G-7,G-8, G-14, G-15, G-23, G-24, G-26, G-27, G-36, G-37, G-38, G-49, G-50and G-55.

Embodiment 45

A compound of Embodiment 44 wherein G is selected from G-1, G-2, G-15.G-26, G-27, G-36, G-37 and G-38.

Embodiment 46

A compound of Embodiment 45 wherein G is selected from G-1, G-2, G-15,G-26 and G-36.

Embodiment 47

A compound of Embodiment 46 wherein G is G-1. Of note are embodiments ofthese compounds within Embodiments 1 through 40, Embodiments 52 through83, and Embodiments A1 through A5.

Embodiment 48

A compound of Embodiment 46 wherein G is G-2. Of note are embodiments ofthese compounds within Embodiments 1 through 40, Embodiments 52 through83, and Embodiments A1 through A5.

Embodiment 49

A compound of Embodiment 46 wherein G is G-15. Of note are embodimentsof these compounds within Embodiments 1 through 40, Embodiments 52through 83, and Embodiments A1 through A5.

Embodiment 50

A compound of Embodiment 46 wherein G is G-26. Of note are embodimentsof these compounds within Embodiments 1 through 40, Embodiments 52through 83, and Embodiments A1 through A5.

Embodiment 51

A compound of Embodiment 46 wherein G is G-36. Of note are embodimentsof these compounds within Embodiments 1 through 40, Embodiments 52through 83, and Embodiments A1 through A5.

Embodiment 52

A compound of any one of Embodiments 41 through 51 wherein R^(3a) is H,C₁-C₃ alkyl or halogen.

Embodiment 53

A compound of Embodiment 52 wherein R^(3a) is H or methyl.

Embodiment 54

A compound of any one of Embodiments 41 through 51 wherein R^(3a) is Hand R^(11a) is H or methyl.

Embodiment 55

A compound of any one of Formula 1 and Embodiments 41 through 51 whereinG is unsubstituted.

Embodiment 56

A compound of Formula 1 wherein J is one of J-1 through J-82 depicted inExhibit 3;

-   -   wherein the bond shown projecting to the left is bonded to Z¹;        and x is an integer from 0 to 5.

Embodiment 56a

A compound of Embodiment 56 wherein J is one of J-29-1 through J-29-58depicted in Exhibit A:

Embodiment 57

A compound of Embodiment 56 wherein J is selected from J-1, J-2, J-3,J-4, J-5, J-7, J-8, J-9, J-10, J-11, J-12, J-14, J-15, J-16, J-20, J-24,J-25, J-26, J-29, J-30, J-37, J-38, J-45 and J-69.

Embodiment 58

A compound of Embodiment 57 wherein J is selected from J-4, J-5, J-8,J-11, J-15, J-16, J-20, J-29, J-30, J-37, J-38, and J-69.

Embodiment 59

A compound of Embodiment 58 wherein J is selected from J-4, J-5, J-11,J-20, J-29, J-37, J-38, and J-69.

Embodiment 60

A compound of Embodiment 59 wherein J is J-11.

Embodiment 61

A compound of Embodiment 59 wherein J is J-29.

Embodiment 61a

A compound of Embodiment 61 wherein J is any one of J-29-1 to J-29-58(depicted in Exhibit A).

Embodiment 62

A compound of Embodiment 59 wherein J is J-69.

Embodiment 63

A compound of Embodiment 60 wherein the 3-position of J-11 is connectedto Z¹ and the 5-position of J-11 is connected to R⁵ other than H.

Embodiment 63a

A compound of Embodiment 63 wherein the 3-position of J-11 is connectedto Z¹ and the 5-position of J-11 is connected to Z²Q.

Embodiment 64

A compound of Embodiment 61 wherein the 3-position of J-29 is connectedto Z¹ and the 5-position of J-29 is connected to R⁵ other than H.

Embodiment 64a

A compound of Embodiment 65 wherein the 3-position of J-29 is connectedto Z¹ and the 5-position of J-29 is connected to Z²Q.

Embodiment 65

A compound of Formula 1 or Embodiment 56 wherein each R⁵ isindependently H, cyano, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl. C₁-C₆haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈halocycloalkyl, C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₂-C₆alkoxyalkyl, C₄-C₁₀ cycloalkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆alkylthioalkyl, C₂-C₆ alkoxycarbonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy,C₃-C₈ cycloalkoxy, C₃-C₈ halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy, C₂-C₆alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆haloalkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy, C₂-C₆haloalkylcarbonyloxy, C₄-C₈ cycloalkylcarbonyloxy, C₃-C₆alkylcarbonylalkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈cycloalkylthio, C₃-C₁₀ trialkylsilyl, —NR²⁵R²⁶ or Z²Q.

Embodiment 66

A compound of Embodiment 65 wherein each R⁵ is independently H, cyano,C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl,C₂-C₆ alkoxyalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy,C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆alkoxyalkoxy, C₁-C₆ alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₁-C₆alkylthio, C₁-C₆ haloalkylthio, C₃-C₁₀ trialkylsilyl, —NR²⁵R²⁶ or Z²Q.

Embodiment 67

A compound of Embodiment 66 wherein each R⁵ is independently H, cyano,C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —NR²⁵R²⁶or Z²Q.

Embodiment 68

A compound of Formula 1 or Embodiment 56 wherein one instance of R⁵ isZ²Q and other instances of R⁵ are independently selected from H, cyano,C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkylcarbonyl and halogen.

Embodiment 69

A compound of Embodiment 68 wherein the other instances of R⁵ areindependently selected from H and C₁-C₃ alkyl.

Embodiment 70

A compound of Embodiment 56 wherein x is 1 or 2.

Embodiment 71

A compound of Embodiment 70 wherein x is 1.

Embodiment 72

A compound of Embodiment 71 wherein R⁵ is Z²Q.

Embodiment 73

A compound of Formula 1 wherein Z¹ is direct bond.

Embodiment 74

A compound of Formula 1 wherein Z² is direct bond.

Embodiment 75

A compound of Formula 1 wherein Q is one of Q-1 through Q-102 depictedin Exhibit 4;

-   -   wherein p is 0, 1, 2, 3, 4 or 5.

Embodiment 76

A compound of Embodiment 75 wherein Q is selected from Q-1, Q-20, Q-32through Q-34, Q-45 through Q-47, Q-60 through Q-73, Q-76 through Q-79,Q-84 through Q-94 and Q-98 through Q-102.

Embodiment 77

A compound of Embodiment 76 wherein Q is Q-1, Q-45, Q-63, Q-64, Q-65,Q-68, Q-69, Q-70, Q-71, Q-72, Q-73, Q-76, Q-78, Q-79, Q-84, Q-85, Q-98.Q-99. Q-100. Q-101 or Q-102.

Embodiment 78

A compound of Embodiment 77 wherein Q is Q-45, Q-63, Q-64, Q-65, Q-68,Q-69, Q-70, Q-71, Q-72 or Q-85.

Embodiment 78a

A compound of Embodiment 78 wherein Q is Q-45, Q-63, Q-65, Q-70, Q-71,Q-72 or Q-85.

Embodiment 78b

A compound of Embodiment 78 wherein Q is Q-45, Q-63, Q-65 or Q-70.

Embodiment 79

A compound of Formula 1 or Embodiment 75 wherein each R⁷ isindependently C₁-C₃ alkyl, C₁-C₃ haloalkyl, halogen, hydroxy, amino,cyano, nitro, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy.

Embodiment 80

A compound of Embodiment 79 wherein each R⁷ is independently C₁-C₃alkyl, halogen, hydroxy, cyano or C₁-C₂ alkoxy.

Embodiment 81

A compound of Embodiment 80 wherein each R⁷ is independently methyl, F,Cl, Br, hydroxy, cyano or methoxy.

Embodiment 82

A compound of Formula 1 wherein when R⁵ and R⁷ are taken together withthe atoms linking R⁵ and R⁷ to form an optionally substituted 5- to7-membered ring, the ring members are selected from carbon andoptionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and upto 1 N and optionally include 1 to 3 ring members selected from thegroup consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸.

Embodiment 82a

A compound of Embodiment 82 wherein when R⁵ and R⁷ are taken togetherwith the atoms linking R⁵ and R⁷ to form an optionally substituted 5- to7-membered ring, then R⁵ and R⁷ are taken together with the atomslinking R⁵ and R⁷ to form a 5- to 7-membered ring containing as ringmembers carbon atoms and optionally 1 to 3 heteroatoms selected from upto 1 O, up to 1 S and up to 1 N, and optionally including 1 to 3 ringmembers selected from the group consisting of C(═O), C(═S), S(O), S(O)₂and SiR¹⁷R¹⁸, optionally substituted with up to 2 substituents selectedfrom R⁸; and each R⁸ is independently C₁-C₃ alkyl.

Embodiment 82b

A compound of Formula 1 wherein when R⁵ and R⁷ are taken together withthe atoms linking R⁵ and R⁷ to form an optionally substituted 5- to7-membered ring, then R⁵ and R⁷ are taken together with the atomslinking R⁵ and R⁷ to form a 5- to 7-membered ring containing ringmembers selected from carbon and optionally 1 to 3 heteroatoms selectedfrom up to 1 O, up to 1 S and up to 1 N, and optionally including 1 to 3ring members selected from the group consisting of C(═O), C(═S), S(O),S(O)₂ and SiR¹⁷R¹⁸, the ring optionally substituted on ring membersother than the atoms linking R⁵ and R⁷ with substituents selected fromR⁸; and each R⁸ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl, halogen, hydroxy,amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio,C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio. C₁-C₄haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino. C₂-C₈dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₁-C₆ alkoxycarbonyl, C₂-C₆alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl,C₃-C₈ dialkylaminocarbonyl or C₃-C₆ trialkylsilyl.

Embodiment 82c

A compound of Formula 1 wherein when R⁵ and R⁷ are taken together withthe atoms linking R⁵ and R⁷ to form an optionally substituted 5- to7-membered ring, then R⁵ and R⁷ are taken together with the atomslinking R⁵ and R⁷ to form a 5- to 7-membered ring containing as ringmembers 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selectedfrom up to 1 O, up to 1 S and up to 1 N and optionally including 1 ringmember selected from SiR¹⁷R¹⁸, the ring optionally substituted on ringmembers other than the atoms linking R⁵ and R⁷ with substituentsselected from R⁸; and each R⁸ is independently C₁-C₆ alkyl, C₂-C₆alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl, halogen, hydroxy,amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio,C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl,C₃-C₈ dialkylaminocarbonyl or C₃-C₆ trialkylsilyl.

Embodiment 82d

A compound of Embodiment 82b or 82c wherein the ring is optionallysubstituted on ring members other than the atoms linking R⁵ and R⁷ withup to 4 substituents selected from R⁸.

Embodiment 82e

A compound of Embodiment 82d wherein the ring is optionally substitutedon ring members other than the atoms linking R⁵ and R⁷ with up to 2substituents selected from R⁸.

Embodiment 82f

A compound of Embodiment 82b or 82c wherein each R⁸ is independentlyC₁-C₃ alkyl.

Embodiment 82g

A compound of Embodiment 82b wherein when R⁵ and R⁷ are taken togetherwith the atoms linking R⁵ and R⁷ to form an optionally substituted 5- to7-membered ring, then R⁵ and R⁷ are taken together with the atomslinking R⁵ and R⁷ to form a 5- to 7-membered ring containing ringmembers selected from carbon and optionally 1 to 3 heteroatoms selectedfrom up to 1 O, up to 1 S and up to 1 N, and optionally including 1 to 3ring members selected from the group consisting of C(═O), C(═S), S(O),S(O)₂ and SiR¹⁷R¹⁸, optionally substituted with up to 2 substituentsselected from R⁸; and each R⁸ is C₁-C₃ alkyl.

Embodiment 82h

A compound of Embodiment 82c wherein when R⁵ and R⁷ are taken togetherwith the atoms linking R⁵ and R⁷ to form an optionally substituted 5- to7-membered ring, then R⁵ and R⁷ are taken together with the atomslinking R⁵ and R⁷ to form a 5- to 7-membered ring containing as ringmembers 2 to 7 carbon atoms and optionally 1 to 3 heteroatoms selectedfrom up to 1 O up to 1 S and up to 1 N, optionally substituted with upto 2 substituents selected from R⁸; and each R⁸ is C₁-C₃ alkyl.

Embodiment 83

A compound of Formula 1 or Embodiment 75 wherein p is 0, 1, 2 or 3.

Embodiment 84

A compound of Formula 1 wherein R¹ is an optionally substituted phenylor 5- or 6-membered heteroaromatic ring.

Embodiment 85

A compound of Formula 1 wherein A is CH₂ or NH.

Embodiment 86

A compound of Formula 1 wherein X is selected from X¹, X², X³, X⁴, X⁵,X⁶, X⁷ and X⁸.

Embodiment 87

A compound of Formula 1 wherein J is a 5- or 6-membered ring, a 8- to11-membered bicyclic ring system or a 7- to 11-membered spirocyclic ringsystem, each ring or ring system containing ring members selected fromcarbon and optionally 1 to 3 heteroatoms selected from up to 1 O, up to1 S and up to 3 N, and optionally including 1 to 3 ring members selectedfrom the group consisting of C(═O), C(═S), S(O) and S(O)₂, each ring orring system optionally substituted with 1 to 5 substituentsindependently selected from R⁵.

Embodiment 88

A compound of Formula 1 wherein J is a phenyl or 5- or 6-memberedheteroaromatic ring, or a naphthalenyl or 8- to 11-memberedheteroaromatic bicyclic ring system, each ring or ring system optionallysubstituted with 1 to 5 substituents independently selected from R⁵; orJ is a 5-, 6- or 7-membered nonaromatic ring, an 8- to 11-memberednonaromatic bicyclic or a 7- to 11-membered spirocyclic ring system,each ring or ring system optionally including 1 to 3 ring membersselected from the group consisting of C(═O), C(═S), S(O), S(O)₂ andSiR¹⁷R¹⁸, and optionally substituted with 1 to 5 substituentsindependently selected from R⁵.

Embodiment 89

A compound of Formula 1 wherein each R⁵ is independently H, C₁-C₆ alkyl,C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl,C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl, halogen,hydroxy, amino, cyano, nitro, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆haloalkylthio, C₁-C₆ haloalkylsulfinyl, C₁-C₆ haloalkylsulfonyl, C₂-C₆alkoxyalkyl, C₂-C₆ haloalkoxyalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₃-C₆ trialkylsilyl or—Z²Q; each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl, halogen, hydroxy,amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio,C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl,C₃-C₈ dialkylaminocarbonyl or C₃-C₆ trialkylsilyl; or R⁵ and R⁷ aretaken together with the atoms linking R⁵ and R⁷ to form an optionallysubstituted 5- to 7-membered ring containing as ring members 2 to 7carbon atoms and optionally 1 to 3 heteroatoms selected from up to 1 O,up to 1 S and up to 1 N.

Embodiment 90

A compound of Formula 1 wherein each Q is independently an optionallysubstituted phenyl, benzyl, naphthalenyl, C₃-C₆ cycloalkyl, C₃-C₆cycloalkenyl or 5- or 6-membered heteroaromatic ring, each optionallysubstituted with 1 to 3 substituents selected from R⁷ on carbon ringmembers and R¹² on nitrogen ring members.

Embodiment 90a

A compound of Formula 1 wherein each Q is independently a 3- to7-membered nonaromatic carbocyclic ring, a 5-, 6- or 7-memberednonaromatic heterocyclic ring or an 8- to 11-membered nonaromaticbicyclic ring system, each optionally including ring members selectedfrom the group consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸, andoptionally substituted with 1 to 5 substituents independently selectedfrom R⁷ on carbon atom ring members and R¹² on nitrogen atom ringmembers;

Embodiment 91

A compound of Formula 1 wherein each Z¹ and Z² is independently a directbond, O, C(═O), S(O)_(m), CHR²⁰ or NR²¹;

Embodiment 92

A compound of Formula 1 wherein R²¹ is H, C₁-C₃ alkyl, C₂-C₃alkylcarbonyl or C₂-C₃ alkoxycarbonyl.

Embodiment 93

A compound of Formula 1 wherein when G is an optionally substitutedthiazole ring connected at its 2-position to X and at its 4-position toZ¹ in Formula 1, A is CHR¹⁵, and J is an optionally substitutedisoxazole ring connected at its 4-position to Z¹, then Z¹ is O, C(═O),S(O)_(m), CHR²⁰ or NR²¹.

Embodiment 94

A compound of Formula 1 wherein when G is an optionally substitutedthiazole ring connected at its 2-position to X and at its 4-position toZ¹ in Formula 1, and J is an optionally substituted isoxazole ringconnected at its 4-position to Z¹, then Z¹ is O, C(═O), S(O)_(m), CHR²⁰or NR²¹.

Embodiment 95

A compound of Formula 1 wherein when G is an optionally substitutedthiazole ring connected at its 2-position to X and at its 4-position toZ¹ in Formula 1. A is CHR¹⁵, Z¹ is a direct bond, and J is an optionallysubstituted isoxazole ring, then J is connected to the remainder of theFormula 1 at the 3- or 5-position of the isoxazole ring.

Embodiment 96

A compound of Formula 1 wherein when G is an optionally substitutedthiazole ring connected at its 2-position to X and at its 4-position toZ¹ in Formula 1, A is CHR¹⁵, Z¹ is a direct bond, and J is an optionallysubstituted isoxazole ring, then J is connected to the remainder of theFormula 1 at the 3-position of the isoxazole ring.

Embodiment 97

A compound of Formula 1 wherein when G is an optionally substitutedthiazole ring connected at its 2-position to X and at its 4-position toZ¹ in Formula 1, Z¹ is a direct bond, and J is an optionally substitutedisoxazole ring, then J is connected to the remainder of the Formula 1 atthe 3-position of the isoxazole ring.

Embodiment 98

A compound of Formula 1 wherein when X is X² and the ring containing Xis saturated, A is CHR¹⁵, G is an optionally substituted 5-memberedheteroaromatic ring, Z¹ is a direct bond, and J is a phenyl or 5- or6-membered heteroaromatic ring or a naphthalenyl or 8- to 11-memberedheteroaromatic bicyclic ring system, then the J ring or ring system issubstituted with at least one R⁵ that is other than H.

Embodiment 99

A compound of Formula 1 wherein when X is X² and the ring containing Xis saturated, A is CHR¹⁵, G is an optionally substituted 5-memberedheteroaromatic ring, Z¹ is a direct bond, and J is a phenyl or 5- or6-membered heteroaromatic ring or a naphthalenyl or 8- to 11-memberedheteroaromatic bicyclic ring system, then the J ring or ring system issubstituted with at least one R⁵ that is Z²Q.

Embodiment 100

A compound of Formula 1 wherein when X is X¹ and the ring containing Xis saturated, A is NH, G is an optionally substituted thiazole ringconnected at its 2-position to X and at its 4-position to Z¹ in Formula1, and J is an optionally substituted imidazole ring connected at its2-position to the remainder of Formula 1, then Z¹ is O, C(═O), S(O)_(m),CHR²⁰ or NR²¹.

Embodiment 101

A compound of Formula 1 wherein when X is X¹ and the ring containing Xis saturated, A is NR¹⁶, G is an optionally substituted thiazole ringconnected at its 2-position to X and at its 4-position to Z¹ in Formula1, and J is an optionally substituted imidazole ring connected at its2-position to the remainder of Formula 1, then Z¹ is O, C(═O), S(O)_(m),CHR²⁰ or NR²¹.

Embodiment 102

A compound of Formula 1 wherein when G is an optionally substitutedthiazole ring connected at its 2-position to X and at its 4-position toZ¹ in Formula 1, then J is other than optionally substituted imidazolyl.

Embodiment 103

A compound of Formula 1 wherein each Z⁴ is independently C(═O) or S(O)₂.

Embodiment 104

A compound of Embodiment 103 wherein each Z⁴ is C(═O).

Embodiment 105

A compound of Formula 1 wherein each R² is independently C₁-C₄ alkyl,C₂-C₄ alkenyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, halogen, cyano or hydroxy;or

-   -   two R² are taken together as C₁-C₃ alkylene or C₂-C₃ alkenylene        to form a bridged bicyclic ring system; or    -   two R² attached to adjacent ring carbon atoms joined by a double        bond are taken together as —CH═CH—CH═CH— optionally substituted        with 1 to 3 substituents selected from C₁-C₄ alkyl, C₁-C₄        haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, halogen, hydroxy,        amino, cyano and nitro.

Combinations of Embodiments 1-105 are illustrated by:

Embodiment A1

A compound of Formula 1 wherein

-   -   G is a 5-membered heteroaromatic ring or 5-membered saturated or        partially saturated heterocyclic ring, each ring optionally        substituted with up to 2 substituents selected from R³ on carbon        ring members and selected from R¹¹ on nitrogen ring members;    -   R¹ is a phenyl or 5- or 6-membered heteroaromatic ring        optionally substituted with 1 to 2 substituents independently        selected from R^(4a) on carbon ring members and R^(4b) on        nitrogen ring members;    -   each R² is independently C₁-C₂ alkyl, C₁-C₂ haloalkyl, C₁-C₂        alkoxy, halogen, cyano or hydroxy;    -   each R³ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or        halogen;    -   each R^(4a) is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl;    -   each R^(4b) is independently C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆        alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ haloalkyl, C₃-C₆ haloalkenyl,        C₃-C₆ haloalkynyl, C₃-C₆ halocycloalkyl or C₂-C₄ alkoxyalkyl;    -   each R¹¹ is independently C₁-C₃ alkyl;    -   R¹⁵ is H, halogen, cyano, hydroxy, —CHO, C₁-C₄ alkyl, C₁-C₄        haloalkyl or C₂-C₅ alkoxycarbonyl;

R¹⁶ is H, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₄ alkylcarbonyl, C₂-C₄haloalkylcarbonyl or C₁-C₄ alkoxycarbonyl;

-   -   when R⁵ and R⁷ are taken together with the atoms linking R⁵ and        R⁷ to form an optionally substituted 5- to 7-membered ring, then        R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to        form a 5- to 7-membered ring containing ring members selected        from carbon and optionally 1 to 3 heteroatoms selected from up        to 1 O, up to 1 S and up to 1 N, and optionally including 1 to 3        ring members selected from the group consisting of C(═O), C(═S),        S(O), S(O)₂ and SiR¹⁷R¹⁸, the ring optionally substituted on        ring members other than the atoms linking R⁵ and R⁷ with up to 4        substituents selected from R⁸;    -   each R⁸ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio. C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl; and    -   each Z⁴ is independently C(═O) or S(O)₂.

Embodiment A2

A compound of Embodiment A1 wherein

-   -   G is one of G-1 through G-59 (as depicted in Exhibit 2) wherein        the bond projecting to the left is bonded to X, and bond        projecting to the right is bonded to Z¹;    -   J is one of J-1 through J-82 (as depicted in Exhibit 3) wherein        the bond shown projecting to the left is bonded to Z¹;    -   Q is one of Q-1 through Q-102 (as depicted in Exhibit 4);    -   R¹ is one of U-1 through U-50 (as depicted in Exhibit 1);    -   each R² is independently methyl, methoxy, cyano or hydroxy;    -   each R^(3a) is independently selected from H and R³;    -   each R⁵ is independently H, cyano, C₁-C₆ alkyl, C₂-C₆ alkenyl,        C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆        haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₄-C₁₀        alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₂-C₆ alkoxyalkyl,        C₄-C₁₀ cycloalkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆        alkylthioalkyl, C₂-C₆ alkoxycarbonyl, C₁-C₆ alkoxy, C₁-C₆        haloalkoxy, C₃-C₈ cycloalkoxy, C₃-C₈ halocycloalkoxy, C₄-C₁₀        cycloalkylalkoxy, C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆        alkynyloxy, C₂-C₆ haloalkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆        alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₄-C₈        cycloalkylcarbonyloxy, C₃-C₆ alkylcarbonylalkoxy, C₁-C₆        alkylthio, C₁-C₆ haloalkylthio, C₃-C₈ cycloalkylthio, C₃-C₁₀        trialkylsilyl, —NR²⁵R²⁶ or Z²Q;    -   R^(11a) is selected from H and R¹¹;    -   R¹⁵ is H, cyano, hydroxy, methyl or methoxycarbonyl;    -   R¹⁶ is H, methyl, methylcarbonyl or methoxycarbonyl;    -   each Z⁴ is C(═O);    -   k is 0, 1 or 2;    -   p is 0, 1, 2 or 3; and    -   x is an integer from 0 to 5;        provided that:    -   (a) when R⁴ is attached to a carbon ring member, said R⁴ is        selected from R^(4a);    -   (b) when R⁴ is attached to a nitrogen ring member (e.g., in U-4,        U-11 through U-15, U-24 through U-26, U-31 or U-35), said R⁴ is        selected from R^(4b);    -   (c) when G is G-6, G-16 or G-42, and each R^(3a) is other than        H, then R^(11a) is H;    -   (d) when G is G-25 or G-31, then at least one R^(3a) is H; and    -   (e) when G is one of G-31 through G-35, then Z¹ is a direct bond        or CHR²⁰.

Embodiment A3

A compound of Embodiment A2 wherein

-   -   G is selected from G-1, G-2, G-7, G-8, G-14, G-15, G-23, G-24,        G-26, G-27, G-36, G-37, G-38, G-49, G-50 and G-55;    -   J is selected from J-1, J-2, J-3, J-4, J-5, J-7, J-8, J-9, J-10.        J-11, J-12, J-14, J-15, J-16, J-20, J-24, J-25, J-26, J-29,        J-30, J-37, J-38, J-45 and J-69;    -   each Q is independently Q-1, Q-20, Q-32 through Q-34, Q-45        through Q-47, Q-60 through Q-73, Q-76 through Q-79, Q-84 through        Q-94 or Q-98 through Q-102;    -   A is CH₂ or NH;    -   W is O;    -   X is X¹, X² or X³;    -   each R⁵ is independently H, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl,        C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₂-C₆ alkoxyalkyl, C₁-C₆        alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy, C₂-C₆ alkenyloxy,        C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆ alkoxyalkoxy,        C₂-C₆ alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₁-C₆        alkylthio, C₁-C₆ haloalkylthio, C₃-C₁₀ trialkylsilyl, —NR²⁵R²⁶        or Z²Q;    -   Z¹ is a direct bond;    -   each Z² is independently a direct bond or NR²¹;    -   R¹ is selected from U-1 through U-3, U-11, U-13, U-20, U-22,        U-23, U-36 through U-39 and U-50;    -   each R³ is independently methyl or halogen;    -   each R^(4a) is independently C₁-C₂ alkyl, C₁-C₂ haloalkyl,        halogen, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy;    -   each R^(4b) is independently C₁-C₂ alkyl or C₁-C₂ haloalkyl;    -   each R⁷ is independently halogen, cyano, C₁-C₃ alkyl, C₁-C₃        haloalkyl, hydroxy, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy;    -   k is 1 or 2; and    -   n is 0.

Of note are Embodiment A3 compounds wherein one R⁵ is Z²Q and any otherR⁵ substituents are independently selected from H, C₁-C₆ alkyl, C₁-C₆haloalkyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₂-C₆ alkoxyalkyl,C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy, C₂-C₆ alkenyloxy,C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆haloalkylthio, C₃-C₁₀ trialkylsilyl and —NR²⁵R²⁶. Also of note areEmbodiment A3 compounds wherein all R⁵ substituents are other than Z²Q(e.g., each R⁵ is independently selected from H, C₁-C₆ alkyl, C₁-C₆haloalkyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl, C₂-C₆ alkoxyalkyl,C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy, C₂-C₆ alkenyloxy,C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₁-C₆ alkylthio, C₁-C₆haloalkylthio, C₃-C₁₀ trialkylsilyl and —NR²⁵R²⁶).

Embodiment A4

A compound of Embodiment A3 wherein

-   -   A is CH₂;    -   G is selected from G-1, G-2, G-15, G-26, G-27, G-36, G-37 and        G-38; and G is unsubstituted;    -   J is selected from J-4, J-5, J-8, J-11, J-15, J-16, J-20, J-29,        J-30, J-37, J-38, and J-69;    -   Q is selected from Q-1, Q-45, Q-63, Q-64, Q-65, Q-68, Q-69,        Q-70, Q-71, Q-72, Q-73, Q-76, Q-78, Q-79, Q-84, Q-85, Q-98,        Q-99, Q-100, Q-101 and Q-102;    -   X is X¹ or X²; and the ring comprising X is saturated;    -   R¹ is U-1 or U-50;    -   each R^(4a) is independently C₁-C₂ alkyl, trifluoromethyl, Cl,        Br, I or methoxy; and    -   each R⁵ is independently H, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl,        C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —NR²⁵R²⁶ or Z²Q.

Embodiment A5

A compound of Embodiment A4 wherein

-   -   G is selected from G-1, G-2, G-15, G-26 and G-36;    -   J is selected from J-4, J-5, J-11, J-20, J-29, J-37, J-38, and        J-69;    -   Q is selected from Q-45, Q-63, Q-64, Q-65, Q-68, Q-69, Q-70,        Q-71, Q-72 and Q-85; and    -   X is X¹.

Embodiment A6

A compound of Formula 1 wherein

-   -   R¹ is an optionally substituted phenyl or 5- or 6-membered        heteroaromatic ring;    -   A is CH₂ or NH;    -   X is X¹, X², X³, X⁴, X⁵, X⁶, X⁷ or X⁸;    -   each R² is independently C₁-C₄ alkyl, C₂-C₄ alkenyl, C₁-C₄        haloalkyl, C₁-C₄ alkoxy, halogen, cyano or hydroxy; or    -   two R² are taken together as C₁-C₃ alkylene or C₂-C₃ alkenylene        to form a bridged bicyclic ring system; or two R² attached to        adjacent ring carbon atoms joined by a double bond are taken        together as —CH═CH—CH═CH— optionally substituted with 1 to 3        substituents selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄        alkoxy, C₁-C₄ haloalkoxy, halogen, hydroxy, amino, cyano and        nitro;    -   J is a 5- or 6-membered ring or a 8- to 11-membered bicyclic        ring system, each ring or ring system containing ring members        selected from carbon and optionally 1 to 3 heteroatoms selected        from up to 1 O, up to 1 S and up to 3 N, and optionally        including 1 to 3 ring members selected from the group consisting        of C(═O), C(═S), S(O), or S(O)₂, each ring or ring system        optionally substituted with 1 to 5 substituents independently        selected from R⁵;    -   each R⁵ is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₆ alkoxy, C₁-C₆        haloalkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆        alkylsulfonyl, C₁-C₆ haloalkylthio, C₁-C₆ haloalkylsulfinyl,        C₁-C₆ haloalkylsulfonyl, C₂-C₆ alkoxyalkyl, C₂-C₆        haloalkoxyalkyl, C₁-C₆ hydroxyalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆        alkoxycarbonyl, C₂-C₆ alkylcarbonyloxy, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₃-C₆        trialkylsilyl or —Z²Q;    -   each Q is independently an optionally substituted phenyl,        benzyl, naphthalenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkenyl or 5-        or 6-membered heteroaromatic ring, each optionally substituted        with 1 to 3 substituents selected from R⁷ on carbon ring members        and R¹² on nitrogen ring members;    -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl; or    -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to        form an optionally substituted 5- to 7-membered ring containing        as ring members 2 to 7 carbon atoms and optionally 1 to 3        heteroatoms selected from up to 1 O, up to 1 S and up to 1 N;    -   each R¹² is independently C₁-C₃ alkyl;    -   each Z¹ and Z² are independently a direct bond, O, S(O)_(m),        CHR²⁰ or NR²¹; and    -   R²¹ is H or C₁-C₃ alkyl.

Embodiment A7

A compound of Embodiment A6 wherein

-   -   G is a 5-membered heteroaromatic ring or 5-membered saturated or        partially saturated heterocyclic ring, each ring optionally        substituted with up to 2 substituents selected from R³ on carbon        ring members and selected from R¹¹ on nitrogen ring members;    -   R¹ is a phenyl or 5- or 6-membered heteroaromatic ring        optionally substituted with 1 to 2 substituents independently        selected from R^(4a) on carbon ring members and R^(4b) on        nitrogen ring members;    -   each R³ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or        halogen;    -   each R^(4a) is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl;    -   each R^(4b) is independently C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆        alkynyl, C₃-C₆ cycloalkyl, C₁-C₆ haloalkyl, C₃-C₆ haloalkenyl,        C₃-C₆ haloalkynyl, C₃-C₆ halocycloalkyl or C₂-C₄ alkoxyalkyl;    -   each R¹¹ is independently C₁-C₃ alkyl; and    -   when R⁵ and R⁷ are taken together with the atoms linking R⁵ and        R⁷ to form an optionally substituted 5- to 7-membered ring, then        R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to        form a 5- to 7-membered ring containing as ring members 2 to 7        carbon atoms and optionally 1 to 3 heteroatoms selected from up        to 1 O, up to 1 S and up to 1 N, optionally substituted with up        to 2 substituents selected from R⁸; and each R⁸ is independently        C₁-C₃ alkyl.

Embodiment A8

A compound of Embodiment A7 wherein

-   -   G is one of G-1 through G-55 (as depicted in Exhibit 2) wherein        the bond projecting to the left is bonded to X, and bond        projecting to the right is bonded to Z¹;    -   J is one of J-1 through J-82 (as depicted in Exhibit 3) wherein        the bond shown projecting to the left is bonded to Z¹;    -   Q is one of Q-1 through Q-55 (as depicted in Exhibit 4);    -   R¹ is one of U-1 through U-50 (as depicted in Exhibit 1);    -   each R^(3a) is independently selected from H and R³;    -   R^(11a) is selected from H and R¹¹;    -   k is 0, 1 or 2;    -   p is 0, 1 or 2; and    -   x is an integer from 0 to 5;        provided that:    -   (a) when R⁴ is attached to a carbon ring member, said R⁴ is        selected from R^(4a);    -   (b) when R⁴ is attached to a nitrogen ring member (e.g., in U-4,        U-11 through U-15, U-24 through U-26, U-31 or U-35), said R⁴ is        selected from R^(4b);    -   (c) when G is G-6, G-16 or G-42, and each R^(3a) is other than        H, then R^(11a) is H;    -   (d) when G is G-25 or G-31, then at least one R^(3a) is H; and    -   (e) when G is one of G-31 through G-35, then Z¹ is a direct bond        or CHR²⁰.

Embodiment A9

A compound of Embodiment A8 wherein

-   -   G is selected from G-1, G-2, G-15, G-26, G-27, G-36, G-37 and        G-38;    -   J is selected from J-1, J-2, J-3, J-4, J-5, J-7, J-8, J-9, J-10,        J-11, J-12, J-14, J-15, J-16, J-20, J-24, J-25, J-26, J-29,        J-30, J-45 and J-69;    -   each Q is independently Q-1, Q-20, Q-32 to 34, Q-45 Q-46 or        Q-47;    -   W is O;    -   X is X¹, X² or X³;    -   each Z¹ and Z² is a direct bond;    -   R¹ is selected from U-1 through U-3, U-11, U-13, U-20, U-22,        U-23, U-36 through U-39 and U-50;    -   each R³ is independently methyl or halogen;    -   each R^(4a) is independently C₁-C₂ alkyl, C₁-C₂ haloalkyl,        halogen or C₁-C₂ alkoxy;    -   each R^(4b) is independently C₁-C₂ alkyl or C₁-C₂ haloalkyl;    -   one instance of R⁵ is Z²Q and other instances of R⁵ are        independently selected from H, C₁-C₄ alkyl, C₁-C₄ haloalkyl and        halogen;    -   each R⁷ is independently halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl,        hydroxy, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy;    -   k is 1 or 2; and    -   n is 0.

Embodiment A10

A compound of Embodiment A9 wherein

-   -   A is CH₂;    -   G is selected from G-1, G-2, G-15, G-26, and G-36; and G is        unsubstituted;    -   J is selected from J-11, J-25, J-26, J-29 and J-30;    -   Q is selected from Q-1 and Q-45;    -   X is X¹ or X²; and the ring comprising X is saturated;    -   R¹ is U-1 or U-50; and    -   each R^(4a) is independently C₁-C₂ alkyl, trifluoromethyl, Cl,        Br, I or methoxy.

Embodiment A11

A compound of Embodiment A10 wherein

-   -   J is selected from J-11 and J-29;    -   X is X¹; and    -   each R^(4a) is independently C₁-C₂ alkyl, trifluoromethyl or Cl.

Embodiment A12

A compound of Formula 1 wherein

-   -   R¹ is U-1 or U-50 (as depicted in Exhibit 1) wherein when R⁴ is        attached to a carbon ring member, said R⁴ is selected from        R^(4a);    -   each R^(4a) is independently C₁-C₂ alkyl, trifluoromethyl, Cl,        Br, I or methoxy;    -   A is CH₂;    -   W is O;    -   X is X¹ or X² and ring comprising X is saturated;    -   each R² is independently ethyl, methoxy, cyano or hydroxy;    -   G is selected from G-1, G-2, G-15, G-26 and G-36 (as depicted in        Exhibit 2) wherein the bond projecting to the left is bonded to        X, and the bond projecting to the right is bonded to Z¹;    -   each R^(3a) is independently selected from H and R³;    -   each R³ is independently methyl or halogen;    -   J is selected from J-11, J-25, J-26, J-29 and J-30 (as depicted        in Exhibit 3); wherein the bond shown projecting to the left is        bonded to Z¹;    -   each R⁵ is independently H, halogen, cyano, hydroxy, amino,        nitro, —CHO, —C(═O)OH, —C(═O)NH₂, —NR²⁵R²⁶, C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl.        C₂-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl,        C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₆-C₁₄        cycloalkylcycloalkyl, C₄-C₁₀ halocycloalkylalkyl, C₅-C₁₀        alkylcycloalkylalkyl, C₃-C₈ cycloalkenyl, C₃-C₈        halocycloalkenyl, C₂-C₆ alkoxyalkyl, C₄-C₁₀ cycloalkoxyalkyl,        C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆ alkylthioalkyl, C₂-C₆        alkylsulfinylalkyl, C₂-C₆ alkylsulfonylalkyl, C₂-C₆        alkylaminoalkyl, C₃-C₈ dialkylaminoalkyl, C₂-C₆        haloalkylaminoalkyl, C₄-C₁₀ cycloalkylaminoalkyl, C₂-C₆        alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₄-C₈        cycloalkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₄-C₈        cycloalkoxycarbonyl, C₅-C₁₀ cycloalkylalkoxycarbonyl, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₄-C₈        cycloalkylaminocarbonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈        cycloalkoxy, C₃-C₈ halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy,        C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆        haloalkynyloxy, C₁-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy,        C₂-C₆ haloalkylcarbonyloxy, C₄-C₈ cycloalkylcarbonyloxy. C₃-C₆        alkylcarbonylalkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈        cycloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl,        C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈        cycloalkylsulfonyl, C₃-C₁₀ trialkylsilyl, C₁-C₆        alkylsulfonylamino, C₁-C₆ haloalkylsulfonylamino or —Z²Q;    -   each Q is independently selected from Q-1, Q-45 and Q-63 (as        depicted in Exhibit 4);    -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio. C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl; or    -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to        form a 5- to 7-membered ring containing as ring members 2 to 7        carbon atoms and optionally 1 to 3 heteroatoms selected from up        to 1 O, up to 1 S, and up to 1 N and optionally including 1 ring        member selected from SiR¹⁷R¹⁸, the ring optionally substituted        on ring members other than the atoms linking R⁵ and R⁷ with up        to 4 substituents selected from R⁸;    -   each R⁸ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl;    -   each Z¹ and Z² is a direct bond;    -   each Z⁴ is independently C(═O) or S(O)₂;    -   n is 0, 1 or 2;    -   k is 0, 1 or 2;    -   p is 0, 1 or 2; and    -   x is an integer from 0 to 5.

Embodiments of the present invention also include:

Embodiment B1

A compound of Formula 1A wherein each R^(4a1) and R^(4a2) isindependently C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, cyclopropyl,C₁-C₃ haloalkyl, halocyclopropyl, halogen, cyano, nitro, C₁-C₂ alkoxy orC₁-C₂ haloalkoxy.

Embodiment B2

A compound of Embodiment B1 wherein each R^(4a1) and R^(4a2) isindependently C₁-C₃ alkyl, C₁-C₃ haloalkyl, halogen, cyano, C₁-C₂ alkoxyor C₁-C₂ haloalkoxy.

Embodiment B3

A compound of Embodiment B2 wherein each R^(4a)1 and R^(4a2) isindependently C₁-C₃ alkyl, C₁-C₃ haloalkyl or halogen.

Embodiment B4

A compound of Formula 1A wherein A^(a) is H.

Embodiment B5

A compound of Formula 1A wherein A^(a) is CH₂CO₂H.

Embodiment B6

A compound of Formula 1A wherein A^(a) is CH₂CO₂R³⁰.

Embodiment B7

A compound of Formula 1A wherein A^(a) is CH₂C(═O)Cl.

Embodiment B8

A compound of Formula 1B wherein each R^(4a1) and R^(4a2) isindependently C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, cyclopropyl,C₁-C₃ haloalkyl, halocyclopropyl, halogen, cyano, nitro, C₁-C₂ alkoxy orC₁-C₂ haloalkoxy.

Embodiment B9

A compound of Embodiment B8 wherein each R^(4a1) and R^(4a2) isindependently C₁-C₃ alkyl, C₁-C₃ haloalkyl, halogen, cyano, C₁-C₂ alkoxyor C₁-C₂ haloalkoxy.

Embodiment B10

A compound of Embodiment B9 wherein each R^(4a1) and R^(4a2) isindependently C₁-C₃ alkyl, C₁-C₃ haloalkyl or halogen.

Embodiment B11

A compound of Formula 1B wherein Z³ is CN.

Embodiment B12

A compound of Formula 1B wherein Z³ is C(═S)NH₂.

With regards to the compounds of Formula 1C of this invention, it isnoted that various embodiments of J-29 can be present in two or moreenantiomeric forms. The enantiomeric forms of J-29 embodiments forcompounds of Formula 1C of this invention are those depicted about inthe Exhibit A above. All J-29 enantiomers are included in the Formula 1Ccompounds in this invention for embodiments where no specific J-29enantiomeric form is depicted (e.g., J-29-33 enantiomers and J-29-22enantiomers based on the methyl group position).

Embodiment B13

A compound of Formula 1C wherein M is C₁-C₂ alkyl, C₁-C₂ haloalkyl,hydroxy, C₁-C₄ alkoxy, C₁-C₂ haloalkoxy, C₁-C₃ alkylamino, C₂-C₆dialkylamino, 1-piperidinyl, 1-pyrrolidinyl or 4-morpholinyl.

Specific embodiments include compounds of Formula 1 selected from thegroup consisting of:

-   4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine    and its enantiomer (Compound 1),-   1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-[4-(5-phenyl-3-isoxazolyl)-2-thiazolyl]piperidine    (Compound 2),-   1-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 15),-   2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(3aS,9bR),3a,4,5,9b-tetrahydronaphth[2,1-d]isoxazol-3-yl]-2-thiazolyl]-1-piperidinyl]ethanone    and its enantiomer (Compound 16),-   1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-ethyl-3-(trifluoromethyl)-1-pyrazol-1-yl]ethanone    and its enantiomer (Compound 19),-   2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]ethanone    and its enantiomer (Compound 22),-   1-[4-[4-[(5R)-3′,4′-dihydrospiro[isoxazole-5(4H),    1′,(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 37),-   1-[4-[4-[(5R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 44),-   2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazoly]-2-thiazolyl]-1-piperidinyl]ethanone    and its enantiomer (Compound 107),-   2-[(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl-5-isoxazolyl]-1H-isoindole-1,3(2H)-dione    and its enantiomer (Compound 129),-   2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1R)-2,3-dihydrospiro[1-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]ethanone    and its enantiomer (Compound 232),-   2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4H),    1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]ethanone and    its enantiomer (Compound 230),-   2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(3R)-spiro[benzofuran-3(2H),5′(4′H)-isoxazol]-3′-yl-2-thiazolyl]-1-piperidinyl]ethanone    and its enantiomer (Compound 185),-   1-[4-[4-[(1R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)ethanone    and its enantiomer (Compound 165),-   2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4H),    1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]ethanone and    its enantiomer (Compound 229),-   2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1R)-2,3-dihydrospiro[1H-indene-1,5′(4′1H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]ethanone    and its enantiomer (Compound 231),-   1-[4-[4-[(5R)-5-(2,6-dichlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 135),-   1-[4-[4-[(5R)-4,    5-dihydro-5-(2-fluorophenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 79),-   1-[4-[4-[(5R)-4,5-dihydro-5-(2-methylphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 161),-   1-[4-[4-[(5R)-5-(2,6-dimethylphenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 178),-   1-[4-[4-[(5R)-4,5-dihydro-5-(2,4,6-trimethylphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 179),-   1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4H),1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)ethanone    and its enantiomer (Compound 164),-   1-[4-[4-[(5R)-4,5-dihydro-5-(2,4,6-trimethoxyphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 155),-   3-[(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]-2(3H)-benzoxazolone    and its enantiomer (Compound 225),-   1-[4-[4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 214),-   2-[(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]benzonitrile    and its enantiomer (Compound 220),-   2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]ethanone    and its enantiomer (Compound 261),-   2-[3,5-bis(triflyoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]ethanone    and its enantiomer (Compound 260),-   1-[4-[4-[(5R)-5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 8),-   1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 128),-   1-[4-[4-[(4S)-2,3-dihydrospiro[4H-1-benzopyran-4,5′(4′H)-isoxazol]-3′-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone    and its enantiomer (Compound 137), and-   (5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-phenyl-5-isoxazolecarbonitrile    and its enantiomer (Compound 265).

Specific embodiments also include compounds of Formula 1B selected fromthe group consisting of:

-   1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide,-   1-[2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide,-   1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile,    and-   1-[2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile.

Of note are compounds of Formula 1, including all geometric andstereoisomers, N-oxides, and agriculturally suitable salts thereof,agricultural compositions containing them and their use as fungicideswherein

-   -   R¹ is an optionally substituted phenyl or 5- or 6-membered        heteroaromatic ring;    -   A is CH₂ or NH;    -   X is X¹, X², X³, X⁴, X⁵, X⁶, X⁷ or X⁸;    -   each R² is independently C₁-C₄ alkyl, C₁-C₄ alkenyl, C₁-C₄        haloalkyl, C₁-C₄ alkoxy, halogen, cyano or hydroxy; or    -   two R² are taken together as C₁-C₃ alkylene or C₂-C₃ alkenylene        to form a bridged bicyclic ring system; or    -   two R² attached to adjacent ring carbon atoms joined by a double        bond are taken together as —CH═CH—CH═CH— optionally substituted        with 1 to 3 substituents selected from C₁-C₄ alkyl, C₁-C₄        haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, halogen, hydroxy,        amino, cyano and nitro;    -   J is a 5- or 6-membered ring or a 8- to 11-membered bicyclic        ring system, each ring or ring system containing ring members        selected from carbon and optionally 1 to 3 heteroatoms selected        from up to 1 O, up to 1 S and up to 3 N, and optionally        including 1 to 3 ring members selected from the group consisting        of C(═O), C(═S), S(O), or S(O)₂, each ring or ring system        optionally substituted with 1 to 5 substituents independently        selected from R⁵;    -   each R⁵ is independently H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₆ alkoxy, C₁-C₆        haloalkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆        alkylsulfonyl, C₁-C₆ haloalkylthio, C₁-C₆ haloalkylsulfinyl,        C₁-C₆ haloalkylsulfonyl, C₁-C₆ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₆ alkoxyalkyl, C₂-C₆ haloalkoxyalkyl,        C₁-C₆ hydroxyalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ alkoxycarbonyl,        C₂-C₆ alkylcarbonyloxy, C₁-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₃-C₆        trialkylsilyl, or —Z²Q;    -   each Q is independently an optionally substituted phenyl,        benzyl, naphthalenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkenyl or 5-        or 6-membered heteroaromatic ring, each optionally substituted        with 1 to 3 substituents selected from R⁷ on carbon ring members        and R¹² on nitrogen ring members;    -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl; or    -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to        form an optionally substituted 5- to 7-membered ring containing        as ring members 2 to 7 carbon atoms and optionally 1 to 3        heteroatoms selected from up to 1 O, up to 1 S and up to 1 N;    -   R¹² is C₁-C₃ alkyl;    -   each Z¹ and Z² is independently a direct bond, O, S(O)_(m),        CHR²⁰ or NR²¹;    -   m is 0, 1 or 2 (which is understood to mean that each m is        independently 0, 1 or 2); and    -   R²¹ is H or C₁-C₃ alkyl (subject to proviso (b) and/or        proviso (c) as applicable).

Also of note are compounds of Formula 1, including all geometric andstereoisomers, N-oxides, and salts thereof, agricultural compositionscontaining them and their use as fungicides wherein

-   -   each R⁵ is independently H, halogen, cyano, hydroxy, amino,        nitro, —CHO, —C(═O)OH, —C(═O)NH₂, —NR²⁵R²⁶, C₁-C₆ alkyl, C₂-C₆        alkenyl, C₂-C₆ alkynyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl,        C₂-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈ halocycloalkyl,        C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₆-C₁₄        cycloalkylcycloalkyl, C₄-C₁₀ halocycloalkylalkyl, C₅-C₁₀        alkylcycloalkylalkyl, C₃-C₈ cycloalkenyl, C₃-C₈        halocycloalkenyl, C₂-C₆ alkoxyalkyl, C₄-C₁₀ cycloalkoxyalkyl,        C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆ alkylthioalkyl, C₂-C₆        alkylsulfinylalkyl, C₂-C₆ alkylsulfonylalkyl, C₂-C₆        alkylaminoalkyl, C₃-C₈ dialkylaminoalkyl, C₂-C₆        haloalkylaminoalkyl, C₄-C₁₀ cycloalkylaminoalkyl, C₂-C₆        alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₄-C₈        cycloalkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₄-C₈        cycloalkoxycarbonyl, C₅-C₁₀ cycloalkylalkoxycarbonyl, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₄-C₈        cycloalkylaminocarbonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈        cycloalkoxy, C₃-C₈ halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy,        C₂-C₆ alkenyloxy, C₂-C₆ haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆        haloalkynyloxy, C₂-C₆ alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy,        C₂-C₆ haloalkylcarbonyloxy, C₄-C₈ cycloalkylcarbonyloxy, C₃-C₆        alkylcarbonylalkoxy, C₁-C₆ alkylthio, C₁-C₆ haloalkylthio, C₃-C₈        cycloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ haloalkylsulfinyl,        C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈        cycloalkylsulfonyl, C₃-C₁₀ trialkylsilyl, C₁-C₆        alkylsulfonylamino, C₁-C₆ haloalkylsulfonylamino or —Z²Q;    -   each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆        alkynyl, C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀        alkylcycloalkyl, C₅-C₁₀ alkylcycloalkylalkyl, C₁-C₆ haloalkyl,        C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₆ halocycloalkyl,        halogen, hydroxy, amino, cyano, nitro, C₁-C₄ alkoxy, C₁-C₄        haloalkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄        alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄ haloalkylsulfinyl,        C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈ dialkylamino,        C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄ hydroxyalkyl,        C₂-C₄ alkylcarbonyl. C₂-C₆ alkoxycarbonyl, C₂-C₆        alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆        alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl or C₃-C₆        trialkylsilyl; or    -   R⁵ and R⁷ are taken together with the atoms linking R⁵ and R⁷ to        form an optionally substituted 5- to 7-membered ring containing        as ring members 2 to 7 carbon atoms and optionally 1 to 3        heteroatoms selected from up to 1 O, up to 1 S, up to 1 Si and        up to 1 N; and    -   R¹² is C₁-C₃ alkyl (subject to proviso (b) and/or proviso (c) as        applicable).

This invention provides a fungicidal composition comprising a compoundof Formula 1 (including all geometric and stereoisomers. N-oxides, andsalts thereof), and at least one other fungicide. Of note as embodimentsof such compositions are compositions comprising a compoundcorresponding to any of the compound embodiments described above.

This invention provides a fungicidal composition comprising afungicidally effective amount of a compound of Formula 1 (including allgeometric and stereoisomers, N-oxides, and agriculturally suitable saltsthereof), and at least one additional component selected from the groupconsisting of surfactants, solid diluents and liquid diluents. Of noteas embodiments of such compositions are compositions comprising acompound corresponding to any of the compound embodiments describedabove.

This invention provides a method for controlling plant diseases causedby fungal plant pathogens comprising applying to the plant or portionthereof, or to the plant seed, a fungicidally effective amount of acompound of Formula 1 (including all geometric and stereoisomers,N-oxides, and agriculturally suitable salts thereof). Of note asembodiment of such methods are methods comprising applying afungicidally effective amount of a compound corresponding to any of thecompound embodiments describe above. Of particular notes are embodimentswhere the compounds are applied as compositions of this invention.

The compounds of Formulae 1, 1A, 1B and 1C can be prepared by one ormore of the following methods and variations as described in Schemes1-20. The definitions of A, G, J, W, X, Q, Z¹, R¹, R², R¹⁵, R¹⁶ and n inthe compounds of Formulae 1-38 below are as defined above in the Summaryof the Invention unless otherwise noted. Formulae 1a-1e and Formulae 1Baand 1Bb are various subsets of Formula 1 and 1B respectively.

As shown in Scheme 1, compounds of Formula 1a (Formula 1 wherein A isCHR¹⁵) wherein W is O can be prepared by coupling of an acid chloride ofFormula 2 with an amine of Formula 3 in the presence of an acidscavenger. Typical acid scavengers include amine bases such astriethylamine, N,N-diisopropylethylamine and pyridine. Other scavengersinclude hydroxides such as sodium and potassium hydroxide and carbonatessuch as sodium carbonate and potassium carbonate. In certain instancesit is useful to use polymer-supported acid scavengers such aspolymer-bound N,N-diisopropylethylamine and polymer-bound4-(dimethylamino)pyridine. Acid salts of the Formula 3 amines can alsobe used in this reaction, provided that at least 2 equivalents of theacid scavenger is present. Typical acids used to form salts with aminesinclude hydrochloric acid, oxalic acid and trifluoroacetic acid. In asubsequent step, amides of Formula 1a wherein W is O can be converted tothioamides of Formula 1a wherein W is S using a variety of standardthiating reagents such as phosphorus pentasulfide or2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide(Lawesson's reagent).

An alternate procedure for the preparation of compounds of Formula 1awherein W is O is depicted in Scheme 2 and involves coupling of an acidof Formula 4 with an amine of Formula 3 (or its acid salt) in thepresence of a dehydrative coupling reagent such asdicyclohexylcarbodiimide (DCC),1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) orO-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate(HBTU). Polymer-supported reagents are again useful here, such aspolymer-bound cyclohexylcarbodiimide. These reactions are typically runat 0-40° C. in a solvent such as dichloromethane or acetonitrile in thepresence of a base such as triethylamine or N,N-diisopropylethylamine.The acids of Formula 4 are known or can be prepared by methods known toone skilled in the art. For example, R¹CH₂COOH where R¹ is aheteroaromatic ring linked through nitrogen can be prepared by reactingthe corresponding R¹H compound with a haloacetic acid or ester in thepresence of base; see, for example, U.S. Pat. No. 4,084,955. R¹CH₂COOHwherein R¹ is a phenyl or a heteroaromatic ring linked through carboncan be prepared from the corresponding R¹CH₂-halogen compounds bydisplacement of the halogen with cyanide followed by hydrolysis; see,for example, K. Adachi, Yuki Gosei Kagaku Kyokaishi 1969, 27, 875-876;from R¹C(═O)CH₃ by the Willgerodt-Kindler reaction; see, for example, H.R. Darabi et al., Tetrahedron Letters 1999, 40, 7549-7552 and M. M. Alamand S. R. Adapa, Synthetic Communications 2003, 33, 59-63 and referencescited therein; or from R¹Br or R¹I by palladium-catalyzed coupling withtert-butyl acetate or diethyl malonate followed by ester hydrolysis;see, for example, W. A. Moradi and S. L. Buchwald, J. Am. Chem. Soc.2001, 123, 7996-8002 and J. F. Hartwig et al., J. Am. Chem. Soc. 2002,124, 12557-12565.

As the synthetic literature includes many amide-forming methods, thesynthetic procedures of Schemes 1 and 2 are simply representativeexamples of an wide variety of methods useful for the preparation ofFormula 1 compounds. One skilled in the art also realizes that acidchlorides of Formula 2 can be prepared from acids of Formula 4 bynumerous well-known methods.

Certain compounds of Formula 1b (Formula 1 wherein A is CHR¹⁵ and W isO) wherein R¹ is a 5-membered nitrogen-containing heteroaromatic ringlinked through the nitrogen atom can be prepared by reaction of theparent heterocycle of Formula 5 and a haloacetamide of Formula 6 asshown in Scheme 3. The reaction is carried out in the presence of a basesuch as sodium hydride or potassium carbonate in a solvent such astetrahydrofuran, N,N-dimethylformamide or acetonitrile at 0 to 80° C.The haloacetamide of Formula 6 can be prepared by the reaction of anamine of Formula 3 with an α-halo carboxylic acid halide or an α-halocarboxylic acid or its anhydride, analogous to the amide-formingreactions described in Schemes 1 and 2, respectively.

wherein R¹ is a 5-membered nitrogen-containing heteroaromatic ringunsubstituted on N; and Y¹ is Cl, Br or I.

Compounds of Formulae 1c (Formula 1 wherein A is NH), wherein R¹ isphenyl, naphthalenyl or a 5- or 6-membered heteroaromatic ring, and W isO or S, can be prepared by reaction of an amine of Formula 3 with anisocyanate or isothiocyanate, respectively, of Formula 7 as depicted inScheme 4. This reaction is typically carried out at an ambienttemperature in an aprotic solvent such as dichloromethane oracetonitrile.

Compounds of Formulae 1c can also be prepared by the reaction of anamine of Formula 8 with a carbamoyl or thiocarbamoyl chloride orimidazole of Formula 9 as shown in Scheme 5. When Y is chlorine, thereaction is typically carried out in the presence of an acid scavenger.Typical acid scavengers include amine bases such as triethylamine,N,N-diisopropylethylamine and pyridine. Other scavengers includehydroxides such as sodium and potassium hydroxide and carbonates such assodium carbonate and potassium carbonate. The carbamoyl or thiocarbamoylchlorides of Formula 9 (wherein Y is Cl) can be prepared from amines ofFormula 3 by treatment with phosgene or thiophosgene, respectively, ortheir equivalents, while carbamoyl or thiocarbamoyl imidazoles ofFormula 9 (wherein Y is imidazol-1-yl) can be prepared from amines ofFormula 3 by treatment with 1,1′-carbonyldiimidazole or1,1′-thiocarbonyldiimidazole, respectively, according to general methodsknown to one skilled in the art.

wherein W is O or S; and Y is Cl or imidazol-1-yl.

Certain compounds of Formula 1d (i.e. Formula 1 in which the ringcontaining X is saturated) can be prepared from compounds of Formula 1ewhere the ring containing X is unsaturated by catalytic hydrogenation asshown in Scheme 6. Typical conditions involve exposing a compound ofFormula 1e to hydrogen gas at a pressure of 70 to 700 kPa, preferably270 to 350 kPa, in the presence of a metal catalyst such as palladiumsupported on an inert carrier such as activated carbon, in a weightratio of 5 to 20% of metal to carrier, suspended in a solvent such asethanol at an ambient temperature. This type of reduction is very wellknown; see, for example, Catalytic Hydrogenation, L. Cerveny, Ed.,Elsevier Science, Amsterdam, 1986. One skilled in the art will recognizethat other certain functionalities that may be present in compounds ofFormula 1e can also be reduced under catalytic hydrogenation conditions,thus requiring a suitable choice of catalyst and conditions.

wherein X is X¹, X², X⁵, X⁸ or X⁹.

Certain compounds of Formula 1 wherein X is X¹, X⁵, X⁷ or X⁹, and G islinked to the ring containing X via a nitrogen atom, can be prepared bydisplacement of an appropriate leaving group Y² on the ring containingthe X of Formula 10 with a nitrogen-containing heterocycle of Formula 11in the presence of a base as depicted in Scheme 7. Suitable basesinclude sodium hydride or potassium carbonate, and the reaction iscarried out in a solvent such as N,N-dimethylformamide or acetonitrileat 0 to 80° C. Suitable leaving groups in the compounds of Formula 10include bromide, iodide, mesylate (OS(O)₂CH₃), triflate (OS(O)₂CF₃) andthe like, and compounds of Formula 10 can be prepared from thecorresponding compounds wherein Y² is OH, using general methods known inthe art.

wherein W is O or S; X is X¹, X⁵, X⁷ or X⁹; and Y² is a leaving groupsuch as Br, I, OS(O)₂Me or OS(O)₂CF₃.

Compounds of Formula 1 wherein X is X² or X⁸ can be prepared by reactionof a compound of Formula 12 with a heterocyclic halide or triflate(OS(O)₂CF₃) of Formula 13 as shown in Scheme 8. The reaction is carriedout in the presence of a base such as potassium carbonate in a solventsuch as dimethylsulfoxide, N,N-dimethylformamide or acetonitrile at 0 to80° C. Compounds of Formula 13 wherein Y² is triflate can be preparedfrom corresponding compounds wherein Y² is OH by methods known to oneskilled in the art.

wherein W is O or S; X is X² or X⁸; and Y² is a leaving group such asBr, I OS(O)₂Me or OS(O)₂CF₃.

The amine compounds of Formula 3 can be prepared from the protectedamine compounds of Formula 14 where Y³ is an amine-protecting group asshown in Scheme 9. A wide array of amine-protecting groups are available(see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups inOrganic Synthesis, 2nd ed.; Wiley: New York, 1991), and the use andchoice of the appropriate protecting groups will be apparent to oneskilled in chemical synthesis. The protecting group can be removed andthe amine isolated as its acid salt or the free amine by general methodsknown in the art. One skilled in the art will also recognize that theprotected amines of Formula 14 can be prepared by methods analogous tothose described in Schemes 6, 7, and 8 above where the group R¹AC(═W) isreplaced by Y³ to give useful intermediates of Formula 14 for thepreparation of compounds of Formula 1.

The compounds of Formula 14 can also be prepared by reaction of asuitably functionalized compound of Formula 15 with a suitablyfunctionalized compound of Formula 16 as shown in Scheme 10. Thefunctional groups Y⁴ and Y⁵ are selected from, but not limited to,moieties such as aldehydes, ketones, esters, acids, amides, thioamides,nitriles, amines, alcohols, thiols, hydrazines, oximes, amidines,amideoximes, olefins, acetylenes, halides, alkyl halides,methanesulfonates, trifluoromethanesulfonates, boronic acids, boronates,and the like, which under the appropriate reaction conditions, willallow the construction of the various heterocyclic rings G. As anexample, reaction of a compound of Formula 15 where Y⁴ is a thioamidegroup with a compound of Formula 16 where Y⁵ is a bromoacetyl group willgive a compound of Formula 14 where G is a thiazole ring. The syntheticliterature describes many general methods for forming 5-memberedheteroaromatic rings and 5-membered partially saturated heterocyclicrings (e.g., G-1 through G-59); see, for example, ComprehensiveHeterocyclic Chemistry, Vol. 4-6, A. R. Katritzky and C. W. Reeseditors, Pergamon Press, New York, 1984; Comprehensive HeterocyclicChemistry II, Vol. 2-4, A. R. Katritzky, C. W. Rees, and E. F. Scriveneditors, Pergamon Press, New York, 1996; and the series, The Chemistryof Heterocyclic Compounds, E. C. Taylor, editor, Wiley, New York. Theuse of intermediates of Formula 15 where X is X¹ and Y⁴ is Br, I,methanesulfonate or trifluoromethanesulfonate to prepare organozincreagents for use in cross-coupling reactions with aromatic rings hasbeen described; see, for example, S. Bellotte, Synlett 1998, 379-380,and M. Nakamura et al., Synlett 2005, 1794-1798. One skilled in the artknows how to select the appropriate functional groups to construct thedesired heterocyclic rings such as G. Compounds of Formula 15 and 16 areknown or can be prepared by one skilled in the art.

wherein Y⁴ and Y⁵ are functional groups suitable for construction of thedesired heterocycle G.

Certain compounds of Formula 14 where Z¹ is O, S, or NR²¹ can beprepared by displacement of an appropriate leaving group Y² on G ofFormula 17 with a compound of Formula 18 in the presence of a base asdepicted in Scheme 11. Suitable bases include sodium hydride orpotassium carbonate, and the reaction is carried out in a solvent suchas N,N-dimethylformamide or acetonitrile at 0 to 80° C. Suitable leavinggroups in the compounds of Formula 17 include bromide, iodide, mesylate(OS(O)₂CH₃), triflate (OS(O)₂CF₃) and the like. Compounds of Formula 17can be prepared from corresponding compounds wherein Y² is OH by generalmethods known in the art. Many of the compounds of Formula 18 are knownor can be prepared by general methods known in the art.

wherein Y² is a leaving group such as Br, I, OS(O)₂Me or OS(O)₂CF₃; andZ¹ is O, S or NR²¹.

Certain compounds of Formula 14 where Z¹ is O, S, or NR²¹ can also beprepared by displacement of an appropriate leaving group Y² on J ofFormula 20 with a compound of Formula 19 in the presence of a base asdepicted in Scheme 12. Suitable bases include sodium hydride orpotassium carbonate, and the reaction is carried out in a solvent suchas N,N-dimethylformamide or acetonitrile at 0 to 80° C. Suitable leavinggroups in the compounds of Formula 20 include bromide, iodide, mesylate(OS(O)₂CH₃), triflate (OS(O)₂CF₃) and the like. Compounds of Formula 20can be prepared from corresponding compounds wherein Y² is OH usinggeneral methods known in the art.

wherein Y² is a leaving group such as Br, I, OS(O)₂Me or OS(O)₂CF₃; andZ¹ is O, S or NR²¹.

Compounds of Formula 14 can also be prepared by reaction of a suitablyfunctionalized compound of Formula 21 with a suitably functionalizedcompound of Formula 22 as shown in Scheme 13. The functional groups Y⁶and Y⁷ are selected from, but not limited to, moieties such asaldehydes, ketones, esters, acids, amides, thioamides, nitriles, amines,alcohols, thiols, hydrazines, oximes, amidines, amide oximes, olefins,acetylenes, halides, alkyl halides, methanesulfonates,trifluoromethanesulfonates, boronic acids, boronates, and the like,which, under the appropriate reaction conditions will allow theconstruction of the various heterocyclic rings J. As an example,reaction of a compound of Formula 21 where Y⁶ is a chloro oxime moietywith a compound of Formula 22 where Y⁷ is a vinyl or acetylene group inthe presence of base will give a compound of Formula 14 where J is anisoxazoline or isoxazole, respectively. The synthetic literatureincludes many general methods for the formation of carbocyclic andheterocyclic rings and ring systems (for example, J-1 through J-82);see, for example, Comprehensive Heterocyclic Chemistry, Vol. 4-6, A. R.Katritzky and C. W. Rees editors, Pergamon Press, New York, 1984;Comprehensive Heterocyclic Chemistry II, Vol. 2-4, A. R. Katritzky, C.W. Rees, and E. F. Scriven editors, Pergamon Press, New York, 1996; theseries, The Chemistry of Heterocyclic Compounds, E. C. Taylor, editor,Wiley, New York, and Rodd's Chemistry of Carbon Compounds, Vol. 2-4,Elsevier, New York. General procedures for cycloaddition of nitrileoxides with olefins are well documented in the chemical literature. Forrelevant references see Lee, Synthesis 1982, 6, 508-509 and Kanemasa etal., Tetrahedron 2000, 56, 1057-1064 as well as references cited within.One skilled in the art knows how to select the appropriate functionalgroups to construct the desired heterocyclic ring J. Compounds ofFormula 22 are known or can be prepared by general methods known in theart.

wherein Y⁶ and Y⁷ are functional groups suitable for construction of thedesired heterocycle J.

An alternate preparation for the compounds of Formula 14 where Z¹ is abond includes the well known Suzuki reaction involving Pd-catalyzedcross-coupling of an iodide or bromide of Formula 23 or 26 with aboronic acid of Formula 24 or 25, respectively, as shown in Scheme 14.Many catalysts are useful for this type of transformation; a typicalcatalyst is tetrakis(triphenylphosphine)palladium. Solvents such astetrahydrofuran, acetonitrile, diethyl ether and dioxane are suitable.The Suzuki reaction and related coupling procedures offer manyalternatives for creation of the G-J bond. For leading references seefor example C. A. Zificsak and D. J. Hlasta, Tetrahedron 2004, 60,8991-9016. For a thorough review of palladium chemistry applicable tothe synthesis of G-J bonds see J. J. Li and G. W. Gribble, editors,Palladium in Heterocyclic Chemistry: A Guide for the Synthetic Chemist,Elsevier: Oxford, UK, 2000. Many variations of catalyst type, base andreaction conditions are known in the art for this general method.

One skilled in the art will recognize that many compounds of Formula 1can be prepared directly by methods analogous to those described inSchemes 10 through 14 above where the group Y³ is replaced by R¹AC(═W).Thus, compounds corresponding to Formulae 15, 17, 19, 21, 23 and 25 inwhich Y³ is replaced by R¹AC(═W) are useful intermediates for thepreparation of compounds of Formula 1.

Thioamides of Formula 1Bb are particularly useful intermediates forpreparing compounds of Formula 1 wherein X is X¹. A thioamide of Formula1Bb can be prepared by the addition of hydrogen sulfide to thecorresponding nitrile of Formula 1Ba as shown in Scheme 15.

wherein R¹ as defined for Formula 1.

The method of Scheme 15 can be carried out by contacting a compound ofFormula 1Ba with hydrogen sulfide in the presence of an amine such aspyridine, diethylamine or diethanolamine. Alternatively, hydrogensulfide can be used in the form of its bisulfide salt with an alkalimetal or ammonia. This type of reaction is well documented in theliterature (e.g., A. Jackson et al., EP 696,581 (1996)).

Certain compounds of Formula 1Ba wherein R¹ is a 5-memberednitrogen-containing heteroaromatic ring linked through a nitrogen atomcan be prepared by reaction of the parent heterocycle of Formula 5 and ahaloacetamide of Formula 27 as shown in Scheme 16. The reaction iscarried out in the presence of a base such as sodium hydride orpotassium carbonate in a solvent such as tetrahydrofuran,N,N-dimethylformamide or acetonitrile at 0 to 80° C.

wherein R¹ is a 5-membered nitrogen-containing heteroaromatic ringunsubstituted on N (i.e. a 5-membered heteroaromatic ring comprising aring member of the formula —(NH)—); and Y¹ is Cl, Br or I.

The haloacetamides of Formula 27 can be prepared by the two methodsshown in Scheme 17.

wherein Y¹ is Cl, Br, or I; and R³¹ is a tertiary alkyl group such as—C(Me)₃.

In one method, 4-cyanopiperidine of Formula 29 is haloacetylated bycontact with the appropriate haloacetyl chloride typically in thepresence of a base according to standard methods. Preferred conditionsinvolve use of an aqueous solution of an inorganic base such as analkali metal or alkaline-earth carbonate, bicarbonate, or phosphate, anda non-water-miscible organic solvent such as toluene, ethyl acetate or1,2-dichloroethane. In the second method depicted in Scheme 17, a1-(haloacetyl)-N-substituted isonipecotamide derivative of Formula 28,wherein R³¹ is tertiary alkyl such as C(Me)₃, is dehydrated using astandard amide dehydrating agent such as thionyl chloride or phosphorusoxychloride in a suitable solvent. A particularly preferred solvent forthis transformation is an N,N-dialkylamide such asN,N-dimethylformamide. The reaction is typically carried out by adding0.9 to 2 equivalents, preferably 1.1 equivalents, of phosphorusoxychloride or thionyl chloride, to a mixture of a compound of Formula28 and 0.5 to 10 parts by weight of solvent, at a temperature at whichthe reaction rapidly proceeds during the addition. The addition time forthis reaction is typically around 20 to 90 minutes at typicaltemperatures of around 35 to 55° C.

As shown in Scheme 18, the compounds of Formula 28 can be prepared fromthe compound of Formula 30 by analogy with the haloacetylation reactiondescribed for Scheme 17.

The compounds of Formula 30 are known or can be prepared from4-cyanopyridine or isonicotinic acid using methods well-known in theart; see, for example, G. Marzolph, et al., DE 3,537,762 (1986) forpreparation of N-t-butyl pyridinecarboxamides from cyanopyridines andt-butanol and S. F. Nelsen, et al., J. Org. Chem., 1990, 55, 3825 forhydrogenation of N-methylisonicotinamide with a platinum catalyst.

Halomethyl isoxazole ketones of Formula 35 are particularly usefulintermediates for preparing certain chiral compounds of Formula 1wherein J is, for example, selected from J-29-1 through J-29-12 asdepicted in Exhibit A. Halomethyl isoxazole ketones of Formula 35 can beprepared by the multi-step reaction sequences shown in Scheme 19.

wherein R³² is C₂-C₈ dialkylamino, C₂-C₆ haloalkylamino, 1-piperidinyl,1-pyrrolidinyl or 4-morpholinyl; and R⁵ are as defined above in theSummary of the Invention.

The preparation of the racemic carboxylic acids of Formula 32 can beaccomplished according to the well-known methods of basic or acidichydrolysis of the corresponding compounds of Formula 31, preferablyusing a slight excess of sodium hydroxide in a water-miscible co-solventsuch as methanol or tetrahydrofuran at about 25 to 45° C. The productcan be isolated by adjusting pH to about 1 to 3 and then filtration orextraction, optionally after removal of the organic solvent byevaporation. The racemic carboxylic acids of Formula 32 can be resolvedby classical fractional crystallization of diastereomeric salts ofsuitable chiral amine bases such as cinchonine, dihydrocinchonine or amixture thereof. A cinchonine-dihydrocinchonine mixture in about a 85:15ratio is particularly useful, as it provides, for example, the(R)-configured carboxylic acids of Formula 33, wherein R⁵ is asubstituted phenyl group, as the less soluble salt. Furthermore, thesechiral amine bases are readily available on a commercial scale. The(R)-configured halomethyl ketone intermediates of Formula 35 afford themore fungicidally active final products of Formula 1 after coupling withthioamides of Formula 1Bb. The halomethyl ketones of Formula 35 can beprepared by first reacting the corresponding amides of Formula 31,either as pure enantiomers (i.e. Formula 31a) or in enantiomericallyenriched or racemic mixtures, with one molar equivalent of amethylmagnesium halide (Grignard reagent) in a suitable solvent orsolvent mixture such as tetrahydrofuran and toluene at about 0 to 20°C., and the crude ketone products of Formula 34 can be isolated byquenching with aqueous acid, extraction, and concentration. Then thecrude ketones of Formula 34 are halogenated with a reagent such assulfuryl chloride to afford the chloromethyl ketones of Formula 35wherein Y¹ is Cl or molecular bromine to afford the correspondingbromomethyl ketones of Formula 35 wherein Y¹ is Br. The halomethylketones of Formula 35 can be purified by crystallization from a solventsuch as hexanes or methanol, or can be used without further purificationin the condensation reaction with thioamides.

The isoxazole carboxamides of Formula 31 can be prepared bycycloaddition of the corresponding hydroxamoyl chlorides of Formula 36with olefin derivatives of Formula 37, as shown in Scheme 20.

In this method, all three reacting components (the compounds of Formulae36 and 37, and the base) are contacted so as to minimize hydrolysis ordimerization of the hydroxamoyl chloride of Formula 36. In one typicalprocedure, the base, which can either be a tertiary amine base such astriethylamine or an inorganic base such as an alkali metal oralkaline-earth carbonate, bicarbonate or phosphate, is mixed with theolefin derivative of Formula 37, and the hydroxamoyl chloride of Formula36 is added gradually at a temperature at which the cycloadditionproceeds at a relatively rapid rate, typically between 5 and 25° C.Alternatively, the base can be added gradually to the other twocomponents (the compounds of Formulae 36 and 37). This alternativeprocedure is preferable when the hydroxamoyl chloride of Formula 36 issubstantially insoluble in the reaction medium. The solvent in thereaction medium can be water or an inert organic solvent such astoluene, hexane or even the olefin derivative used in excess. Theproduct can be separated from the salt co-product by filtration orwashing with water, followed by evaporation of the solvent. The crudeproduct can be purified by crystallization, or the crude product can beused directly in the methods of Scheme 19. Compounds of Formula 31 areuseful precursors to the corresponding methyl ketones of Formula 34 andhalomethyl ketones of Formula 35, and are also useful for preparing theresolved enantiomers of the compounds of Formulae 34 and 35 byhydrolysis, resolution, methyl ketone synthesis and halogenation, asshown in Scheme 19.

It is recognized that some reagents and reaction conditions describedabove for preparing compounds of Formulae 1, 1A, 1B and 1C may not becompatible with certain functionalities present in the intermediates. Inthese instances, the incorporation of protection/deprotection sequencesor functional group interconversions into the synthesis will aid inobtaining the desired products. The use and choice of the protectinggroups will be apparent to one skilled in chemical synthesis (see, forexample, T. W. Greene and P. G. M. Wuts, Protective Groups in OrganicSynthesis, 2nd ed.; Wiley: New York, 1991). One skilled in the art willrecognize that, in some cases, after the introduction of a given reagentas it is depicted in any individual scheme, it may be necessary toperform additional routine synthetic steps not described in detail tocomplete the synthesis of compounds of Formulae 1, 1A, 1B and 1C. Oneskilled in the art will also recognize that it may be necessary toperform a combination of the steps illustrated in the above schemes inan order other than that implied by the particular sequence presented toprepare the compounds of Formulae 1, 1A, 1B and 1C.

One skilled in the art will also recognize that compounds of Formulae 1,1A, 1B and 1C and the intermediates described herein can be subjected tovarious electrophilic, nucleophilic, radical, organometallic, oxidation,and reduction reactions to add substituents or modify existingsubstituents.

Without further elaboration, it is believed that one skilled in the artusing the preceding description can utilize the present invention to itsfullest extent. The following Examples are, therefore, to be construedas merely illustrative, and not limiting of the disclosure in any waywhatsoever. Steps in the following Examples illustrate a procedure foreach step in an overall synthetic transformation, and the startingmaterial for each step may not have necessarily been prepared by aparticular preparative run whose procedure is described in otherExamples or Steps. Percentages are by weight except for chromatographicsolvent mixtures or where otherwise indicated. Parts and percentages forchromatographic solvent mixtures are by volume unless otherwiseindicated. ¹H NMR spectra are reported in ppm downfield fromtetramethylsilane; “s” means singlet, “d” means doublet, “t” meanstriplet, “m” means multiplet, “q” means quartet, “dd” means doublet ofdoublet, “br s” means broad singlet, “br d” means broad doublet. “br t”means broad triplet, “br m” means broad multiplet.

Example 1 Preparation of4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine(Compound 1) Step A: Preparation of 1,1-dimethylethyl4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinecarboxylate

To a suspension of 1,1-dimethylethyl4-(4-formyl-2-thiazolyl)-1-piperidinecarboxylate (1.0 g, 3.4 mmol) inethanol (5 mL) was added an aqueous solution of hydroxylamine (50 wt. %,0.25 mL, 4.0 mmol). The reaction mixture was heated at 60° C. for 1 h,during which time the reaction mixture became homogeneous. The resultingsolution was cooled to room temperature and diluted with tetrahydrofuran(10 mL). To the reaction mixture was added styrene (0.57 mL, 5 mmol),followed by portionwise addition of Clorox® aqueous sodium hypochloritesolution (10.5 mL) over 3 h. The reaction mixture was stirred overnightat room temperature, and the resulting solid was filtered, washed withwater and diethyl ether, and air dried to give the title compound as awhite powder (610 mg). The filtrate was diluted with saturated aqueoussodium bicarbonate solution and extracted with diethyl ether. Theextract was dried (MgSO₄) and concentrated under reduced pressure togive 850 mg of the title compound as a yellow oil. The oil was dilutedwith diethyl ether (4 mL) and allowed to stand to give additional 233 mgof the product as a white solid.

¹H NMR (CDCl₃) δ 1.47 (s, 9H), 1.7 (m, 2H), 2.1 (m, 2H), 2.85 (m, 2H),3.2 (m, 1H), 3.45 (m, 1H), 3.84 (m, 1H) 4.2 (br s, 2H), 5.75 (m, 1H),7.25-7.40 (m, 5H), 7.61 (s, 1H).

Step B: Preparation of4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine

To a solution of 1,1-dimethylethyl4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinecarboxylate(i.e. the product of Example 1, Step A) (0.815 g, 1.97 mmol) indichloromethane (50 mL) was added a solution of hydrogen chloride indiethyl ether (2 M, 10 mL, 20 mmol). The reaction mixture was stirred atroom temperature for 1 h to give a gummy precipitate. Methanol was addedto dissolve the precipitate, and the reaction mixture was stirred for anadditional 1 h. The reaction mixture was concentrated under reducedpressure and partitioned between ethyl acetate and saturated aqueoussodium bicarbonate solution, and the organic layer was dried (MgSO₄) andconcentrated to give the free amine as a clear oil (0.31 g), whichsolidified on standing. A mixture of the resulting free amine (0.31 g,1.0 mmol), 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (0.208g, 1.0 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimidehydrochloride (0.25 g, 1.3 mmol), triethylamine (150 μL, 1.08 mmol) anda catalytic amount of 1-hydroxybenzotriazole hydrate (˜1 mg) indichloromethane (5 mL) was swirled to form a vortex and held at roomtemperature for 16 h. The reaction mixture was diluted withdichloromethane (10 mL), and washed with 1 N aqueous hydrochloric acidand saturated aqueous sodium bicarbonate solution. The organic layer wasdried (MgSO₄) and concentrated under reduced pressure to give 0.47 g ofthe title product, a compound of present invention, as a white foam.

¹H NMR (CDCl₃) δ 1.8 (m, 2H), 2.2 (m, 2H), 2.32 (s, 3H), 2.9 (m, 1H),3.3 (m, 2H), 3.42 (m, 1H), 3.85 (m, 1H) 4.05 (m, 1H), 4.55 (m, 1H), 4.98(m, 2H), 5.75 (m, 1H), 6.33 (s, 1H), 7.25-7.42 (m, 5H), 7.63 (s, 1H).

The following compounds were prepared by procedures analogous to Step Bof Example 1:

1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 128); 1H NMR (CDCl₃) δ 1.7-1.9 (m, 2H), 2.16 (m, 1H), 2.24 (m,1H), 2.29 (s, 3H), 2.84-2.92 (br t, 1H), 3.30 (m, 2H), 3.43 (m, 1H),3.86 (m, 2H), 4.59 (br d, 1H), 5.04 (s, 2H), 5.75 (m, 1H), 6.47 (s, 1H),7.29-7.39 (m, 5H), 7.64 (s, 1H).

1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 19); m.p. 128-133° C. (crystallized from methylacetate/petroleum ether); 1H NMR (CDCl₃) δ 1.28 (t, 3H), 1.8 (m, 2H),2.2 (m, 2H), 2.62 (q, 2H), 2.9 (m, 1H), 3.3 (m, 2H), 3.42 (m, 1H), 3.85(m, 1H) 4.05 (m, 1H), 4.55 (m, 1H), 4.98 (m, 2H), 5.75 (m, 1H), 6.33 (s,1H), 7.25-7.42 (m, 5H), 7.63 (s, 1H).

2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]ethanone(Compound 22) m.p. 130-133° C. (crystallized from methylacetate/petroleum ether); 1H NMR (CDCl₃) δ 1.8 (m, 2H), 2.2 (m, 2H), 2.9(m, 1H), 3.3 (m, 2H), 3.42 (m, 1H), 3.85 (m, 2H), 4.55 (m, 1H), 5.10 (s,2H), 5.77 (m, 1H), 6.95 (s, 1H), 7.25-7.42 (m, 5H), 7.64 (s, 1H).

1-[4-[4-(2,3-dihydrospiro[4H-1-benzopyran-4,5′(4′H)-isoxazol]-3′-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 137); ¹H NMR (CDCl₃) δ 1.83 (m, 2H), 2.18 (m, 3H), 2.33 (s,3H), 2.42 (m, 1H), 2.90 (m, 1H), 3.31 (m, 2H), 3.47 (d, 1H), 3.83 (d,1H), 4.05 (m, 1H), 4.27 (m, 1H), 4.40 (m, 1H), 4.58 (d, 1H), 4.97 (m,2H), 6.33 (s, 1H), 6.87 (d, 1H), 6.95 (dd, 1H), 7.21 (dd, 1H), 7.38 (d,1H), 7.67 (s, 1H).

1-[4-[4-(2,3-dihydrospiro[4H-1-benzothiopyran-4,5′(4′H)-isoxazol]-3′-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 102); ¹H NMR (CDCl₃) δ 1.82 (m, 2H), 2.23 (m, 2H), 2.31 (s,3H), 2.37 (m, 1H), 2.50 (m, 1H), 2.90 (m, 1H), 3.14 (m, 1H), 3.17 (m,1H), 3.27 (m, 2H), 3.48 (d, 1H), 3.66 (d, 1H), 4.05 (m, 1H), 4.57 (d,1H), 4.97 (m, 2H), 6.33 (s, 1H), 7.06 (m, 3H), 7.45 (d, 1H), 7.65 (s,1H).

Example 2 Preparation of 1-[[5-methyl-3-(trifluoromethyl)-1t-pyrazol-1-yl]acetyl]-4-[4-(5-phenyl-3-isoxazolyl)-2-thiazolyl]piperidine(Compound 2) Step A: Preparation of2-(4-piperidinyl)-4-thiazolecarboxaldehyde monohydrochloride

To a solution of 1,1-dimethylethyl4-(4-formyl-2-thiazolyl)-1-piperidinecarboxylate (1.0 g, 3.4 mmol) indichloromethane (20 mL) was added a solution of hydrogen chloride indiethyl ether (2.0 mL, 15 ml, 30 mmol). The reaction mixture was stirredunder nitrogen at room temperature for 2 h and then evaporated underreduced pressure to give 1.2 g of the title compound as a white solid.

¹H NMR (CDCl₃) δ 2.31-2.38 (m, 2H), 2.44-2.50 (m, 2H), 3.11-3.20 (m,2H), 3.36-3.44 (m, 1H), 3.57-3.65 (m, 2H), 8.14 (s, 1H), 10.01 (s, 1H).

Step B: Preparation of4-(4-formyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine

To a solution of 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid(0.8 g, 3.8 mmol) in dichloromethane (10 mL) was added oxalyl chloride(2.4 g, 19.2 mmol) and two drops of N,N-dimethylformamide, resulting inslight exothermicity. The reaction mixture was then heated at reflux for15 minutes. The reaction mixture was concentrated in vacuo, and theresidue was suspended in tetrahydrofuran (10 mL) and treated with asolution of 2-(4-piperidinyl)-4-thiazolecarboxaldehyde monohydrochloride(i.e. the product of Example 2, Step A) (1.1 g, 5.1 mmol) intetrahydrofuran (10 mL), followed by dropwise addition of triethylamine(1.2 g, 11.9 mmol). The reaction mixture was stirred overnight at roomtemperature and then partitioned between 1 N aqueous hydrochloric acidand ethyl acetate. The organic layer was separated, and the aqueouslayer was extracted with additional ethyl acetate (2×30 mL). Thecombined organic layers were washed with 1 N aqueous hydrochloric acid,saturated aqueous sodium bicarbonate solution, and brine. The organiclayer was dried (MgSO₄) and evaporated under reduced pressure to give0.8 g of the title compound as a yellow oil.

¹H NMR (CDCl₃) δ 1.79-1.90 (m, 2H), 2.18-2.29 (m, 2H), 2.33 (s, 3H),2.87-2.94 (m, 1H), 3.28-3.40 (m, 2H), 4.05-4.15 (m, 1H), 4.56-4.64 (m,1H), 4.99-5.02 (m, 2H), 6.35 (s, 1H), 8.12 (s, 1H), 10.01 (s, 1H).

Step C: Preparation of4-[4-[(hydroxyimino)methyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine

To a solution of4-(4-formyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine(i.e. the product of Example 2, Step B) (0.8 g, 2.07 mmol) in ethylalcohol (15 mL) was added hydroxylamine (50% aqueous solution, 0.136 g,4.1 mmol), and the reaction mixture was stirred at room temperature for10 minutes. The reaction mixture was concentrated under reduced pressureto give a yellow oil, which was purified by flash column chromatographyon silica gel using 50% ethyl acetate in hexanes as eluant to give 0.7 gof the title compound as a white solid.

¹H NMR (CDCl₃) δ 1.72-1.85 (m, 2H), 2.17-2.27 (m, 2H), 2.32 (s, 3H),2.82-2.91 (m, 1H), 3.25-3.37 (m, 2H), 4.02-4.09 (m, 1H), 4.58-4.63 (m,1H), 4.95-5.03 (m, 2H), 6.35 (s, 1H), 7.43 (s, 1H), 7.71 (s, 1H), 8.19(s, 1H).

Step D: Preparation of1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-[4-(5-phenyl-3-isoxazolyl)-2-thiazolyl]piperidine

4-[4-[(Hydroxyimino)methyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine(i.e. the product of Example 2, Step C) (0.2 g, 0.5 mmol) was suspendedin tetrahydrofuran (20 mL), and phenylacetylene (1.1 mL, 1 mmol) wasadded, followed by a slow dropwise addition of Clorox® bleach solution(6.15 wt. % sodium hypochlorite, 10 mL) over 1 h. The reaction mixturewas partitioned between saturated aqueous sodium bicarbonate solutionand ethyl acetate. The organic layer was separated, and the aqueouslayer was extracted with ethyl acetate (3×30 mL). The combined organiclayers were washed with brine, dried (MgSO₄) and concentrated underreduced pressure to give an oil, which was purified by flash columnchromatography on silica gel using 10% methanol in ethyl acetate aseluant to give 70 mg of the title product, a compound of presentinvention, as a clear yellow oil.

¹H NMR (CDCl₃) δ 1.80-1.92 (m, 2H), 2.22-2.32 (m, 2H), 2.34 (s, 3H),2.90-2.98 (m, 1H), 3.31-3.41 (m, 2H), 4.05-4.11 (m, 1H), 4.58-4.65 (m,1H), 4.97-5.07 (m, 2H), 6.36 (s, 1H), 6.98 (s, 1H), 7.47-7.53 (m, 3H),7.84 (s, 2H), 7.88 (m, 1H).

Example 3 Preparation of4-[4-(4,5-dihydro-1-methyl-5-phenyl-1H-imidazol-2-yl)-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine(Compound 7)

To a solution of4-(4-formyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine(i.e. the product of Example 2, Step B) (0.8 g, 2.07 mmol) intert-butanol (5 mL) was added N¹-methyl-1-phenyl-1,2-ethanediamine(43.57 mg, 0.29 mmol). The reaction mixture was stirred at roomtemperature under a nitrogen atmosphere for 30 minutes, and thenpotassium carbonate (107.8 mg, 0.78 mmol) and iodine (43.57 mg, 0.33mmol) were added. The reaction mixture was stirred at 70° C. for 3 h andthen quenched by addition of saturated aqueous sodium sulfite solutionuntil the iodine color almost disappeared. The reaction mixture wasextracted with chloroform, and the organic layer was washed withsaturated aqueous sodium bicarbonate solution and brine, dried (Na₂SO₄),filtered and concentrated. The residue was purified by preparativethin-layer chromatography on silica gel using a mixture of 94% ethylacetate, 5% methanol and 1% triethylamine as eluant to give 64 mg of thetitle product, a compound of the present invention, as an oil.

¹H NMR (CDCl₃) δ 1.72-1.87 (m, 2H), 2.15-2.28 (m, 2H), 2.31 (s, 3H),2.86-2.92 (m, 1H), 2.97 (s, 3H), 3.26-3.37 (m, 2H), 3.62-4.39 (m, 2H),4.0-4.6 (m, 2H), 4.93-5.05 (m, 2H), 6.31 (s, 1H), 7.30-7.41 (m, 5H),7.88 (s, 1H).

Example 4 Preparation of4-[4-(4,5-dihydro-3-phenyl-5-isoxazolyl)-2-thiazolyl]-1-[(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl]piperidine(Compound 6) Step A: Preparation of 1,1-dimethylethyl4-(4-ethenyl-2-thiazolyl)-1-piperidinecarboxylate

To a cold (−50° C.) suspension of methyltriphenylphosphonium bromide(1.2 g, 3.3 mmol) in tetrahydrofuran (5 mL) was added a solution ofsodium bis(trimethylsilyl)-amide (3.4 mL, 3.4 mmol), and the resultingmixture was stirred for 1 h at room temperature. The resulting cloudyyellow solution was re-cooled to −30° C., and 1,1-dimethylethyl4-(4-formyl-2-thiazolyl)-1-piperidinecarboxylate (0.5 g, 1.68 mmol) wasadded. The resulting slightly yellow solution was stirred at roomtemperature for 3 h, then diluted with water, and extracted with ethylacetate. The organic layer was washed with brine, dried (MgSO₄),filtered, and purified by column chromatography on silica gel using15-30% ethyl acetate in hexanes as eluant to give 471 mg of the titlecompound as a colorless oil.

¹H NMR (CDCl₃) δ 1.47 (s, 9H), 1.68 (m, 2H), 2.10 (m, 2H), 2.88 (m, 2H),3.15 (m, 1H), 4.18 (m, 2H), 5.34 (d, 1H), 6.02 (d, 1H), 6.68 (dd, 1H),6.99 (s, 1H).

Step B: Preparation of 4-(4-ethenyl-2-thiazolyl)piperidine

To a solution of 1,1-dimethylethyl4-(4-ethenyl-2-thiazolyl)-1-piperidinecarboxylate (i.e. the product ofExample 4, Step A) (471 mg, 1.6 mmol) in dichloromethane (5 mL) wasadded a solution of hydrogen chloride in diethyl ether (2.0 M, 7 mL, 14mmol). The reaction mixture was stirred under nitrogen at roomtemperature for 4 h, and then 1 N aqueous sodium hydroxide solution wasadded until pH of the reaction mixture increased to about 10. Theresulting mixture was extracted with dichloromethane (2×). The organiclayers were combined, washed with brine, dried (MgSO₄), filtered andconcentrated in vacuo to give 302 mg of the title compound as an oil.

¹H NMR (CDCl₃) δ 1.70 (m, 2H), 1.82 (br s, 1H), 2.12 (br d, 2H), 2.76(br t, 2H), 3.11 (m, 1H), 3.18 (m, 2H), 5.32 (d, 1H), 6.02 (d, 1H), 6.70(dd, 1H), 6.99 (s, 1H).

Step C: Preparation of4-(4-ethenyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine

To a solution of 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid(0.5 g, 2.4 mmol) in dichloromethane (4 mL) was added oxalyl chloride(0.3 mL, 3.6 mmol) and one drop of N,N-dimethylformamide, resulting inslight exothermicity. The reaction mixture was then heated at reflux for15 minutes. The reaction mixture was evaporated, and the resultingresidue was suspended in dichloromethane (4 mL) and treated with asolution of 4-(4-ethenyl-2-thiazolyl)piperidine (i.e. the product ofExample 4. Step B) (302 mg, 1.5 mmol) in dichloromethane (2 mL),followed by addition of triethylamine (0.32 mL, 2.3 mmol). The reactionmixture was stirred overnight at room temperature, then concentrated,and purified by column chromatography on silica gel using 30-40% ethylacetate in hexanes as eluant to give 414 mg of the title compound as awhite solid.

¹H NMR (CDCl₃) δ 1.78 (m, 2H), 2.18 (m, 2H), 2.32 (s, 3H), 2.90 (br t,1H), 3.30 (m, 2H), 4.03 (d, 1H), 4.55 (d, 1H), 5.00 (m, 2H), 5.35 (d,1H), 6.02 (d, 1H), 6.33 (s, 1H), 6.68 (dd, 1H), 7.01 (s, 1H).

Step D: Preparation of4-[4-(4,5-dihydro-3-phenyl-5-isoxazolyl)-2-thiazolyl]-1-[(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl]piperidine

To a solution of benzaldehyde oxime (49 mg, 0.4 mmol) inN,N-dimethylformamide (3 mL) was added N-chlorosuccinimide (54 mg, 0.4mmol), followed by addition of4-(4-ethenyl-2-thiazolyl)-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine(i.e. the product of Example 4, Step C) (103 mg, 0.27 mmol) andtriethylamine (41 mg, 0.4 mmol). The resulting mixture was stirred atroom temperature for 5 h, then diluted with water, extracted withdichloromethane (2×). The organic layers were combined and dried(MgSO₄), and filtered. The filtrate was concentrated, and the residuewas purified by column chromatography on silica gel using 55-70% ethylacetate in hexanes as eluant to give 90 mg of the title product, acompound of the present invention as a white solid.

¹H NMR (CDCl₃) δ 1.76 (m, 2H), 2.17 (m, 2H), 2.31 (s, 3H), 2.88 (br t,1H), 3.25 (m, 2H), 3.65 (m, 1H), 3.78 (m, 1H), 4.02 (br d, 1H), 4.56 (brd, 1H), 4.99 (m, 2H), 5.84 (dd, 1H), 6.32 (s, 1H), 7.28 (s, 1H),7.40-7.42 (m, 3H), 7.69-7.71 (m, 2H).

Example 5 Preparation of1-[4-[4-[5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 8)

To a solution of 1-chloro-2-ethenylbenzene (0.035 g, 0.25 mmol),triethylamine (2.5 mg, 0.025 mmol) and Clorox® aqueous sodiumhypochlorite solution (1 mL, 16.1 mmol) in dichloromethane (5 mL) wasadded4-[4-[(hydroxyimino)methyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine(i.e. the product of Example 2, Step C) (0.10 g, 0.25 mmol) indichloromethane (5 mL) dropwise over 1 h at 0° C. The reaction mixturewas allowed to stir for 1h, then filtered through Celite® diatomaceousfilter aid, and concentrated under reduced pressure to give an oil,which was purified by column chromatography on silica gel using 50%ethyl acetate in hexane as eluant to give 73 mg of the title compound asa white foam, melting at 115-122° C. (crystallized from methylacetate/petroleum ether).

¹H NMR (CDCl₃) δ 1.74-1.80 (m, 2H), 2.14-2.22 (m, 2H), 2.32 (s, 3H),2.85-2.91 (m, 1H), 3.26-3.30 (m, 2H), 3.31-3.32 (m, 1H), 4.05-4.07 (m,1H), 4.55-4.58 (m, 1H), 4.93-5.03 (q, 2H), 6.01-6.06 (m, 1H), 6.331 (s,1H), 7.25-7.29 (m, 2H), 7.38-7.40 (m, 1H), 7.56-7.58 (m, 1H), 7.62 (s,1H).

Example 6 Preparation of1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanethione(Compound 130)

A solution of4-[4-[4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidine(i.e. the product of Example 1, Step B) (235 mg, 0.47 mmol) andphosphorus pentasulfide (104.5 mg, 0.235 mmol) in pyridine (5 ml) washeated under reflux for 2 h. The reaction mixture was then concentratedunder reduced pressure, and the residue was distributed betweendichloromethane (10 mL) and water (10 mL). The organic layer was washedwith 1 N hydrochloric acid, water, saturated aqueous sodium bicarbonatesolution and brine, dried (MgSO₄), and concentrated under reducedpressure to give 240 mg of the title product, a compound of the presentinvention, as a white foam.

¹H NMR (CDCl₃) δ 1.80-2.00 (m, 2H), 2.20-2.28 (m, 2H), 2.45 (s, 3H),3.35-3.46 (3H, m), 3.50-3.61 (m, 1H), 3.80-3.88 (m, 1H), 4.70-4.80 (m,1H), 5.30-5.33 (m, 2H), 5.35-5.40 (m, 1H), 5.74-5.80 (nm, 1H), 6.32 (s,1H), 7.30-7.40 (m, 5H), 7.65 (s, 1H).

Example 7 Preparation of1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperazinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 154) Step A: Preparation of 1,1-dimethylethyl4-(aminothioxomethyl)-1-piperazinecarboxylate

To a solution of thiocarbonyldiimidazole (2.1 g, 11.8 mmol) intetrahydrofuran (30 mL) at room temperature, was added 1,1-dimethylethyl1-piperazinecarboxylate (2 g, 10.75 mmol). The reaction mixture wasstirred at room temperature for 2 h and then heated to 55° C. foradditional 2 h. The reaction mixture was cooled to room temperature, andconcentrated under reduced pressure until approximately 20 mL oftetrahydrofuran remained. The residue was then treated with a 2 Msolution of ammonia in methanol (10 mL) and stirred at room temperaturefor 24 h. The reaction mixture was concentrated under reduced pressure,and the residue was triturated with diethyl ether (25 mL) to give awhite precipitate. The precipitate was filtered and dried to give 1.5 gof the title compound as a white solid.

¹H NMR (CDCl₃) δ 1.39 (s, 9H), 3.32 (m, 4H), 3.73 (m, 4H), 7.49 (br s,2H).

Step B: Preparation of 3-chloro-N-hydroxy-2-oxo-propanimidoyl chloride

To a solution of 1,3-dichloroacetone (100 g, 0.79 mol) in 2 M solutionof hydrogen chloride in diethyl ether (400 mL) at 15° C. was addedt-butyl nitrite (55 g, 0.534 mol) over 10 minutes. The reaction progresswas monitored by 1H NMR to obtain ˜85% conversion with no more than 3%of the bis-nitrosation side product. The reaction mixture wasconcentrated under reduced pressure to leave a semi-solid, which wasthen thoroughly rinsed with n-BuCl. The resulting solid was collectedunder filtration to give a 77 g of the title compound as a white solid.The filtrate was further concentrated under reduced pressure to give asemi-solid residue, which was rinsed with additional n-BuCl. Theresulting solid was collected under filtration to give additional 15 gof the title compound as a white solid.

¹H NMR (DMSO-d₆) δ 4.96 (s, 2H), 13.76 (s, 1H).

Step C: Preparation of2-chloro-1-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone

To a mixture of styrene (6.79 g, 65.3 mmol) and sodium bicarbonate (32.1g, powder) in acetonitrile (100 mL),3-chloro-N-hydroxy-2-oxo-propanimidoyl chloride (i.e. the product ofExample 7, Step B) (10 g, 64.1 mmol) was added in 10 portions over 20minutes. The reaction mixture was then stirred for additional 1 h andfiltered. The filtered solid was rinsed with acetonitrile, and thecombined filtrates were concentrated under reduced pressure to leave anoil, which was triturated first with hexanes and then with1-chlorobutane to give 13.6 g of the title compound as a white solid.

¹H NMR (CDCl₃) δ 3.13 (m, 1H), 3.66 (m, 1H), 4.96 (s, 2H), 5.83 (m, 1H),7.34-7.44 (m, 5H).

Step D: Preparation of 1,1-dimethylethyl4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperazineacetate

To a solution of 2-chloro-1-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone(i.e. the product of Example 7, Step C) (0.450 g, 2.018 mmol) and1,1-dimethylethyl 4-(aminothioxomethyl)-1-piperazinecarboxylate (i.e.the product of Example 7, Step A) (0.5 g, 2.04 mmol) in ethanol (10 mL)was added triethylamine (0.204 g, 2.013 mmol), and the reaction mixturewas stirred at room temperature for 12 h. The reaction mixture wasconcentrated under reduced pressure, and the residue was partitionedbetween ethyl acetate (30 mL) and water (30 mL). The organic layer wasseparated and washed with brine (25 mL), dried (Na₂SO₄), andconcentrated under reduced pressure. The crude residue was purified bycolumn chromatography using 20% ethyl acetate in petroleum ether aseluant to give 700 mg of the title compound as a white solid.

¹H NMR (CDCl₃) δ 1.48 (s, 9H), 3.30 (m, 1H), 3.54 (m, 8H), 3.74 (m, 1H),5.71 (m, 1H), 6.91 (s, 1H), 7.40-7.29 (m, 5H).

Step E: Preparation of1-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-piperazinehydrochloride

To a solution of 1,1-dimethylethyl4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperazineacetate(i.e. the product of Example 7, Step D) (0.7 g, 1.686 mmol) in diethylether (10 mL) was added a 2 M solution of hydrogen chloride in methanol(10 mL) at room temperature. The reaction mixture was stirred at roomtemperature for 8 h. The resulting white precipitate was filtered, anddried to give 500 mg of the title compound as a white solid.

¹H NMR (CDCl₃) δ 3.21 (m, 4H), 3.27 (m, 1H), 3.68 (m, 4H), 3.79 (m, 1H),5.68 (m, 1H), 7.41-7.29 (m, 6H), 9.49 (br s, 2H).

Step F: Preparation of1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperazinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone

To a solution of1-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]piperazinehydrochloride (i.e. the product of Example 7, Step E) (200 mg, 0.57mmol) and 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (0.120g, 0.57 mmol) in dichloromethane (10 mL) at room temperature was added1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.110 g,0.57 mmol), triethylamine (0.086 g, 0.85 mmol) and1-hydroxybenzotriazole hydrate (0.020 g, 0.14 mmol). The reactionmixture was stirred at room temperature for 24 h. The reaction mixturewas diluted with dichloromethane (30 mL), and washed with water (20 mL)and brine (20 mL). The organic layer was dried (Na₂SO₄) and concentratedunder reduced pressure. The crude residue was purified by columnchromatography using 3% methanol in chloroform as eluant to give 180 mgof the title product, a compound of the present invention as a whitesolid.

¹H NMR (CDCl₃) δ 2.32 (s, 3H), 3.29 (m, 1H), 3.52 (m, 2H), 3.61 (m, 2H),3.79-3.72 (m, 5H), 4.98 (m, 2H), 5.69 (m, 1H), 6.33 (s, 1H), 6.93 (s,1H), 7.38-7.28 (m, 5H).

Mass spectrum at 505.5 (M+1).

Example 8 Preparation of 1-[4-[4-(3′,4′-dihydrospiro[isoxazole-5(4H),1′,(2′H)-naphthalen]-3-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 37) Step A: Preparation of1-(2-chloroacetyl)-4-piperidinecarbonitrile

A mixture of 4-piperidinecarbonitrile (200 g, 1.80 mol) and 40% aqueouspotassium carbonate solution (342 g, 0.99 mol) in dichloromethane (1 L)was cooled to −10° C., and a solution of chloroacetyl chloride (210 g,1.86 mol) in dichloromethane (300 mL) was added over about 75 minuteswhile maintaining the reaction mixture at −10 to 0° C. After theaddition was complete, the reaction mixture was separated, the upperaqueous phase was extracted with dichloromethane (2×300 mL), and thecombined organic phases were concentrated under reduced pressure to give312 g of the title compound as a liquid which slowly crystallized onstanding. This compound was of sufficient purity to use in subsequentreactions.

¹H NMR (CDCl₃) δ 1.8-2.1 (m, 4H), 2.95 (m, 1H), 3.5-3.8 (m, 4H), 4.08(q, 2H).

Step A1: Alternative preparation of1-(2-chloroacetyl)-4-piperidinecarbonitrile

A solution of N-(1,1-dimethylethyl)-4-piperidinecarboxamide (201 g, 1.0mol) in dichloromethane (1 L) was cooled under nitrogen to −5° C., andchloroacetyl chloride (124 g, 1.1 mol) in 300 mL of dichloromethane wasadded dropwise over 30 minutes while maintaining the reaction mixture at0 to 5° C. Then 20% aqueous potassium carbonate solution (450 g, 0.65mol) was added dropwise over 30 minutes while keeping reactiontemperature between 0 and 5° C. The reaction mixture was stirred for anadditional 30 minutes at 0° C., and then allowed to warm to roomtemperature. The layers were separated, and the aqueous layer wasextracted with dichloromethane (200 mL). The combined dichloromethanelayers were concentrated under reduced pressure to yield a solid, whichwas triturated with 400 mL of hexanes. The slurry was filtered, and thefilter cake was washed with 100 mL of hexanes and dried in a vacuum ovenovernight at 50° C. to give 185.5 g of1-(2-chloroacetyl)-N-(1,1-dimethylethyl)-4-piperidinecarboxamide as asolid, melting at 140.5-141.5° C.

¹H NMR (CDCl₃) δ 1.35 (s, 9H), 1.6-2.0 (m, 4H), 2.25 (m, 1H), 2.8 (t,1H), 3.2 (t, 1H), 3.9 (d, 1H), 4.07 (s, 2H), 4.5 (d, 1H), 5.3 (br s,1H).

To a solution of1-(2-chloroacetyl)-N-(1,1-dimethylethyl)-4-piperidinecarboxamide (26.1g, 0.10 mol) in N,N-dimethylformamide (35 mL) was added phosphorusoxychloride (18.8 g, 0.123 mol) dropwise over 30 minutes while allowingthe temperature of the reaction mixture to rise to 37° C. The reactionmixture was heated at 55° C. for 1 h and then was slowly added to water(about 150 g) cooled with ice to maintain a temperature of about 10° C.The pH of the reaction mixture was adjusted to 5.5 with 50% NaOH aqueoussolution. The mixture was extracted with dichloromethane (4×100 mL), andthe combined extract was concentrated under reduced pressure to give18.1 g of the title compound as a solid. This compound was of sufficientpurity to use in subsequent reactions.

Step B: Preparation of1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile

A solution of 3-methyl-5-trifluoromethylpyrazole (9.3 g, 62 mmol) and45% aqueous potassium hydroxide solution (7.79 g, 62 mmol) inN,N-dimethylformamide (25 mL) was cooled to 5° C., and1-(2-chloroacetyl)-4-piperidinecarbonitrile (i.e. the product of Example8, Step A or A1) (11.2 g, 60 mmol) was added. The reaction mixture wasstirred for 8 h at 5-10° C., then diluted with water (100 mL), andfiltered. The filter cake was washed with water and dried at 50° C. in avacuum-oven to give 15 g of the title compound as a solid containing 3%of its regioisomer, i.e.1-[2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile.

¹H NMR (CDCl₃) δ 1.88 (m, 4H), 2.32 (s, 3H), 2.95 (m, 1H), 3.7 (m, 4H),5.0 (q, 2H), 6.34 (s, 1H).

Step C: Preparation of1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide

Hydrogen sulfide gas was passed into a solution of1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbonitrile(i.e. the product of Example 8, Step B) (9.0 g, 30 mmol) anddiethanolamine (3.15 g, 30 mmol) in N,N-dimethylformamide (15 mL) at 50°C. in a flask equipped with dry-ice condenser. The hydrogen sulfide feedwas stopped when the reaction mixture became saturated with hydrogensulfide, as indicated by condensation on the cold-finger. The reactionmixture was stirred for an additional 30 minutes at 50° C. Then excesshydrogen sulfide gas was sparged into the scrubber by a subsurfacenitrogen flow, and water (70 mL) was gradually added. The reactionmixture was cooled to 5° C., filtered, and washed with water (2×30 mL).The filter cake was dried at 50° C. in a vacuum-oven to give 8.0 g ofthe title compound as a solid, melting at 185-186° C.

¹H NMR (CDCl₃) δ 1.7 (m, 2H), 2.0 (m, 2H), 2.29 (m, 3H), 2.65 (t, 1H),3.0 (m, 3H), 3.2 (t, 1H), 4.0 (d, 1H), 4.6 (d, 1H), 4.96 (d, 1H), 5.4(d, 1H), 6.35 (s, 1H), 7.4 (br s, 1H), 7.5 (br s, 1H).

Step D: Preparation of 1-[4-[4-(3′,4′-dihydrospiro[isoxazole-5(4H),1′,(2′H)-naphthalen]-3-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone

A solution of1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide(i.e. the product of Example 8, Step C) (0.5 g, 1.5 mmol),2-chloro-1-(3′,4′-dihydrospiro[isoxazole-5(4H),1′,(2′H)-naphthalen]-3-yl)ethanone (prepared by a method analogous toExample 7, Step C) (0.4 g, 1.5 mmol) and tetrabutylammonium bromide(0.030 g, 0.10 mmol) in tetrahydrofuran (15 mL) was stirred overnight atroom temperature, and then heated at 55-60° C. for 3 h. The reactionmixture was diluted with water and extracted with dichloromethane. Theextract was washed with brine, dried (MgSO₄), and concentrated underreduced pressure. The crude product was further purified bymedium-pressure liquid chromatography using 50% ethyl acetate in hexanesas eluant to give 260 mg of the title product, a compound of the presentinvention, as an off-white solid, melting at 81-84° C.

¹H NMR (CDCl₃) δ 1.76-1.86 (m, 3H), 2.04-2.08 (m, 2H), 2.16-2.26 (m,2H), 2.32 (s, 3H), 2.83-2.87 (m, 2H), 2.88-2.93 (m, 1H), 3.27-3.35 (m,2H), 3.48-3.65 (m, 2H), 4.02-4.06 (m, 1H), 4.55-4.59 (m, 1H), 4.94-5.04(q, 2H), 6.33 (s, 1H), 7.10-7.12 (m, 1H), 7.19-7.21 (m, 2H), 7.40-7.43(m, 1H), 7.62 (s, 1H).

The following compounds were prepared by procedures analogous to Step Dof Example 8:

1-[4-[4-(4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 15); m.p. 97-100° C. (crystallized from methylacetate/petroleum ether); ¹H NMR (CDCl₃) δ 1.74-1.80 (m, 1H), 1.81 (s,3H), 2.14-2.20 (m, 2H), 2.32 (s, 3H), 2.85-2.91 (m, 1H), 3.26-3.32 (m,2H), 3.52-3.62 (m, 2H), 4.01-4.05 (m, 1H), 4.54-4.58 (m, 1H), 4.94-5.04(q, 2H), 6.33 (s, 1H), 7.26-7.29 (m, 1H), 7.35-7.38 (m, 2H), 7.48-7.50(m, 2H), 7.58 (s, 1H).

2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(3a,4,5,9b-tetrahydronaphth[2,1-d]isoxazol-3-yl)-2-thiazolyl]-1-piperidinyl]ethanone(Compound 16); m.p. 162-165° C. (crystallized from methylacetate/petroleum ether); ¹H NMR (CDCl₃) δ 1.79-1.85 (m, 2H), 2.00-2.05(m, 2H), 2.20-2.26 (m, 2H), 2.33 (s, 3H), 2.68-2.72 (m, 2H), 2.88-2.94(m, 1H), 3.30-3.35 (m, 2H), 3.92-3.98 (m, 1H), 4.06-4.10 (m, 1H),4.58-4.60 (m, 1H), 4.94-5.06 (m, 2H), 5.58-5.60 (d, 1H), 6.34 (s, 1H),7.17-7.20 (m, 1H), 7.28-7.30 (m, 2H), 7.47-7.49 (m, 1H), 7.72 (s, 1H).

1-[4-[4-(2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 44); ¹H NMR (CDCl₃) δ 1.77-1.84 (m, 2H), 2.17-2.25 (m, 2H),2.33 (s, 3H), 2.61-2.68 (m, 1H), 2.90-2.96 (m, 2H), 3.12-3.20 (m, 1H),3.31-3.35 (m, 2H), 3.54-3.75 (m, 2H), 4.04-4.10 (m, 1H), 4.56-4.60 (m,1H), 4.94-5.04 (q, 2H), 6.34 (s, 1H), 7.28-7.30 (m, 3H), 7.37-7.38 (m,1H), 7.64 (s, 1H).

1-[4-[4-[4,5-dihydro-5-(4-methoxyphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 18); m.p.t 119-124° C. (crystallized from methylacetate/petroleum ether); ¹H NMR (CDCl₃) δ 1.76-1.82 (m, 2H), 2.16-2.24(m, 2H), 2.32 (s, 3H), 2.86-2.92 (m, 1H), 3.28-3.34 (m, 2H), 3.37-3.43(m, 1H), 3.76-3.83 (m, 1H), 3.81 (s, 3H), 4.03-4.06 (m, 1H), 4.56-4.59(m, 1H), 4.94-5.04 (q, 2H), 5.67-5.72 (m, 1H), 6.33 (s, 1H), 6.89-6.91(d, 2H), 7.31-7.33 (d, 2H), 7.62 (s, 1H).

Example 9 Preparation of1-[4-[4-(4,5-dihydro-5-(2-pyridinyl)-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 98)

To a solution of1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide(i.e. the product of Example 8, Step C) (200 mg, 0.6 mmol) intetrahydrofuran (8 mL) was added 3-chloro-N-hydroxy-2-oxopropanimidoylchloride (i.e. the product of Example 7, Step B) (93 mg, 0.6 mmol),followed by tetrabutylammonium bromide (15 mg, 0.05 mmol). The reactionmixture was heated at 50° C. for 4 h. The reaction mixture was cooledand concentrated under reduced pressure. To the resulting residue,acetonitrile (8 mL) and finely powdered sodium bicarbonate (151 mg, 1.0mmol) were added followed by 2-ethenylpyridine (63 mg, 0.6 mmol), andthe resulting mixture was stirred at room temperature overnight. Thereaction mixture was concentrated under reduced pressure and purified byflash chromatography on a silica gel (20 g), Varian Bond Elute SI®column using 0 to 75% ethyl acetate in hexanes as eluant to give 80 mgof the title product, a compound of the present invention, as a yellowsemi-solid.

¹H NMR (CDCl₃) δ 1.47-1.62 (m, 1H), 1.70-1.85 (m, 1H), 2.01-2.18 (m,2H), 2.49 (s, 3H), 2.82 (t, 1H), 3.20-3.42 (m, 2H), 3.73 (dd, 1H), 3.82(dd, 1H), 3.98 (d, 1H), 4.38 (d, 1H), 5.26 (m, 2H), 5.80 (dd, 1H), 6.50(s, 1H), 7.38 (dd, 1H), 7.50 (d, 1H), 7.82 (t, 1H), 8.05 (s, 1H), 8.60(d, 1H).

Example 10 Preparation of2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]ethanone(Compound 107) Step A: Preparation ofN,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide

To a solution of 3-trifluoromethylpyrazole (5.0 g, 36 mmol),triethylamine (7.0 mL, 50 mmol) in dichloromethane (40 mL) was addeddimethylsulfamoyl chloride (5.5 mL, 51 mmol), and the reaction mixturewas heated at reflux for 2 days. The resulting mixture was cooled toambient temperature and filtered through a pad of silica gel usingdichloromethane as eluent. The filtrate was then concentrated underreduced pressure to give an amber residue. The resulting residue wasdissolved in diethyl ether. The ether solution was washed with water,dried (MgSO₄), and concentrated under reduced pressure to give 8.71 g ofthe title compound.

¹H NMR (CDCl₃) δ 3.01 (s, 6H), 6.65 (s, 1H), 8.03 (s, 1H).

Step B: Preparation of5-chloro-N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide

A stirred solution ofN,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide (i.e. theproduct of Example 10, Step A) (4.0 g, 16 mmol) in tetrahydrofuran (25mL) was cooled to −78° C., and then treated dropwise with 2 Mn-butyllithium in cyclohexane (8.6 mL, 17.2 mmol). The reaction mixturewas stirred for a further 30 minutes, and then a solution ofhexachloroethane (4.2 g, 18 mmol) in tetrahydrofuran (15 mL) was addeddropwise. The reaction mixture was stirred for 1 h, warmed to roomtemperature, and quenched with water (50 mL). The resulting solution wasextracted with dichloromethane, dried (MgSO₄), and concentrated underreduced pressure to give 4.38 g of title compound. This compound was ofsufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 3.15 (s, 6H), 6.58 (s, 1H).

Step C: Preparation 5-chloro-3-(trifluoromethyl)-1H-pyrazole

A solution of5-chloro-N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide(i.e. the product of Example 10, Step B) (4.38 g, 15.8 mmol) andtrifluoroacetic acid (2.7 mL, 35 mmol) was stirred at 0° C. for 1.5 h.The reaction mixture was diluted with water (15 mL), and sodiumcarbonate was added to raise the pH to 12. The solution was extractedwith diethyl ether, dried (MgSO₄), and concentrated under reducedpressure to give 2.1 g of the title compound. This compound was ofsufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 6.57 (m, 1H).

Step D: Preparation of ethyl5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetate

To a suspension of 5-chloro-3-(trifluoromethyl)-1H-pyrazole (i.e. theproduct of Example 10, Step C) (2.1 g, 12.3 mmol) and potassiumcarbonate (3.6 g, 26.0 mmol) in 20 mL of N,N-dimethylformamide was addedethyl bromoacetate (2.1 mL, 18.8 mmol), and the resulting mixture wasstirred at room temperature for 12 h. The resulting mixture was dilutedwith ethyl acetate, washed with water, and dried (MgSO₄). The reactionmixture was concentrated in vacuo and further purified bymedium-pressure liquid chromatography using 0-50% of ethyl acetate inhexanes as eluant to give 940 mg of the title compound as an oil.

¹H NMR (CDCl₃) δ 1.29 (m, 3H), 4.27 (q, 2H), 4.96 (m, 2H), 6.55 (s, 1H).

Step D1: Alternative preparation of ethyl5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetate

To a solution of aluminum chloride (3.0 g, 22.5 mmol) in dichloromethane(100 mL) was added dropwise a solution of trifluoroacetyl chloride (3 g,22.6 mmol) in dichloromethane (5 mL) while keeping the temperature ofthe reaction mixture below −30° C. The reaction mixture was stirred for15 minutes at −50° C. Then a solution of vinylidene chloride (2.2 g,22.7 mmol) in dichloromethane (10 mL) was added dropwise over 2 h to thereaction mixture. The reaction mixture was stirred an additional 2 h at−50° C. and then warmed gradually to room temperature. The reactionmixture was diluted with water, and the aqueous layer was extracted withdichloromethane. The organic layers were combined, dried (MgSO₄), andconcentrated under reduced pressure to give4,4-dichloro-1,1,1-trifluoro-3-buten-2-one as an oil which was used forthe next step without further purification.

¹H NMR (CDCl₃) δ 5.30 (s, 1H).

¹⁹F NMR (CDCl₃) δ −63.6.

To a mixture of ethyl hydrazinoacetate hydrochloride (2.8 g, 18.1 mmol)and triethylamine (9.2 g, 91 mmol) in a solution of ethanol (20 mL) andN,N-dimethylformamide (1 mL), a solution of crude4,4-dichloro-1,1,1-trifluoro-3-buten-2-one in dichloromethane (20 mL)was added dropwise while keeping the temperature of the reaction mixturebelow 10° C. After stirring a further 2 h at below 10° C., the reactionmixture was concentrated under reduced pressure. The residue was dilutedwith diethyl ether, and the mixture was filtered. The resulting filtratewas concentrated to give 4.34 g of the title compound as a solid. Thiscompound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 1.29 (t, 3H), 4.27 (q, 2H), 4.97 (s, 1H), 6.55 (s, 1H).

¹⁹F NMR (CDCl₃) δ −63.4.

Step E: Preparation of 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-aceticacid

A solution of ethyl 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetate(i.e. the product of Example 10, Step D or D1) (218 mg, 0.85 mmol) intetrahydrofuran (1 mL) was treated with a 50 wt. % aqueous solution ofsodium hydroxide (0.2 mL) in water (0.6 mL). The reaction mixture wasstirred at room temperature for 4 h. The reaction mixture was treatedwith concentrated aqueous hydrochloric acid to lower the pH to 1, andthen extracted with ethyl acetate. The extract was dried (MgSO₄) andconcentrated under pressure to give 140 mg of the title compound. Thiscompound was of sufficient purity to use in subsequent reactions.

¹H NMR (DMSO-d₆) δ 5.41 (s, 2H), 7.09 (s, 1H).

Step F: Preparation of2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinyl]ethanone

To a solution of 1,1-dimethylethyl4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinecarboxylate(i.e. the product of Example 1, Step A) (1.026 g, 2.48 mmol) in ethanol(10 mL) was added a 2 M solution of hydrogen chloride in diethyl ether(4.2 mL, 12.6 mmol). The reaction mixture was stirred at roomtemperature overnight. Then the reaction mixture was heated at 60° C.for 2 h. The reaction mixture was cooled to room temperature andconcentrated under reduced pressure to give 0.710 g of4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidine,hydrochloride as a white solid.

To 5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (i.e. theproduct of Example 10, Step E) (0.14 g, 0.61 mmol) in dichloromethane (5mL) was added N,N-dimethylformamide (1 drop) followed by oxalyl chloride(0.07 mL, 0.80 mmol) at room temperature. The reaction mixture wasstirred at room temperature for 1 h, and then concentrated under reducedpressure. The resulting crude5-chloro-3-(trifluoromethyl)-1H-pyrazole-1-acetyl chloride was taken upin 5 mL of dichloromethane, and the resulting solution was addeddropwise to a mixture of4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidine,hydrochloride (0.20 g, 0.57 mmol) prepared above and triethylamine (0.40mL, 2.85 mmol) in 10 mL of dichloromethane at 0° C. The reaction mixturewas stirred overnight at room temperature, and then diluted with 1.0 Naqueous hydrochloric acid solution. The organic layer was separated,washed with water, dried (MgSO₄), and concentrated under reducedpressure and purified by medium-pressure liquid chromatography usingethyl acetate in hexanes as eluant to give 40 mg of the title product, acompound of the present invention, as a solid, melting at 128-131° C.

¹H NMR (CDCl₃) δ 1.81 (nm, 2H), 2.20 (m, 2H), 2.89 (m, 1H), 3.31 (nm,2H), 3.46 (m, 1H), 3.87 (m, 2H), 4.55 (m, 1H), 5.08 (M, 2H), 5.75 (m,1H), 6.54 (s, 1H), 7.25-7.42 (m, 5H), 7.63 (s, 1H).

Example 11 Preparation of2-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazoly)-2-thiazolyl]-1-piperidinyl]ethanone(Compound 126) Step A: Preparation of5-bromo-N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide

A stirred solution ofN,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide (i.e. theproduct of Example 10, Step A) (4.25 g, 17.5 mmol) in tetrahydrofuran(50 mL) was cooled to −78° C., and then 2 M n-butyllithium incyclohexane (10.0 mL, 20.0 mmol) was added dropwise. The reactionmixture was stirred a further 30 minutes, and then bromine (1.0 mL, 3.1g, 18.7 mmol) was added dropwise. The reaction mixture was stirred for10 minutes, warmed to room temperature, and quenched with brine (50 mL).The resulting solution was extracted with diethyl ether, dried (MgSO₄),and concentrated under reduced pressure to give 6.77 g of title compoundas a light yellow oil. This compound was of sufficient purity to use insubsequent reactions.

¹H NMR (CDCl₃) δ 3.15 (s, 6H), 6.69 (s, 1H).

Step B: Preparation 5-bromo-3-(trifluoromethyl)-1H-pyrazole

A solution of5-bromo-N,N-dimethyl-3-(trifluoromethyl)-1H-pyrazole-1-sulfonamide (i.e.the product of Example 11, Step A) (4.50 g, 14.0 mmol) andtrifluoroacetic acid (2.0 mL, 26 mmol) was stirred at 25° C. for 4 h.The reaction mixture was diluted with water (20 mL), and sodiumhydroxide was added to raise the pH to 12. The solution was extractedwith chloroform, dried (MgSO₄), and concentrated under reduced pressureto give 2.73 g of the title compound as a yellow light oil. Thiscompound was of sufficient purity to use in subsequent reactions.

¹H NMR (CDCl₃) δ 6.63 (m, 1H).

Step C: Preparation of ethyl5-bromo-3-(trifluoromethyl)-1-pyrazole-1-acetate

A suspension of 5-bromo-3-(trifluoromethyl)-1H-pyrazole (i.e. theproduct of Example 11, Step B) (2.73 g, 12.7 mmol) and potassiumcarbonate (2.0 g, 14.5 mmol) in N,N-dimethylformamide (20 mL) wastreated with ethyl iodoacetate (3.0 ml, 25.3 mmol), and the resultingmixture was stirred at 95° C. for 3 h. The resulting mixture was dilutedwith ethyl acetate, washed with water, and dried (MgSO₄). The reactionmixture was concentrated in vacuo and further purified bymedium-pressure liquid chromatography using 0-50% of ethyl acetate inhexanes as eluant to give 2.84 g of the title compound as a brown oil.

¹H NMR (CDCl₃) δ 1.29 (m, 3H), 4.26 (q, 2H), 5.00 (m, 2H), 6.64 (s, 1H).

Step D: Preparation of 5-bromo-3-(trifluoromethyl)-1H-pyrazole-1-aceticacid

A solution of ethyl 5-bromo-3-(trifluoromethyl)-1H-pyrazole-1-acetate(i.e. the product of Example 11, Step C) (2.84 g, 9.4 mmol) intetrahydrofuran (10 mL) was treated with a 50 wt. % aqueous solution ofsodium hydroxide solution (1.0 mL). The reaction mixture was stirred atroom temperature for 2 h. The reaction mixture was treated withconcentrated aqueous hydrochloric acid to lower the pH to 1, and thenextracted with ethyl acetate. The extract was dried (MgSO₄) andconcentrated under pressure to give 2.26 g of the title compound as alight brown solid. Recrystallization from 1-chlorobutane (20 mL) gave0.68 g of the title compound as lustrous light pink plates.

¹H NMR (CDCl₃) δ 5.08 (s, 2H), 6.65 (s, 1H).

Step E: Preparation of2-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazoly)-2-thiazolyl]-1-piperidinyl]ethanone

To a solution of 5-bromo-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid(i.e. the product of Example 11, Step D) (0.12 g, 0.61 mmol) indichloromethane (5 mL) was added N,N-dimethylformamide (1 drop) followedby oxalyl chloride (0.25 mL, 2.86 mmol). The reaction mixture wasstirred at room temperature for 1 h and then concentrated under reducedpressure. The residue containing crude acid chloride was taken up indichloromethane (5 mL), and the solution was added dropwise to a mixtureof 4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1-piperidinehydrochloride (i.e. the intermediate product of Example 10, Step F)(0.15 g, 0.43 mmol) and triethylamine (0.25 mL, 1.8 mmol) indichloromethane (5 mL) at 0° C. The reaction mixture was allowed to warmto room temperature, and then stirred overnight at room temperature. Themixture was then partitioned between 1.0 N aqueous hydrochloric acidsolution and dichloromethane. The organic layer was washed with water,dried (MgSO₄), concentrated under reduced pressure, and purified bymedium-pressure liquid chromatography using ethyl acetate in hexanes aseluant to give 90 mg of the title product, a compound of the presentinvention, as an amorphous solid.

¹H NMR (CDCl₃) δ 1.84 (m, 2H), 2.20 (m, 2H), 2.89 (m, 1H), 3.31 (m, 2H),3.46 (m, 1H), 3.89 (m, 2H), 4.58 (m, 1H), 5.11 (m, 2H), 5.75 (m, 1H),6.63 (s, 1H), 7.25-7.42 (m, 5H), 7.66 (s, 1H).

Example 12 Preparation of1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone(Compound 3) Step A: Preparation of4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazolecarboxamide

To a solution of 2-(dimethylamino)-N-hydroxy-2-oxoethanimidoyl chloride(prepared according to the procedure of E. Raleigh. U.S. Pat. No.3,557,089) (6.0 g, 40 mmol), styrene (6.0 g, 60 mmol) in toluene (15 mL)was added a solution of potassium hydrogen carbonate (5.0 g, 50 mmol) inwater (25 mL) over 1 h, while keeping the reaction temperature between 7and 10° C. The reaction mixture was diluted with 10 mL of toluene, andstirred for an additional 10 minutes. The organic layer was separatedand washed with water. The organic layer was concentrated under reducedpressure until no styrene remained to give 8.7 g of the title compoundas a light yellow oil. This compound was of sufficient purity to use insubsequent reactions.

¹H NMR (CDCl₃) δ 3.08 (s, 3H), 3.32 (s, 3H), 3.35 (dd, 1H), 3.71 (dd,1H), 5.65 (dd, 1H), 7.35 (m, 5H).

Step B: Preparation of 4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid

To a solution of4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazolecarboxamide (i.e. theproduct of Example 12, Step A) (60.0 g, 275 mmol) in methanol (300 mL)was added an aqueous sodium hydroxide solution (44 g of 50 wt. % aqueousNaOH in 50 mL of water) dropwise over 30 minutes while maintaining thetemperature of the reaction mixture at 45° C. The reaction mixture wasallowed to cool to room temperature and stirred overnight. The resultingmixture was concentrated under reduced pressure, and treated with 200 mLof water. The pH of the reaction mixture was adjusted using concentratedhydrochloric acid to about 1.0. The crude product was extracted intoethyl acetate (200 mL). The ethyl acetate solution was concentratedunder reduced pressure, and the residue was triturated with hexanes. Theresulting precipitate was filtered, washed with hexanes (2×20 mL), anddried under vacuum to give 46.5 g of the title compound as a solid.

¹H NMR (CDCl₃) δ 3.25 (dd, 1H), 3.75 (dd, 1H), 5.85 (dd, 1H), 7.35 (m,5H), 8.1 (br s, 1H).

Step C: Preparation of the cinchonine salt of(5R)-4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid

A mixture of racemic 4,5-dihydro-5-phenyl-3-isoxazolecarboxylic acid(i.e. the product of Example 12, Step B) (9.5 g, 50 mmol) in methanol(70 mL) was heated to 55° C., and cinchonine (containing about 15%dihydrocinchonine, 14.5 g, 50 mmol) was added over 20 minutes whilekeeping the temperature of the reaction mixture between 53 and 57° C.The reaction mixture was allowed to cool to room temperature over 60minutes, and then water (35 mL) was added dropwise over 30 minutes. Theresulting slurry was cooled to 10° C. and filtered. The filter cake waswashed twice with 10 mL of 25% methanol in water, and air dried to give8.52 g of the title compound as a solid. The diastereomeric ratio of theproduct was determined using chiral high performance liquidchromatography (HPLC) analysis on a Daicel Chiralcel®, OD HPLC column tobe about 99:1.

¹H NMR (CDCl₃) δ 3.25 (dd, 1H), 3.75 (dd, 1H), 5.85 (dd, 1H), 7.35 (m,5H), 8.1 (br s, 1H).

Step D: Preparation of(5R)-4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazolecarboxamide

The cinchonine salt of (5R)-4,5-dihydro-5-phenyl-3-isoxazolecarboxylicacid (i.e. the product of Example 12, Step C) (98% diastereomericexcess, 16.5 g, 34.3 mmol) was slurried in a mixture of 1 N hydrochloricacid (90 mL), cyclohexane (100 mL) and ethyl acetate (40 mL). After allthe solids dissolved, the phases were separated, and the organic layerwas washed with brine (20 mL) and concentrated under reduced pressure togive 5.6 g of white solid. To a solution of the resulting free acid (5.0g, 26.2 mmol) in ethyl acetate (100 mL) at room temperature was addedN,N-dimethylformamide (1 drop) followed by thionyl chloride (4.25 g,35.7 mmol). The reaction mixture was then heated under reflux for 3 h.The resulting mixture was cooled and concentrated under reducedpressure. The residue containing crude acid chloride was dissolved inethyl acetate (25 mL), and this solution was added in portions to apre-cooled (5° C.) mixture of dimethylamine in tetrahydrofuran (29 mL ofa 2.0 M solution), while maintaining the temperature of the mixture at5-10° C. When the addition was complete, the reaction mixture wasconcentrated under reduced pressure, and diluted with water (50 mL). Theresulting precipitate was filtered, washed with water and suction-driedovernight to give 4.1 g of the title compound as a light tan solid,melting at 59-61° C. This compound was of sufficient purity to use insubsequent reactions.

Step E: Preparation of2-bromo-1-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]ethanone

A solution of(5R)-4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazole-carboxamide (i.e. theproduct of Example 12, Step D) (3.5 g, 16.0 mmol) in a mixture oftetrahydrofuran (5 mL) and toluene (10 mL) was cooled to −15° C., andmethyl magnesium bromide (3.0 M solution in tetrahydrofuran, 8.8 mL,26.4 mmol) was added over 1 h at −15° C. Then the reaction mixture waspoured over a mixture of 20 g of concentrated hydrochloric acid and 80 gof ice, and the organic phase was separated. The aqueous phase wasextracted with ethyl acetate (100 mL), and the combined extract waswashed with brine (40 mL) and concentrated under reduced pressure togive 3.2 g of 1-[(5R)-4,5-dihydro-5-phenyl-3-isoxazoyl]ethanone.

¹H NMR (CDCl₃) δ 2.55 (s, 3H), 3.17 (dd, 1H), 3.54 (dd, 1H), 5.75 (dd,1H), 7.35 (m, 5H).

1-[(5R)-4,5-dihydro-5-phenyl-3-isoxazoyl]ethanone (3.2 g, 16.7 mmol) wasdissolved in 1,2-dichloroethane (15 mL), and a solution of bromine (2.13g, 13.3 mmol) in dichloroethane (5 mL) was added over 30 minutes whilemaintaining the temperature of the reaction mixture at about 30° C. Thereaction mixture was diluted with water (10 mL), and the organic layerwas concentrated under reduced pressure and purified by medium-pressureliquid chromatography using 35% of dichloromethane in hexanes as eluantto give 2.6 g of the title compound as a white solid, melting at 31-33°C.

¹H NMR (CDCl₃) δ 3.20 (dd, 1H), 3.60 (dd, 1H), 4.49 (s, 2H), 5.80 (dd,1H), 7.35 (m, 5H).

Step E1: Alternative preparation of2-bromo-1-(4,5-dihydro-5-phenyl-3-isoxazolyl)-ethanone

To a solution of4,5-dihydro-N,N-dimethyl-5-phenyl-3-isoxazolecarboxamide (i.e. theproduct of Example 12, Step A) (17 g, 78.0 mmol) in a mixture oftetrahydrofuran (20 mL) and toluene (80 mL) was added methyl magnesiumbromide (3.0 M solution in tetrahydrofuran, 28 mL, 84 mmol) over 1 h,while keeping the reaction temperature between −10 and −15° C. Thereaction mixture was poured over a mixture of concentrated hydrochloricacid (20 g) and ice (80 g), and the organic phase was separated. Theaqueous phase was extracted with ethyl acetate (100 mL), and thecombined organic extracts were washed with brine (40 mL) andconcentrated under reduced pressure to give 14.4 g of1-(4,5-dihydro-5-phenyl-3-isoxazoyl)ethanone as a light yellow oil.

¹H NMR (CDCl₃) δ 2.55 (s, 3H), 3.17 (dd, 1H), 3.54 (dd, 1H), 5.75 (dd,1H), 7.35 (m, 5H).

1-(4,5-Dihydro-5-phenyl-3-isoxazoyl)ethanone (11.5 g, 60 mmol) wasdissolved in ethyl acetate (45 mL), and a solution of bromine (9.6 g,60.0 mmol) in ethyl acetate (30 mL) was added over 30 minutes whilemaintaining the temperature of the reaction mixture at about 30° C.After 1 h, the reaction mixture was diluted with water (10 mL), and theorganic layer was concentrated under reduced pressure to give 16.7 g ofreddish oil which contained about 10% starting methyl ketone and ˜10%dibrominated ketone.

¹H NMR (CDCl₃) δ 3.20 (dd, 1H), 3.60 (dd, 1H), 4.49 (s, 2H), 5.80 (dd,1H), 7.35 (m, 5H).

Step F: Preparation of1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone

A mixture of1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinecarbothioamide(i.e. the product of Example 8, Step C) (1.7 g, 5.0 mmol) and2-bromo-1-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]ethanone (i.e. theproduct of Example 12, Step E or E1) (1.35 g, 5 mmol) in ethanol (15 mL)was heated at 50° C. for 30 minutes. The reaction mixture was dilutedwith water and extracted with dichloromethane. The extract was washedwith brine, dried (MgSO₄), and concentrated under reduced pressure togive the title product, a compound of the present invention, as apale-yellow gum. High performance liquid chromatography (HPLC) analysisshowed that the title product was about 95% pure and contained the(R)-enantiomer in about 98% enantiomeric excess.

¹H NMR (CDCl₃) δ 1.8 (m, 2H), 2.2 (m, 2H), 2.32 (s, 3H), 2.9 (m, 1H),3.3 (m, 2H), 3.42 (dd, 1H), 3.82 (dd, 1H), 4.05 (m, 1H), 4.6 (m, 1H),5.0 (q, 2H), 5.78 (dd, 1H), 6.35 (s, 1H), 7.4 (m, 5H), 7.62 (s, 1H).

Example 13 Preparation of1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-3,6-dihydro-1(2H)-pyridinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1yl]ethanone (Compound 217) Step A: Preparation of4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]pyridine

To a solution of thioisonicotinamide (0.5 g, 3.6 mmol) in1-methyl-2-pyrrolidinone (25 mL) was added2-chloro-1-(4,5-dihydro-5-phenyl-3-isoxazolyl)ethanone (0.807 g, 3.6mmol), at room temperature. The reaction mixture was then heated to 100°C. for 3 h. Then the reaction mixture was cooled to room temperature,quenched with water (100 mL), extracted with ethyl acetate (50 mL×2).The reaction mixture was diluted with water (50 mL) and brine (50 mL),and the organic layer was concentrated under reduced pressure andpurified by medium-pressure liquid chromatography using 2% of methanolin chloroform as eluant to give 0.7 g of the title compound as a brownsolid.

¹H NMR (CDCl₃) δ 3.5 (m, 1H), 3.9 (m, 1H), 5.8 (m, 1H), 7.35 (m, 5H),8.16 (s, 1H), 8.3 (d, 2H), 8.8 (d, 2H).

Step B: Preparation of4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine

To a solution of4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]pyridine (i.e. theproduct of Example 13, Step A) (0.60 g, 1.95 mmol) in toluene (10 mL)was added benzyl bromide (0.670 g, 3.90 mmol), and the reaction mixturewas heated to 100° C. for 12 h. Then the reaction mixture was cooled toroom temperature. The solid that precipitated out was filtered anddried. The solid was dissolved in methanol (10 mL), and sodiumborohydride (0.072 g, 1.95 mmol) was added in portions. The reactionmixture was stirred at room temperature for 2 h, diluted with water (50mL), neutralized with 1.5 N aqueous hydrochloric acid solution, andextracted with ethyl acetate (50 mL). The organic layer was separated,washed with brine (25 mL), and concentrated under reduced pressure. Theresidue was purified by medium-pressure liquid chromatography using 3%of methanol in chloroform as eluant to give 0.4 g of the title compoundas a white solid.

¹H NMR (CDCl₃) δ 3.03-3.1 (m, 2H), 3.4-3.6 (m, 4H), 3.8-4.0 (m, 2H),4.25-4.32 (m, 2H), 5.76-5.79 (m, 1H), 6.47 (s, 1H), 7.34-7.48 (m, 10H),7.72 (s, 1H).

Step C: Preparation of4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1,2,3,6-tetrahydropyridinehydrochloride

To a solution of4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1,2,3,6-tetrahydro-1-(phenylmethyl)pyridine(i.e. the product of Example 13, Step B) (0.400 g, 0.99 mmol) indichloroethane (10 mL) was added 1-chloroethyl chloroformate (0.286 g,1.99 mmol), and the reaction mixture was heated to 80° C. for 5 h. Thereaction mixture was cooled to room temperature and concentrated underreduced pressure. Methanol (10 mL) was added to the residue, and theresulting mixture was heated to 60° C. for 1 h, cooled to roomtemperature, and concentrated under reduced pressure. The residue wastriturated with 50% of petroleum ether in ethyl acetate, and the solidformed was filtered and dried to give 0.25 g of the title compound as awhite solid.

¹H NMR (DMSO-d₆) δ 2.50-2.55 (m, 2H), 3.31-3.39 (m, 3H), 3.86-3.91 (m,3H), 5.73-5.78 (m, 1H), 6.67 (s, 1H), 7.34-7.39 (m, 5H), 7.68 (s, 1H),9.47 (s, 2H).

Step D: Preparation of1-[4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-3,6-dihydro-1(2H)-pyridinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1yl]ethanone

To a solution of4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)-2-thiazolyl]-1,2,3,6-tetrahydropyridinehydrochloride (i.e. the product of Example 13, Step C) (0.250 g, 0.720mmol) and 5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-acetic acid (0.150g, 0.720 mmol) in dichloromethane (10 mL) was addedN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (0.138 g, 0.720 mmol),1-hydroxybenzotriazole (0.024 g, 0.177 mmol), and triethylamine (0.145g, 1.44 mmol) at room temperature. The reaction mixture was stirred atroom temperature for 24 h. The reaction mixture was diluted withdichloromethane (30 mL) and washed with water (20 mL) and brine (20 mL).The organic layer was separated, washed with water, dried (Na₂SO₄), andconcentrated under reduced pressure and purified by medium-pressureliquid chromatography using 3% methanol in chloroform as eluant to give200 mg of the title product, a compound of the present invention, as awhite solid.

¹H NMR (CDCl₃) δ 2.3 (s, 3H), 2.71-2.75 (m, 2H), 3.42-3.46 (m, 1H),3.74-3.88 (m, 3H), 4.24-4.27 (m, 2H), 5.02 (s, 2H), 5.71-5.76 (m, 1H),6.32 (s, 1H), 6.57 (s, 1H), 7.3-7.38 (m, 5H), 7.64 (s, 1H).

By the procedures described herein, together with methods known in theart, the following compounds of Tables 1A to 8 can be prepared. Thefollowing abbreviations are used in the Tables which follow: t meanstertiary, s means secondary, n means normal, i means iso, c means cyclo,Ac means acetyl, Me means methyl, Et means ethyl, Pr means propyl (i.e.n-propyl), i-Pr means isopropyl, c-Pr means cyclopropyl, Bu means butyl,Pen means pentyl, Hex means hexyl, Am means amyl, CN means cyano. A dash(-) indicates no substituents.

The invention includes but is not limited to the following exemplaryspecies.

TABLE 1A

R¹ phenyl 2-methylphenyl 2-methoxyphenyl 2-chlorophenyl 2-bromophenyl2-ethylphenyl 2-ethoxyphenyl 2-(methylthio)phenyl 2-(ethylthio)phenyl2-(trifluoromethoxy)phenyl 3-chlorophenyl 3-bromophenyl 3-iodophenyl3-methylphenyl 2-chloro-5-(trifluoromethyl)phenyl2-chloro-5-(2,2,2-trifluoroethyl)phenyl2-chloro-5-(pentafluoroethyl)phenyl 2-chloro-5-cyanophenyl2-chloro-5-nitrophenyl 2-bromo-5-chlorophenyl 2,5-dibromophenyl2-bromo-5-iodophenyl 2-bromo-5-methylphenyl 2-bromo-5-ethylphenyl2-bromo-5-propylphenyl 2-bromo-5-isopropylphenyl2-bromo-5-(trifluoromethyl)phenyl 2-bromo-5-(2,2,2-trifluoroethyl)phenyl2-bromo-5-(pentafluoroethyl)phenyl 2-bromo-5-cyanophenyl2-bromo-5-nitrophenyl 5-chloro-2-methylphenyl 5-bromo-2-methylphenyl5-iodo-2-methylphenyl 2,5-dimethylphenyl 5-ethyl-2-methylphenyl2-methyl-5-propylphenyl 5-isopropyl-2-methylphenyl2-methyl-5-(tifluoromethyl)phenyl2-methyl-5-(2,2,2-trifluoroethyl)phenyl2-methyl-5-(pentafluoroethyl)phenyl 5-cyano-2-methylphenyl2-methyl-5-nitrophenyl 5-chloro-2-methoxyphenyl 5-bromo-2-methoxyphenyl5-iodo-2-methoxyphenyl 2-methoxy-5-methylphenyl3-iodo-5-methylpyrazol-1-yl 3-ethyl-5-methylpyrazol-1-yl5-methyl-3-propylpyrazol-1-yl 3-isopropyl-5-methylpyrazol-1-yl5-methyl-3-(trifluoromethyl)pyrazol-1-yl5-methyl-3-(2,2,2-trifluoroethyl)pyrazol-1-yl5-methyl-3-(pentafluoroethyl)pyrazol-1-yl 3-cyano-5-methylpyrazol-1-yl5-methyl-3-nitropyrazol-1-yl 5-chloro-3-methylpyrazol-1-yl3,5-dichloropyrazol-1-yl 5-chloro-3-bromopyrazol-1-yl5-chloro-3-iodopyrazol-1-yl 5-chloro-3-ethylpyrazol-1-yl5-chloro-3-propylpyrazol-1-yl 5-chloro-3-isopropylpyrazol-1-yl5-chloro-3-(trifluoromethyl)pyrazol-1-yl5-chloro-3-(2,2,2-trifluoroethyl)pyrazol-1-yl5-chloro-3-(pentafluoroethyl)pyrazol-1-yl 5-chloro-3-cyanopyrazol-1-yl5-chloro-3-nitropyrazol-1-yl 5-bromo-3-methylpyrazol-1-yl5-bromo-3-chloropyrazol-1-yl 3,5-dibromopyrazol-1-yl5-bromo-3-iodopyrazol-1-yl 5-bromo-3-ethylpyrazol-1-yl5-bromo-3-propylpyrazol-1-yl 5-bromo-3-isopropylpyrazol-1-yl5-bromo-3-(trifluoromethyl)pyrazol-1-yl5-bromo-3-(2,2,2-trifluoroethyl)pyrazol-1-yl5-bromo-3-(pentafluoroethyl)pyrazol-1-yl 5-bromo-3-cyanopyrazol-1-yl5-bromo-3-nitropyrazol-1-yl 2-chloro-5-(dimethylamino)phenyl2-chloro-5-(diethylamino)phenyl 2-chloro-5-(cyclopropylamino)phenyl3-(methoxymethyl)phenyl 2-chloro-5-(ethoxymethyl)phenyl2-chloro-5-(hyroxymethyl)phenyl 2-chloro-5-(methoxycarbonyl)phenyl2-chloro-5-(ethylcarbonyl)phenyl 2-chloro-5-(methylcarbonyloxy)phenyl2-chloro-5-(methylaminocarbonyl)phenyl2-chloro-5-(dimethylaminocarbonyl)phenyl2-methyl-5-(trimethylsilyl)phenyl 3,5-dimethyl-2-thienyl3,5-dichloro-2-thienyl 3,5-dimethyl-2-furyl 1-methyl-2-pyrrolyl4-methyl-2-(trifluoromethyl)-5-thiazolyl 4-(trifluoromethyl)-2-thiazolyl4-(trifluoromethyl)-2-oxazolyl 4-methyl-2-(trifluoromethyl)-5-oxazolyl4-bromo-5-isothiazolyl 4-bromo-5-isoxazolyl 1-methyl-5-pyrazolyl1-methyl-5-imidazolyl 1-methy-1-4-(trifluoromethyl)-2-imidazolyl4-methyl-3-(1,3,4-triazolyl) 2-methyl-3-(1,2,4-triazolyl)5-(trifluoromethyl)-2-(1,3,4-thiadiazolyl)5-(trifluoromethyl)-2-(1,3,4-oxadiazolyl)3-(trifluoromethyl)-5-(1,2,4-thiadiazolyl)3-(trifluoromethyl)-5-(1,2,4-oxadiazolyl)3-(trifluoromethyl)-1-(1,2,4-triazolyl) 2,5-dimethyl-1-pyrrolyl1-methyl-3-(trifluoromethyl)pyrazol-5-yl3-bromo-5-(trifluoromethyl)pyrazol-1-yl3-iodo-5-(trifluoromethyl)pyrazol-1-yl3-ethyl-5-(trifluoromethyl)-pyrazol-1-yl3-propyl-5-(trifluoromethyl)pyrazol-1-yl3-isopropyl-5-(trifluoromethyl)pyrazol-1-yl3-methyl-5-(trifluoromethyl)-pyrazol-1-yl3-methoxy-5-(trifluoromethyl)-pyrazol-1-yl5-difluoromethoxy-3-methylpyrazol-1-yl5-difluoromethoxy-3-chloropyrazol-1-yl 3,5-dibromopyrazol-1-yl5-difluoromethoxy-3-iodopyrazol-1-yl5-difluoromethoxy-3-ethylpyrazol-1-yl5-difluoromethoxy-3-propylpyrazol-1-yl5-difluoromethoxy-3-isopropylpyrazol-1-yl5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl5-difluoromethoxy-3-(2,2,2-trifluoroethyl)pyrazol-1-yl5-difluoromethoxy-3-(pentafluoroethyl)pyrazol-1-yl5-difluoromethoxy-3-cyanopyrazol-1-yl5-difluoromethoxy-3-nitropyrazol-1-yl3-carbomethoxy-5-(trifluoromethyl)pyrazol-1-yl5-methoxy-3-methylpyrazol-1-yl 5-methoxy-3-bromopyrazol-1-yl5-methoxy-3-iodopyrazol-1-yl 5-methoxy-3-ethylpyrazol-1-yl5-methoxy-3-propylpyrazol-1-yl 5-methoxy-3-isopropylpyrazol-1-yl5-methoxy-3-(trifluoromethyl)pyrazol-1-yl5-methoxy-3-(2,2,2-trifluoroethyl)pyrazol-1-yl5-methoxy-3-(pentafluoroethyl)pyrazol-1-yl 5-methoxy-3-cyanopyrazol-1-yl5-methoxy-3-nitropyrazol-1-yl 3-ethylphenyl 3-propylphenyl3-isopropylphenyl 3-(trifluoromethyl)phenyl3-(2,2,2-trifluoroethyl)phenyl 3-(pentafluoroethyl)phenyl 3-cyanophenyl3-nitrophenyl 2,5-dichlorophenyl 5-bromo-2-chlorophenyl2-chloro-5-iodophenyl 2-chloro-5-methylphenyl 2-chloro-5-ethylphenyl2-chloro-5-propylphenyl 2-chloro-5-isopropylphenyl5-ethyl-2-methoxyphenyl 2-methoxy-5-propylphenyl5-isopropyl-2-methoxyphenyl 2-methoxy-5-(trifluoromethyl)phenyl2-methoxy-5-(2,2,2-trifluoroethyl)phenyl2-methoxy-5-(pentafluoroethyl)phenyl 5-cyano-2-methoxyphenyl2-methoxy-5-nitrophenyl 5-chloro-2-ethylphenyl 5-bromo-2-ethylphenyl2-ethyl-5-iodophenyl 2-ethyl-5-methylphenyl 2,5-diethylphenyl2-ethyl-5-propylphenyl 2-ethyl-5-isopropylphenyl2-ethyl-5-(trifluoromethyl)phenyl 2-ethyl-5-(2,2,2-trifluoroethyl)phenyl2-ethyl-5-(pentafluoroethyl)phenyl 5-cyano-2-ethylphenyl2-ethyl-5-nitrophenyl 3-methylpyrazol-1-yl 3-chloropyrazol-1-yl3-bromopyrazol-1-yl 3-iodopyrazol-1-yl 3-ethylpyrazol-1-yl3-(trifluoromethyl)pyrazol-1-yl 3-(2,2,2-trifluoroethyl)pyrazol-1-yl3-(pentafluoroethyl)pyrazol-1-yl 3-cyanopyrazol-1-yl 3-nitropyrazol-1-yl3,5-dimethylpyrazol-1-yl 3-chloro-5-methylpyrazol-1-yl3-bromo-5-methylpyrazol-1-yl 5-methoxy-3-methylpyrazol-1-yl3-chloro-5-methoxypyrazol-1-yl 5-ethyl-3-methylpyrazol-1-yl3-chloro-5-ethylpyrazol-1-yl 3-bromo-5-ethylpyrazol-1-yl5-ethyl-3-iodopyrazol-1-yl 3,5-diethylpyrazol-1-yl5-ethyl-3-propylpyrazol-1-yl 5-ethyl-3-isopropylpyrazol-1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl5-ethyl-3-(2,2,2-trifluoroethyl)pyrazol-1-yl5-ethyl-3-(pentafluoroethyl)pyrazol-1-yl 3-cyano-5-ethylpyrazol-1-yl5-ethyl-3-nitropyrazol-1-yl 5-butyl-2-methylphenyl5-hexyl-2-methylphenyl 5-allyl-2-methylphenyl2-methyl-5-(4-methyl-3-pentenyl)phenyl 2-methyl-5-propargylphenyl2-methyl-5-(3-methylpropargyl)phenyl 5-cyclopropyl-2-methylphenyl5-cyclohexyl-2-methylphenyl 2-metlyl-5-(pentafluoroisopropyl)phenyl5-(3,3-dichloro-2-propen-1-yl)-2-methylphenyl2-methyl-5-(4,4,4-trifluoro-2-butyn-1-yl)phenyl5-(2,2-dichlorocyclopropan-1-yl)-2-methylphenyl2-methyl-5-(trifluoromethoxy)phenyl 2-chloro-5-(isobutylthio)phenyl2-chloro-5-(ethylsulfonyl)phenyl 2-chloro-5-(trifluoromethylthio)phenyl2-chloro-5-(trifluoromethylsulfonyl)phenyl2-chloro-5-(methylamino)phenyl 2-chloro-5-(tert-butylamino)phenyl2,5-dimethyl-3-furyl 2,5-dimethyl-3-thienyl 2,5-dichloro-3-thienyl1,4-dimethyl-3-pyrrolyl 1,4-dimethyl-3-pyrazolyl1,3-dimethyl-4-pyrazolyl 2,5-dimethyl-4-oxazolyl2,5-dimethyl-4-thiazolyl 3-bromo-4-isothiazolyl 3-bromo-4-isooxazolyl1-methyl-4-imidazolyl 5-(trifluoromethyl)-3-(1,2,4-oxadiazolyl)5-(trifluoromethyl)-3-(1,2,4-thiadiazolyl) 2-bromo-1-(1,3,4-triazolyl)5-(trifluoromethyl)-3-(1,2,4-triazolyl) 2-bromo-1-imidazolyl3,6-dimethyl-2-pyridyl 2,5-dimethyl-3-pyridyl 2,5-dimethyl-4-pyridyl3,6-dichloro-2-pyridyl 2,5-dichloro-3-pyridyl 2,5-dichloro-4-pyridyl4-bromo-3-pyridazinyl 4-(trifluoromethyl)-2-pyrimidinyl3,6-dimethyl-2-pyrazinyl 2,5-dimethyl-4-pyrimidinyl4-methoxy-5-pyrimidinyl 3,6-dimethyl-4-pyridazinyl5-(trifluoromethyl)-3-(1,2,4-triazinyl) 5-methoxy-6-(1,2,4-triazinyl)4-(trifluoromethyl)-2-(1,3,5-triazinyl) 3,6-dimethyl-5-(1,2,4-triazinyl)1-methyl-4-(trifluoromethyl)imidazol-2-yl3,5-bis-(trifluoromethyl)pyrazol-1-yl3-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)pyrazol-1-yl3-(pentafluoroethyl)-5-(trifluoromethyl)pyrazol-1-yl3-cyano-5-(trifluoromethyl)pyrazol-1-yl3-nitro-5-(trifluoromethyl)pyrazol-1-yl3-chloro-5-(trifluoromethyl)-pyrazol-1-yl3,5-bis-(trichloromethyl)pyrazol-1-yl3-difluoromethoxy-5-methylpyrazol-1-yl3-difluoromethoxy-5-chloropyrazol-1-yl3-difluoromethoxy-5-bromopyrazol-1-yl3-difluoromethoxy-5-iodopyrazol-1-yl3-difluoromethoxy-5-ethylpyrazol-1-yl3-difluoromethoxy-5-(trifluoromethyl)pyrazol-1-yl3-difluoromethoxy-5-(2,2,2-trifluoroethyl)pyrazol-1-yl3-difluoromethoxy-5-(pentafluoroethyl)pyrazol-1-yl3-difluoromethoxy-5-cyanopyrazol-1-yl3-difluoromethoxy-5-nitropyrazol-1-yl3,5-bis-(difluoromethoxy)pyrazol-1-yl5-carbomethoxy-3-(trifluoromethyl)pyrazol-1-yl 3,5-dimethoxypyrazol-1-yl5-ethoxy-3-methylpyrazol-1-yl 5-ethoxy-3-bromopyrazol-1-yl5-ethoxy-3-iodopyrazol-1-yl 5-ethoxy-3-ethylpyrrazol-1-yl5-ethoxy-3-propylpyrazol-1-yl 5-ethoxy-3-isopropylpyrazol-1-yl5-ethoxy-3-(trifluoromethyl)pyrazol-1-yl5-ethoxy-3-(2,2,2-trifluoroethyl)pyrazol-1-yl5-ethoxy-3-(pentafluoroethyl)pyrazol-1-yl 5-ethoxy-3-cyanopyrazol-1-yl5-ethoxy-3-nitropyrazol-1-yl

TABLE 1B

R¹ A W 2-methoxyphenyl NH O 2,5-dichlorophenyl NH O5-bromo-2-chlorophenol NH O 2-chloro-5-methylphenyl NH O2-chloro-5-(trifluoromethyl)phenyl NH O 2,5-dibromophenyl NH O2-bromo-5-methylphenyl NH O 2-bromo-5-(trifluoromethyl)phenyl NH O5-chloro-2-methylphenyl NH O 5-bromo-2-methylphenyl NH O2,5-dimethylphenyl NH O 5-ethyl-2-methylphenyl NH O2-methyl-5-(trifluoromethyl)phenyl NH O 5-bromo-2-methoxyphenyl NH O2-methoxy-5-methylphenyl NH O 2-methoxy-5-(trifluoromethyl)phenyl NH O3-ethyl-5-methylpyrazol-1-yl CH₂ S5-methyl-3-(trifluoromethyl)pyrazol-1-yl CH₂ S 3,5-dichloropyrazol-1-ylCH₂ S 5-chloro-3-(trifluoromethyl)pyrazol-1-yl CH₂ S3,5-bis-(trifluoromethyl)pyrazol-1-yl CH₂ S 3,5-dimethylpyrazol-1-yl CH₂S 3,5-dibromopyrazol-1-yl CH₂ S 5-bromo-3-(trifluoromethyl)pyrazol-1-ylCH₂ S 3,5-diethylpyrazol-1-yl CH₂ S5-ethyl-3-(trifluoromethyl)pyrazol-1-yl CH₂ S 2-methoxyphenyl NH S2,5-dichlorophenyl NH S 5-bromo-2-chlorophenyl NH S2-chloro-5-methylphenyl NH S 2-chloro-5-(trifluoromethyl)phenyl NH S2,5-dibromophenyl NH S 2-bromo-5-methylphenyl NH S2-bomo-5-(trifluoromethyl)phenyl NH S 5-chloro-2-methylphenyl NH S5-bromo-2-methylphenyl NH S 2,5-dimethylphenyl NH S5-ethyl-2-methylphenyl NH S 2-methyl-5-(trifluoromethyl)phenyl NH S5-bromo-2-methoxyphenyl NH S 2-methoxy-5-methylphenyl NH S2-methoxy-5-(trifluoromethyl)phenyl NH S5-methyl-3-(trifluoromethyl)pyrazol-1-yl NCH₃ O5-methyl-3-(trifluoromethyl)pyrazol-1-yl NAc O3-methyl-5-(trifluoromethyl)pyrazol-1-yl CH₂ S5-methyl-3-(trifluoromethyl)pyrazol-1-yl CHCH₃ O5-methyl-3-(trifluoromethyl)pyrazol-1-yl CHCOOCH₃ O5-methyl-3-(trifluoromethyl)pyrazol-1-yl CHCl O5-methyl-3-(trifluoromethyl)pyrazol-1-yl NCOOCH₃ O5-methyl-3-(trifluoromethyl)pyrazol-1-yl NH S 3,5-dimethylpyrazol-1-ylNH O 3,5-dichloropyrazol-1-yl NH O 3,5-dibromopyrazol-1-yl NH O5-methyl-3-(trifluoromethyl)pyrazol-1-yl NH O5-chloro-3-(trifluoromethyl)pyrazol-1-yl NH O5-bromo-3-(trifluoromethyl)pyrazol-1-yl NH O5-ethyl-3-(trifluoromethyl)pyrazol-1-yl NH O3,5-bis-(trifluoromethyl)pyrazol-1-yl NH O3-methyl-5-(triifluoromethyl)pyrazol-1-yl NH O3-chloro-5-(trifluoromethyl)pyrazol-1-yl NH O3-bromo-5-(trifluoromethyl)pyrazol-1-yl NH O5-methoxy-3-(trifluoromethyl)pyrazol-1-yl NH O5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl NH O

TABLE 2*

Z¹ J (R⁵)_(x) Z² Q (R⁷)_(p) R¹² J-orientation** bond J-1  — bond Q-45 —— 2/4 bond J-1  — bond Q-45 — — 2/5 bond J-1  — bond Q-45 — — 4/2 bondJ-1  — bond Q-45 — — 5/2 bond J-2  — bond Q-45 — — 2/4 bond J-2  — bondQ-45 — — 2/5 bond J-2  — bond Q-45 — — 4/2 bond J-2  — bond Q-45 — — 5/2bond J-3  1-Me bond Q-45 — — 2/4 bond J-3  1-Me bond Q-45 — — 2/5 bondJ-3  1-Me bond Q-45 — — 4/2 bond J-3  1-Me bond Q-45 — — 5/2 CH₂ J-3  —bond Q-45 — — 1/4 bond J-3  — bond Q-45 — — 4/1 bond J-4  — bond Q-45 —— 2/4 bond J-4  — bond Q-45 — — 2/5 bond J-4  — bond Q-45 — — 4/2 bondJ-4  — bond Q-45 — — 5/2 bond J-4  — bond Q-45 — — 3/5 bond J-4  — bondQ-45 — — 5/3 bond J-5  — bond Q-45 — — 2/4 bond J-5  — bond Q-45 — — 2/5bond J-5  — bond Q-45 — — 4/2 bond J-5  — bond Q-45 — — 5/2 bond J-5  —bond Q-45 — — 3/5 bond J-5  — bond Q-45 — — 5/3 bond J-6  — bond Q-45 —— 2/4 bond J-6  — bond Q-45 — — 2/5 bond J-6  — bond Q-45 — — 4/2 bondJ-6  — bond Q-45 — — 5/2 bond J-6  — bond Q-45 — — 3/5 bond J-6  — bondQ-45 — — 5/3 CH₂ J-6  — bond Q-45 — — 1/3 bond J-6  — bond Q-45 — — 3/1bond J-7  — bond Q-45 — — 5/3 bond J-7  — bond Q-45 — — 3/5 bond J-8  —bond Q-45 — — 5/3 bond J-8  — bond Q-45 — — 3/5 bond J-9  1-Me bond Q-45— — 5/3 bond J-9  1-Me bond Q-45 — — 3/5 CH₂ J-9  — bond Q-45 — — 1/4bond J-9  — bond Q-45 — — 4/1 bond J-10 — bond Q-45 — — 3/5 bond J-10 —bond Q-45 — — 5/3 bond J-11 — bond Q-45 — — 3/5 bond J-11 — bond Q-45 —— 5/3 bond J-12 1-Me bond Q-45 — — 3/5 bond J-12 1-Me bond Q-45 — — 5/3CH₂ J-12 — bond Q-45 — — 1/3 bond J-12 — bond Q-45 — — 3/1 bond J-13 —bond Q-45 — — 1/4 bond J-13 — bond Q-45 — — 4/1 bond J-14 1-Me bond Q-45— — 3/5 bond J-14 — bond Q-45 — — 5/3 bond J-15 — bond Q-45 — — 2/5 bondJ-16 — bond Q-45 — — 2/5 CH₂ J-17 — bond Q-45 — — 2/4 bond J-17 — bondQ-45 — — 4/2 CH₂ J-18 — bond Q-45 — — 2/5 bond J-18 — bond Q-45 — — 5/2bond J-19 — bond Q-45 — — 2/4 bond J-19 — bond Q-45 — — 4/2 bond J-20 —bond Q-45 — — 2/4 bond J-20 — bond Q-45 — — 2/5 bond J-20 — bond Q-45 —— 2/6 bond J-20 — bond Q-45 — — 3/5 bond J-20 — bond Q-45 — — 4/2 bondJ-20 — bond Q-45 — — 5/2 bond J-21 — bond Q-45 — — 3/5 bond J-21 — bondQ-45 — — 3/6 bond J-21 — bond Q-45 — — 5/3 bond J-22 — bond Q-45 — — 2/4bond J-22 — bond Q-45 — — 2/5 bond J-22 — bond Q-45 — — 4/6 bond J-22 —bond Q-45 — — 4/2 bond J-22 — bond Q-45 — — 5/2 bond J-23 — bond Q-45 —— 2/5 bond J-23 — bond Q-45 — — 2/6 bond J-24 — bond Q-45 — — 2/4 bondJ-24 — bond Q-45 — — 2/5 bond J-24 — bond Q-45 — — 4/2 bond J-24 — bondQ-45 — — 5/2 bond J-25 — bond Q-45 — — 2/4 bond J-25 — bond Q-45 — — 2/5bond J-25 — bond Q-45 — — 4/2 bond J-25 — bond Q-45 — — 5/2 bond J-26 —bond Q-45 — — 2/4 bond J-26 — bond Q-45 — — 2/5 bond J-26 — bond Q-45 —— 4/2 bond J-26 — bond Q-45 — — 5/2 CH₂ J-26 — bond Q-45 — — 1/4 bondJ-26 — bond Q-45 — — 4/1 bond J-27 — bond Q-45 — — 2/4 bond J-27 — bondQ-45 — — 2/5 bond J-27 — bond Q-45 — — 3/5 bond J-27 — bond Q-45 — — 4/2bond J-27 — bond Q-45 — — 5/2 bond J-27 — bond Q-45 — — 5/3 bond J-28 —bond Q-45 — — 3/5 bond J-28 — bond Q-45 — — 5/3 bond J-29 — bond Q-45 —— 3/5 bond J-29 — bond Q-45 — — 5/3 bond J-30 — bond Q-45 — — 3/5 bondJ-30 — bond Q-45 — — 5/3 CH₂ J-30 — bond Q-45 — — 1/3 bond J-30 — bondQ-45 — — 3/1 CH₂ J-30 — bond Q-45 — — 1/4 bond J-30 — bond Q-45 — — 4/1CH₂ J-31 — bond Q-45 — — 1/3 CH₂ J-31 — bond Q-45 — — 1/4 bond J-31 —bond Q-45 — — 2/4 bond J-31 — bond Q-45 — — 2/5 bond J-31 — bond Q-45 —— 3/5 bond J-31 — bond Q-45 — — 3/1 bond J-31 — bond Q-45 — — 4/1 bondJ-31 — bond Q-45 — — 4/2 bond J-31 — bond Q-45 — — 5/2 bond J-32 — bondQ-45 — — 2/4 bond J-32 — bond Q-45 — — 2/5 bond J-32 — bond Q-45 — — 3/5bond J-32 — bond Q-45 — — 5/3 bond J-32 — bond Q-45 — — 5/2 bond J-32 —bond Q-45 — — 4/2 bond J-33 — bond Q-45 — — 2/4 bond J-33 — bond Q-45 —— 2/5 bond J-33 — bond Q-45 — — 3/5 bond J-33 — bond Q-45 — — 5/3 bondJ-33 — bond Q-45 — — 5/2 bond J-33 — bond Q-45 — — 4/2 bond J-34 — bondQ-45 — — 1/3 bond J-34 — bond Q-45 — — 1/4 bond J-34 — bond Q-45 — — 3/5bond J-34 — bond Q-45 — — 3/1 bond J-34 — bond Q-45 — — 4/1 CH₂ J-35 —bond Q-45 — — 1/4 bond J-35 — bond Q-45 — — 4/1 CH₂ J-36 — bond Q-45 — —1/3 bond J-36 — bond Q-45 — — 3/1 bond J-36 — bond Q-45 — — 3/5 bondJ-36 — bond Q-45 — — 5/3 bond J-37 — bond Q-45 — — 2/5 bond J-37 — bondQ-45 — — 5/2 bond J-37 — bond Q-45 — — 2/4 bond J-37 — bond Q-45 — — 4/2bond J-38 — bond Q-45 — — 2/5 bond J-38 — bond Q-45 — — 5/2 bond J-38 —bond Q-45 — — 2/4 bond J-38 — bond Q-45 — — 4/2 bond J-39 4-Me bond Q-45— — 3/5 bond J-39 4-Me bond Q-45 — — 5/3 bond J-40 — bond Q-45 — — 3/5bond J-40 — bond Q-45 — — 5/3 bond J-41 — bond Q-45 — — 1/3 bond J-41 —bond Q-45 — — 1/4 CH₂ J-42 — bond Q-45 — — 1/3 CH₂ J-42 — bond Q-45 — —1/4 CH₂ J-43 — bond Q-45 — — 1/4 bond J-44 — bond Q-45 — — 1/3 bond J-44— bond Q-45 — — 2/4 bond J-44 — bond Q-45 — — 2/5 bond J-44 — bond Q-45— — 2/6 bond J-45 — bond Q-45 — — 2/4 bond J-45 — bond Q-45 — — 2/5 bondJ-45 — bond Q-45 — — 2/6 bond J-46 — bond Q-45 — — 2/4 bond J-46 — bondQ-45 — — 2/5 bond J-46 — bond Q-45 — — 4/2 bond J-46 — bond Q-45 — — 5/2bond J-47 — bond Q-45 — — 2/4 bond J-47 — bond Q-45 — — 2/5 bond J-47 —bond Q-45 — — 4/2 bond J-47 — bond Q-45 — — 5/2 bond J-48 — bond Q-45 —— 3/5 bond J-49 — bond Q-45 — — 2/4 bond J-49 — bond Q-45 — — 2/5 bondJ-49 — bond Q-45 — — 4/2 bond J-49 — bond Q-45 — — 5/2 bond J-50 — bondQ-45 — — 2/6 bond J-51 — bond Q-45 — — 2/6 bond J-52 — bond Q-45 — — 2/6bond J-53 — — — — — 2/3 bond J-54 — — — — — 2/3 bond J-55 — — — — — 2/3bond J-56 — — — — — 2/3 bond J-57 1-Me — — — — 2/4 bond J-58 1-Me — — —— 3/4 bond J-59 — — — — — 2/4 bond J-60 — — — — — 2/4 bond J-61 — — — —— 2/4 bond J-62 — — — — — 2/4 bond J-63 — — — — — 3/4 bond J-64 — — — —— 2/3 bond J-65 — — — — — 3/4 bond J-66 — — — — — 6/7 bond J-67 — — — —— 2/3 bond J-68 — — — — — 2/3 bond J-69 — bond Q-45 — — 1/3 bond J-69 —bond Q-45 — — 1/4 bond J-70 — bond Q-45 — — 1/3 bond J-71 — bond Q-45 —— 2/4 bond J-71 — bond Q-45 — — 4/2 bond J-72 — bond Q-45 — — 2/4 bondJ-72 — bond Q-45 — — 4/2 bond J-73 — bond Q-45 — — 2/4 bond J-73 — bondQ-45 — — 4/2 bond J-73 — bond Q-45 — — 1/3 bond J-73 — bond Q-45 — — 1/4bond J-73 — bond Q-45 — — 4/1 bond J-74 3-Me bond Q-45 — — 2/4 bond J-743-Me bond Q-45 — — 2/5 bond J-74 3-Me bond Q-45 — — 4/2 bond J-74 3-Mebond Q-45 — — 5/2 bond J-74 — bond Q-45 — — 3/5 bond J-74 — bond Q-45 —— 5/3 bond J-75 — bond Q-45 — — 3/5 bond J-75 — bond Q-45 — — 5/3 bondJ-75 — bond Q-45 — — 2/4 bond J-75 — bond Q-45 — — 2/5 bond J-75 2-Mebond Q-45 — — 3/5 bond J-75 2-Me bond Q-45 — — 5/3 bond J-76 — bond Q-45— — 3/6 bond J-76 — bond Q-45 — — 6/3 bond J-77 — bond Q-45 — — 3/5 bondJ-77 — bond Q-45 — — 5/3 bond J-78 — bond Q-45 — — 1/3 bond J-79 — bondQ-45 — — 1/3 bond J-79 — bond Q-45 — — 3/1 bond J-80 — bond Q-45 — — 1/3bond J-80 — bond Q-45 — — 3/1 bond J-81 — bond Q-45 — — 3/5 bond J-81 —bond Q-45 — — 5/3 bond J-82 — bond Q-45 — — 3/5 bond J-82 — bond Q-45 —— 3/6 bond J-82 — bond Q-45 — — 5/3 bond J-82 — bond Q-45 — — 6/3 CH₂J-83 — — — — — 2/6 O J-29 — bond Q-45 — — 3/5 S J-29 — bond Q-45 — — 3/5SO J-29 — bond Q-45 — — 3/5 SO₂ J-29 — bond Q-45 — — 3/5 NH J-29 — bondQ-45 — — 3/5 NMe J-29 — bond Q-45 — — 3/5 NPr J-29 — bond Q-45 — — 3/5CH₂ J-29 — bond Q-45 — — 3/5 CH-i-Bu J-29 — bond Q-45 — — 3/5 bond J-294-Me bond Q-45 — — 3/5 bond J-29 5-Me bond Q-45 — — 3/5 bond J-294,5-di-Me bond Q-45 — — 3/5 bond J-29 4,4-di-Me bond Q-45 — — 3/5 bondJ-29 [Note 1] bond Q-45 6-Me, — 3/5 [Note 1] bond J-29 [Note 2] bondQ-45 6-Me, — 3/5 [Note 2] bond J-29 5-Et bond Q-45 — — 3/5 bond J-295-t-Bu — — — — 3/5 bond J-29 5-t-amyl — — — — 3/5 bond J-295-(4-Me-3-penten-1-yl) — — — — 3/5 bond J-29 5-(3,3-di-Me-1-butyn-1-yl)— — — — 3/5 bond J-29 5-c-Pr bond Q-45 — — 3/5 bond J-295-(4-Me-cyclohexyl) — — — — 3/5 bond J-29 5-CF₃ bond Q-45 — — 3/5 bondJ-29 5-perfluoropropyl — — — — 3/5 bond J-29 5-(3,3-di-Cl-2-propen-1-yl)— — — — 3/5 bond J-29 5-OMe bond Q-45 — — 3/5 bond J-29 5-SiMe₃ — — — —3/5 bond J-69 4-F bond Q-45 — — 1/3 bond J-69 4-Cl bond Q-45 — — 1/3bond J-69 4-OH bond Q-45 — — 1/3 bond J-69 4-NH₂ bond Q-45 — — 1/3 bondJ-69 4-CN O Q-45 — — 1/3 bond J-69 4-NO₂ NH Q-45 — — 1/3 bond J-69 4-CF₃S Q-45 — — 1/3 bond J-69 — O Q-45 — — 1/3 bond J-69 — S Q-45 — — 1/3bond J-69 — SO Q-45 — — 1/3 bond J-69 — SO₂ Q-45 — — 1/3 bond J-69 — NHQ-45 — — 1/3 bond J-69 — N—Me Q-45 — — 1/3 bond J-69 — CH₂ Q-45 — — 1/3bond J-69 4-OEt bond Q-45 — — 1/3 bond J-69 4-OCF₃ bond Q-45 — — 1/3bond J-69 4-SMe bond Q-45 — — 1/3 bond J-69 4-SOMe bond Q-45 — — 1/3bond J-69 4-SO₂Me bond Q-45 — — 1/3 bond J-69 4-SO₂-t-Bu — — — — 1/3bond J-69 4-SCF₃ bond Q-45 — — 1/3 bond J-69 4-SO₂CH₂CF₃ — — — — 1/4bond J-22 4-NH-i-Bu — — — — 2/4 bond J-22 4-di-EtN — — — — 2/4 bond J-224-NH-cyclohexyl — — — — 2/4 bond J-69 4-CH₂O-i-Pr — — — — 1/4 bond J-694-CH₂OCHF₂ bond Q-45 — — 1/3 bond J-69 4-CH₂OH bond Q-45 — — 1/3 bondJ-74 3-acetyl bond Q-45 — — 2/5 bond J-69 4-CO₂-i-Pr — — — — 1/4 bondJ-69 4-O-acetyl bond Q-45 — — 1/3 bond J-69 4-S-acetyl bond Q-45 — — 1/3bond J-69 4-CONHMe bond Q-45 — — 1/3 bond J-69 4-CONEt₂ — — — — 1/4 bondJ-69 — O Q-45 — — 1/4 bond J-29 — bond Q-1  — — 3/5 bond J-29 — bondQ-2  — — 3/5 bond J-29 — bond Q-3  — Me 3/5 bond J-29 — bond Q-4  — —3/5 bond J-29 — bond Q-5  — — 3/5 bond J-29 — bond Q-6  — — 3/5 bondJ-29 — bond Q-7  — — 3/5 bond J-29 — bond Q-8  — — 3/5 bond J-29 — bondQ-9  — — 3/5 bond J-29 — bond Q-10 — Me 3/5 bond J-29 — bond Q-11 — Me3/5 bond J-29 — bond Q-12 — Me 3/5 bond J-29 — bond Q-13 — Me 3/5 bondJ-29 — bond Q-14 — Me 3/5 bond J-29 — bond Q-15 — — 3/5 bond J-29 — bondQ-16 — — 3/5 bond J-29 — bond Q-17 — — 3/5 bond J-29 — bond Q-18 — — 3/5bond J-29 — bond Q-19 — — 3/5 bond J-29 — bond Q-20 — — 3/5 bond J-29 —bond Q-21 — Me 3/5 bond J-29 — bond Q-22 — Me 3/5 bond J-29 — bond Q-23— Me 3/5 bond J-29 — bond Q-24 — — 3/5 bond J-29 — bond Q-25 — — 3/5bond J-29 — bond Q-26 — — 3/5 bond J-29 — bond Q-27 — — 3/5 bond J-29 —bond Q-28 — Me 3/5 bond J-29 — bond Q-29 — — 3/5 bond J-29 — bond Q-30 —— 3/5 bond J-29 — bond Q-31 — Me 3/5 bond J-29 — bond Q-32 — — 3/5 bondJ-29 — bond Q-33 — — 3/5 bond J-29 — bond Q-34 — — 3/5 bond J-29 — bondQ-35 — — 3/5 bond J-29 — bond Q-36 — — 3/5 bond J-29 — bond Q-37 — — 3/5bond J-29 — bond Q-38 — — 3/5 bond J-29 — bond Q-39 — — 3/5 bond J-29 —bond Q-40 — — 3/5 bond J-29 — bond Q-41 — — 3/5 bond J-29 — bond Q-42 —— 3/5 bond J-29 — bond Q-43 — — 3/5 bond J-29 — bond Q-44 — — 3/5 bondJ-29 — CH₂ Q-46 — — 3/5 bond J-29 — bond Q-47 — — 3/5 bond J-29 — bondQ-48 — — 3/5 bond J-29 — bond Q-49 — — 3/5 bond J-29 — bond Q-50 — — 3/5bond J-29 — bond Q-51 — — 3/5 bond J-29 — bond Q-52 — — 3/5 bond J-29 —bond Q-53 — — 3/5 bond J-29 — bond Q-54 — — 3/5 bond J-29 — bond Q-55 —— 3/5 bond J-29 — bond Q-56 — — 3/5 bond J-29 — bond Q-57 — — 3/5 bondJ-29 — bond Q-58 — — 3/5 bond J-29 — bond Q-59 — — 3/5 bond J-29 — bondQ-60 — — 3/5 bond J-29 — bond Q-61 — — 3/5 bond J-29 — bond Q-62 — — 3/5bond J-29 — bond Q-63 — — 3/5 bond J-29 — bond Q-64 — — 3/5 bond J-29 —bond Q-65 — — 3/5 bond J-29 — bond Q-66 — — 3/5 bond J-29 — bond Q-67 —— 3/5 bond J-29 — bond Q-68 — — 3/5 bond J-29 — bond Q-69 — — 3/5 bondJ-29 — bond Q-45 2-Me — 3/5 bond J-29 — bond Q-45 3-Me — 3/5 bond J-29 —bond Q-45 4-Me — 3/5 bond J-29 — bond Q-45 2-Cl — 3/5 bond J-29 — bondQ-45 3-Cl — 3/5 bond J-29 — bond Q-45 4-Cl — 3/5 bond J-29 — bond Q-452-OMe — 3/5 bond J-29 — bond Q-45 3-OMe — 3/5 bond J-29 — bond Q-454-OMe — 3/5 bond J-29 — bond Q-45 2-Et — 3/5 bond J-29 — bond Q-453-i-Pr — 3/5 bond J-29 — bond Q-45 2,6-di-Me — 3/5 bond J-29 — bond Q-454-vinyl — 3/5 bond J-29 — bond Q-45 4-ethynyl — 3/5 bond J-29 — bondQ-45 4-c-Pr — 3/5 bond J-29 — bond Q-45 3-CF₃ — 3/5 bond J-29 — bondQ-45 3-OCF₃ — 3/5 bond J-29 — bond Q-45 4-Br — 3/5 bond J-29 — bond Q-453-OH — 3/5 bond J-29 — bond Q-45 3-NH₂ — 3/5 bond J-29 — bond Q-45 2-CN— 3/5 bond J-29 — bond Q-45 2-NO₂ — 3/5 bond J-29 — bond Q-45 4-O-t-Bu —3/5 bond J-29 — bond Q-45 4-SMe — 3/5 bond J-29 — bond Q-45 4-SCF₃ — 3/5bond J-29 — bond Q-45 3-SO₂Me — 3/5 bond J-29 — bond Q-45 3-NHMe — 3/5bond J-29 — bond Q-45 4-NMe₂ — 3/5 bond J-29 — bond Q-45 2-CH₂OMe — 3/5bond J-29 — bond Q-45 3-COMe — 3/5 bond J-29 — bond Q-45 3-CO₂Me — 3/5bond J-29 — bond Q-45 3-CONHMe — 3/5 bond J-29 — bond Q-45 4-OCOMe — 3/5bond J-29 — bond Q-45 4-SCOMe — 3/5 bond J-29 — bond Q-45 3-CONMe₂ — 3/5bond J-29 — bond Q-45 4-SiMe₃ — 3/5 bond J-29 — bond Q-45 2,6-di-F — 3/5bond J-29 — bond Q-45 2,6-di-Cl — 3/5 bond J-29 — bond Q-45 2-OH — 3/5bond J-29 — bond Q-45 4-OCHF₂ — 3/5 bond J-26 1-Me bond Q-45 — — 2/5bond J-26 [Note 3] bond Q-45 [Note 3] — 2/5 bond J-26 1-Me, [Note 3]bond Q-45 [Note 3] — 2/5 bond J-26 — bond Q-45 4-OH — 2/5 bond J-26 —bond Q-45 4-OMe — 2/5 bond J-26 — CH₂ Q-45 4-OH — 2/5 bond J-26 — CH₂Q-45 4-OMe — 2/5 bond J-26 — bond Q-45 4-OH — 2/4 bond J-26 — bond Q-454-OMe — 2/4 bond J-26 — CH₂ Q-45 4-OH — 2/4 bond J-26 — CH₂ Q-45 4-OMe —2/4 bond J-25 — bond Q-45 4-OH — 2/4 bond J-25 — bond Q-45 4-OMe — 2/4bond J-25 — CH₂ Q-45 4-OH — 2/4 bond J-25 — CH₂ Q-45 4-OMe — 2/4 bondJ-1  5-Me bond Q-45 — — 2/4 bond J-3  — bond Q-45 — — 2/4 bond J-3 [Note 4] bond Q-45 [Note 4] — 2/5 bond J-29 5-CO₂Me bond Q-45 — — 3/5bond J-29 5-CO₂-Et bond Q-45 — — 3/5 bond J-29 4,4-di-Me-5-CO₂-Me bondQ-45 — — 3/5 bond J-29 5-CONEt₂ bond Q-45 — — 3/5 bond J-29 — NH Q-45 —— 3/5 bond J-29 — NMe Q-45 — — 3/5 bond J-29 — NEt Q-45 — — 3/5 bondJ-29 — NPr Q-45 — — 3/5 bond J-29 5-NHAc — — — — 3/5 bond J-29 5-NAc₂ —— — — 3/5 bond J-29 5-N(Me)Ac — — — — 3/5 bond J-29 5-N(Me)C(═O)Ph — — —— 3/5 bond J-29 5-N(Et)Ac — — — — 3/5 bond J-29 5-N(Et)C(═O)Ph — — — —3/5 bond J-29 5-NHC(═O)OMe — — — — 3/5 bond J-29 5-N(Me)C(═O)OMe — — — —3/5 bond J-29 5-NHC(═O)OEt — — — — 3/5 bond J-29 5-N(Me)C(═O)OEt — — — —3/5 bond J-69 3-Cl — — — — 1/3 bond J-69 3-Br — — — — 1/3 bond J-69 3-I— — — — 1/3 bond J-69 3-Me — — — — 1/3 bond J-69 3-Et — — — — 1/3 bondJ-69 3-Pr — — — — 1/3 bond J-69 3-i-Pr — — — — 1/3 bond J-69 3-Bu — — —— 1/3 bond J-69 3-i-Bu — — — — 1/3 bond J-69 3-s-Bu — — — — 1/3 bondJ-69 3-t-Bu — — — — 1/3 bond J-69 3-Am — — — — 1/3 bond J-69 3-i-Am — —— — 1/3 bond J-69 3-t-Am — — — — 1/3 bond J-69 3-cyclopropyl — — — — 1/3bond J-69 3-cyclobutyl — — — — 1/3 bond J-69 3-cyclopentyl — — — — 1/3bond J-69 3-cyclohexyl — — — — 1/3 bond J-69 3-triflurometoxy — — — —1/3 bond J-69 3-isopropyoxy — — — — 1/3 bond J-69 3-isobutoxy — — — —1/3 bond J-69 4-Cl — — — — 1/4 bond J-69 4-Br — — — — 1/4 bond J-69 4-I— — — — 1/4 bond J-69 4-Me — — — — 1/4 bond J-69 4-Et — — — — 1/4 bondJ-69 4-Pr — — — — 1/4 bond J-69 4-i-Pr — — — — 1/4 bond J-69 4-Bu — — —— 1/4 bond J-69 4-i-Bu — — — — 1/4 bond J-69 4-s-Bu — — — — 1/4 bondJ-69 4-t-Bu — — — — 1/4 bond J-69 4-Am — — — — 1/4 bond J-69 4-i-Am — —— — 1/4 bond J-69 4-t-Am — — — — 1/4 bond J-69 4-cyclopropyl — — — — 1/4bond J-69 4-cyclobutyl — — — — 1/4 bond J-69 4-cyclopentyl — — — — 1/4bond J-69 4-cyclohexyl — — — — 1/4 bond J-69 4-triflurometoxy — — — —1/4 bond J-69 4-isopropyoxy — — — — 1/4 bond J-69 4-isobutoxy — — — —1/4 bond J-69 3,4-di-Cl — — — — 1/4 bond J-69 3,4-di-Br — — — — 1/4 bondJ-69 3,4-di-Me — — — — 1/4 bond J-69 3,4-di-Et — — — — 1/4 bond J-693,4-di-OMe — — — — 1/4 bond J-69 3,4-di-OEt — — — — 1/4 bond J-693-OMe-4-O-propargyl — — — — 1/4 bond J-4  5-i-Bu — — — — 2/5 bond J-4 5-i-Am — — — — 2/5 bond J-5  5-i-Bu — — — — 2/5 bond J-5  5-i-Am — — — —2/5 bond J-11 5-i-Bu — — — — 3/5 bond J-11 5-i-Am — — — — 3/5 bond J-29— bond Q-70 — — 3/5 bond J-29 — bond Q-71 — — 3/5 bond J-29 — bond Q-72— Me 3/5 bond J-29 — bond Q-73 — — 3/5 bond J-29 — bond Q-74 — — 3/5bond J-29 — bond Q-75 — Me 3/5 bond J-29 — bond Q-76 — — 3/5 bond J-29 —bond Q-77 — — 3/5 bond J-29 — bond Q-78 — Me 3/5 bond J-29 — bond Q-79 —Me 3/5 bond J-29 — bond Q-80 — — 3/5 bond J-29 — bond Q-81 — — 3/5 bondJ-29 — bond Q-82 — — 3/5 bond J-29 — bond Q-83 — — 3/5 bond J-29 — bondQ-84 — — 3/5 bond J-29 — bond Q-85 — — 3/5 bond J-29 — bond Q-86 — Me3/5 bond J-29 — bond Q-87 — — 3/5 bond J-29 — bond Q-88 — Me 3/5 bondJ-29 — bond Q-89 — — 3/5 bond J-29 — bond Q-90 — — 3/5 bond J-29 — bondQ-91 — — 3/5 bond J-29 — bond Q-92 — Me 3/5 bond J-29 — bond Q-93 — —3/5 bond J-29 — bond Q-94 — — 3/5 bond J-29 — bond Q-95 — Me 3/5 bondJ-29 — bond Q-96 — — 3/5 bond J-29 — bond Q-97 — — 3/5 bond J-29 — bondQ-98 — — 3/5 bond J-29 — bond Q-99 — — 3/5 bond J-29 — bond  Q-100 — —3/5 bond J-29 — bond  Q-101 — — 3/5 bond J-29 — bond  Q-102 — Me 3/5bond J-29 — bond Q-87 4-phenyl — 3/5 bond J-29 — bond Q-72 — acetyl 3/5bond J-29 — bond Q-72 — methoxycarbonyl 3/5 bond J-29 — bond Q-72 —methoxy 3/5 bond J-29 — bond Q-71 4-Cl — 3/5 bond J-29 — bond Q-71 5-Cl— 3/5 bond J-29 — bond Q-71 6-Cl — 3/5 bond J-29 — bond Q-71 7-Cl — 3/5bond J-29 — bond Q-71 4-Me — 3/5 bond J-29 — bond Q-71 5-Me — 3/5 bondJ-29 — bond Q-71 6-Me — 3/5 bond J-29 — bond Q-71 5-CF₃ — 3/5 bond J-29— bond Q-71 5-NO₂ — 3/5 bond J-29 — bond Q-71 6-Br — 3/5 bond J-29 —bond Q-71 6-NO₂ — 3/5 bond J-29 — bond Q-71 6-NH₂ — 3/5 bond J-29 — bondQ-71 6-OMe — 3/5 bond J-29 — bond Q-71 5,6-di-OMe — 3/5 bond J-29 — bondQ-71 5,6-di-Cl — 3/5 bond J-29 — bond Q-70 5-Cl — 3/5 bond J-29 — bondQ-70 5-Me — 3/5 bond J-29 — bond Q-70 5-NO₂ — 3/5 bond J-29 — bond Q-705-NH₂ — 3/5 bond J-29 — bond Q-70 6-Cl — 3/5 bond J-29 — bond Q-70 6-Me— 3/5 bond J-29 — bond Q-70 6-NO₂ — 3/5 bond J-29 — bond Q-70 6-NH₂ —3/5 bond J-29 — bond Q-70 5,6-di-Cl — 3/5 bond J-29 — bond Q-705-Cl-6-OH — 3/5 bond J-29 — bond Q-72 5-Cl Me 3/5 bond J-29 — bond Q-725-Me Me 3/5 bond J-29 — bond Q-72 5-NO₂ Me 3/5 bond J-29 — bond Q-725-NH₂ Me 3/5 bond J-29 — bond Q-72 6-Cl Me 3/5 bond J-29 — bond Q-726-Me Me 3/5 bond J-29 — bond Q-72 6-NO₂ Me 3/5 bond J-29 — bond Q-726-NH₂ Me 3/5 bond J-29 — bond Q-72 5,6-di-Cl Me 3/5 bond J-29 — bondQ-63 4-Me — 3/5 bond J-29 — bond Q-63 4-NO₂ — 3/5 bond J-29 — bond Q-634-NH₂ — 3/5 bond J-29 — bond Q-63 5-Cl — 3/5 bond J-29 — bond Q-63 5-Me— 3/5 bond J-29 — bond Q-63 5-CN — 3/5 bond J-29 — bond Q-63 5-NO₂ — 3/5bond J-29 — bond Q-63 5-NH₂ — 3/5 bond J-29 — bond Q-63 5-COOMe — 3/5bond J-29 — bond Q-63 5,6-di-Cl — 3/5 bond J-29 5-N(Ac)C(═O)Ph bond — —— 3/5 bond J-29 5-N(Ac)C(═O)(2-carbomethoxy-Ph bond — — — 3/5 *Thedefinitions of J, R⁵, Q, R⁷ and R¹² in the compounds of this table areas defined in Exhibits 3 and 4 in the above Embodiments. A dash “—” inthe (R⁵)_(x) column indicates no substitution on J. A dash in each ofthe Z² and Q columns indicates that no Z²Q substituent is attached as R⁵to J. A dash in the (R⁷)_(p) and/or R¹² columns indicates nosubstitution on Q. **J-orientation refers to the attachment points forZ¹ and Z² (or another R⁵ when Z² is not present) on ring J. The firstnumber refers to the ring position on J where Z¹ is attached, and thesecond number refers to the ring position on J where Z² is attached or,when Z² is not present, the ring position on J where the substituentlisted under (R⁵)_(x) is attached. [Note 1]: R⁵ and R⁷ taken together toform a CH₂CH₂ bridge between position 4 of J-29 and position 2 of Q-45.[Note 2]: R⁵ and R⁷ taken together to form a CH₂ bridge between position4 of J-29 and position 2 of Q-45. [Note 3]: R⁵ and R⁷ taken together toform a CH₂CH₂ bridge between position 4 of J-26 and position 2 of Q-45.[Note 4]: R⁵ and R⁷ taken together to form a CH₂CH₂ bridge betweenposition 1of J-3 and position 2 of Q-45.

TABLE 3*

X (R²)_(n) G R^(3a) R^(11a) X¹ — G-1 H — X¹ — G-2 H — X¹ — G-3 H H X¹ —G-4 H — X¹ — G-5 H — X¹ — G-6 H H X¹ — G-7 H — X¹ — G-8 H — X¹ — G-9 H HX¹ — G-10 H — X¹ — G-11 H — X¹ — G-12 H H X¹ — G-13 H H X¹ — G-14 H — X¹— G-15 H — X¹ — G-16 H H X¹ — G-17 H — X¹ — G-18 H — X¹ — G-19 H H X¹ —G-20 H — X¹ — G-21 H — X¹ — G-22 H H X¹ — G-23 H — X¹ — G-24 H — X¹ —G-25 H — X¹ — G-26 H — X¹ — G-27 H — X¹ — G-28 H — X¹ — G-29 H — X¹ —G-30 H — X¹ — G-31 H — X¹ — G-32 H — X¹ — G-33 H — X¹ — G-34 H — X¹ —G-35 H — X¹ — G-36 H — X¹ — G-37 H — X¹ — G-38 H — X¹ — G-39 H H X¹ —G-40 H — X¹ — G-41 H — X¹ — G-42 H H X¹ — G-43 H H X¹ — G-44 H — X¹ —G-45 H — X¹ — G-46 H — X¹ — G-47 H — X¹ — G-48 H H X¹ — G-49 H — X¹ —G-50 H — X¹ — G-51 H H X¹ — G-52 H — X¹ — G-53 H — X¹ — G-54 H H X¹ —G-55 H — X¹ — G-56 H — X¹ — G-57 H — X¹ — G-58 H H X¹ — G-59 H H X¹ —G-2 Me — X¹ — G-2 Cl — X¹ — G-2 F — X¹ — G-2 CF₃ — X¹ — G-14 n-Pr — X¹ —G-3 H Me X¹ — G-3 H n-Pr X¹ — G-26 5-Me — X¹ 2-Me G-1 H — X¹ 3-Me G-1 H— X¹ 2,6-di-Me G-1 H — X¹ 3,5-di-Me G-1 H — X¹ 3-n-Bu G-1 H — X¹ 4-MeOG-1 H — X¹ 4-OH G-1 H — X¹ 4-Cl G-1 H — X¹ 4-Br G-1 H — X¹ 4-CN G-1 H —X² — G-1 H — X² — G-2 H — X² — G-3 H H X² — G-4 H — X² — G-5 H — X² —G-6 H H X² — G-7 H — X² — G-8 H — X² — G-9 H H X² — G-10 H — X² — G-11 H— X² — G-12 H H X² — G-13 H H X² — G-14 H — X² — G-15 H — X² — G-16 H HX² — G-17 H — X² — G-18 H — X² — G-19 H H X² — G-20 H — X² — G-21 H — X²— G-22 H H X² — G-23 H — X² — G-24 H — X² — G-31 H — X² — G-32 H — X² —G-33 H — X² — G-34 H — X² — G-35 H — X² — G-37 H — X² — G-38 H — X² —G-39 H H X² — G-40 H — X² — G-41 H — X² — G-42 H H X² — G-43 H H X² —G-44 H — X² — G-45 H — X² — G-46 H — X² — G-47 H — X² — G-48 H H X² —G-49 H — X² — G-50 H — X² — G-51 H H X² — G-52 H — X² — G-53 H — X² —G-54 H H X² — G-2 Me — X² — G-2 Cl — X² — G-2 F — X² — G-2 CF₃ — X² —G-14 n-Pr — X² — G-3 H Me X² — G-3 H n-Pr X² 2-Me G-1 H — X² 3-Me G-1 H— X² 2,6-di-Me G-1 H — X² 3,5-di-Me G-1 H — X² 3-n-Bu G-1 H — X³ — G-1 H— X³ — G-2 H — X³ — G-3 H H X³ — G-4 H — X³ — G-5 H — X³ — G-6 H H X³ —G-7 H — X³ — G-8 H — X³ — G-9 H H X³ — G-10 H — X³ — G-11 H — X³ — G-12H H X³ — G-13 H H X³ — G-14 H — X³ — G-15 H — X³ — G-16 H H X³ — G-17 H— X³ — G-18 H — X³ — G-19 H H X³ — G-20 H — X³ — G-21 H — X³ — G-22 H HX³ — G-23 H — X³ — G-24 H — X³ — G-31 H — X³ — G-32 H — X³ — G-33 H — X³— G-34 H — X³ — G-35 H — X³ — G-37 H — X³ — G-38 H — X³ — G-39 H H X³ —G-40 H — X³ — G-41 H — X³ — G-42 H H X³ — G-43 H H X³ — G-44 H — X³ —G-45 H — X³ — G-46 H — X³ — G-47 H — X³ — G-48 H H X³ — G-49 H — X³ —G-50 H — X³ — G-51 H H X³ — G-52 H — X³ — G-53 H — X³ — G-54 H H X³ —G-2 Me — X³ — G-2 Cl — X³ — G-2 F — X³ — G-2 CF₃ — X³ — G-14 n-Pr — X³ —G-3 H Me X³ — G-3 H n-Pr X³ 2-Me G-1 H — X³ 3-Me G-1 H — X³ 2,6-di-MeG-1 H — X³ 3,5-di-Me G-1 H — X³ 3-n-Bu G-1 H — X³ 5-Me G-1 H — X³ 6-MeG-1 H — X⁴ — G-1 H — X⁵ — G-1 H — X⁶ — G-1 H — X⁷ — G-1 H — X⁸ — G-1 H —X⁹ — G-1 H — *The definitions of X, G, R³ _(a) and R¹¹ _(a) in thecompounds of this table are as defined in the Summary of the Inventionand Exhibit 2 in the above Embodiments. A dash “—” in the (R²)_(n)column indicates no substituents.

TABLE 4*

R¹ X G** J*** (R⁵)_(y) R^(7a) 2,5-dichlorophenyl X¹ G-1 J-1 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-1 (2/4) — H2,5-dimethylphenyl X¹ G-1 J-1 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-1 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-1 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-1 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-1 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-1 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-1 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-1 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-1 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-1 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-2 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-2 (2/4) — H2,5-dimethylphenyl X¹ G-1 J-2 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-2 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-2 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-2 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-2 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-2 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-2 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-2 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-2 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-2 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-3 (2/4) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-3 (2/4) 1-Me H2,5-dimethylphenyl X¹ G-1 J-3 (2/4) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-3 (2/4) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-1 J-3 (2/4) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-3 (2/4) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-3 (2/4) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-3 (2/4) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-3 (2/4) 1-Me H3,5-bis(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-3 (2/4) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-3 (2/4) 1-Me H 5-yl1-methyl-4-(trifuoromethyl)imidazol- X¹ G-1 J-3 (2/4) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-1 J-4 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-4 (2/5) — H2,5-dimethylphenyl X¹ G-1 J-4 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-4 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-4 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-4 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-4 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-4 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-4 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-4 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-4 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-4 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-8 (5/3) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-8 (5/3) — H2,5-dimethylphenyl X¹ G-1 J-8 (5/3) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-8 (5/3) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-8 (5/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-8 (5/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-8 (5/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-8 (5/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-8 (5/3) — H 1-yl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-8 (5/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-8 (5/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-8 (5/3) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-9 (5/3) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-9 (5/3) — H2,5-dimethylphenyl X¹ G-1 J-9 (5/3) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-9 (5/3) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-9 (5/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-9 (5/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-9 (5/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-9 (5/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-9 (5/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-9 (5/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-9 (5/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-9 (5/3) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-11 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-12 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-12 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-12 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-12 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-12 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) 1-Me H2,5-dimethylphenyl X¹ G-1 J-12 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-12 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-1 J-14 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-14 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-14 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-14 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-14 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-14 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-14 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-14 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-14 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-14 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-14 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-14 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-15 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-15 (2/5) — H2,5-dimethylphenyl X¹ G-1 J-15 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-15 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-15 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-15 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-15 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-15 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-15 (2/5) — H 1-yl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-15 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-15 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-15 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-16 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-16 (2/5) — H2,5-dimethylphenyl X¹ G-1 J-16 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-16 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-16 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-16 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-16 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-16 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-16 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-16 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-16 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-16 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-22 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-22 (2/4) — H2,5-dimethylphenyl X¹ G-1 J-22 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-22 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-22 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-22 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-22 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-22 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-22 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-22 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-22 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-22 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-24 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-24 (2/4) — H2,5-dimethylphenyl X¹ G-1 J-24 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-24 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-24 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-24 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-24 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-24 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-24 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-24 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-24 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-24 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-25 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-25 (2/4) — H2,5-dimethylphenyl X¹ G-1 J-25 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-25 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-25 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-25 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-25 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-25 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-25 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-25 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-25 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-25 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-26 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/4) — H2,5-dimethylphenyl X¹ G-1 J-26 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-26 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-26 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-26 (2/4) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/4) 1-Me H2,5-dimethylphenyl X¹ G-1 J-26 (2/4) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/4) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/4) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/4) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/4) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/4) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/4) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-26 (2/4) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-1 J-26 (2/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/5) 1-Me H2,5-dimethylphenyl X¹ G-1 J-26 (2/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-26 (2/5) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-26 (2/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-26 (2/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-26 (2/5) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-1 J-28 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-28 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-28 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-28 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-28 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-28 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-28 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-28 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-28 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-28 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-28 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-28 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-30 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-30 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-30 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-30 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-30 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) 1-Me H2,5-dimethylphenyl X¹ G-1 J-30 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-30 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-1 J-36 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-36 (3/5) 1-Me H2,5-dimethylphenyl X¹ G-1 J-36 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-36 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-36 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-36 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-36 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-36 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-36 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-36 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-1 J-37 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-37 (2/5) — H2,5-dimethylphenyl X¹ G-1 J-37 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-37 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-37 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-37 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-37 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-37 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-37 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-37 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-37 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-37 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-38 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-38 (2/5) — H2,5-dimethylphenyl X¹ G-1 J-38 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-38 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-38 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-38 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-38 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-38 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-38 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-38 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-38 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-38 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-39 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-39 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-39 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-39 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-39 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-39 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-39 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-39 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-39 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-39 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-39 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-39 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-40 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-40 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-40 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-40 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-40 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-40 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-40 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-40 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-40 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-40 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-40 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-40 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-69 (1/3) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-69 (1/3) — H2,5-dimethylphenyl X¹ G-1 J-69 (1/3) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-69 (1/3) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-69 (1/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-69 (1/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-69 (1/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-69 (1/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-69 (1/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-69 (1/3) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-69 (1/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-69 (1/4) — H2,5-dimethylphenyl X¹ G-1 J-69 (1/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-69 (1/4) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-69 (1/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-69 (1/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-69 (1/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-69 (1/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-69 (1/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-69 (1/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-69 (1/4) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 2- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 2- Me2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 2- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 2- Me3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 2- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 2- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 2- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 2- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 2- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-11 (3/5) — 2- 2-yl Me2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 3- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 3- Me2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 3- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 3- Me3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 3- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 3- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 3- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 3- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 3- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 3- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 3- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-11 (3/5) — 3- 2-yl Me2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 4- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 4- Me2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 4- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 4- Me3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 4- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 4- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 4- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 4- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 4- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-11 (3/5) — 4- 2-yl Me2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 2-Cl2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 2-Cl2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 2-Cl2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 2-Cl3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 2-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 2-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 2-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 2-Cl1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 2-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-11 (3/5) — 2-Cl 2-yl2,5-dichlorophenyl X¹ G-1 J-11 (3/5) — 4-Cl2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 4-Cl2,5-dimethylphenyl X¹ G-1 J-11 (3/5) — 4-Cl2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-11 (3/5) — 4-Cl3,5-dimethylpyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 4-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 4-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 4-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-11 (3/5) — 4-Cl1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-11 (3/5) — 4-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-11 (3/5) — 4-Cl 2-yl2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 5-Me 2- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me 2- Me2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 5-Me 2- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me 2- Me3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me 2- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me 2- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me 2- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me 2- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-29 (3/5) 5-Me 2- 2-yl Me2,5-dichlorophenyl X¹ G-1 J-29 (3/5) — 3- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 3- Me2,5-dimethylphenyl X¹ G-1 J-29 (3/5) — 3- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 3- Me3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) — 3- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 3- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 3- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 3- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 3- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 3- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 3- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-29 (3/5) — 3- 2-yl Me2,5-dichlorophenyl X¹ G-1 J-29 (3/5) — 4- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 4- Me2,5-dimethylphenyl X¹ G-1 J-29 (3/5) — 4- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 4- Me3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) — 4- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 4- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 4- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 4- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 4- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-29 (3/5) — 4- 2-yl Me2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 5-Me 2-Cl2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me 2-Cl2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 5-Me 2-Cl2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me 2-Cl3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me 2-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me 2-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me 2-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me 2-Cl1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me 2-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-29 (3/5) 5-Me 2-Cl 2-yl2,5-dichlorophenyl X¹ G-1 J-29 (3/5) — 4-Cl2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 4-Cl2,5-dimethylphenyl X¹ G-1 J-29 (3/5) — 4-Cl2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) — 4-Cl3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 4-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 4-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 4-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) — 4-Cl1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) — 4-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-29 (3/5) — 4-Cl 2-yl2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 5-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me H2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 5-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 5-Me H3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 5-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 5-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-29 (3/5) 5-Me H 2-yl2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 4-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 4-Me H2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 4-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 4-Me H3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 4-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 4-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 4-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 4-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-29 (3/5) 4-Me H 2-yl2,5-dichlorophenyl X¹ G-1 J-29 (3/5) 4,4- H di-Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 4,4- H di-Me2,5-dimethylphenyl X¹ G-1 J-29 (3/5) 4,4- H di-Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-29 (3/5) 4,4- H di-Me3,5-dimethylpyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4- H di-Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 4,4- H 1-yl di-Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 4,4- H 1-yl di-Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 4,4- H 1-yl di-Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4- H di-Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-29 (3/5) 4,4- H di-Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-29 (3/5) 4,4- H 5-yl di-Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-29 (3/5) 4,4- H 2-yldi-Me 2,5-dichlorophenyl X¹ G-2 J-1 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-1 (2/4) — H2,5-dimethylphenyl X¹ G-2 J-1 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-1 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-1 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-1 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-1 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-1 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-1 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-1 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-1 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-1 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-2 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-2 (2/4) — H2,5-dimethylphenyl X¹ G-2 J-2 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-2 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-2 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-2 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-2 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-2 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-2 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-2 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-2 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-2 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-3 (2/4) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-3 (2/4) 1-Me H2,5-dimethylphenyl X¹ G-2 J-3 (2/4) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-3 (2/4) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-3 (2/4) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-3 (2/4) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-3 (2/4) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-3 (2/4) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-3 (2/4) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-3 (2/4) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-2 J-4 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-4 (2/5) — H2,5-dimethylphenyl X¹ G-2 J-4 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-4 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-4 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-4 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-4 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-4 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-4 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-4 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-4 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-4 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-8 (5/3) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-8 (5/3) — H2,5-dimethylphenyl X¹ G-2 J-8 (5/3) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-8 (5/3) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-8 (5/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-8 (5/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-8 (5/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-8 (5/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-8 (5/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-8 (5/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-8 (5/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-8 (5/3) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-9 (5/3) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-9 (5/3) — H2,5-dimethylphenyl X¹ G-2 J-9 (5/3) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-9 (5/3) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-9 (5/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-9 (5/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-9 (5/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-9 (5/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-9 (5/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-9 (5/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-9 (5/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-9 (5/3) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — H2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-11 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-12 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-12 (3/5) — H2,5-dimethylphenyl X¹ G-2 J-12 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-12 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-12 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-12 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-12 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-12 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-12 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-12 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-12 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-12 (3/5) 1-Me H2,5-dimethylphenyl X¹ G-2 J-12 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-12 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-12 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-12 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-12 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-12 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-12 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-12 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-2 J-14 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-14 (3/5) — H2,5-dimethylphenyl X¹ G-2 J-14 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-14 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-14 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-14 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-14 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-14 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-14 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-14 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-14 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-14 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-15 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-15 (2/5) — H2,5-dimethylphenyl X¹ G-2 J-15 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-15 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-15 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-15 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-15 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-15 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-15 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-15 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-15 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-15 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-16 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-16 (2/5) — H2,5-dimethylphenyl X¹ G-2 J-16 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-16 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-16 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-16 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-16 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-16 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-16 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-16 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-16 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-16 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-22 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-22 (2/4) — H2,5-dimethylphenyl X¹ G-2 J-22 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-22 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-22 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-22 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-22 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-22 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-22 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-22 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-22 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-22 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-24 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-24 (2/4) — H2,5-dimethylphenyl X¹ G-2 J-24 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-24 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-24 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-24 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-24 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-24 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-24 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-24 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-24 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-24 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-25 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-25 (2/4) — H2,5-dimethylphenyl X¹ G-2 J-25 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-25 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-25 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-25 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-25 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-25 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-25 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-25 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-25 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-25 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-26 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/4) — H2,5-dimethylphenyl X¹ G-2 J-26 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/4) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-26 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-26 (2/4) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-26 (2/4) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/4) 1-Me H2,5-dimethylphenyl X¹ G-2 J-26 (2/4) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/4) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/4) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/4) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/4) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/4) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/4) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-26 (2/4) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-2 J-26 (2/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/5) 1-Me H2,5-dimethylphenyl X¹ G-2 J-26 (2/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-26 (2/5) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-26 (2/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-26 (2/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-26 (2/5) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-2 J-28 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-28 (3/5) — H2,5-dimethylphenyl X¹ G-2 J-28 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-28 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-28 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-28 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-28 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-28 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-28 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-28 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-28 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-28 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-30 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-30 (3/5) — H2,5-dimethylphenyl X¹ G-2 J-30 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-30 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-30 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-30 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-30 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-30 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-30 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-30 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-30 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-30 (3/5) 1-Me H2,5-dimethylphenyl X¹ G-2 J-30 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-30 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-30 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-30 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-30 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-30 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-30 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-30 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-2 J-36 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-36 (3/5) 1-Me H2,5-dimethylphenyl X¹ G-2 J-36 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-36 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-36 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-36 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-36 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-36 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-36 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-36 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X¹ G-2 J-37 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-37 (2/5) — H2,5-dimethylphenyl X¹ G-2 J-37 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-37 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-37 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-37 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-37 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-37 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-37 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-37 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-37 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-37 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-38 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-38 (2/5) — H2,5-dimethylphenyl X¹ G-2 J-38 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-38 (2/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-38 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-38 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-38 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-38 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-38 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-38 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-38 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-38 (2/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-39 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-39 (3/5) — H2,5-dimethylphenyl X¹ G-2 J-39 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-39 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-39 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-39 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-39 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-39 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-39 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-39 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-39 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-39 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-40 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-40 (3/5) — H2,5-dimethylphenyl X¹ G-2 J-40 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-40 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-40 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-40 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-40 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-40 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-40 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-40 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-40 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-40 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-69 (1/3) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-69 (1/3) — H2,5-dimethylphenyl X¹ G-2 J-69 (1/3) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-69 (1/3) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-69 (1/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-69 (1/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-69 (1/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-69 (1/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-69 (1/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-69 (1/3) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-69 (1/4) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-69 (1/4) — H2,5-dimethylphenyl X¹ G-2 J-69 (1/4) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-69 (1/4) — H3,5-dimethylpyrazol-1-yl X¹ G-2 J-69 (1/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-69 (1/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-69 (1/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-69 (1/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-69 (1/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-69 (1/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-69 (1/4) — H 2-yl2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 2- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 2- Me2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 2- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 2- Me3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 2- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 2- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 2- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 2- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 2- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-11 (3/5) — 2- 2-yl Me2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 3- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 3- Me2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 3- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 3- Me3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 3- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 3- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 3- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 3- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 3- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 3- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 3- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-11 (3/5) — 3- 2-yl Me2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 4- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 4- Me2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 4- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 4- Me3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 4- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 4- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 4- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 4- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 4- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-11 (3/5) — 4- 2-yl Me2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 2-Cl2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 2-Cl2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 2-Cl2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 2-Cl3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 2-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 2-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 2-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 2-Cl1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 2-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-11 (3/5) — 2-Cl 2-yl2,5-dichlorophenyl X¹ G-2 J-11 (3/5) — 4-Cl2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 4-Cl2,5-dimethylphenyl X¹ G-2 J-11 (3/5) — 4-Cl2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-11 (3/5) — 4-Cl3,5-dimethylpyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 4-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 4-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 4-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-11 (3/5) — 4-Cl1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-11 (3/5) — 4-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-11 (3/5) — 4-Cl 2-yl2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 2- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 2- Me2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 2- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 2- Me3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 2- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 2- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 2- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 2- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 2- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-29 (3/5) — 2- 2-yl Me2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 3- Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 3- Me2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 3- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 3- Me3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 3- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 3- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 3- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 3- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 3- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 3- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 3- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-29 (3/5) — 3- 2-yl Me2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 4- 157 Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 4- Me2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 4- Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 4- Me3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 4- Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 4- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 4- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 4- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4- Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 4- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-29 (3/5) — 4- 2-yl Me2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 2-Cl2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 2-Cl2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 2-Cl2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 2-Cl3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 2-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 2-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 2-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 2-Cl1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 2-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-29 (3/5) — 2-Cl 2-yl2,5-dichlorophenyl X¹ G-2 J-29 (3/5) — 4-Cl2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 4-Cl2,5-dimethylphenyl X¹ G-2 J-29 (3/5) — 4-Cl2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) — 4-Cl3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 4-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 4-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 4-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) — 4-Cl1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) — 4-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-29 (3/5) — 4-Cl 2-yl2,5-dichlorophenyl X¹ G-2 J-29 (3/5) 5-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 5-Me H2,5-dimethylphenyl X¹ G-2 J-29 (3/5) 5-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 5-Me H3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 5-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 5-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 5-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 5-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 5-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-29 (3/5) 5-Me H 2-yl2,5-dichlorophenyl X¹ G-2 J-29 (3/5) 4-Me H2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 4-Me H2,5-dimethylphenyl X¹ G-2 J-29 (3/5) 4-Me H2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 4-Me H3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 4-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 4-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 4-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4-Me H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 4-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-29 (3/5) 4-Me H 2-yl2,5-dichlorophenyl X¹ G-2 J-29 (3/5) 4,4- H di-Me2-chloro-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 4,4- H di-Me2,5-dimethylphenyl X¹ G-2 J-29 (3/5) 4,4- H di-Me2-methyl-5-(trifluoromethyl)phenyl X¹ G-2 J-29 (3/5) 4,4- H di-Me3,5-dimethylpyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4- H di-Me5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 4,4- H 1-yl di-Me5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 4,4- H 1-yl di-Me5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 4,4- H 1-yl di-Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4- H di-Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-2 J-29 (3/5) 4,4- H di-Me1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-2 J-29 (3/5) 4,4- H 5-yl di-Me1-methyl-4-(trifluoromethyl)imidazol- X¹ G-2 J-29 (3/5) 4,4- H 2-yldi-Me 2,5-dichlorophenyl X² G-1 J-1 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-1 (2/4) — H2,5-dimethylphenyl X² G-1 J-1 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-1 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-1 J-1 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-1 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-1 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-1 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-1 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-1 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-1 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-1 (2/4) — H 2-yl2,5-dichlorophenyl X² G-1 J-2 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-2 (2/4) — H2,5-dimethylphenyl X² G-1 J-2 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-2 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-1 J-2 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-2 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-2 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-2 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-2 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-2 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-2 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-2 (2/4) — H 2-yl2,5-dichlorophenyl X² G-1 J-3 (2/4) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-3 (2/4) 1-Me H2,5-dimethylphenyl X² G-1 J-3 (2/4) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-3 (2/4) 1-Me H3,5-dimethylpyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-3 (2/4) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-3 (2/4) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-3 (2/4) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-3 (2/4) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-3 (2/4) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-3 (2/4) 1-Me H 2-yl2,5-dichlorophenyl X² G-1 J-4 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-4 (2/5) — H2,5-dimethylphenyl X² G-1 J-4 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-4 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-4 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-4 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-4 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-4 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-4 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-4 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-4 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-4 (2/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-8 (5/3) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-8 (5/3) — H2,5-dimethylphenyl X² G-1 J-8 (5/3) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-8 (5/3) — H3,5-dimethylpyrazol-1-yl X² G-1 J-8 (5/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-8 (5/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-8 (5/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-8 (5/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-8 (5/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-8 (5/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-8 (5/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-8 (5/3) — H 2-yl2,5-dichlorophenyl X² G-1 J-9 (5/3) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-9 (5/3) — H2,5-dimethylphenyl X² G-1 J-9 (5/3) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-9 (5/3) — H3,5-dimethylpyrazol-1-yl X² G-1 J-9 (5/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-9 (5/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-9 (5/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-9 (5/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-9 (5/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-9 (5/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-9 (5/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-9 (5/3) — H 2-yl2,5-dichlorophenyl X² G-1 J-11 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — H2,5-dimethylphenyl X² G-1 J-11 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-11 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-12 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-12 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-12 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-12 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-12 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-12 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-12 (3/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-12 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-12 (3/5) 1-Me H2,5-dimethylphenyl X² G-1 J-12 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-12 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-12 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-12 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-12 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-12 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-12 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-12 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X² G-1 J-14 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-14 (3/5) — H2,5-dimethylphenyl X² G-1 J-14 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-14 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-14 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-14 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-14 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-14 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-14 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-14 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-14 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-14 (3/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-15 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-15 (2/5) — H2,5-dimethylphenyl X² G-1 J-15 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-15 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-15 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-15 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-15 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-15 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-15 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-15 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-15 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-15 (2/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-16 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-16 (2/5) — H2,5-dimethylphenyl X² G-1 J-16 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-16 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-16 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-16 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-16 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-16 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-16 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-16 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-16 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-16 (2/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-22 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-22 (2/4) — H2,5-dimethylphenyl X² G-1 J-22 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-22 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-1 J-22 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-22 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-22 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-22 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-22 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-22 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-22 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-22 (2/4) — H 2-yl2,5-dichlorophenyl X² G-1 J-24 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-24 (2/4) — H2,5-dimethylphenyl X² G-1 J-24 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-24 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-1 J-24 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-24 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-24 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-24 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-24 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-24 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-24 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-24 (2/4) — H 2-yl2,5-dichlorophenyl X² G-1 J-25 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-25 (2/4) — H2,5-dimethylphenyl X² G-1 J-25 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-25 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-1 J-25 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-25 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-25 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-25 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-25 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-25 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-25 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-25 (2/4) — H 2-yl2,5-dichlorophenyl X² G-1 J-26 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/4) — H2,5-dimethylphenyl X² G-1 J-26 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-1 J-26 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-26 (2/4) — H 2-yl2,5-dichlorophenyl X² G-1 J-26 (2/4) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/4) 1-Me H2,5-dimethylphenyl X² G-1 J-26 (2/4) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/4) 1-Me H3,5-dimethylpyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/4) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/4) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/4) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/4) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/4) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-26 (2/4) 1-Me H 2-yl2,5-dichlorophenyl X² G-1 J-26 (2/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/5) 1-Me H2,5-dimethylphenyl X² G-1 J-26 (2/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-26 (2/5) 1-Me H3,5-dimethylpyrazol-1-yl X² G-1 J-26 (2/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-26 (2/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-26 (2/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-26 (2/5) 1-Me H 2-yl2,5-dichlorophenyl X² G-1 J-28 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-28 (3/5) — H2,5-dimethylphenyl X² G-1 J-28 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-28 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-28 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-28 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-28 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-28 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-28 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-28 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-28 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-28 (3/5) — H 2-yl2,5-dichlorophenyl X¹ G-1 J-30 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) — H2,5-dimethylphenyl X¹ G-1 J-30 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X¹ G-1 J-30 (3/5) — H3,5-dimethylpyrazol-1-yl X¹ G-1 J-30 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X¹ G-1 J-30 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X¹ G-1 J-30 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X¹ G-1 J-30 (3/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-30 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-30 (3/5) 1-Me H2,5-dimethylphenyl X² G-1 J-30 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-30 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-30 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-30 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-30 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-30 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-30 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-30 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X² G-1 J-36 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-36 (3/5) 1-Me H2,5-dimethylphenyl X² G-1 J-36 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-36 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-36 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-36 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-36 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-36 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-36 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-36 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X² G-1 J-37 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-37 (2/5) — H2,5-dimethylphenyl X² G-1 J-37 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-37 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-37 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-37 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-37 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-37 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-37 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-37 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-37 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-37 (2/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-38 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-38 (2/5) — H2,5-dimethylphenyl X² G-1 J-38 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-38 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-38 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-38 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-38 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-38 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-38 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-38 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-38 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-38 (2/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-39 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-39 (3/5) — H2,5-dimethylphenyl X² G-1 J-39 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-39 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-39 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-39 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-39 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-39 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-39 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-39 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-39 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-39 (3/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-40 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-40 (3/5) — H2,5-dimethylphenyl X² G-1 J-40 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-40 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-1 J-40 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-40 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-40 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-40 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-40 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-40 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-40 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-40 (3/5) — H 2-yl2,5-dichlorophenyl X² G-1 J-69 (1/3) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-69 (1/3) — H2,5-dimethylphenyl X² G-1 J-69 (1/3) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-69 (1/3) — H3,5-dimethylpyrazol-1-yl X² G-1 J-69 (1/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-69 (1/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-69 (1/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-69 (1/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-69 (1/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-69 (1/3) — H 2-yl2,5-dichlorophenyl X² G-1 J-69 (1/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-69 (1/4) — H2,5-dimethylphenyl X² G-1 J-69 (1/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-69 (1/4) — H3,5-dimethylpyrazol-1-yl X² G-1 J-69 (1/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-69 (1/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-69 (1/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-69 (1/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-69 (1/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-69 (1/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-69 (1/4) — H 2-yl2,5-dichlorophenyl X² G-1 J-11 (3/5) — 2- Me2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 2- Me2,5-dimethylphenyl X² G-1 J-11 (3/5) — 2- Me2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 2- Me3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 2- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 2- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 2- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 2- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 2- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-11 (3/5) — 2- 2-yl Me2,5-dichlorophenyl X² G-1 J-11 (3/5) — 3- Me2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 3- Me2,5-dimethylphenyl X² G-1 J-11 (3/5) — 3- Me2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 3- Me3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 3- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 3- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 3- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 3- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 3- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 3- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 3- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-11 (3/5) — 3- 2-yl Me2,5-dichlorophenyl X² G-1 J-11 (3/5) — 4- Me2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 4- Me2,5-dimethylphenyl X² G-1 J-11 (3/5) — 4- Me2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 4- Me3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 4- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 4- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 4- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 4- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 4- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-11 (3/5) — 4- 2-yl Me2,5-dichlorophenyl X² G-1 J-11 (3/5) — 2-Cl2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 2-Cl2,5-dimethylphenyl X² G-1 J-11 (3/5) — 2-Cl2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 2-Cl3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 2-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 2-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 2-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 2-Cl1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 2-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-11 (3/5) — 2-Cl 2-yl2,5-dichlorophenyl X² G-1 J-11 (3/5) — 4-Cl2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 4-Cl2,5-dimethylphenyl X² G-1 J-11 (3/5) — 4-Cl2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-11 (3/5) — 4-Cl3,5-dimethylpyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 4-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 4-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 4-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-11 (3/5) — 4-Cl1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-11 (3/5) — 4-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-11 (3/5) — 4-Cl 2-yl2,5-dichlorophenyl X² G-1 J-29 (3/5) — 2- Me2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 2- Me2,5-dimethylphenyl X² G-1 J-29 (3/5) — 2- Me2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 2- Me3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 2- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 2- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 2- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 2- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 2- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-29 (3/5) — 2- 2-yl Me2,5-dichlorophenyl X² G-1 J-29 (3/5) — 3- Me2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 3- Me2,5-dimethylphenyl X² G-1 J-29 (3/5) — 3- Me2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 3- Me3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 3- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 3- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 3- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 3- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 3- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 3- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 3- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-29 (3/5) — 3- 2-yl Me2,5-dichlorophenyl X² G-1 J-29 (3/5) — 4- Me2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 4- Me2,5-dimethylphenyl X² G-1 J-29 (3/5) — 4- Me2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 4- Me3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 4- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 4- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 4- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 4- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 4- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-29 (3/5) — 4- 2-yl Me2,5-dichlorophenyl X² G-1 J-29 (3/5) — 2-Cl2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 2-Cl2,5-dimethylphenyl X² G-1 J-29 (3/5) — 2-Cl2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 2-Cl3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 2-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 2-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 2-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 2-Cl1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 2-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-29 (3/5) — 2-Cl 2-yl2,5-dichlorophenyl X² G-1 J-29 (3/5) — 4-Cl2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 4-Cl2,5-dimethylphenyl X² G-1 J-29 (3/5) — 4-Cl2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) — 4-Cl3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) — 4-Cl5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 4-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 4-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 4-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) — 4-Cl1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) — 4-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-29 (3/5) — 4-Cl 2-yl2,5-dichlorophenyl X² G-1 J-29 (3/5) 5-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 5-Me H2,5-dimethylphenyl X² G-1 J-29 (3/5) 5-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 5-Me H3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 5-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 5-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 5-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 5-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 5-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-29 (3/5) 5-Me H 2-yl2,5-dichlorophenyl X² G-1 J-29 (3/5) 4-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 4-Me H2,5-dimethylphenyl X² G-1 J-29 (3/5) 4-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 4-Me H3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 4-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 4-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 4-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 4-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-29 (3/5) 4-Me H 2-yl2,5-dichlorophenyl X² G-1 J-29 (3/5) 4,4- H di-Me2-chloro-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 4,4- H di-Me2,5-dimethylphenyl X² G-1 J-29 (3/5) 4,4- H di-Me2-methyl-5-(trifluoromethyl)phenyl X² G-1 J-29 (3/5) 4,4- H di-Me3,5-dimethylpyrazol-1-yl X² G-1 J-29 (3/5) 4,4- H di-Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 4,4- H 1-yl di-Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 4,4- H 1-yl di-Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 4,4- H 1-yl di-Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4,4- H di-Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-1 J-29 (3/5) 4,4- H di-Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-1 J-29 (3/5) 4,4- H 5-yl di-Me1-methyl-4-(trifluoromethyl)imidazol- X² G-1 J-29 (3/5) 4,4- H 2-yldi-Me 2,5-dichlorophenyl X² G-2 J-1 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-1 (2/4) — H2,5-dimethylphenyl X² G-2 J-1 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-1 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-2 J-1 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-1 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-1 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-1 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-1 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-1 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-1 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-1 (2/4) — H 2-yl2,5-dichlorophenyl X² G-2 J-2 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-2 (2/4) — H2,5-dimethylphenyl X² G-2 J-2 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-2 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-2 J-2 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-2 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-2 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-2 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-2 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-2 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-2 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-2 (2/4) — H 2-yl2,5-dichlorophenyl X² G-2 J-3 (2/4) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-3 (2/4) 1-Me H2,5-dimethylphenyl X² G-2 J-3 (2/4) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-3 (2/4) 1-Me H3,5-dimethylpyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-3 (2/4) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-3 (2/4) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-3 (2/4) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-3 (2/4) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-3 (2/4) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-3 (2/4) 1-Me H 2-yl2,5-dichlorophenyl X² G-2 J-4 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-4 (2/5) — H2,5-dimethylphenyl X² G-2 J-4 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-4 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-4 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-4 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-4 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-4 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-4 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-4 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-4 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-4 (2/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-8 (5/3) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-8 (5/3) — H2,5-dimethylphenyl X² G-2 J-8 (5/3) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-8 (5/3) — H3,5-dimethylpyrazol-1-yl X² G-2 J-8 (5/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-8 (5/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-8 (5/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-8 (5/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-8 (5/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-8 (5/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-8 (5/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-8 (5/3) — H 2-yl2,5-dichlorophenyl X² G-2 J-9 (5/3) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-9 (5/3) — H2,5-dimethylphenyl X² G-2 J-9 (5/3) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-9 (5/3) — H3,5-dimethylpyrazol-1-yl X² G-2 J-9 (5/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-9 (5/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-9 (5/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-9 (5/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-9 (5/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-9 (5/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-9 (5/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-9 (5/3) — H 2-yl2,5-dichlorophenyl X² G-2 J-11 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — H2,5-dimethylphenyl X² G-2 J-11 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-11 (3/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-12 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-12 (3/5) — H2,5-dimethylphenyl X² G-2 J-12 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-12 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-12 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-12 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-12 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-12 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-12 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-12 (3/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-12 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-12 (3/5) 1-Me H2,5-dimethylphenyl X² G-2 J-12 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-12 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-12 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-12 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-12 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-12 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-12 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-12 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X² G-2 J-14 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-14 (3/5) — H2,5-dimethylphenyl X² G-2 J-14 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-14 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-14 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-14 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-14 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-14 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-14 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-14 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-14 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-14 (3/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-15 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-15 (2/5) — H2,5-dimethylphenyl X² G-2 J-15 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-15 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-15 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-15 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-15 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-15 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-15 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-15 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-15 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-15 (2/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-16 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-16 (2/5) — H2,5-dimethylphenyl X² G-2 J-16 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-16 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-16 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-16 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-16 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-16 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-16 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-16 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-16 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-16 (2/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-22 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-22 (2/4) — H2,5-dimethylphenyl X² G-2 J-22 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-22 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-2 J-22 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-22 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-22 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-22 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-22 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-22 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-22 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-22 (2/4) — H 2-yl2,5-dichlorophenyl X² G-2 J-24 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-24 (2/4) — H2,5-dimethylphenyl X² G-2 J-24 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-24 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-2 J-24 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-24 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-24 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-24 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-24 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-24 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-24 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-24 (2/4) — H 2-yl2,5-dichlorophenyl X² G-2 J-25 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-25 (2/4) — H2,5-dimethylphenyl X² G-2 J-25 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-25 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-2 J-25 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-25 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-25 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-25 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-25 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-25 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-25 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-25 (2/4) — H 2-yl2,5-dichlorophenyl X² G-2 J-26 (2/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/4) — H2,5-dimethylphenyl X² G-2 J-26 (2/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/4) — H3,5-dimethylpyrazol-1-yl X² G-2 J-26 (2/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-26 (2/4) — H 2-yl2,5-dichlorophenyl X² G-2 J-26 (2/4) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/4) 1-Me H2,5-dimethylphenyl X² G-2 J-26 (2/4) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/4) 1-Me H3,5-dimethylpyrazol-1-yl X² G-2 J-26 (2/4) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/4) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/4) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/4) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/4) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/4) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-26 (2/4) 1-Me H 2-yl2,5-dichlorophenyl X² G-2 J-26 (2/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/5) 1-Me H2,5-dimethylphenyl X² G-2 J-26 (2/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-26 (2/5) 1-Me H3,5-dimethylpyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-26 (2/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-26 (2/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-26 (2/5) 1-Me H 2-yl2,5-dichlorophenyl X² G-2 J-28 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-28 (3/5) — H2,5-dimethylphenyl X² G-2 J-28 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-28 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-28 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-28 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-28 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-28 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-28 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-28 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-28 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-28 (3/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-30 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-30 (3/5) — H2,5-dimethylphenyl X² G-2 J-30 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-30 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-30 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-30 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-30 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-30 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-30 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-30 (3/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-30 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-30 (3/5) 1-Me H2,5-dimethylphenyl X² G-2 J-30 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-30 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-30 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-30 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-30 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-30 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-30 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-30 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X² G-2 J-36 (3/5) 1-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-36 (3/5) 1-Me H2,5-dimethylphenyl X² G-2 J-36 (3/5) 1-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-36 (3/5) 1-Me H3,5-dimethylpyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-36 (3/5) 1-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-36 (3/5) 1-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-36 (3/5) 1-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-36 (3/5) 1-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-36 (3/5) 1-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-36 (3/5) 1-Me H 2-yl2,5-dichlorophenyl X² G-2 J-37 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-37 (2/5) — H2,5-dimethylphenyl X² G-2 J-37 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-37 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-37 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-37 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-37 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-37 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-37 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-37 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-37 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-37 (2/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-38 (2/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-38 (2/5) — H2,5-dimethylphenyl X² G-2 J-38 (2/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-38 (2/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-38 (2/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-38 (2/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-38 (2/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-38 (2/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-38 (2/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-38 (2/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-38 (2/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-38 (2/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-39 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-39 (3/5) — H2,5-dimethylphenyl X² G-2 J-39 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-39 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-39 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-39 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-39 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-39 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-39 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-39 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-39 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-39 (3/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-40 (3/5) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-40 (3/5) — H2,5-dimethylphenyl X² G-2 J-40 (3/5) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-40 (3/5) — H3,5-dimethylpyrazol-1-yl X² G-2 J-40 (3/5) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-40 (3/5) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-40 (3/5) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-40 (3/5) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-40 (3/5) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-40 (3/5) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-40 (3/5) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-40 (3/5) — H 2-yl2,5-dichlorophenyl X² G-2 J-69 (1/3) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-69 (1/3) — H2,5-dimethylphenyl X² G-2 J-69 (1/3) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-69 (1/3) — H3,5-dimethylpyrazol-1-yl X² G-2 J-69 (1/3) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-69 (1/3) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-69 (1/3) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-69 (1/3) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/3) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/3) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-69 (1/3) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-69 (1/3) — H 2-yl2,5-dichlorophenyl X² G-2 J-69 (1/4) — H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-69 (1/4) — H2,5-dimethylphenyl X² G-2 J-69 (1/4) — H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-69 (1/4) — H3,5-dimethylpyrazol-1-yl X² G-2 J-69 (1/4) — H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-69 (1/4) — H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-69 (1/4) — H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-69 (1/4) — H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/4) — H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-69 (1/4) — H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-69 (1/4) — H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-69 (1/4) — H 2-yl2,5-dichlorophenyl X² G-2 J-11 (3/5) — 2- Me2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 2- Me2,5-dimethylphenyl X² G-2 J-11 (3/5) — 2- Me2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 2- Me3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 2- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 2- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 2- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 2- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 2- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-11 (3/5) — 2- 2-yl Me2,5-dichlorophenyl X² G-2 J-11 (3/5) — 3- Me2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 3- Me2,5-dimethylphenyl X² G-2 J-11 (3/5) — 3- Me2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 3- Me3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 3- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 3- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 3- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 3- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 3- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 3- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 3- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-11 (3/5) — 3- 2-yl Me2,5-dichlorophenyl X² G-2 J-11 (3/5) — 4- Me2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 4- Me2,5-dimethylphenyl X² G-2 J-11 (3/5) — 4- Me2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 4- Me3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 4- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 4- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 4- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 4- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 4- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-11 (3/5) — 4- 2-yl Me2,5-dichlorophenyl X² G-2 J-11 (3/5) — 2-Cl2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 2-Cl2,5-dimethylphenyl X² G-2 J-11 (3/5) — 2-Cl2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 2-Cl3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 2-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 2-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 2-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 2-Cl1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 2-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-11 (3/5) — 2-Cl 2-yl2,5-dichlorophenyl X² G-2 J-11 (3/5) — 4-Cl2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 4-Cl2,5-dimethylphenyl X² G-2 J-11 (3/5) — 4-Cl2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-11 (3/5) — 4-Cl3,5-dimethylpyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 4-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 4-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 4-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-11 (3/5) — 4-Cl1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-11 (3/5) — 4-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-11 (3/5) — 4-Cl 2-yl2,5-dichlorophenyl X² G-2 J-29 (3/5) — 2- Me2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 2- Me2,5-dimethylphenyl X² G-2 J-29 (3/5) — 2- Me2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 2- Me3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 2- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 2- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 2- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 2- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 2- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-29 (3/5) — 2- 2-yl Me2,5-dichlorophenyl X² G-2 J-29 (3/5) — 3- Me2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 3- Me2,5-dimethylphenyl X² G-2 J-29 (3/5) — 3- Me2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 3- Me3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 3- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 3- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 3- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 3- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 3- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 3- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 3- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-29 (3/5) — 3- 2-yl Me2,5-dichlorophenyl X² G-2 J-29 (3/5) — 4- Me2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 4- Me2,5-dimethylphenyl X² G-2 J-29 (3/5) — 4- Me2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 4- Me3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 4- Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 4- 1-yl Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 4- 1-yl Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 4- 1-yl Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4- Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4- Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 4- 5-yl Me1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-29 (3/5) — 4- 2-yl Me2,5-dichlorophenyl X² G-2 J-29 (3/5) — 2-Cl2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 2-Cl2,5-dimethylphenyl X² G-2 J-29 (3/5) — 2-Cl2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 2-Cl3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 2-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 2-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 2-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 2-Cl1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 2-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-29 (3/5) — 2-Cl 2-yl2,5-dichlorophenyl X² G-2 J-29 (3/5) — 4-Cl2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 4-Cl2,5-dimethylphenyl X² G-2 J-29 (3/5) — 4-Cl2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) — 4-Cl3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 4-Cl 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 4-Cl 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 4-Cl 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) — 4-Cl1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) — 4-Cl 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-29 (3/5) — 4-Cl 2-yl2,5-dichlorophenyl X² G-2 J-29 (3/5) 5-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 5-Me H2,5-dimethylphenyl X² G-2 J-29 (3/5) 5-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 5-Me H3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 5-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 5-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 5-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 5-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 5-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-29 (3/5) 5-Me H 2-yl2,5-dichlorophenyl X² G-2 J-29 (3/5) 4-Me H2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 4-Me H2,5-dimethylphenyl X² G-2 J-29 (3/5) 4-Me H2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 4-Me H3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 4-Me H 1-yl5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 4-Me H 1-yl5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 4-Me H 1-yl5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4-Me H1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 4-Me H 5-yl1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-29 (3/5) 4-Me H 2-yl2,5-dichlorophenyl X² G-2 J-29 (3/5) 4,4- H di-Me2-chloro-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 4,4- H di-Me2,5-dimethylphenyl X² G-2 J-29 (3/5) 4,4- H di-Me2-methyl-5-(trifluoromethyl)phenyl X² G-2 J-29 (3/5) 4,4- H di-Me3,5-dimethylpyrazol-1-yl X² G-2 J-29 (3/5) 4,4- H di-Me5-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 4,4- H 1-yl di-Me5-chloro-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 4,4- H 1-yl di-Me5-bromo-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 4,4- H 1-yl di-Me5-ethyl-3-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4,4- H di-Me3,5-bis-(trifluoromethyl)pyrazol-1-yl X² G-2 J-29 (3/5) 4,4- H di-Me1-methyl-3-(trifluoromethyl)pyrazol- X² G-2 J-29 (3/5) 4,4- H 5-yl di-Me1-methyl-4-(trifluoromethyl)imidazol- X² G-2 J-29 (3/5) 4,4- H 2-yldi-Me *The definitions of G and J in the compounds of this table are asdefined in Exhibits 2 and 3 in the above Embodiments. The (R⁵)_(y)column refers the substituents (R⁵)_(x) shown on J groups in Exhibit 3other than the phenyl ring substituted by R^(7a) shown in the structureheading this table. R^(7a) may be selected from H (to indicate nosubstitution on the phenyl ring) as well as the substitutents definedfor R⁷. A dash “—” in the (R⁵)_(y) column indicates no substitution on Jbesides the phenyl ring substituted by R^(7a). **R^(3a) substituent in Gis H. ***Numbers in parenthesis refer to the attachment points on ringJ. The first number is the attachment point for ring G; the secondnumber is the attachment point for the phenyl ring.

TABLE 5

wherein J is one of J-29-1 through J-29-57 (as depicted in Exhibit Aabove). J R¹ is 2,5-dichlorophenyl; X is X¹; G* is G-1. J-29-1  J-29-2 J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56J-29-57 R¹ is 2,5-dichlorophenyl; X is X²; G* is G-1. J-29-1  J-29-2 J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56J-29-57 R¹ is 2,5-dichlorophenyl; X is X¹; G* is G-2. J-29-1  J-29-2 J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56J-29-57 R¹ is 2,5-dichlorophenyl; X is X²; G* is G-2. J-29-1  J-29-2 J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56J-29-57 R¹ is 2-chloro-5-(trifluoromethyl)phenyl; X is X¹; G* is G-1.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 2-chloro-5-(trifluoromethyl)phenyl; X isX²; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is2-chloro-5-(trifluoromethyl)phenyl; X is X¹; G* is G-2. J-29-1  J-29-2 J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56J-29-57 R¹ is 2-chloro-5-(trifluoromethyl)phenyl; X is X²; G* is G-2.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 2,5-dimethylphenyl; X is X¹; G* is G-1.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 2,5-dimethylphenyl; X is X²; G* is G-1.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 2,5-dimethylphenyl; X is X¹; G* is G-2.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 2,5-dimethylphenyl; X is X²; G* is G-2.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 2-methyl-5-(trifluoromethyl)phenyl; X isX¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is2-methyl-5-(trifluoromethyl)phenyl; X is X²; G* is G-1. J-29-1  J-29-2 J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56J-29-57 R¹ is 2-methyl-5-(trifluoromethyl)phenyl; X is X¹; G* is G-2.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 2-methyl-5-(trifluoromethyl)phenyl; X isX²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dimethylpyrazol-1-yl;X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6 J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3,5-dimethylpyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2  J-29-3 J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57R¹ is 3,5-dimethylpyrazol-1-yl; X is X¹; G* is G-2. J-29-1  J-29-2 J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56J-29-57 R¹ is 3,5-dimethylpyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3,5-dichloropyrazol-1-yl; X is X¹; G* is G-1.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 3,5-dichloropyrazol-1-yl; X is X²; G* isG-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8 J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dichloropyrazol-1-yl; X is X¹;G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is 3,5-dichloropyrazol-1-yl;X is X²; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6 J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3,5-dibromopyrazol-1-yl; X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3 J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57R¹ is 3,5-dibromopyrazol-1-yl; X is X²; G* is G-1. J-29-1  J-29-2 J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10 J-29-11J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19 J-29-20J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28 J-29-29J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37 J-29-38J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46 J-29-47J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55 J-29-56J-29-57 R¹ is 3,5-dibromopyrazol-1-yl; X is X¹; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3,5-dibromopyrazol-1-yl; X is X²; G* is G-2.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is 5-methyl-3-(trifluoromethyl)pyrazol-1-yl;X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6 J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-methyl-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-methyl-3-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-methyl-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-chloro-3-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-chloro-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-chloro-3-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-chloro-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-bromo-3-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-bromo-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-bromo-3-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-bromo-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-ethyl-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-ethyl-3-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-ethyl-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3,5-bis-(trifluoromethyl)pyrazol-1-yl; X is X¹; G*is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8 J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3,5-bis-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3,5-bis-(trifluoromethyl)pyrazol-1-yl; X is X¹; G*is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8 J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3,5-bis-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3-methyl-5-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3-methyl-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3-methyl-5-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3-methyl-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3-chloro-5-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3-chloro-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3-chloro-5-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3-chloro-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3-bromo-5-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3-bromo-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 3-bromo-5-(trifluoromethyl)pyrazol-1-yl; X is X¹;G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is3-bromo-5-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-methoxy-3-(trifluoromethyl)pyrazol-1-yl; X isX¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-methoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-methoxy-3-(trifluoromethyl)pyrazol-1-yl; X isX¹; G* is G-2. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7 J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-methoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2. J-29-1 J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9  J-29-10J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18 J-29-19J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27 J-29-28J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36 J-29-37J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45 J-29-46J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54 J-29-55J-29-56 J-29-57 R¹ is 5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl;X is X¹; G* is G-1. J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6 J-29-7  J-29-8  J-29-9  J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15J-29-16 J-29-17 J-29-18 J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24J-29-25 J-29-26 J-29-27 J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33J-29-34 J-29-35 J-29-36 J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42J-29-43 J-29-44 J-29-45 J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51J-29-52 J-29-53 J-29-54 J-29-55 J-29-56 J-29-57 R¹ is5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-1.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X¹; G* is G-2.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 R¹ is5-difluoromethoxy-3-(trifluoromethyl)pyrazol-1-yl; X is X²; G* is G-2.J-29-1  J-29-2  J-29-3  J-29-4  J-29-5  J-29-6  J-29-7  J-29-8  J-29-9 J-29-10 J-29-11 J-29-12 J-29-13 J-29-14 J-29-15 J-29-16 J-29-17 J-29-18J-29-19 J-29-20 J-29-21 J-29-22 J-29-23 J-29-24 J-29-25 J-29-26 J-29-27J-29-28 J-29-29 J-29-30 J-29-31 J-29-32 J-29-33 J-29-34 J-29-35 J-29-36J-29-37 J-29-38 J-29-39 J-29-40 J-29-41 J-29-42 J-29-43 J-29-44 J-29-45J-29-46 J-29-47 J-29-48 J-29-49 J-29-50 J-29-51 J-29-52 J-29-53 J-29-54J-29-55 J-29-56 J-29-57 Table 5 above identifies particular compoundscomprising a J group selected from J-29-1 through J-29-57 (i.e.particular examples of J-29). As many J-29-1 to J-29-57 include a chiralcenter, these J groups are illustrated in a particular enantiomericconfiguration, which in some instances may provide the greatestfungicidal activity. One skilled in the art immediately recognizes theantipode (i.e. opposite enantiomer) for each of the compounds listed,and furthermore understands that the enantiomers can be present as pureenantiomers or in mixtures enriched in one enantiomer or in racemicmixtures. ** R^(3a) substituent in G is H.

TABLE 6

R^(4a1) R^(4a2) A^(a) Me Me H Me Et H Me Cl H Me Br H Me I H Me CF₂H HMe CF₃ H Me CF₃CH₂ H Me CF₃CF₂ H Me CCl₃ H Me MeO H Et Me H Et Et H EtCl H Et Br H Et I H Et CF₂H H Et CF₃ H Et CF₃CH₂ H Et CF₃CF₂ H Et CCl₃ HEt MeO H Cl Me H Cl Et H Cl Cl H Cl Br H Cl I H Cl CF₂H H Cl CF₃ H ClCF₃CH₂ H Cl CF₃CF₂ H Cl CCl₃ H Cl MeO H Br Me H Br Et H Br Cl H Br Br HBr I H Br CF₂H H Br CF₃ H Br CF₃CH₂ H Br CF₃CF₂ H Br CCl₃ H Br MeO H IMe H I Et H I Cl H I Br H I I H I CF₂H H I CF₃ H I CF₃CH₂ H I CF₃CF₂ H ICCl₃ H I MeO H CF₂H Me H CF₂H Et H CF₂H Cl H CF₂H Br H CF₂H I H CF₂HCF₂H H CF₂H CF₃ H CF₂H CF₃CH₂ H CF₂H CF₃CF₂ H CF₂H CCl₃ H CF₂H MeO H CF₃Me H CF₃ Et H CF₃ Cl H CF₃ Br H CF₃ I H CF₃ CF₂H H CF₃ CF₃ H CF₃ CF₃CH₂H CF₃ CF₃CF₂ H CF₃ CCl₃ H CF₃ MeO H CF₃CH₂ Me H CF₃CH₂ Et H CF₃CH₂ Cl HCF₃CH₂ Br H CF₃CH₂ I H CF₃CH₂ CF₂H H CF₃CH₂ CF₃ H CF₃CH₂ CF₃CH₂ H CF₃CH₂CF₃CF₂ H CF₃CH₂ CCl₃ H CF₃CH₂ MeO H CF₃CF₂ Me H CF₃CF₂ Et H CF₃CF₂ Cl HCF₃CF₂ Br H CF₃CF₂ I H CF₃CF₂ CF₂H H CF₃CF₂ CF₃ H CF₃CF₂ CF₃CH₂ H CF₃CF₂CF₃CF₂ H CF₃CF₂ CCl₃ H CF₃CF₂ MeO H CCl₃ Me H CCl₃ Et H CCl₃ Cl H CCl₃Br H CCl₃ I H CCl₃ CF₂H H CCl₃ CF₃ H CCl₃ CF₃CH₂ H CCl₃ CF₃CF₂ H CCl₃CCl₃ H CCl₃ MeO H MeO Me H MeO Et H MeO Cl H MeO Br H MeO I H MeO CF₂H HMeO CF₃ H MeO CF₃CH₂ H MeO CF₃CF₂ H MeO CCl₃ H MeO MeO H Me Me CH₂CO₂HMe Et CH₂CO₂H Me Cl CH₂CO₂H Me Br CH₂CO₂H Me I CH₂CO₂H Me CF₂H CH₂CO₂HMe CF₃ CH₂CO₂H Me CF₃CH₂ CH₂CO₂H Me CF₃CF₂ CH₂CO₂H Me CCl₃ CH₂CO₂H MeMeO CH₂CO₂H Et Me CH₂CO₂H Et Et CH₂CO₂H Et Cl CH₂CO₂H Et Br CH₂CO₂H Et ICH₂CO₂H Et CF₂H CH₂CO₂H Et CF₃ CH₂CO₂H Et CF₃CH₂ CH₂CO₂H Et CF₃CF₂CH₂CO₂H Et CCl₃ CH₂CO₂H Et MeO CH₂CO₂H Cl Me CH₂CO₂H Cl Et CH₂CO₂H Cl ClCH₂CO₂H Cl Br CH₂CO₂H Cl I CH₂CO₂H Cl CF₂H CH₂CO₂H Cl CF₃ CH₂CO₂H ClCF₃CH₂ CH₂CO₂H Cl CF₃CF₂ CH₂CO₂H Cl CCl₃ CH₂CO₂H Cl MeO CH₂CO₂H Br MeCH₂CO₂H Br Et CH₂CO₂H Br Cl CH₂CO₂H Br Br CH₂CO₂H Br I CH₂CO₂H Br CF₂HCH₂CO₂H Br CF₃ CH₂CO₂H Br CF₃CH₂ CH₂CO₂H Br CF₃CF₂ CH₂CO₂H Br CCl₃CH₂CO₂H Br MeO CH₂CO₂H I Me CH₂CO₂H I Et CH₂CO₂H I Cl CH₂CO₂H I BrCH₂CO₂H I I CH₂CO₂H I CF₂H CH₂CO₂H I CF₃ CH₂CO₂H I CF₃CH₂ CH₂CO₂H ICF₃CF₂ CH₂CO₂H I CCl₃ CH₂CO₂H I MeO CH₂CO₂H CF₂H Me CH₂CO₂H CF₂H EtCH₂CO₂H CF₂H Cl CH₂CO₂H CF₂H Br CH₂CO₂H CF₂H I CH₂CO₂H CF₂H CF₂H CH₂CO₂HCF₂H CF₃ CH₂CO₂H CF₂H CF₃CH₂ CH₂CO₂H CF₂H CF₃CF₂ CH₂CO₂H CF₂H CCl₃CH₂CO₂H CF₂H MeO CH₂CO₂H CF₃ Me CH₂CO₂H CF₃ Et CH₂CO₂H CF₃ Cl CH₂CO₂HCF₃ Br CH₂CO₂H CF₃ I CH₂CO₂H CF₃ CF₂H CH₂CO₂H CF₃ CF₃ CH₂CO₂H CF₃ CF₃CH₂CH₂CO₂H CF₃ CF₃CF₂ CH₂CO₂H CF₃ CCl₃ CH₂CO₂H CF₃ MeO CH₂CO₂H CF₃CH₂ MeCH₂CO₂H CF₃CH₂ Et CH₂CO₂H CF₃CH₂ Cl CH₂CO₂H CF₃CH₂ Br CH₂CO₂H CF₃CH₂ ICH₂CO₂H CF₃CH₂ CF₂H CH₂CO₂H CF₃CH₂ CF₃ CH₂CO₂H CF₃CH₂ CF₃CH₂ CH₂CO₂HCF₃CH₂ CF₃CF₂ CH₂CO₂H CF₃CH₂ CCl₃ CH₂CO₂H CF₃CH₂ MeO CH₂CO₂H CF₃CF₂ MeCH₂CO₂H CF₃CF₂ Et CH₂CO₂H CF₃CF₂ Cl CH₂CO₂H CF₃CF₂ Br CH₂CO₂H CF₃CF₂ ICH₂CO₂H CF₃CF₂ CF₂H CH₂CO₂H CF₃CF₂ CF₃ CH₂CO₂H CF₃CF₂ CF₃CH₂ CH₂CO₂HCF₃CF₂ CF₃CF₂ CH₂CO₂H CF₃CF₂ CCl₃ CH₂CO₂H CF₃CF₂ MeO CH₂CO₂H CCl₃ MeCH₂CO₂H CCl₃ Et CH₂CO₂H CCl₃ Cl CH₂CO₂H CCl₃ Br CH₂CO₂H CCl₃ I CH₂CO₂HCCl₃ CF₂H CH₂CO₂H CCl₃ CF₃ CH₂CO₂H CCl₃ CF₃CH₂ CH₂CO₂H CCl₃ CF₃CF₂CH₂CO₂H CCl₃ CCl₃ CH₂CO₂H CCl₃ MeO CH₂CO₂H MeO Me CH₂CO₂H MeO Et CH₂CO₂HMeO Cl CH₂CO₂H MeO Br CH₂CO₂H MeO I CH₂CO₂H MeO CF₂H CH₂CO₂H MeO CF₃CH₂CO₂H MeO CF₃CH₂ CH₂CO₂H MeO CF₃CF₂ CH₂CO₂H MeO CCl₃ CH₂CO₂H MeO MeOCH₂CO₂H OCF₂H Me CH₂CO₂H OCF₂H Et CH₂CO₂H OCF₂H Cl CH₂CO₂H OCF₂H BrCH₂CO₂H OCF₂H I CH₂CO₂H OCF₂H CF₂H CH₂CO₂H OCF₂H CF₃ CH₂CO₂H OCF₂HCF₃CH₂ CH₂CO₂H OCF₂H CF₃CF₂ CH₂CO₂H OCF₂H CCl₃ CH₂CO₂H OCF₂H MeO CH₂CO₂HMe Me CH₂CO₂Et Me Et CH₂CO₂Et Me Cl CH₂CO₂Et Me Br CH₂CO₂Et Me ICH₂CO₂Et Me CF₂H CH₂CO₂Et Me CF₃ CH₂CO₂Et Me CF₃CH₂ CH₂CO₂Et Me CF₃CF₂CH₂CO₂Et Me CCl₃ CH₂CO₂Et Me MeO CH₂CO₂Et Et Me CH₂CO₂Et Et Et CH₂CO₂EtEt Cl CH₂CO₂Et Et Br CH₂CO₂Et Et I CH₂CO₂Et Et CF₂H CH₂CO₂Et Et CF₃CH₂CO₂Et Et CF₃CH₂ CH₂CO₂Et Et CF₃CF₂ CH₂CO₂Et Et CCl₃ CH₂CO₂Et Et MeOCH₂CO₂Et Cl Me CH₂CO₂Et Cl Et CH₂CO₂Et Cl Cl CH₂CO₂Et Cl Br CH₂CO₂Et ClI CH₂CO₂Et Cl CF₂H CH₂CO₂Et Cl CF₃ CH₂CO₂Et Cl CF₃CH₂ CH₂CO₂Et Cl CF₃CF₂CH₂CO₂Et Cl CCl₃ CH₂CO₂Et Cl MeO CH₂CO₂Et Br Me CH₂CO₂Et Br Et CH₂CO₂EtBr Cl CH₂CO₂Et Br Br CH₂CO₂Et Br I CH₂CO₂Et Br CF₂H CH₂CO₂Et Br CF₃CH₂CO₂Et Br CF₃CH₂ CH₂CO₂Et Br CF₃CF₂ CH₂CO₂Et Br CCl₃ CH₂CO₂Et Br MeOCH₂CO₂Et I Me CH₂CO₂Et I Et CH₂CO₂Et I Cl CH₂CO₂Et I Br CH₂CO₂Et I ICH₂CO₂Et I CF₂H CH₂CO₂Et I CF₃ CH₂CO₂Et I CF₃CH₂ CH₂CO₂Et I CF₃CF₂CH₂CO₂Et I CCl₃ CH₂CO₂Et I MeO CH₂CO₂Et CF₂H Me CH₂CO₂Et CF₂H EtCH₂CO₂Et CF₂H Cl CH₂CO₂Et CF₂H Br CH₂CO₂Et CF₂H I CH₂CO₂Et CF₂H CF₂HCH₂CO₂Et CF₂H CF₃ CH₂CO₂Et CF₂H CF₃CH₂ CH₂CO₂Et CF₂H CF₃CF₂ CH₂CO₂EtCF₂H CCl₃ CH₂CO₂Et CF₂H MeO CH₂CO₂Et CF₃ Me CH₂CO₂Et CF₃ Et CH₂CO₂Et CF₃Cl CH₂CO₂Et CF₃ Br CH₂CO₂Et CF₃ I CH₂CO₂Et CF₃ CF₂H CH₂CO₂Et CF₃ CF₃CH₂CO₂Et CF₃ CF₃CH₂ CH₂CO₂Et CF₃ CF₃CF₂ CH₂CO₂Et CF₃ CCl₃ CH₂CO₂Et CF₃MeO CH₂CO₂Et CF₃CH₂ Me CH₂CO₂Et CF₃CH₂ Et CH₂CO₂Et CF₃CH₂ Cl CH₂CO₂EtCF₃CH₂ Br CH₂CO₂Et CF₃CH₂ I CH₂CO₂Et CF₃CH₂ CF₂H CH₂CO₂Et CF₃CH₂ CF₃CH₂CO₂Et CF₃CH₂ CF₃CH₂ CH₂CO₂Et CF₃CH₂ CF₃CF₂ CH₂CO₂Et CF₃CH₂ CCl₃CH₂CO₂Et CF₃CH₂ MeO CH₂CO₂Et CF₃CF₂ Me CH₂CO₂Et CF₃CF₂ Et CH₂CO₂EtCF₃CF₂ Cl CH₂CO₂Et CF₃CF₂ Br CH₂CO₂Et CF₃CF₂ I CH₂CO₂Et CF₃CF₂ CF₂HCH₂CO₂Et CF₃CF₂ CF₃ CH₂CO₂Et CF₃CF₂ CF₃CH₂ CH₂CO₂Et CF₃CF₂ CF₃CF₂CH₂CO₂Et CF₃CF₂ CCl₃ CH₂CO₂Et CF₃CF₂ MeO CH₂CO₂Et CCl₃ Me CH₂CO₂Et CCl₃Et CH₂CO₂Et CCl₃ Cl CH₂CO₂Et CCl₃ Br CH₂CO₂Et CCl₃ I CH₂CO₂Et CCl₃ CF₂HCH₂CO₂Et CCl₃ CF₃ CH₂CO₂Et CCl₃ CF₃CH₂ CH₂CO₂Et CCl₃ CF₃CF₂ CH₂CO₂EtCCl₃ CCl₃ CH₂CO₂Et CCl₃ MeO CH₂CO₂Et MeO Me CH₂CO₂Et MeO Et CH₂CO₂Et MeOCl CH₂CO₂Et MeO Br CH₂CO₂Et MeO I CH₂CO₂Et MeO CF₂H CH₂CO₂Et MeO CF₃CH₂CO₂Et MeO CF₃CH₂ CH₂CO₂Et MeO CF₃CF₂ CH₂CO₂Et MeO CCl₃ CH₂CO₂Et MeOMeO CH₂CO₂Et Me Me CH₂C(═O)Cl Me Et CH₂C(═O)Cl Me Cl CH₂C(═O)Cl Me BrCH₂C(═O)Cl Me I CH₂C(═O)Cl Me CF₂H CH₂C(═O)Cl Me CF₃ CH₂C(═O)Cl MeCF₃CH₂ CH₂C(═O)Cl Me CF₃CF₂ CH₂C(═O)Cl Me CCl₃ CH₂C(═O)Cl Me MeOCH₂C(═O)Cl Et Me CH₂C(═O)Cl Et Et CH₂C(═O)Cl Et Cl CH₂C(═O)Cl Et BrCH₂C(═O)Cl Et I CH₂C(═O)Cl Et CF₂H CH₂C(═O)Cl Et CF₃ CH₂C(═O)Cl EtCF₃CH₂ CH₂C(═O)Cl Et CF₃CF₂ CH₂C(═O)Cl Et CCl₃ CH₂C(═O)Cl Et MeOCH₂C(═O)Cl Cl Me CH₂C(═O)Cl Cl Et CH₂C(═O)Cl Cl Cl CH₂C(═O)Cl Cl BrCH₂C(═O)Cl Cl I CH₂C(═O)Cl Cl CF₂H CH₂C(═O)Cl Cl CF₃ CH₂C(═O)Cl ClCF₃CH₂ CH₂C(═O)Cl Cl CF₃CF₂ CH₂C(═O)Cl Cl CCl₃ CH₂C(═O)Cl Cl MeOCH₂C(═O)Cl Br Me CH₂C(═O)Cl Br Et CH₂C(═O)Cl Br Cl CH₂C(═O)Cl Br BrCH₂C(═O)Cl Br I CH₂C(═O)Cl Br CF₂H CH₂C(═O)Cl Br CF₃ CH₂C(═O)Cl BrCF₃CH₂ CH₂C(═O)Cl Br CF₃CF₂ CH₂C(═O)Cl Br CCl₃ CH₂C(═O)Cl Br MeOCH₂C(═O)Cl I Me CH₂C(═O)Cl I Et CH₂C(═O)Cl I Cl CH₂C(═O)Cl I BrCH₂C(═O)Cl I I CH₂C(═O)Cl I CF₂H CH₂C(═O)Cl I CF₃ CH₂C(═O)Cl I CF₃CH₂CH₂C(═O)Cl I CF₃CF₂ CH₂C(═O)Cl I CCl₃ CH₂C(═O)Cl I MeO CH₂C(═O)Cl CF₂HMe CH₂C(═O)Cl CF₂H Et CH₂C(═O)Cl CF₂H Cl CH₂C(═O)Cl CF₂H Br CH₂C(═O)ClCF₂H I CH₂C(═O)Cl CF₂H CF₂H CH₂C(═O)Cl CF₂H CF₃ CH₂C(═O)Cl CF₂H CF₃CH₂CH₂C(═O)Cl CF₂H CF₃CF₂ CH₂C(═O)Cl CF₂H CCl₃ CH₂C(═O)Cl CF₂H MeOCH₂C(═O)Cl CF₃ Me CH₂C(═O)Cl CF₃ Et CH₂C(═O)Cl CF₃ Cl CH₂C(═O)Cl CF₃ BrCH₂C(═O)Cl CF₃ I CH₂C(═O)Cl CF₃ CF₂H CH₂C(═O)Cl CF₃ CF₃ CH₂C(═O)Cl CF₃CF₃CH₂ CH₂C(═O)Cl CF₃ CF₃CF₂ CH₂C(═O)Cl CF₃ CCl₃ CH₂C(═O)Cl CF₃ MeOCH₂C(═O)Cl CF₃CH₂ Me CH₂C(═O)Cl CF₃CH₂ Et CH₂C(═O)Cl CF₃CH₂ ClCH₂C(═O)Cl CF₃CH₂ Br CH₂C(═O)Cl CF₃CH₂ I CH₂C(═O)Cl CF₃CH₂ CF₂HCH₂C(═O)Cl CF₃CH₂ CF₃ CH₂C(═O)Cl CF₃CH₂ CF₃CH₂ CH₂C(═O)Cl CF₃CH₂ CF₃CF₂CH₂C(═O)Cl CF₃CH₂ CCl₃ CH₂C(═O)Cl CF₃CH₂ MeO CH₂C(═O)Cl CF₃CF₂ MeCH₂C(═O)Cl CF₃CF₂ Et CH₂C(═O)Cl CF₃CF₂ Cl CH₂C(═O)Cl CF₃CF₂ BrCH₂C(═O)Cl CF₃CF₂ I CH₂C(═O)Cl CF₃CF₂ CF₂H CH₂C(═O)Cl CF₃CF₂ CF₃CH₂C(═O)Cl CF₃CF₂ CF₃CH₂ CH₂C(═O)Cl CF₃CF₂ CF₃CF₂ CH₂C(═O)Cl CF₃CF₂ CCl₃CH₂C(═O)Cl CF₃CF₂ MeO CH₂C(═O)Cl CCl₃ Me CH₂C(═O)Cl CCl₃ Et CH₂C(═O)ClCCl₃ Cl CH₂C(═O)Cl CCl₃ Br CH₂C(═O)Cl CCl₃ I CH₂C(═O)Cl CCl₃ CF₂HCH₂C(═O)Cl CCl₃ CF₃ CH₂C(═O)Cl CCl₃ CF₃CH₂ CH₂C(═O)Cl CCl₃ CF₃CF₂CH₂C(═O)Cl CCl₃ CCl₃ CH₂C(═O)Cl CCl₃ MeO CH₂C(═O)Cl MeO Me CH₂C(═O)ClMeO Et CH₂C(═O)Cl MeO Cl CH₂C(═O)Cl MeO Br CH₂C(═O)Cl MeO I CH₂C(═O)ClMeO CF₂H CH₂C(═O)Cl MeO CF₃ CH₂C(═O)Cl MeO CF₃CH₂ CH₂C(═O)Cl MeO CF₃CF₂CH₂C(═O)Cl MeO CCl₃ CH₂C(═O)Cl MeO MeO CH₂C(═O)Cl OCF₂H Me CH₂C(═O)ClOCF₂H Et CH₂C(═O)Cl OCF₂H Cl CH₂C(═O)Cl OCF₂H Br CH₂C(═O)Cl OCF₂H ICH₂C(═O)Cl OCF₂H CF₂H CH₂C(═O)Cl OCF₂H CF₃ CH₂C(═O)Cl OCF₂H CF₃CH₂CH₂C(═O)Cl OCF₂H CF₃CF₂ CH₂C(═O)Cl OCF₂H CCl₃ CH₂C(═O)Cl OCF₂H MeOCH₂C(═O)Cl

TABLE 7

R^(4a1) R^(4a2) Z³ Me Me CN Me Et CN Me Cl CN Me Br CN Me I CN Me CF₂HCN Me CF₃ CN Me CF₃CH₂ CN Me CF₃CF₂ CN Me CCl₃ CN Me MeO CN Et Me CN EtEt CN Et Cl CN Et Br CN Et I CN Et CF₂H CN Et CF₃ CN Et CF₃CH₂ CN EtCF₃CF₂ CN Et CCl₃ CN Et MeO CN Cl Me CN Cl Et CN Cl Cl CN Cl Br CN Cl ICN Cl CF₂H CN Cl CF₃ CN Cl CF₃CH₂ CN Cl CF₃CF₂ CN Cl CCl₃ CN Cl MeO CNBr Me CN Br Et CN Br Cl CN Br Br CN Br I CN Br CF₂H CN Br CF₃ CN BrCF₃CH₂ CN Br CF₃CF₂ CN Br CCl₃ CN Br MeO CN I Me CN I Et CN I Cl CN I BrCN I I CN I CF₂H CN I CF₃ CN I CF₃CH₂ CN I CF₃CF₂ CN I CCl₃ CN I MeO CNCF₂H Me CN CF₂H Et CN CF₂H Cl CN CF₂H Br CN CF₂H I CN CF₂H CF₂H CN CF₂HCF₃ CN CF₂H CF₃CH₂ CN CF₂H CF₃CF₂ CN CF₂H CCl₃ CN CF₂H MeO CN CF₃ Me CNCF₃ Et CN CF₃ Cl CN CF₃ Br CN CF₃ I CN CF₃ CF₂H CN CF₃ CF₃ CN CF₃ CF₃CH₂CN CF₃ CF₃CF₂ CN CF₃ CCl₃ CN CF₃ MeO CN CF₃CH₂ Me CN CF₃CH₂ Et CN CF₃CH₂Cl CN CF₃CH₂ Br CN CF₃CH₂ I CN CF₃CH₂ CF₂H CN CF₃CH₂ CF₃ CN CF₃CH₂CF₃CH₂ CN CF₃CH₂ CF₃CF₂ CN CF₃CH₂ CCl₃ CN CF₃CH₂ MeO CN CF₃CF₂ Me CNCF₃CF₂ Et CN CF₃CF₂ Cl CN CF₃CF₂ Br CN CF₃CF₂ I CN CF₃CF₂ CF₂H CN CF₃CF₂CF₃ CN CF₃CF₂ CF₃CH₂ CN CF₃CF₂ CF₃CF₂ CN CF₃CF₂ CCl₃ CN CF₃CF₂ MeO CNCCl₃ Me CN CCl₃ Et CN CCl₃ Cl CN CCl₃ Br CN CCl₃ I CN CCl₃ CF₂H CN CCl₃CF₃ CN CCl₃ CF₃CH₂ CN CCl₃ CF₃CF₂ CN CCl₃ CCl₃ CN CCl₃ MeO CN MeO Me CNMeO Et CN MeO Cl CN MeO Br CN MeO I CN MeO CF₂H CN MeO CF₃ CN MeO CF₃CH₂CN MeO CF₃CF₂ CN MeO CCl₃ CN MeO MeO CN OCF₂H Me CN OCF₂H Et CN OCF₂H ClCN OCF₂H Br CN OCF₂H I CN OCF₂H CF₂H CN OCF₂H CF₃ CN OCF₂H CF₃CH₂ CNOCF₂H CF₃CF₂ CN OCF₂H CCl₃ CN OCF₂H MeO CN Me Me C(═S)NH₂ Me Et C(═S)NH₂Me Cl C(═S)NH₂ Me Br C(═S)NH₂ Me I C(═S)NH₂ Me CF₂H C(═S)NH₂ Me CF₃C(═S)NH₂ Me CF₃CH₂ C(═S)NH₂ Me CF₃CF₂ C(═S)NH₂ Me CCl₃ C(═S)NH₂ Me MeOC(═S)NH₂ Et Me C(═S)NH₂ Et Et C(═S)NH₂ Et Cl C(═S)NH₂ Et Br C(═S)NH₂ EtI C(═S)NH₂ Et CF₂H C(═S)NH₂ Et CF₃ C(═S)NH₂ Et CF₃CH₂ C(═S)NH₂ Et CF₃CF₂C(═S)NH₂ Et CCl₃ C(═S)NH₂ Et MeO C(═S)NH₂ Cl Me C(═S)NH₂ Cl Et C(═S)NH₂Cl Cl C(═S)NH₂ Cl Br C(═S)NH₂ Cl I C(═S)NH₂ Cl CF₂H C(═S)NH₂ Cl CF₃C(═S)NH₂ Cl CF₃CH₂ C(═S)NH₂ Cl CF₃CF₂ C(═S)NH₂ Cl CCl₃ C(═S)NH₂ Cl MeOC(═S)NH₂ Br Me C(═S)NH₂ Br Et C(═S)NH₂ Br Cl C(═S)NH₂ Br Br C(═S)NH₂ BrI C(═S)NH₂ Br CF₂H C(═S)NH₂ Br CF₃ C(═S)NH₂ Br CF₃CH₂ C(═S)NH₂ Br CF₃CF₂C(═S)NH₂ Br CCl₃ C(═S)NH₂ Br MeO C(═S)NH₂ I Me C(═S)NH₂ I Et C(═S)NH₂ ICl C(═S)NH₂ I Br C(═S)NH₂ I I C(═S)NH₂ I CF₂H C(═S)NH₂ I CF₃ C(═S)NH₂ ICF₃CH₂ C(═S)NH₂ I CF₃CF₂ C(═S)NH₂ I CCl₃ C(═S)NH₂ I MeO C(═S)NH₂ CF₂H MeC(═S)NH₂ CF₂H Et C(═S)NH₂ CF₂H Cl C(═S)NH₂ CF₂H Br C(═S)NH₂ CF₂H IC(═S)NH₂ CF₂H CF₂H C(═S)NH₂ CF₂H CF₃ C(═S)NH₂ CF₂H CF₃CH₂ C(═S)NH₂ CF₂HCF₃CF₂ C(═S)NH₂ CF₂H CCl₃ C(═S)NH₂ CF₂H MeO C(═S)NH₂ CF₃ Me C(═S)NH₂ CF₃Et C(═S)NH₂ CF₃ Cl C(═S)NH₂ CF₃ Br C(═S)NH₂ CF₃ I C(═S)NH₂ CF₃ CF₂HC(═S)NH₂ CF₃ CF₃ C(═S)NH₂ CF₃ CF₃CH₂ C(═S)NH₂ CF₃ CF₃CF₂ C(═S)NH₂ CF₃CCl₃ C(═S)NH₂ CF₃ MeO C(═S)NH₂ CF₃CH₂ Me C(═S)NH₂ CF₃CH₂ Et C(═S)NH₂CF₃CH₂ Cl C(═S)NH₂ CF₃CH₂ Br C(═S)NH₂ CF₃CH₂ I C(═S)NH₂ CF₃CH₂ CF₂HC(═S)NH₂ CF₃CH₂ CF₃ C(═S)NH₂ CF₃CH₂ CF₃CH₂ C(═S)NH₂ CF₃CH₂ CF₃CF₂C(═S)NH₂ CF₃CH₂ CCl₃ C(═S)NH₂ CF₃CH₂ MeO C(═S)NH₂ CF₃CF₂ Me C(═S)NH₂CF₃CF₂ Et C(═S)NH₂ CF₃CF₂ Cl C(═S)NH₂ CF₃CF₂ Br C(═S)NH₂ CF₃CF₂ IC(═S)NH₂ CF₃CF₂ CF₂H C(═S)NH₂ CF₃CF₂ CF₃ C(═S)NH₂ CF₃CF₂ CF₃CH₂ C(═S)NH₂CF₃CF₂ CF₃CF₂ C(═S)NH₂ CF₃CF₂ CCl₃ C(═S)NH₂ CF₃CF₂ MeO C(═S)NH₂ CCl₃ MeC(═S)NH₂ CCl₃ Et C(═S)NH₂ CCl₃ Cl C(═S)NH₂ CCl₃ Br C(═S)NH₂ CCl₃ IC(═S)NH₂ CCl₃ CF₂H C(═S)NH₂ CCl₃ CF₃ C(═S)NH₂ CCl₃ CF₃CH₂ C(═S)NH₂ CCl₃CF₃CF₂ C(═S)NH₂ CCl₃ CCl₃ C(═S)NH₂ CCl₃ MeO C(═S)NH₂ MeO Me C(═S)NH₂ MeOEt C(═S)NH₂ MeO Cl C(═S)NH₂ MeO Br C(═S)NH₂ MeO I C(═S)NH₂ MeO CF₂HC(═S)NH₂ MeO CF₃ C(═S)NH₂ MeO CF₃CH₂ C(═S)NH₂ MeO CF₃CF₂ C(═S)NH₂ MeOCCl₃ C(═S)NH₂ MeO MeO C(═S)NH₂ OCF₂H Me C(═S)NH₂ OCF₂H Et C(═S)NH₂ OCF₂HCl C(═S)NH₂ OCF₂H Br C(═S)NH₂ OCF₂H I C(═S)NH₂ OCF₂H CF₂H C(═S)NH₂ OCF₂HCF₃ C(═S)NH₂ OCF₂H CF₃CH₂ C(═S)NH₂ OCF₂H CF₃CF₂ C(═S)NH₂ OCF₂H CCl₃C(═S)NH₂ OCF₂H MeO C(═S)NH₂

TABLE 8

wherein J¹ is one of J-29-1 through J-29-58 (as depicted in Exhibit Aabove). M J¹ CH₃ J-29-1 CH₂Cl J-29-1 CH₂Br J-29-1 CH₂I J-29-1 OH J-29-1OMe J-29-1 OEt J-29-1 OPr J-29-1 O—i-Pr J-29-1 O—n-Bu J-29-1 O—t-BuJ-29-1 NMe₂ J-29-1 NEt₂ J-29-1 N(n-Pr)₂ J-29-1 1-piperdinyl J-29-11-pyrrolidinyl J-29-1 4-morpholinyl J-29-1 CH₃ J-29-2 CH₂Cl J-29-2 CH₂BrJ-29-2 CH₂I J-29-2 OH J-29-2 OMe J-29-2 OEt J-29-2 OPr J-29-2 O—i-PrJ-29-2 O—n-Bu J-29-2 O—t-Bu J-29-2 NMe₂ J-29-2 NEt₂ J-29-2 N(n-Pr)₂J-29-2 1-piperdinyl J-29-2 1-pyrrolidinyl J-29-2 4-morpholinyl J-29-2CH₃ J-29-3 CH₂Cl J-29-3 CH₂Br J-29-3 CH₂I J-29-3 OH J-29-3 OMe J-29-3OEt J-29-3 OPr J-29-3 O—i-Pr J-29-3 O—n-Bu J-29-3 O—t-Bu J-29-3 NMe₂J-29-3 NEt₂ J-29-3 N(n-Pr)₂ J-29-3 1-piperdinyl J-29-3 1-pyrrolidinylJ-29-3 4-morpholinyl J-29-3 CH₃ J-29-4 CH₂Cl J-29-4 CH₂Br J-29-4 CH₂IJ-29-4 OH J-29-4 OMe J-29-4 OEt J-29-4 OPr J-29-4 O—i-Pr J-29-4 O—n-BuJ-29-4 O—t-Bu J-29-4 NMe₂ J-29-4 NEt₂ J-29-4 N(n-Pr)₂ J-29-41-piperdinyl J-29-4 1-pyrrolidinyl J-29-4 4-morpholinyl J-29-4 CH₃J-29-5 CH₂Cl J-29-5 CH₂Br J-29-5 CH₂I J-29-5 OH J-29-5 OMe J-29-5 OEtJ-29-5 OPr J-29-5 O—i-Pr J-29-5 O—n-Bu J-29-5 O—t-Bu J-29-5 NMe₂ J-29-5NEt₂ J-29-5 N(n-Pr)₂ J-29-5 1-piperdinyl J-29-5 1-pyrrolidinyl J-29-54-morpholinyl J-29-5 CH₃ J-29-6 CH₂Cl J-29-6 CH₂Br J-29-6 CH₂I J-29-6 OHJ-29-6 OMe J-29-6 OEt J-29-6 OPr J-29-6 O—i-Pr J-29-6 O—n-Bu J-29-6O—t-Bu J-29-6 NMe₂ J-29-6 NEt₂ J-29-6 N(n-Pr)₂ J-29-6 1-piperdinylJ-29-6 1-pyrrolidinyl J-29-6 4-morpholinyl J-29-6 CH₃ J-29-7 CH₂ClJ-29-7 CH₂Br J-29-7 CH₂I J-29-7 OH J-29-7 OMe J-29-7 OEt J-29-7 OPrJ-29-7 O—i-Pr J-29-7 O—n-Bu J-29-7 O—t-Bu J-29-7 NMe₂ J-29-7 NEt₂ J-29-7N(n-Pr)₂ J-29-7 1-piperdinyl J-29-7 1-pyrrolidinyl J-29-7 4-morpholinylJ-29-7 CH₃ J-29-8 CH₂Cl J-29-8 CH₂Br J-29-8 CH₂I J-29-8 OH J-29-8 OMeJ-29-8 OEt J-29-8 OPr J-29-8 O—i-Pr J-29-8 O—n-Bu J-29-8 O—t-Bu J-29-8NMe₂ J-29-8 NEt₂ J-29-8 N(n-Pr)₂ J-29-8 1-piperdinyl J-29-81-pyrrolidinyl J-29-8 4-morpholinyl J-29-8 CH₃ J-29-9 CH₂Cl J-29-9 CH₂BrJ-29-9 CH₂I J-29-9 OH J-29-9 OMe J-29-9 OEt J-29-9 OPr J-29-9 O—i-PrJ-29-9 O—n-Bu J-29-9 O—t-Bu J-29-9 NMe₂ J-29-9 NEt₂ J-29-9 N(n-Pr)₂J-29-9 1-piperdinyl J-29-9 1-pyrrolidinyl J-29-9 4-morpholinyl J-29-9CH₃ J-29-10 CH₂Cl J-29-10 CH₂Br J-29-10 CH₂I J-29-10 OH J-29-10 OMeJ-29-10 OEt J-29-10 OPr J-29-10 O—i-Pr J-29-10 O—n-Bu J-29-10 O—t-BuJ-29-10 NMe₂ J-29-10 NEt₂ J-29-10 N(n-Pr)₂ J-29-10 1-piperdinyl J-29-101-pyrrolidinyl J-29-10 4-morpholinyl J-29-10 CH₃ J-29-11 CH₂Cl J-29-11CH₂Br J-29-11 CH₂I J-29-11 OH J-29-11 OMe J-29-11 OEt J-29-11 OPrJ-29-11 O—i-Pr J-29-11 O—n-Bu J-29-11 O—t-Bu J-29-11 NMe₂ J-29-11 NEt₂J-29-11 N(n-Pr)₂ J-29-11 1-piperdinyl J-29-11 1-pyrrolidinyl J-29-114-morpholinyl J-29-11 CH₃ J-29-12 CH₂Cl J-29-12 CH₂Br J-29-12 CH₂IJ-29-12 OH J-29-12 OMe J-29-12 OEt J-29-12 OPr J-29-12 O—i-Pr J-29-12O—n-Bu J-29-12 O—t-Bu J-29-12 NMe₂ J-29-12 NEt₂ J-29-12 N(n-Pr)₂ J-29-121-piperdinyl J-29-12 1-pyrrolidinyl J-29-12 4-morpholinyl J-29-12 CH₃J-29-13 CH₂Cl J-29-13 CH₂Br J-29-13 CH₂I J-29-13 OH J-29-13 OMe J-29-13OEt J-29-13 OPr J-29-13 O—i-Pr J-29-13 O—n-Bu J-29-13 O—t-Bu J-29-13NMe₂ J-29-13 NEt₂ J-29-13 N(n-Pr)₂ J-29-13 1-piperdinyl J-29-131-pyrrolidinyl J-29-13 4-morpholinyl J-29-13 CH₃ J-29-14 CH₂Cl J-29-14CH₂Br J-29-14 CH₂I J-29-14 OH J-29-14 OMe J-29-14 OEt J-29-14 OPrJ-29-14 O—i-Pr J-29-14 O—n-Bu J-29-14 O—t-Bu J-29-14 NMe₂ J-29-14 NEt₂J-29-14 N(n-Pr)₂ J-29-14 1-piperdinyl J-29-14 1-pyrrolidinyl J-29-144-morpholinyl J-29-14 CH₃ J-29-15 CH₂Cl J-29-15 CH₂Br J-29-15 CH₂IJ-29-15 OH J-29-15 OMe J-29-15 OEt J-29-15 OPr J-29-15 O—i-Pr J-29-15O—n-Bu J-29-15 O—t-Bu J-29-15 NMe₂ J-29-15 NEt₂ J-29-15 N(n-Pr)₂ J-29-151-piperdinyl J-29-15 1-pyrrolidinyl J-29-15 4-morpholinyl J-29-15 CH₃J-29-16 CH₂Cl J-29-16 CH₂Br J-29-16 CH₂I J-29-16 OH J-29-16 OMe J-29-16OEt J-29-16 OPr J-29-16 O—i-Pr J-29-16 O—n-Bu J-29-16 O—t-Bu J-29-16NMe₂ J-29-16 NEt₂ J-29-16 N(n-Pr)₂ J-29-16 1-piperdinyl J-29-161-pyrrolidinyl J-29-16 4-morpholinyl J-29-16 CH₃ J-29-17 CH₂Cl J-29-17CH₂Br J-29-17 CH₂I J-29-17 OH J-29-17 OMe J-29-17 OEt J-29-17 OPrJ-29-17 O—i-Pr J-29-17 O—n-Bu J-29-17 O—t-Bu J-29-17 NMe₂ J-29-17 NEt₂J-29-17 N(n-Pr)₂ J-29-17 1-piperdinyl J-29-17 1-pyrrolidinyl J-29-174-morpholinyl J-29-17 CH₃ J-29-18 CH₂Cl J-29-18 CH₂Br J-29-18 CH₂IJ-29-18 OH J-29-18 OMe J-29-18 OEt J-29-18 OPr J-29-18 O—i-Pr J-29-18O—n-Bu J-29-18 O—t-Bu J-29-18 NMe₂ J-29-18 NEt₂ J-29-18 N(n-Pr)₂ J-29-181-piperdinyl J-29-18 1-pyrrolidinyl J-29-18 4-morpholinyl J-29-18 CH₃J-29-19 CH₂Cl J-29-19 CH₂Br J-29-19 CH₂I J-29-19 OH J-29-19 OMe J-29-19OEt J-29-19 OPr J-29-19 O—i-Pr J-29-19 O—n-Bu J-29-19 O—t-Bu J-29-19NMe₂ J-29-19 NEt₂ J-29-19 N(n-Pr)₂ J-29-19 1-piperdinyl J-29-191-pyrrolidinyl J-29-19 4-morpholinyl J-29-19 CH₃ J-29-20 CH₂Cl J-29-20CH₂Br J-29-20 CH₂I J-29-20 OH J-29-20 OMe J-29-20 OEt J-29-20 OPrJ-29-20 O—i-Pr J-29-20 O—n-Bu J-29-20 O—t-Bu J-29-20 NMe₂ J-29-20 NEt₂J-29-20 N(n-Pr)₂ J-29-20 1-piperdinyl J-29-20 1-pyrrolidinyl J-29-204-morpholinyl J-29-20 CH₃ J-29-21 CH₂Cl J-29-21 CH₂Br J-29-21 CH₂IJ-29-21 OH J-29-21 OMe J-29-21 OEt J-29-21 OPr J-29-21 O—i-Pr J-29-21O—n-Bu J-29-21 O—t-Bu J-29-21 NMe₂ J-29-21 NEt₂ J-29-21 N(n-Pr)₂ J-29-211-piperdinyl J-29-21 1-pyrrolidinyl J-29-21 4-morpholinyl J-29-21 CH₃J-29-22 CH₂Cl J-29-22 CH₂Br J-29-22 CH₂I J-29-22 OH J-29-22 OMe J-29-22OEt J-29-22 OPr J-29-22 O—i-Pr J-29-22 O—n-Bu J-29-22 O—t-Bu J-29-22NMe₂ J-29-22 NEt₂ J-29-22 N(n-Pr)₂ J-29-22 1-piperdinyl J-29-221-pyrrolidinyl J-29-22 4-morpholinyl J-29-22 CH₃ J-29-23 CH₂Cl J-29-23CH₂Br J-29-23 CH₂I J-29-23 OH J-29-23 OMe J-29-23 OEt J-29-23 OPrJ-29-23 O—i-Pr J-29-23 O—n-Bu J-29-23 O—t-Bu J-29-23 NMe₂ J-29-23 NEt₂J-29-23 N(n-Pr)₂ J-29-23 1-piperdinyl J-29-23 1-pyrrolidinyl J-29-234-morpholinyl J-29-23 CH₃ J-29-24 CH₂Cl J-29-24 CH₂Br J-29-24 CH₂IJ-29-24 OH J-29-24 OMe J-29-24 OEt J-29-24 OPr J-29-24 O—i-Pr J-29-24O—n-Bu J-29-24 O—t-Bu J-29-24 NMe₂ J-29-24 NEt₂ J-29-24 N(n-Pr)₂ J-29-241-piperdinyl J-29-24 1-pyrrolidinyl J-29-24 4-morpholinyl J-29-24 CH₃J-29-25 CH₂Cl J-29-25 CH₂Br J-29-25 CH₂I J-29-25 OH J-29-25 OMe J-29-25OEt J-29-25 OPr J-29-25 O—i-Pr J-29-25 O—n-Bu J-29-25 O—t-Bu J-29-25NMe₂ J-29-25 NEt₂ J-29-25 N(n-Pr)₂ J-29-25 1-piperdinyl J-29-251-pyrrolidinyl J-29-25 4-morpholinyl J-29-25 CH₃ J-29-26 CH₂Cl J-29-26CH₂Br J-29-26 CH₂I J-29-26 OH J-29-26 OMe J-29-26 OEt J-29-26 OPrJ-29-26 O—i-Pr J-29-26 O—n-Bu J-29-26 O—t-Bu J-29-26 NMe₂ J-29-26 NEt₂J-29-26 N(n-Pr)₂ J-29-26 1-piperdinyl J-29-26 1-pyrrolidinyl J-29-264-morpholinyl J-29-26 CH₃ J-29-27 CH₂Cl J-29-27 CH₂Br J-29-27 CH₂IJ-29-27 OH J-29-27 OMe J-29-27 OEt J-29-27 OPr J-29-27 O—i-Pr J-29-27O—n-Bu J-29-27 O—t-Bu J-29-27 NMe₂ J-29-27 NEt₂ J-29-27 N(n-Pr)₂ J-29-271-piperdinyl J-29-27 1-pyrrolidinyl J-29-27 4-morpholinyl J-29-27 CH₃J-29-28 CH₂Cl J-29-28 CH₂Br J-29-28 CH₂I J-29-28 OH J-29-28 OMe J-29-28OEt J-29-28 OPr J-29-28 O—i-Pr J-29-28 O—n-Bu J-29-28 O—t-Bu J-29-28NMe₂ J-29-28 NEt₂ J-29-28 N(n-Pr)₂ J-29-28 1-piperdinyl J-29-281-pyrrolidinyl J-29-28 4-morpholinyl J-29-28 CH₃ J-29-29 CH₂Cl J-29-29CH₂Br J-29-29 CH₂I J-29-29 OH J-29-29 OMe J-29-29 OEt J-29-29 OPrJ-29-29 O—i-Pr J-29-29 O—n-Bu J-29-29 O—t-Bu J-29-29 NMe₂ J-29-29 NEt₂J-29-29 N(n-Pr)₂ J-29-29 1-piperdinyl J-29-29 1-pyrrolidinyl J-29-294-morpholinyl J-29-29 CH₃ J-29-30 CH₂Cl J-29-30 CH₂Br J-29-30 CH₂IJ-29-30 OH J-29-30 OMe J-29-30 OEt J-29-30 OPr J-29-30 O—i-Pr J-29-30O—n-Bu J-29-30 O—t-Bu J-29-30 NMe₂ J-29-30 NEt₂ J-29-30 N(n-Pr)₂ J-29-301-piperdinyl J-29-30 1-pyrrolidinyl J-29-30 4-morpholinyl J-29-30 CH₃J-29-31 CH₂Cl J-29-31 CH₂Br J-29-31 CH₂I J-29-31 OH J-29-31 OMe J-29-31OEt J-29-31 OPr J-29-31 O—i-Pr J-29-31 O—n-Bu J-29-31 O—t-Bu J-29-31NMe₂ J-29-31 NEt₂ J-29-31 N(n-Pr)₂ J-29-31 1-piperdinyl J-29-311-pyrrolidinyl J-29-31 4-morpholinyl J-29-31 CH₃ J-29-32 CH₂Cl J-29-32CH₂Br J-29-32 CH₂I J-29-32 OH J-29-32 OMe J-29-32 OEt J-29-32 OPrJ-29-32 O—i-Pr J-29-32 O—n-Bu J-29-32 O—t-Bu J-29-32 NMe₂ J-29-32 NEt₂J-29-32 N(n-Pr)₂ J-29-32 1-piperdinyl J-29-32 1-pyrrolidinyl J-29-324-morpholinyl J-29-32 CH₃ J-29-33 CH₂Cl J-29-33 CH₂Br J-29-33 CH₂IJ-29-33 OH J-29-33 OMe J-29-33 OEt J-29-33 OPr J-29-33 O—i-Pr J-29-33O—n-Bu J-29-33 O—t-Bu J-29-33 NMe₂ J-29-33 NEt₂ J-29-33 N(n-Pr)₂ J-29-331-piperdinyl J-29-33 1-pyrrolidinyl J-29-33 4-morpholinyl J-29-33 CH₃J-29-34 CH₂Cl J-29-34 CH₂Br J-29-34 CH₂I J-29-34 OH J-29-34 OMe J-29-34OEt J-29-34 OPr J-29-34 O—i-Pr J-29-34 O—n-Bu J-29-34 O—t-Bu J-29-34NMe₂ J-29-34 NEt₂ J-29-34 N(n-Pr)₂ J-29-34 1-piperdinyl J-29-341-pyrrolidinyl J-29-34 4-morpholinyl J-29-34 CH₃ J-29-35 CH₂Cl J-29-35CH₂Br J-29-35 CH₂I J-29-35 OH J-29-35 OMe J-29-35 OEt J-29-35 OPrJ-29-35 O—i-Pr J-29-35 O—n-Bu J-29-35 O—t-Bu J-29-35 NMe₂ J-29-35 NEt₂J-29-35 N(n-Pr)₂ J-29-35 1-piperdinyl J-29-35 1-pyrrolidinyl J-29-354-morpholinyl J-29-35 CH₃ J-29-36 CH₂Cl J-29-36 CH₂Br J-29-36 CH₂IJ-29-36 OH J-29-36 OMe J-29-36 OEt J-29-36 OPr J-29-36 O—i-Pr J-29-36O—n-Bu J-29-36 O—t-Bu J-29-36 NMe₂ J-29-36 NEt₂ J-29-36 N(n-Pr)₂ J-29-361-piperdinyl J-29-36 1-pyrrolidinyl J-29-36 4-morpholinyl J-29-36 CH₃J-29-37 CH₂Cl J-29-37 CH₂Br J-29-37 CH₂I J-29-37 OH J-29-37 OMe J-29-37OEt J-29-37 OPr J-29-37 O—i-Pr J-29-37 O—n-Bu J-29-37 O—t-Bu J-29-37NMe₂ J-29-37 NEt₂ J-29-37 N(n-Pr)₂ J-29-37 1-piperdinyl J-29-371-pyrrolidinyl J-29-37 4-morpholinyl J-29-37 CH₃ J-29-38 CH₂Cl J-29-38CH₂Br J-29-38 CH₂I J-29-38 OH J-29-38 OMe J-29-38 OEt J-29-38 OPrJ-29-38 O—i-Pr J-29-38 O—n-Bu J-29-38 O—t-Bu J-29-38 NMe₂ J-29-38 NEt₂J-29-38 N(n-Pr)₂ J-29-38 1-piperdinyl J-29-38 1-pyrrolidinyl J-29-384-morpholinyl J-29-38 CH₃ J-29-39 CH₂Cl J-29-39 CH₂Br J-29-39 CH₂IJ-29-39 OH J-29-39 OMe J-29-39 OEt J-29-39 OPr J-29-39 O—i-Pr J-29-39O—n-Bu J-29-39 O—t-Bu J-29-39 NMe₂ J-29-39 NEt₂ J-29-39 N(n-Pr)₂ J-29-391-piperdinyl J-29-39 1-pyrrolidinyl J-29-39 4-morpholinyl J-29-39 CH₃J-29-40 CH₂Cl J-29-40 CH₂Br J-29-40 CH₂I J-29-40 OH J-29-40 OMe J-29-40OEt J-29-40 OPr J-29-40 O—i-Pr J-29-40 O—n-Bu J-29-40 O—t-Bu J-29-40NMe₂ J-29-40 NEt₂ J-29-40 N(n-Pr)₂ J-29-40 1-piperdinyl J-29-401-pyrrolidinyl J-29-40 4-morpholinyl J-29-40 CH₃ J-29-41 CH₂Cl J-29-41CH₂Br J-29-41 CH₂I J-29-41 OH J-29-41 OMe J-29-41 OEt J-29-41 OPrJ-29-41 O—i-Pr J-29-41 O—n-Bu J-29-41 O—t-Bu J-29-41 NMe₂ J-29-41 NEt₂J-29-41 N(n-Pr)₂ J-29-41 1-piperdinyl J-29-41 1-pyrrolidinyl J-29-414-morpholinyl J-29-41 CH₃ J-29-42 CH₂Cl J-29-42 CH₂Br J-29-42 CH₂IJ-29-42 OH J-29-42 OMe J-29-42 OEt J-29-42 OPr J-29-42 O—i-Pr J-29-42O—n-Bu J-29-42 O—t-Bu J-29-42 NMe₂ J-29-42 NEt₂ J-29-42 N(n-Pr)₂ J-29-421-piperdinyl J-29-42 1-pyrrolidinyl J-29-42 4-morpholinyl J-29-42 CH₃J-29-43 CH₂Cl J-29-43 CH₂Br J-29-43 CH₂I J-29-43 OH J-29-43 OMe J-29-43OEt J-29-43 OPr J-29-43 O—i-Pr J-29-43 O—n-Bu J-29-43 O—t-Bu J-29-43NMe₂ J-29-43 NEt₂ J-29-43 N(n-Pr)₂ J-29-43 1-piperdinyl J-29-431-pyrrolidinyl J-29-43 4-morpholinyl J-29-43 CH₃ J-29-44 CH₂Cl J-29-44CH₂Br J-29-44 CH₂I J-29-44 OH J-29-44 OMe J-29-44 OEt J-29-44 OPrJ-29-44 O—i-Pr J-29-44 O—n-Bu J-29-44 O—t-Bu J-29-44 NMe₂ J-29-44 NEt₂J-29-44 N(n-Pr)₂ J-29-44 1-piperdinyl J-29-44 1-pyrrolidinyl J-29-444-morpholinyl J-29-44 CH₃ J-29-45 CH₂Cl J-29-45 CH₂Br J-29-45 CH₂IJ-29-45 OH J-29-45 OMe J-29-45 OEt J-29-45 OPr J-29-45 O—i-Pr J-29-45O—n-Bu J-29-45 O—t-Bu J-29-45 NMe₂ J-29-45 NEt₂ J-29-45 N(n-Pr)₂ J-29-451-piperdinyl J-29-45 1-pyrrolidinyl J-29-45 4-morpholinyl J-29-45 CH₃J-29-46 CH₂Cl J-29-46 CH₂Br J-29-46 CH₂I J-29-46 OH J-29-46 OMe J-29-46OEt J-29-46 OPr J-29-46 O—i-Pr J-29-46 O—n-Bu J-29-46 O—t-Bu J-29-46NMe₂ J-29-46 NEt₂ J-29-46 N(n-Pr)₂ J-29-46 1-piperdinyl J-29-461-pyrrolidinyl J-29-46 4-morpholinyl J-29-46 CH₃ J-29-47 CH₂Cl J-29-47CH₂Br J-29-47 CH₂I J-29-47 OH J-29-47 OMe J-29-47 OEt J-29-47 OPrJ-29-47 O—i-Pr J-29-47 O—n-Bu J-29-47 O—t-Bu J-29-47 NMe₂ J-29-47 NEt₂J-29-47 N(n-Pr)₂ J-29-47 1-piperdinyl J-29-47 1-pyrrolidinyl J-29-474-morpholinyl J-29-47 CH₃ J-29-48 CH₂Cl J-29-48 CH₂Br J-29-48 CH₂IJ-29-48 OH J-29-48 OMe J-29-48 OEt J-29-48 OPr J-29-48 O—i-Pr J-29-48O—n-Bu J-29-48 O—t-Bu J-29-48 NMe₂ J-29-48 NEt₂ J-29-48 N(n-Pr)₂ J-29-481-piperdinyl J-29-48 1-pyrrolidinyl J-29-48 4-morpholinyl J-29-48 CH₃J-29-49 CH₂Cl J-29-49 CH₂Br J-29-49 CH₂I J-29-49 OH J-29-49 OMe J-29-49OEt J-29-49 OPr J-29-49 O—i-Pr J-29-49 O—n-Bu J-29-49 O—t-Bu J-29-49NMe₂ J-29-49 NEt₂ J-29-49 N(n-Pr)₂ J-29-49 1-piperdinyl J-29-491-pyrrolidinyl J-29-49 4-morpholinyl J-29-49 CH₃ J-29-50 CH₂Cl J-29-50CH₂Br J-29-50 CH₂I J-29-50 OH J-29-50 OMe J-29-50 OEt J-29-50 OPrJ-29-50 O—i-Pr J-29-50 O—n-Bu J-29-50 O—t-Bu J-29-50 NMe₂ J-29-50 NEt₂J-29-50 N(n-Pr)₂ J-29-50 1-piperdinyl J-29-50 1-pyrrolidinyl J-29-504-morpholinyl J-29-50 CH₃ J-29-51 CH₂Cl J-29-51 CH₂Br J-29-51 CH₂IJ-29-51 OH J-29-51 OMe J-29-51 OEt J-29-51 OPr J-29-51 O—i-Pr J-29-51O—n-Bu J-29-51 O—t-Bu J-29-51 NMe₂ J-29-51 NEt₂ J-29-51 N(n-Pr)₂ J-29-511-piperdinyl J-29-51 1-pyrrolidinyl J-29-51 4-morpholinyl J-29-51 CH₃J-29-52 CH₂Cl J-29-52 CH₂Br J-29-52 CH₂I J-29-52 OH J-29-52 OMe J-29-52OEt J-29-52 OPr J-29-52 O—i-Pr J-29-52 O—n-Bu J-29-52 O—t-Bu J-29-52NMe₂ J-29-52 NEt₂ J-29-52 N(n-Pr)₂ J-29-52 1-piperdinyl J-29-521-pyrrolidinyl J-29-52 4-morpholinyl J-29-52 CH₃ J-29-53 CH₂Cl J-29-53CH₂Br J-29-53 CH₂I J-29-53 OH J-29-53 OMe J-29-53 OEt J-29-53 OPrJ-29-53 O—i-Pr J-29-53 O—n-Bu J-29-53 O—t-Bu J-29-53 NMe₂ J-29-53 NEt₂J-29-53 N(n-Pr)₂ J-29-53 1-piperdinyl J-29-53 1-pyrrolidinyl J-29-534-morpholinyl J-29-53 CH₃ J-29-54 CH₂Cl J-29-54 CH₂Br J-29-54 CH₂IJ-29-54 OH J-29-54 OMe J-29-54 OEt J-29-54 OPr J-29-54 O—i-Pr J-29-54O—n-Bu J-29-54 O—t-Bu J-29-54 NMe₂ J-29-54 NEt₂ J-29-54 N(n-Pr)₂ J-29-541-piperdinyl J-29-54 1-pyrrolidinyl J-29-54 4-morpholinyl J-29-54 CH₃J-29-55 CH₂Cl J-29-55 CH₂Br J-29-55 CH₂I J-29-55 OH J-29-55 OMe J-29-55OEt J-29-55 OPr J-29-55 O—i-Pr J-29-55 O—n-Bu J-29-55 O—t-Bu J-29-55NMe₂ J-29-55 NEt₂ J-29-55 N(n-Pr)₂ J-29-55 1-piperdinyl J-29-551-pyrrolidinyl J-29-55 4-morpholinyl J-29-55 CH₃ J-29-56 CH₂Cl J-29-56CH₂Br J-29-56 CH₂I J-29-56 OH J-29-56 OMe J-29-56 OEt J-29-56 OPrJ-29-56 O—i-Pr J-29-56 O—n-Bu J-29-56 O—t-Bu J-29-56 NMe₂ J-29-56 NEt₂J-29-56 N(n-Pr)₂ J-29-56 1-piperdinyl J-29-56 1-pyrrolidinyl J-29-564-morpholinyl J-29-56 CH₃ J-29-57 CH₂Cl J-29-57 CH₂Br J-29-57 CH₂IJ-29-57 OH J-29-57 OMe J-29-57 OEt J-29-57 OPr J-29-57 O—i-Pr J-29-57O—n-Bu J-29-57 O—t-Bu J-29-57 NMe₂ J-29-57 NEt₂ J-29-57 N(n-Pr)₂ J-29-571-piperdinyl J-29-57 1-pyrrolidinyl J-29-57 4-morpholinyl J-29-57 CH₃J-29-58 CH₂Cl J-29-58 CH₂Br J-29-58 CH₂I J-29-58 OH J-29-58 OMe J-29-58OEt J-29-58 OPr J-29-58 O—i-Pr J-29-58 O—n-Bu J-29-58 O—t-Bu J-29-58NMe₂ J-29-58 NEt₂ J-29-58 N(n-Pr)₂ J-29-58 1-piperdinyl J-29-581-pyrrolidinyl J-29-58 4-morpholinyl J-29-58

Table 8 above identifies particular compounds comprising a J¹ groupselected from J-29-1 through J-29-58. As many J-29-1 through J-29-58include a chiral center, these J¹ groups are illustrated in a particularenantiomeric configuration, which in some instances may provide thegreatest fungicidal activity for compounds of Formula 1. One skilled inthe art immediately recognizes the antipode (i.e. opposite enantiomer)for each of the compounds listed, and furthermore understands that theenantiomers can be present as pure enantiomers or in mixtures enrichedin one enantiomer or in racemic mixtures.

Formulation/Utility

A compound of Formula 1 of this invention will generally be used as afungicidal active ingredient in a composition, i.e. formulation, with atleast one additional component selected from the group consisting ofsurfactants, solid diluents and liquid diluents, which serve as acarrier. Compounds within the scope of exclusion of proviso (a) ofFormula 1 can also be used. The formulation or composition ingredientsare selected to be consistent with the physical properties of the activeingredient, mode of application and environmental factors such as soiltype, moisture and temperature.

Useful formulations include both liquid and solid compositions. Liquidcompositions include solutions (including emulsifiable concentrates),suspensions, emulsions (including microemulsions and/or suspoemulsions)and the like, which optionally can be thickened into gels. The generaltypes of aqueous liquid compositions are soluble concentrate, suspensionconcentrate, capsule suspension, concentrated emulsion, microemulsionand suspo-emulsion. The general types of nonaqueous liquid compositionsare emulsifiable concentrate, microemulsifiable concentrate, dispersibleconcentrate and oil dispersion.

The general types of solid compositions are dusts, powders, granules,pellets, pills, pastilles, tablets, filled films (including seedcoatings) and the like, which can be water-dispersible (“wettable”) orwater-soluble. Films and coatings formed from film-forming solutions orflowable suspensions are particularly useful for seed treatment. Activeingredient can be (micro)encapsulated and further formed into asuspension or solid formulation; alternatively the entire formulation ofactive ingredient can be encapsulated (or “overcoated”). Encapsulationcan control or delay release of the active ingredient. An emulsifiablegranule combines the advantages of both an emulsifiable concentrateformulation and a dry granular formulation. High-strength compositionsare primarily used as intermediates for further formulation.

Sprayable formulations are typically extended in a suitable mediumbefore spraying. Such liquid and solid formulations are formulated to bereadily diluted in the spray medium, usually water. Spray volumes canrange from about from about one to several thousand liters per hectare,but more typically are in the range from about ten to several hundredliters per hectare. Sprayable formulations can be tank mixed with wateror another suitable medium for foliar treatment by aerial or groundapplication, or for application to the growing medium of the plant.Liquid and dry formulations can be metered directly into drip irrigationsystems or metered into the furrow during planting. Liquid and solidformulations can be applied onto vegetable seeds as seed treatmentsbefore planting to protect developing roots and other subterranean plantparts and/or foliage through systemic uptake.

The formulations will typically contain effective amounts of activeingredient, diluent and surfactant within the following approximateranges which add up to 100 percent by weight.

Weight Percent Active Surfac- Ingredient Diluent tant Water-Dispersibleand Water-soluble 0.001-90 0-99.999 0-15 Granules, Tablets and Powders.Oil Dispersions, Suspensions,    1-50 40-99    0-50 Emulsions, Solutions(including Emulsifiable Concentrates) Dusts    1-25 70-99    0-5 Granules and Pellets 0.001-99 5-99.999 0-15 High Strength Compositions  90-99 0-10    0-2 

Solid diluents include, for example, clays such as bentonite,montmorillonite, attapulgite and kaolin, gypsum, cellulose, titaniumdioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose),silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodiumcarbonate and bicarbonate, and sodium sulfate. Typical solid diluentsare described in Watkins et al., Handbook of Insecticide Dust Diluentsand Carriers, 2nd Ed., Dorland Books. Caldwell, N.J.

Liquid diluents include, for example, water, N,N-dimethylalkanamides(e.g., N,N-dimethylformamide), limonene, dimethyl sulfoxide,N-alkylpyrrolidones (e.g., N-methylpyrrolidinone), ethylene glycol,triethylene glycol, propylene glycol, dipropylene glycol, polypropyleneglycol, propylene carbonate, butylene carbonate, paraffins (e.g., whitemineral oils, normal paraffins, isoparaffins), alkylbenzenes,alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol, triacetin,aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes,alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone,isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamylacetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate,tridecyl acetate and isobornyl acetate, other esters such as alkylatedlactate esters, dibasic esters and γ-butyrolactone, and alcohols, whichcan be linear, branched, saturated or unsaturated, such as methanol,ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol,n-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol,isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleylalcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol andbenzyl alcohol. Liquid diluents also include glycerol esters ofsaturated and unsaturated fatty acids (typically C₆-C₂₂), such as plantseed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn(maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean,rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beeftallow, pork tallow, lard, cod liver oil, fish oil), and mixturesthereof. Liquid diluents also include alkylated fatty acids (e.g.,methylated, ethylated, butylated) wherein the fatty acids may beobtained by hydrolysis of glycerol esters from plant and animal sources,and can be purified by distillation. Typical liquid diluents armdescribed in Marsden, Solvents Guide, 2nd Ed., Interscience, New York,1950.

The solid and liquid compositions of the present invention often includeone or more surfactants. Surfactants can be classified as nonionic,anionic or cationic. Nonionic surfactants useful for the presentcompositions include, but are not limited to: alcohol alkoxylates suchas alcohol alkoxylates based on natural and synthetic alcohols (whichmay be branched or linear) and prepared from the alcohols and ethyleneoxide, propylene oxide, butylene oxide or mixtures thereof; amineethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylatedtriglycerides such as ethoxylated soybean, castor and rapeseed oils;alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenolethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates(prepared from the phenols and ethylene oxide, propylene oxide, butyleneoxide or mixtures thereof); block polymers prepared from ethylene oxideor propylene oxide and reverse block polymers where the terminal blocksare prepared from propylene oxide; ethoxylated fatty acids; ethoxylatedfatty esters and oils; ethoxylated methyl esters; ethoxylatedtristyrylphenol (including those prepared from ethylene oxide, propyleneoxide, butylene oxide or mixtures thereof); fatty acid esters, glycerolesters, lanolin-based derivatives, polyethoxylate esters such aspolyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitolfatty acid esters and polyethoxylated glycerol fatty acid esters; othersorbitan derivatives such as sorbitan esters; polymeric surfactants suchas random copolymers, block copolymers, alkyl peg (polyethylene glycol)resins, graft or comb polymers and star polymers; polyethylene glycols(pegs); polyethylene glycol fatty acid esters; silicone-basedsurfactants; and sugar-derivatives such as sucrose esters, alkylpolyglycosides and alkyl polysaccharides.

Useful anionic surfactants include, but are not limited to: alkylarylsulfonic acids and their salts; carboxylated alcohol or alkylphenolethoxylates; diphenyl sulfonate derivatives; lignin and ligninderivatives such as lignosulfonates; maleic or succinic acids or theiranhydrides; olefin sulfonates; phosphate esters such as phosphate estersof alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates andphosphate esters of styryl phenol ethoxylates; protein-basedsurfactants; sarcosine derivatives; styryl phenol ether sulfate;sulfates and sulfonates of oils and fatty acids; sulfates and sulfonatesof ethoxylated alkylphenols; sulfates of alcohols; sulfates ofethoxylated alcohols; sulfonates of amines and amides such asN,N-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, anddodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes;sulfonates of naphthalene and alkyl naphthalene; sulfonates offractionated petroleum; sulfosuccinamates; and sulfosuccinates and theirderivatives such as dialkyl sulfosuccinate salts.

Useful cationic surfactants include, but are not limited to: amides andethoxylated amides; amines such as N-alkyl propanediamines,tripropylenetriamines and dipropylenetetramines, and ethoxylated amines,ethoxylated diamines and propoxylated amines (prepared from the aminesand ethylene oxide, propylene oxide, butylene oxide or mixturesthereof); amine salts such as amine acetates and diamine salts;quaternary ammonium salts such as quaternary salts, ethoxylatedquaternary salts and diquaternary salts; and amine oxides such asalkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.

Also useful for the present compositions are mixtures of nonionic andanionic surfactants or mixtures of nonionic and cationic surfactants.Nonionic, anionic and cationic surfactants and their recommended usesare disclosed in a variety of published references includingMcCutcheon's Emulsifiers and Detergents, annual American andInternational Editions published by McCutcheon's Division, TheManufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopediaof Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; andA. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition,John Wiley and Sons, New York, 1987.

Compositions of this invention may also contain formulation auxiliariesand additives, known to those skilled in the art as formulation aids.Such formulation auxiliaries and additives may control: pH (buffers),foaming during processing (antifoams such polyorganosiloxanes (e.g.,Rhodorsil®) 416)), sedimentation of active ingredients (suspendingagents), viscosity (thixotropic thickeners), in-container microbialgrowth (antimicrobials), product freezing (antifreezes), color(dyes/pigment dispersions (e.g., Pro-Ized® Colorant Red)), wash-off(film formers or stickers), evaporation (evaporation retardants), andother formulation attributes. Film formers include, for example,polyvinyl acetates, polyvinyl acetate copolymers,polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols,polyvinyl alcohol copolymers and waxes. Examples of formulationauxiliaries and additives include those listed in McCutcheon's Volume 2:Functional Materials, annual International and North American editionspublished by McCutcheon's Division, The Manufacturing ConfectionerPublishing Co.; and PCT Publication WO 03/024222.

Solutions, including emulsifiable concentrates, can be prepared bysimply mixing the ingredients. If the solvent of a liquid compositionintended for use as an emulsifiable concentrate is water-immiscible, anemulsifier is typically added to emulsify the active-containing solventupon dilution with water. Active ingredient slurries, with particlediameters of up to 2,000 μm can be wet milled using media mills toobtain particles with average diameters below 3 μm. Aqueous slurries canbe made into finished suspension concentrates (see, for example, U.S.Pat. No. 3,060,084) or further processed by spray drying to formwater-dispersible granules. Dry formulations usually require dry millingprocesses, which produce average particle diameters in the 2 to 10 μmrange. Dusts and powders can be prepared by blending and, usually,grinding as in a hammer mill or fluid-energy mill. Granules and pelletscan be prepared by spraying the active material upon preformed granularcarriers or by agglomeration techniques. See Browning, “Agglomeration”,Chemical Engineering, Dec. 4, 1967, pp 147-48, Perry's ChemicalEngineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57and following, and WO 91/13546. Pellets can be prepared as described inU.S. Pat. No. 4,172,714. Water-dispersible and water-soluble granulescan be prepared as taught in U.S. Pat. No. 4,144,050, U.S. Pat. No.3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S.Pat. No. 5,180,587, U.S. Pat. No. 5,232,701 and U.S. Pat. No. 5,208,030.Films can be prepared as taught in GB 2,095,558 and U.S. Pat. No.3,299,566.

For further information regarding the art of formulation, see T. S.Woods, “The Formulator's Toolbox—Product Forms for Modern Agriculture”in Pesticide Chemistry and Bioscience, The Food-Environment Challenge,T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th InternationalCongress on Pesticide Chemistry. The Royal Society of Chemistry,Cambridge, 1999, pp. 120-133. See also U.S. Pat. No. 3,235,361, Col. 6,line 16 through Col. 7, line 19 and Examples 10-41; U.S. Pat. No.3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12,15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182;U.S. Pat. No. 2,891,855, Col. 3, line 66 through Col. 5, line 17 andExamples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons,Inc., New York, 1961, pp 81-96; Hance et al., Weed Control Handbook, 8thEd., Blackwell Scientific Publications, Oxford, 1989; and Developmentsin formulation technology, PJB Publications, Richmond, UK, 2000.

In the following Examples, all percentages are by weight and allformulations are prepared in conventional ways. Compound numbers referto compounds in Index Table A.

Example A

High Strength Concentrate Compound 1 98.5%  silica aerogel 0.5%synthetic amorphous fine silica  1.0%.

Example B

Wettable Powder Compound 2 65.0%  dodecylphenol polyethylene glycolether 2.0% sodium ligninsulfonate 4.0% sodium silicoaluminate 6.0%montmorillonite (calcined) 23.0%. 

Example C

Granule Compound 16 10.0%  attapulgite granules (low volatile matter,0.71/0.30 mm; U.S.S. No. 25-50 sieves) 90.0%.

Example D

Aqueous Suspension Compound 37 25.0%  hydrated attapulgite 3.0% crudecalcium ligninsulfonate 10.0%  sodium dihydrogen phosphate 0.5% water61.5%. 

Example E

Extruded Pellet Compound 107 25.0%  anhydrous sodium sulfate 10.0% crude calcium ligninsulfonate 5.0% sodium alkylnaphthalenesulfonate 1.0%calcium/magnesium bentonite 59.0%. 

Example F

Microemulsion Compound 44  1.0% triacetine 30.0% C₈-C₁₀alkylpolyglycoside 30.0% glyceryl monooleate 19.0% water  20.0%.

Example G

Emulsifiable Concentrate Compound 1 10.0% C₈-C₁₀ fatty acid methyl ester70.0% polyoxyethylene sorbitol hexoleate  20.0%.

The compounds of Formula 1 of this invention are useful as plant diseasecontrol agents. The present invention therefore further comprises amethod for controlling plant diseases caused by fungal plant pathogenscomprising applying to the plant or portion thereof to be protected, orto the plant seed to be protected, an effective amount of a compound ofthe invention or a fungicidal composition containing said compound.Compounds within the scope of exclusion of proviso (a) of Formula 1 andfungicidal compositions containing them can also be used to controlplant diseases in accordance with this invention. The compounds and/orcompositions of this invention provide control of diseases caused by abroad spectrum of fungal plant pathogens in the Basidiomycete,Ascomycete, Oomycete and Deuteromycete classes. They are effective incontrolling a broad spectrum of plant diseases, particularly foliarpathogens of ornamental, turf, vegetable, field, cereal, and fruitcrops. These pathogens include: Oomycetes, including Phytophthoradiseases such as Phytophthora infestans, Phytophthora megasperma,Phytophthora parasitica, Phytophthora cinnamomi and Phytophthoracapsici, Pythium diseases such as Pythium aphanidermatum, and diseasesin the Peronosporaceae family such as Plasmopara viticola, Peronosporaspp. (including Peronospora tabacina and Peronospora parasitica),Pseudoperonospora spp. (including Pseudoperonospora cubensis) and Bremialactucae; Ascomycetes, including Alternaria diseases such as Alternariasolani and Alternaria brassicae, Guignardia diseases such as Guignardiabidwell, Venturia diseases such as Venturia inaequalis, Septoriadiseases such as Septoria nodorum and Septoria tritici, powdery mildewdiseases such as Erysiphe spp. (including Erysiphe graminis and Ervsiphepolygoni), Uncinula necatur, Sphaerotheca fuligena and Podosphaeraleucotricha, Pseudocercosporella herpotrichoides, Botrvtis diseases suchas Botrvtis cinerea, Monilinia fructicola, Sclerotinia diseases such asSclerotinia sclerotiorum, Magnaporthe Grisea, Phomopsis Viticola,Helminthosporium diseases such as Helminthosporium tritici repentis,Pyrenophora teres, anthracnose diseases such as Glomerella orColletotrichum spp. (such as Colletotrichum graminicola andColletotrichum orbiculare), and Gaeumannomyces graminis; Basidiomycetes,including rust diseases caused by Puccinia spp. (such as Pucciniarecondita, Puccinia striiformis, Puccinia hordei, Puccinia graminis andPuccinia arachidis), Hemileia vastatrix and Phakopsora pachyrhizi; otherpathogens including Rhizoctonia spp. (such as Rhizoctonia solani);Fusarium diseases such as Fusarium roseum, Fusarium graminearum andFusarium oxysporum; Verticillium dahliae; Sclerotium rolfsii;Rynchosporium secalis; Cercosporidium personatum, Cercosporaarachidicola and Cercospora beticola; and other genera and speciesclosely related to these pathogens. In addition to their fungicidalactivity, the compositions or combinations also have activity againstbacteria such as Erwinia amylovora, Xanthomonas campestris, Pseudomonassyringae, and other related species. Of note is control provided ofdisease caused by the Ascomycete and Oomycete classes. Of particularnote is control provided of disease caused by the Oomycete class.

Plant disease control is ordinarily accomplished by applying aneffective amount of a compound of this invention either pre- orpost-infection, to the portion of the plant to be protected such as theroots, stems, foliage, fruit, seeds, tubers or bulbs, or to the media(soil or sand) in which the plants to be protected are growing. Thecompounds can also be applied to seeds to protect the seeds andseedlings developing from the seeds. The compounds can also be appliedthrough irrigation water to treat plants.

Rates of application for these compounds can be influenced by manyfactors of the environment and should be determined under actual useconditions. Foliage can normally be protected when treated at a rate offrom less than about 1 g/ha to about 5,000 g/ha of active ingredient.Seed and seedlings can normally be protected when seed is treated at arate of from about 0.1 to about 10 g per kilogram of seed.

Compounds of this invention can also be mixed with one or more otherinsecticides, fungicides, nematocides, bactericides, acaricides, growthregulators, chemosterilants, semiochemicals, repellents, attractants,pheromones, feeding stimulants or other biologically active compounds toform a multi-component pesticide giving an even broader spectrum ofagricultural protection. Examples of such agricultural protectants withwhich compounds of this invention can be formulated are: insecticidessuch as abamectin, acephate, acetamiprid, amidoflumet (S-1955),avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate,buprofezin, carbofuran, cartap, chlorantraniliprole (DPX-E2Y45),chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl,chromafenozide, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin,cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin,diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin,dimethoate, dinotefuran, diofenolan, emamectin, endosulfan,esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin,fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate,tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonophos,halofenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb,isofenphos, lufenuron, malathion, metaflumizone, metaldehyde,methamidophos, methidathion, methomyl, methoprene, methoxychlor,metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine,novaluron, noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl,permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb,profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin,pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, rotenone,ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060),spirotetramat, sulprofos, tebufenozide, teflubenzuron, tefluthrin,terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb,thiosultap-sodium, tralomethrin, triazamate, trichlorfon andtriflumuron; fungicides such as acibenzolar, aldimorph, amisulbrom,anilazine, azaconazole, azoxystrobin, benalaxyl, benodanil, benomyl,benthiavalicarb, benthiavalicarb-isopropyl, binapacryl, biphenyl,bitertanol, bixafen, blasticidin-S, Bordeaux mixture (tribasic coppersulfate), boscalid/nicobifen, bromuconazole, bupirimate, buthiobate,carboxin, carpropamid, captafol, captan, carbendazim, chloroneb,chlorothalonil,5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine,chlozolinate, clotrimazole, copper oxychloride, copper salts such ascopper sulfate and copper hydroxide, cyazofamid, cyflufenamid,cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet,diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim,dimethirimol,N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazol-4-carboxamide,dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinocap,discostrobin, dithianon, dodemorph, dodine, econazole, edifenphos,enestroburin, epoxiconazole, etaconazole, ethaboxam, ethirimol,ethridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole,fencaramid, fenfuram, fenhexamide, fenoxanil, fenpiclonil, fenpropidin,fenpropimorph, fentin acetate, fentin chloride, fentin hydroxide,ferbam, ferfurazoate, ferimzone, fluazinam, fludioxonil, flumetover,flumorph, fluopicolide, fluopyram, fluoxastrobin, fluquinconazole,fluquinconazole, flusilazole, flusulfamide, flutolanil, flutriafol,folpet, fosetyl-aluminum, fuberidazole, furalaxyl, furametapyr,hexaconazole, hymexazole, guazatine, imazalil, imibenconazole,iminoctadine, iodicarb, ipconazole, iprobenfos, iprodione, iprovalicarb,isoconazole, isoprothiolane, isotianil, kasugamycin, kresoxim-methyl,mancozeb, mandipropamid, maneb, mapanipyrin, mefenoxam, mepronil,meptyldinocap, metalaxyl, metconazole, methasulfocarb, metiram,metominostrobin, mepanipyrim, metiram, metrafenone, miconazole,myclobutanil, naftifine, neo-asozin (ferric methanearsonate), nuarimol,octhilinone, ofurace, orysastrobin, oxadixyl, oxolinic acid,oxpoconazole, oxycarboxin, oxytetracycline, paclobutrazol, penconazole,pencycuron, penthiopyrad, perfurazoate, phosphonic acid, phthalide,picobenzamid, picoxystrobin, piperalin, polyoxin, probenazole,prochloraz, procymidone, propamocarb, propamocarb-hydrochloride,propiconazole, propineb, proquinazid, prothiocarb, prothioconazole,pyraclostrobin, pryazophos, pyribencarb, pyrifenox, pyrimethanil,pyrifenox, pyrolnitrine, pyroquilon, quinconazole, quinoxyfen,quintozene, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur,tebuconazole, techrazene, tecloftalam, tecnazene, terbinafine,tetraconazole, thiabendazole, thifluzamide, thiophanate,thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolyfluanid,triadimefon, triadimenol, triarimol, triazoxide, tricyclazole,tridemorph, triflumizole, trimoprhamide tricyclazole, trifloxystrobin,triforine, triticonazole, uniconazole, validamycin, vinclozolin, zineb,ziram and zoxamide; nematocides such as aldicarb, aldoxycarb,fenamiphos, imicyafos and oxamyl; bactericides such as streptomycin;acaricides such as amitraz, chinomethionat, chlorobenzilate,cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazole, fenazaquin,fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite,pyridaben and tebufenpyrad; and biological agents such as Bacillusthuringiensis, Bacillus thuringiensis delta endotoxin, baculovirus, andentomopathogenic bacteria, virus and fungi. Descriptions of variouscommercially available compounds listed above may be found in ThePesticide Manual, Thirteenth Edition, C. D. S. Thomlin, ed., BritishCrop Protection Council, 2003. For embodiments where one or more ofthese various mixing partners are used, the weight ratio of thesevarious mixing partners (in total) to the compound of Formula 1 istypically between about 1:100 and about 3000:1. Of note are weightratios between about 1:30 and about 300:1 (for example ratios betweenabout 1:1 and about 30:1). It will be evident that including theseadditional components may expand the spectrum of diseases controlledbeyond the spectrum controlled by the compound of Formula 1 alone.

In one mixture embodiment, granules of a solid composition comprising acompound of Formula 1 is mixed with granules of a solid compositioncomprising another agricultural protectant. These granule mixtures canbe in accordance with the general granule mixture disclosure of PCTPatent Publication WO 94/24861 or more preferably the homogenous granulemixture teaching of U.S. Pat. No. 6,022,552.

Of note are combinations (e.g., in the form of compositions) of acompound of Formula 1 with at least one other fungicide. Of particularnote are such combinations where the other fungicide has different siteof action from the compound of Formula 1. In certain instances,combinations with other fungicides having a similar spectrum of controlbut a different site of action will be particularly advantageous forresistance management. Of particular note are compositions which inaddition to compound of Formula 1 include at least one compound selectedfrom the group consisting of (1) alkylenebis(dithiocarbamate)fungicides; (2) cymoxanil; (3) phenylamide fungicides; (4) pyrimidinonefungicides; (5) chlorothalonil; (6) carboxamides acting at complex II ofthe fungal mitochondrial respiratory electron transfer site; (7)quinoxyfen; (8) metrafenone; (9) cyflufenamid; (10) cyprodinil; (11)copper compounds; (12) phthalimide fungicides; (13) fosetyl-aluminum;(14) benzimidazole fungicides; (15) cyazofamid; (16) fluazinam; (17)iprovalicarb; (18) propamocarb; (19) validomycin; (20) dichlorophenyldicarboximide fungicides; (21) zoxamide; (22) fluopicolide; (23)mandipropamid; (24) carboxylic acid amides acting on phospholipidbiosynthesis and cell wall deposition; (25) dimethomorph; (26) non-DMIsterol biosynthesis inhibitors; (27) inhibitors of demethylase in sterolbiosynthesis; (28) bc₁ complex fungicides; and salts of compounds of (1)through (28).

Further descriptions of classes of fungicidal compounds are providedbelow.

Pyrimidinone fungicides (group (4)) include compounds of Formula A1

wherein M forms a fused phenyl, thiophene or pyridine ring; R¹¹ is C₁-C₆alkyl; R¹² is C₁-C₆ alkyl or C₁-C₆ alkoxy; R¹³ is halogen; and R¹⁴ ishydrogen or halogen.

Pyrimidinone fungicides are described in PCT Patent ApplicationPublication WO 94/26722 and U.S. Pat. Nos. 6,066,638, 6,245,770,6,262,058 and 6,277,858. Of note are pyrimidinone fungicides selectedfrom the group: 6-bromo-3-propyl-2-propyloxy-4(3H)-quinazolinone,6,8-diiodo-3-propyl-2-propyloxy-4(3H)-quinazolinone,6-iodo-3-propyl-2-propyloxy-4(3H)-quinazolinone (proquinazid),6-chloro-2-propoxy-3-propylthieno[2,3-d]pyrimidin-4(3H)-one,6-bromo-2-propoxy-3-propylthieno[2,3-d]pyrimidin-4(3H)-one,7-bromo-2-propoxy-3-propylthieno[3,2-d]pyrimidin-4(3H)-one,6-bromo-2-propoxy-3-propylpyrido[2,3-d]pyrimidin-4(3H)-one,6,7-dibromo-2-propoxy-3-propylthieno[3,2-d]pyrimidin-4(3H)-one, and3-(cyclopropylmethyl)-6-iodo-2-(propylthio)pyrido-[2,3-d]pyrimidin-4(3H)-one.

Sterol biosynthesis inhibitors (group (27)) control fungi by inhibitingenzymes in the sterol biosynthesis pathway. Demethylase-inhibitingfungicides have a common site of action within the fungal sterolbiosynthesis pathway, involving inhibition of demethylation at position14 of lanosterol or 24-methylene dihydrolanosterol, which are precursorsto sterols in fungi. Compounds acting at this site are often referred toas demethylase inhibitors, DMI fungicides, or DMIs. The demethylaseenzyme is sometimes referred to by other names in the biochemicalliterature, including cytochrome P-450 (14DM). The demethylase enzyme isdescribed in, for example, J. Biol. Chem. 1992, 267, 13175-79 andreferences cited therein. DMI fungicides are divided between severalchemical classes: azoles (including triazoles and imidazoles),pyrimidines, piperazines and pyridines. The triazoles includeazaconazole, bromuconazole, cyproconazole, difenoconazole, diniconazole(including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole,fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole,ipconazole, metconazole, myclobutanil, penconazole, propiconazole,prothioconazole, quinconazole, simeconazole, tebuconazole,tetraconazole, triadimefon, triadimenol, triticonazole and uniconazole.The imidazoles include clotrimazole, econazole, imazalil, isoconazole,miconazole, oxpoconazole, prochloraz and triflumizole. The pyrimidinesinclude fenarimol, nuarimol and triarimol. The piperazines includetriforine. The pyridines include buthiobate and pyrifenox. Biochemicalinvestigations have shown that all of the above mentioned fungicides areDMI fungicides as described by K. H. Kuck et al. in Modern SelectiveFungicides-Properties, Applications and Mechanisms of Action, H. Lyr(Ed.), Gustav Fischer Verlag: New York, 1995, 205-258.

bc₁ Complex Fungicides (group 28) have a fungicidal mode of action whichinhibits the bc₁ complex in the mitochondrial respiration chain. The bc₁complex is sometimes referred to by other names in the biochemicalliterature, including complex III of the electron transfer chain, andubihydroquinone:cytochrome c oxidoreductase. This complex is uniquelyidentified by Enzyme Commission number EC1.10.2.2. The bc₁ complex isdescribed in, for example, J. Biol. Chem. 1989, 264, 14543-48; MethodsEnzymol. 1986, 126, 253-71; and references cited therein. Strobilurinfungicides such as azoxystrobin, dimoxystrobin, enestroburin (SYP-Z071),fluoxastrobin, kresoxim-methyl, metominostrobin, orysastrobin,picoxystrobin, pyraclostrobin and trifloxystrobin are known to have thismode of action (H. Sauter et al., Angew. Chem. Int. Ed. 1999, 38,1328-1349). Other fungicidal compounds that inhibit the bc₁ complex inthe mitochondrial respiration chain include famoxadone and fenamidone.

Alkylenebis(dithiocarbamate) fungicides (group (1)) include compoundssuch as mancozeb, maneb, propineb and zineb. Phenylamide fungicides(group (3)) include compounds such as metalaxyl, benalaxyl, furalaxyland oxadixyl. Carboxamides (group (6)) include compounds such asboscalid, carboxin, fenfuram, flutolanil, furametpyr, mepronil,oxycarboxin, thifluzamide, penthiopyrad andN-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide(PCT Patent Publication WO 2003/010149), and are known to inhibitmitochondrial function by disrupting complex II (succinatedehydrogenase) in the respiratory electron transport chain. Coppercompounds (group (11)) include compounds such as copper oxychloride,copper sulfate and copper hydroxide, including compositions such asBordeaux mixture (tribasic copper sulfate). Phthalimide fungicides(group (12)) include compounds such as folpet and captan. Benzimidazolefungicides (group (14)) include benomyl and carbendazim. Dichlorophenyldicarboximide fungicides (group (20)) include chlozolinate,dichlozoline, iprodione, isovaledione, myclozolin, procymidone andvinclozolin.

Non-DMI sterol biosynthesis inhibitors (group (26)) include morpholineand piperidine fungicides. The morpholines and piperidines are sterolbiosynthesis inhibitors that have been shown to inhibit steps in thesterol biosynthesis pathway at a point later than the inhibitionsachieved by the DMI sterol biosynthesis (group (27)). The morpholinesinclude aldimorph, dodemorph, fenpropimorph, tridemorph andtrimorphamide. The piperidines include fenpropidin.

Of note are these methods where plant diseases caused by Oomycete fungalplant pathogens are controlled.

The discussion above relating to the use of compounds of Formula 1 incompositions (e.g., certain compositions comprising surfactants, soliddiluents, liquid diluents and/or biologically active compounds) and inmethods for controlling plant diseases (e.g., controlling plant diseasescaused by Oomycete fungal plant pathogens) also applies to compoundswithin the scope of exclusion of proviso (a) of Formula 1.

The following Tests demonstrate the control efficacy of compounds ofthis invention on specific pathogens. The pathogen control protectionafforded by the compounds is not limited, however, to these species. SeeIndex Tables A for compound descriptions. The stereocenters labeled as“R” (rectus) and “S” (sinister) are based on the Cahn-Ingold-Prelogsystem as used by Chemical Abstracts; a stereocenter label followed byan asterisks “**” means the stereochemical description is relative toother stereocenters, and the compound is racemic. The abbreviation “Ex.”stands for “Example” and is followed by a number indicating in whichexample the compound is prepared. Index Table A lists the molecularweight of the highest isotopic abundance parent ion (M+1) formed byaddition of H⁺ (molecular weight of 1) to the molecule, observed by massspectrometry using atmospheric pressure chemical ionization (AP⁺).Chiral separation of Compound 1 into Compounds 3 and 4 was accomplishedusing a preparative CHIRALPAK® AD-RH column (Chiral Technologies, Inc.,West Chester, Pa., U.S.A.) containing silica gel coated withamylose-tris(3,5-dimethylphenyl carbamate) and eluted with awater-methanol gradient. Specific rotation ([α]_(D)) was measured inethanol solution at 25° C. using a 100-mm path cell.

INDEX TABLE A

G is as defined in Exhibit 2; R^(3a) in G is H. L groups are defined asillustrated below

L-1 L-2

L-3 L-4

L-5 L-6

L-7 L-8

L-9 L-10

L-11 L-12

L-13 L-14

L-15 L-16

L-17 L-18

L-19 L-20

L-21 L-22

L-23 L-24

L-25 L-26

L-27 L-28

L-29 L-30

L-31 L-32

L-33 AP⁺ Cmpd. L X G Z₁—J (M + 1) 1 L-1 X¹ G-1  4,5-dihydro-5-phenyl-3-504 (Ex. 1) isoxazolyl 2 L-1 X¹ G-1  5-phenyl-3-isoxazolyl 502 (Ex. 2) 3L-1 X¹ G-1  4,5-dihydro-5-phenyl- 504 (Ex. 12) 3-isoxazolyl [Note 1] 4L-1 X¹ G-1  4,5-dihydro-5-phenyl- 504 3-isoxazolyl [Note 2] 5 L-1 X¹G-1  5,6-dihydro-6-phenyl-4H- 518 1,2-oxazin-3-yl 6 L-1 X¹ G-1 4,5-dihydro-3-phenyl- 504 (Ex. 4) 5-isoxazolyl 7 L-1 X¹ G-1 (5S)-4,5-dihydro-1-methyl-5- 517 (Ex. 3) phenyl-1H-imidazol-2-yl 8 L-1X¹ G-1  5-(2-chlorophenyl)-4,5-dihydro- 538 (Ex. 5) 3-isoxazolyl 9 L-1X¹ G-1  5-(4-chlorophenyl)-4,5-dihydro- 538 3-isoxazolyl 10 L-1 X¹ G-1 4,5-dihydro-5-(4-methylphenyl)- 518 3-isoxazolyl 11 L-1 X¹ G-1 (4R**,5R**)-4,5-dihydro-4- 518 methyl-5-phenyl-3-isoxazolyl 12 L-1 X¹G-27 3-phenyl-1H-pyrazol-1-yl 483 13 L-1 X¹ G-1  4-phenyl-2-oxazolidinyl506 14 L-1 X¹ G-1  3-acetyl-4-phenyl-2-oxazolidinyl 548 15 L-1 X¹ G-1 4,5-dihydro-5-methyl-5-phenyl- 518 (Ex. 8) 3-isoxazolyl 16 L-1 X¹ G-1 3a,4,5,9b-tetrahydronaphth 530 (Ex. 8) [2,1-d]isoxazol-3-yl 17 L-1 X¹G-1  5-(3-chlorophenyl)-4,5-dihydro- 538 3-isoxazolyl 18 L-1 X¹ G-1 4,5-dihydro-5-(4- 534 (Ex. 8) methoxyphenyl)-3-isoxazolyl 19 L-2 X¹ G-1 4,5-dihydro-5-phenyl- 518 (Ex. 1) 3-isoxazolyl 20 L-3 X¹ G-1 4,5-dihydro-5-phenyl- 504 3-isoxazolyl 21 L-4 X¹ G-1 4,5-dihydro-5-phenyl- 491 3-isoxazolyl 22 L-5 X¹ G-1 4,5-dihydro-5-phenyl- 558 (Ex. 1) 3-isoxazolyl 23 L-6 X¹ G-1 4,5-dihydro-5-phenyl- 460 3-isoxazolyl 24 L-1 X¹ G-1 4,5-dihydro-5-(phenylmethyl)- 518 3-isoxazolyl 25 L-1 X¹ G-1 (4R**,5S**)-4,5-dihydro-4- 518 methyl-5-phenyl-3-isoxazolyl 26 L-1 X¹G-1  4-biphenyl 511 27 L-1 X¹ G-1  4,5-dihydro-5-(3-methylbutyl)- 4983-isoxazolyl 28 L-1 X¹ G-1  4,5-dihydro-5-(2,2- 498dimethylpropyl)-3-isoxazolyl 29 L-1 X¹ G-1 5,6-dihydro-6-methyl-6-phenyl- 532 4H-1,2-oxazin-3-yl 30 L-1 X¹ G-1 3-phenyl-5-isoxazolyl 502 31 L-1 X¹ G-1  4,5-dihydro-4-phenyl-2-oxazolyl504 32 L-1 X¹ G-1  4,5-dihydro-1-(phenylmethyl)- 517 1H-imidazol-2-yl 33L-1 X¹ G-27 3-biphenyl 494 34 L-1 X¹ G-27 6-phenyl-2-pyridyl 495 35 L-1X¹ G-1  4,5-dihydro-5-phenyl-5- 572 (trifluoromethyl)-3-isoxazolyl 36L-1 X¹ G-1  5-[3-(trifluoromethyl)phenyl]- 570 3-isoxazolyl 37 (Ex. 8)L-1 X¹ G-1 

544 38 L-1 X¹ G-1  5-(4-biphenyl)-3-isoxazolyl 578 39 L-1 X¹ G-1 4,5-dihydro-5-(3,5- 640 dichlorophenyl)-5-(trifluoro-methyl)-3-isoxazolyl 40 L-1 X¹ G-1  5-phenyl-1,3,4-oxadiazol-2-yl 503 41L-1 X¹ G-1  4,5-dihydro-5-phenyl-2-oxazolyl 504 42 L-1 X¹ G-1 5-phenyl-2-oxazolyl 502 43 L-1 X¹ G-1  2-benzothiazolyl 492 44 (Ex. 8)L-1 X¹ G-1 

530 45 L-1 X¹ G-1 

511 46 L-1 X¹ G-1  (4R)-4,5-dihydro-4-phenyl- 504 2-oxazolyl 47 L-1 X¹G-1  (5S)-4,5-dihydro-5-phenyl- 504 2-oxazolyl 48 L-1 X¹ G-1 5,6-dihydro-6-phenyl-4H-1,3- 518 oxazin-2-yl 49 L-1 X¹ G-1 (4S)-4,5-dihydro-4-phenyl- 504 2-oxazolyl 50 L-1 X¹ G-1 (5R)-4,5-dihydro-5-phenyl- 504 2-oxazolyl 51 L-1 X¹ G-1 

516 52 L-1 X¹ G-1  2-benzoxazolyl 475 53 L-1 X¹ G-1 5,6-dihydro-5-phenyl-4H-1,3- 518 oxazin-2-yl 54 L-1 X¹ G-1 5,6-dihydro-4-phenyl-4H-1,3- 518 oxazin-2-yl 55 L-1 X¹ G-1 4,5-dihydro-5- 486 (methoxycarbonyl)-3-isoxazolyl 56 L-1 X¹ G-1 4,5-dihydro-5-(1,1- 484 dimethylethyl)-3-isoxazolyl 57 L-1 X¹ G-1 4,5-dihydro-5-(2-bromoethyl)- 534 3-isoxazolyl 58 L-1 X¹ G-1 2-benzimidazolyl 475 59 L-1 X¹ G-1  5-(2-fluorophenyl)-3-isoxazolyl 52060 L-1 X¹ G-1  5-(2-trifluoromethylphenyl)- 570 3-isoxazolyl 61 L-1 X¹G-1  2-naphthalenyl 485 62 L-1 X¹ G-1  phenyl 435 63 L-7 X¹ G-1 4,5-dihydro-5-phenyl-3- 518 isoxazolyl 64 L-1 X¹ G-1 5-(2,4-difluorophenyl)-3- 538 isoxazolyl 65 L-1 X¹ G-1 1-phenyl-2-pyrrolidon-4-yl 518 66 L-1 X¹ G-1  4,5-dihydro-5-cyano-3- 453isoxazolyl 67 L-1 X¹ G-1 

482 68 L-1 X¹ G-1  3-phenyl-1,2,4-oxadiazol-5-yl 503 69  L-15 X¹ G-1 4,5-dihydro-5-phenyl-3- 532 isoxazolyl 70  L-16 X¹ G-1 4,5-dihydro-5-phenyl-3- 478 isoxazolyl 71  L-17 X¹ G-1 4,5-dihydro-5-phenyl-3- 500 isoxazolyl 72 L-1 X¹ G-1  4-phenoxyphenyl527 73 L-1 X¹ G-1  1-naphthalenyl 485 74 L-1 X¹ G-1  3-biphenyl 511 75L-1 X¹ G-1  3-phenoxyphenyl 527 76 L-1 X¹ G-1  1-phenylpyrazol-3-yl 50177 L-1 X¹ G-1  1-(4-methylphenyl)-1,2,3- 516 triazol-4-yl 78 L-1 X¹ G-1 1-phenylpyrazol-5-yl 501 79 L-1 X¹ G-1  4,5-dihydro-5-(2-fluorophenyl)-522 3-isoxazolyl 80  L-17 X¹ G-1  4,5-dihydro-5-(2-fluorophenyl)- 5183-isoxazolyl 81 L-1 X¹ G-1  5,6-dihydro-5-phenyl-6- 548methoxy-4H-1,2-oxazin-3-yl 82 L-1 X¹ G-1 

518 83 L-1 X¹ G-1  5-phenyl-2-furanyl 501 84 L-1 X¹ G-1 2-phenyl-4-thiazoyl 518 85 L-1 X¹ G-1  5-phenyl-2-thienyl 517 86 L-1 X¹G-1  3-(2,4-dichlorophenyl)-5- 570 isoxazoyl 87 L-1 X¹ G-1 3-(3,4-dichlorophenyl)-5- 570 isoxazoyl 88 L-1 X¹ G-1 4,5-dihydro-5-(naphthalen- 554 2-yl)-3-isoxazolyl 89  L-18 X¹ G-1 4,5-dihydro-5-phenyl-3- 462 isoxazolyl 90  L-19 X¹ G-1 4,5-dihydro-5-phenyl-3- 468 isoxazolyl 91 L-1 X¹ G-1 4,5-dihydro-5-(4-t-butyl- 560 phenyl)-3-isoxazolyl 92 L-1 X¹ G-1 (5R)-4,5-dihydro-5-phenyl- 503 1H-imidazol-2-yl 93 L-8 X¹ G-1 4,5-dihydro-5-phenyl-3- 450 isoxazolyl 94 L-9 X¹ G-1 4,5-dihydro-5-phenyl- 478 3-isoxazolyl 95 L-1 X¹ G-1 

536 96 L-1 X¹ G-1  4,5-dihydro-5-(4-fluorophenyl)- 522 3-isoxazolyl 97L-1 X¹ G-1  4,5-dihydro-5-(4- 572 trifluoromethylphenyl)-3- isoxazolyl98 L-1 X¹ G-1  4,5-dihydro-5-(2-pyridyl)-3- 505 (Ex. 9) isoxazolyl 99L-1 X¹ G-1 

481 100 L-1 X¹ G-1  4,5-dihydro-5-isopropyl-5- 546 phenyl-3-isoxazolyl101 L-1 X¹ G-1  4,5-dihydro-5-propyl-5-phenyl- 546 3-isoxazolyl 102(Ex. 1) L-1 X¹ G-1 

562 103 L-1 X¹ G-1  4,5-dihydro-5-cyclopropyl- 544 5-phenyl-3-isoxazolyl104 L-1 X¹ G-1 

572 105 L-1 X¹ G-1  4,5-dihydro-5-ethyl-5-phenyl- 532 3-isoxazolyl 106L-1 X¹ G-1  4,5-dihydro-5-(4-biphenyl)- 580 3-isoxazolyl 107  L-10 X¹G-1  4,5-dihydro-5-phenyl- 524 (Ex. 10) 3-isoxazolyl 108 L-1 X¹ G-1 (4R,5R)-4,5-dihydro-4,5- 579 diphenyl-1H-imidazol-2-yl 109 L-1 X¹ G-1 

550 110 L-1 X¹ G-1  4,5-dihydro-5-(4-hydroxy- 520 phenyl)-3-isoxazolyl111 L-1 X¹ G-1  4,5-dihydro-5-(2-pyrazinyl)- 506 3-isoxazolyl 112 L-1 X¹G-1 

643 113 L-1 X¹ G-1  4,5-dihydro-5-(4-acetoxy- 562 phenyl)-3-isoxazolyl114 L-1 X¹ G-1  4,5-dihydro-5-(2- 572 trifluoromethylphenyl)-3-isoxazolyl 115 L-1 X¹ G-1  4,5-dihydro-5-(3- 572trifluoromethylphenyl)- 3-isoxazolyl 116 L-1 X¹ G-1  4,5-dihydro-5- 500(methoxycarbonylmethyl)- 3-isoxazolyl 117 L-1 X¹ G-1 4,5-dihydro-5-(phenylsulfonyl)- 568 3-isoxazolyl 118 L-1 X¹ G-1 (5R)-4,5-dihydro-1-methyl-5- 517 phenyl-1H-imidazol-2-yl 119 L-1 X¹ G-1 (4S,5R)-4,5-dihydro-4,5- 579 diphenyl-1H-imidazol-2-yl 120 L-1 X¹ G-1 4-chlorophenyl 469 121 L-1 X¹ G-1  2-chlorophenyl 469 122 L-1 X¹ G-1 4-(trifluoromethyl)phenyl 503 123 L-1 X¹ G-1  3-chlorophenyl 469 124 L-1X¹ G-1  3-pyridyl 436 125 L-1 X¹ G-1  4,5-dihydro-5-(3,4- 536dihydroxyphenyl)-3-isoxazolyl 126  L-11 X¹ G-1  4,5-dihydro-5-phenyl-3-568 (Ex. 11) isoxazolyl 127  L-12 X¹ G-1  4,5-dihydro-5-phenyl-3- 658isoxazolyl 128  L-13 X¹ G-1  4,5-dihydro-5-phenyl-3- 504 (Ex. 1)isoxazolyl 129 L-1 X¹ G-1 

573 130  L-14 X¹ G-1  4,5-dihydro-5-phenyl-3- 520 (Ex. 6) isoxazolyl 131L-1 X¹ G-1  4,5-dihydro-5-(2- 534 methoxyphenyl)-3-isoxazolyl 132 L-1 X¹G-1  4,5-dihydro-5-methyl-5-(2,5- 592 dichloro-3-thienyl)-3-isoxazolyl133 L-1 X¹ G-1  4,5-dihydro-5-(2,5- 532 dimethylphenyl)-3-isoxazolyl 134L-1 X¹ G-1  4,5-dihydro-5-(4- 562 methoxycarbonylphenyl)- 3-isoxazolyl135 L-1 X¹ G-1  4,5-dihydro-5-(2,6- 572 dichlorophenyl)-3-isoxazolyl 136L-1 X¹ G-1  4,5-dihydro-5-(2,4- 532 dimethylphenyl)-3-isoxazolyl 137(Ex. 1) L-1 X¹ G-1 

546 138 L-1 X¹ G-1 

552 139 L-1 X¹ G-1  4,5-dihydro-5,5-diphenyl-3- 580 isoxazolyl 140 L-1X¹ G-1  4,5-dihydro-5-(2- 548 methoxyphenyl)-5-methyl- 3-isoxazolyl 141L-1 X¹ G-1  4,5-dihydro-5-(methoxymethyl)- 548 5-phenyl-3-isoxazolyl 142L-1 X¹ G-1  4,5-dihydro-5- 564 (methylthiomethyl)-5-phenyl- 3-isoxazolyl143 L-1 X¹ G-1  4,5-dihydro-5- 596 (methylsulfonylmethyl)-5-phenyl-3-isoxazolyl 144 L-1 X¹ G-1  4,5-dihydro-5- 580(methylsulfinylmethyl)-5- phenyl-3-isoxazolyl 145 L-1 X¹ G-1 

531 146 L-1 X¹ G-1 

622 147 L-1 X¹ G-1 

574 148 L-1 X¹ G-1  4,5-dihydro-5-(3-thienyl)-3- 510 isoxazolyl 149 L-1X¹ G-1  3-methylphenyl 449 150 L-1 X¹ G-1  4-methoxyphenyl 465 151 L-1X¹ G-1  4-methylphenyl 449 152 L-1 X¹ G-1  3-methoxyphenyl 465 153 L-1X¹ G-1  2-methoxyphenyl 465 154 L-1 X² G-1  4,5-dihydro-5-phenyl-3- 505(Ex 7) isoxazolyl 155 L-1 X¹ G-1  4,5-dihydro-5-(2,4,6- 594trimethoxyphenyl)-3-isoxazolyl 156 L-1 X¹ G-1 4,5-dihydro-5-acetoxymethyl-5- 576 phenyl-3-isoxazolyl 157 L-1 X¹ G-1 

558 [Note 3] 158 L-1 X¹ G-1 

558 [Note 4] 159 L-1 X¹ G-1  4,5-dihydro-5-hydroxymethyl-5- 534phenyl-3-isoxazolyl 160 L-1 X¹ G-1 

515 161 L-1 X¹ G-1  4,5-dihydro-5-(2-methyl- 518 phenyl)-3-isoxazolyl162 L-1 X¹ G-1  4,5-dihydro-5-thien-2-yl-3- 510 isoxazolyl 163 L-8 X¹G-1  4,5-dihydro-5-methyl-5-phenyl- 464 3-isoxazolyl 164 L-8 X¹ G-1 

490 165 L-8 X¹ G-1 

476 166  L-20 X¹ G-1  4,5-dihydro-5-phenyl-3- 490 isoxazolyl 167  L-21X¹ G-1  4,5-dihydro-5-phenyl-3- 647 isoxazolyl 168  L-23 X¹ G-1 4,5-dihydro-5-phenyl-3- 579 isoxazolyl 169 L-1 X¹ G-1 

496 170 L-1 X¹ G-1 

572 [Note 5] 171 L-1 X¹ G-1 

572 [Note 5] 172  L-24 X¹ G-1  4,5-dihydro-5-phenyl-3- 562 isoxazolyl173 L-1 X¹ G-1 

498 174 L-1 X¹ G-1 

510 175 L-1 X¹ G-1 

576 [Note 3] 176 L-1 X¹ G-1 

576 [Note 4] 177 L-1 X¹ G-1 

587 178 L-1 X¹ G-1  4,5-dihydro-5-(2,6- 532 dimethylphenyl)-3-isoxazolyl179 L-1 X¹ G-1  4,5-dihydro-5-(2,4,6- 546 trimethylphenyl)-3-isoxazolyl180 L-1 X¹ G-1  4,5-dihydro-5-pyridin-4-yl- 505 3-isoxazolyl 181 L-1 X¹G-1 

547 182 L-1 X¹ G-1 

561 183 L-1 X¹ G-1  4,5-dihydro-5-phenyl-1H- 503 pyrazol-3-yl 184 L-1 X¹G-1  4,5-dihydro-5-phenyl-(1-methyl- 517 1H-pyrazol-3-yl) 185 L-1 X¹G-1 

532 186 L-1 X¹ G-1 

586 [Note 3] 187 L-1 X¹ G-1 

586 [Note 4] 188 L-1 X¹ G-1 

511 189 L-1 X¹ G-1  4,5-dihydro-5-(2-bromo- 582 phenyl)-3-isoxazolyl 190 L-26 X¹ G-1  4,5-dihydro-5-phenyl- 524 3-isoxazolyl 191 L-1 X¹ G-1 

518 192 L-1 X¹ G-1 

558 193 L-1 X¹ G-1 

468 194 L-1 X¹ G-1 

597 195 L-1 X¹ G-1 

497 196 L-1 X¹ G-1 

539 197 L-1 X¹ G-1  4,5-dihydro-5-phenyl-(1- 545 acetyl-1H-pyrazol-3-yl)198  L-28 X¹ G-1  4,5-dihydro-5-phenyl-3- 524 isoxazolyl 199 L-1 X¹ G-1 

500 200 L-1 X¹ G-1 

484 201 L-1 X¹ G-1  4,5-dihydro-5-(4-methylthiazol- 5255-yl)-3-isoxazolyl 202 L-1 X¹ G-1 

566 203 L-1 X¹ G-1  3-isoxazolyl 425 204 L-1 X¹ G-1 4,5-dihydro-5-phenoxy-3- 520 isoxazolyl 205 L-1 X¹ G-1 4,5-dihydro-5-methyl-5-(2- 532 methylphenyl)-3-isoxazolyl 206 L-1 X¹G-1  4,5-dihydro-5-(2,6- 564 dimethoxyphenyl)-3-isoxazolyl 207 L-1 X¹G-1 

469 208 L-1 X¹ G-1 

500 209 L-1 X¹ G-1 

558 210 L-1 X¹ G-1  5-(2-hydroxycarbonylphenyl)- 546 3-isoxazolyl 211L-1 X¹ G-1  4,5-dihydro-5-(1,1- 500 dimethylethoxy)-3-isoxazolyl 212 L-1X¹ G-1 

573 213 L-1 X¹ G-1 

513 214 L-1 X¹ G-1  4,5-dihydro-5-(2,6- 540 difluorophenyl-3-isoxazolyl215 L-1 X¹ G-1 

525 216 L-1 X¹ G-1 

613 217 L-1 X³ G-1  4,5-dihydro-5-phenyl-3- 502 (Ex. 13) isoxazolyl 218L-1 X¹ G-1 

572 219 L-1 X¹ G-1  4,5-dihydro-5-(1- 558 methylbenzimidazol-2-yl)-3-isoxazolyl 220 L-1 X¹ G-1  4,5-dihydro-5-(2-cyano- 529phenyl)-3-isoxazolyl 221 L-1 X¹ G-1  4,5-dihydro-5-2- 562methoxycarbonylphenyl)- 3-isoxazolyl 222 L-1 X¹ G-1 

573 223 L-1 X¹ G-1 

555 224 L-1 X¹ G-1 

523 225 L-1 X¹ G-1 

561 226 L1 X¹ G-1 

541 227 L-1 X¹ G-1 

601 228 L-1 X¹ G-1 

615 229 L-5 X¹ G-1 

598 230  L-10 X¹ G-1 

564 231 L-5 X¹ G-1 

584 232  L-10 X¹ G-1 

550 233 L-1 X¹ G-1 

559 234 L-1 X¹ G-1 

540 235 L-1 X¹ G-1 

568 236 L-1 X¹ G-1 

609 237  L-29 X¹ G-1  4,5-dihydro-5-phenyl-3- 508 isoxazolyl 238  L-30X¹ G-1  4,5-dihydro-5-phenyl-3- 508 isoxazolyl 239  L-31 X¹ G-1 4,5-dihydro-5-phenyl-3- 566 isoxazolyl 240  L-32 X¹ G-1 4,5-dihydro-5-phenyl-3- 562 isoxazolyl 241  L-33 X¹ G-1 4,5-dihydro-5-phenyl-3- 534 isoxazolyl 242 L-1 X¹ G-1 

520 243 L-1 X¹ G-1 

539 244 L-1 X¹ G-1 

570 245 L-1 X¹ G-1  4-fluorophenyl 453 246 L-1 X¹ G-1  4-t-butylphenyl491 247 L-1 X¹ G-1  4-cyanophenyl 460 248 L-1 X¹ G-1  4-nitrophenyl 480249 L-1 X¹ G-1  4-bromophenyl 513 250 L-1 X¹ G-1  4-iodophenyl 561 251L-1 X¹ G-1 

569 252 L-1 X¹ G-1 

587 253 L-1 X¹ G-1 

521 [Note 3] 254 L-1 X¹ G-1 

521 [Note 4] 255 L-1 X¹ G-1 

521 [Note 3] 256 L-1 X¹ G-1 

521 [Note 4] 257  L-22 X¹ G-1  4,5-dihydro-5-phenyl-3- 506 isoxazolyl258  L-25 X¹ G-1  4,5-dihydro-5-phenyl-3- 556 isoxazolyl 259  L-27 X¹G-1  4,5-dihydro-5-phenyl-3- 520 isoxazolyl 260 L-5 X¹ G-1 4,5-dihydro-5-methyl-5-phenyl- 572 3-isoxazolyl 261  L-10 X¹ G-1 4,5-dihydro-5-methyl-5- 538 phenyl-3-isoxazolyl 262 L-1 X¹ G-1 4,5-dihydro-5-(2- 597 aminosulfonylbenzyl)- 3-isoxazolyl 263 L-1 X¹ G-1 4,5-dihydro-5-(2-acetoxy- 562 phenyl)-3-isoxazolyl 264 L-1 X¹ G-1 4,5-dihydro-5-(N-methyl-N- 561 phenylcarbonylamino)- 3-isoxazolyl 265L-1 X¹ G-1  4,5-dihydro-5-cyano-5- 529 phenyl-3-isoxazolyl 266 L-8 X¹G-1 

478 267 L-1 X¹ G-1 

525 268 L-1 X¹ G-1  4-ethylphenyl 463 269 L-1 X¹ G-1 4-trifluoromethoxyphenyl 519 270 L-1 X¹ G-1  4-methoxycarbonylphenyl 493271 L-1 X¹ G-1  4-propylphenyl 477 272 L-1 X¹ G-1  4-methylthiophenyl481 273 L-1 X¹ G-1  4-isopropylphenyl 477 274 L-1 X¹ G-1 4-isobutylphenyl 491 275 L-1 X¹ G-1 

574 276 L-5 X¹ G-1 

627 277 L-8 X¹ G-1  4,5-dihydro-5-(2,4,6-tri- 540methoxyphenyl)-3-isoxazolyl 278 L-1 X¹ G-1 

587 279 L-1 X¹ G-1 

596 280 L-1 X¹ G-1 

611 281 L-1 X¹ G-1 

595 282 L-1 X¹ G-1 

583 [Note 3] 283 L-1 X¹ G-1 

583 [Note 4] 284 L-8 X¹ G-1 

519 [Note 1]: Faster eluting enantiomer from the CHIRALPAK ® AD-RHcolumn using methanol in water as eluant, specific rotation = −98.8°.Analysis using analytical CHIRALPAK ® AD-RH column indicated about 100%optical purity. [Note 2]: Slower eluting enantiomer from the CHIRALPAK ®AD-RH reverse phase column using methanol in water as eluant, specificrotation = +88°. Analysis using analytical CHIRALPAK ® AD-RH columnindicated about 93% optical purity. [Note 3]: Diastereomer A. [Note 4]:Diastereomer B. [Note 5]: Mixture of isomers.

BIOLOGICAL EXAMPLES OF THE INVENTION

General protocol for preparing test suspensions for Test A-C: The testcompounds were first dissolved in acetone in an amount equal to 3% ofthe final volume and then suspended at the desired concentration (inppm) in acetone and purified water (50/50 mix by volume) containing 250ppm of the surfactant Trem® 014 (polyhydric alcohol esters). Theresulting test suspensions were then used in Tests A-C. Spraying a 200ppm test suspension to the point of run-off on the test plants wasequivalent to a rate of 500 g/ha.

Test A

Grape seedlings were inoculated with a spore suspension of Plasmoparavilicola (the causal agent of grape downy mildew) and incubated in asaturated atmosphere at 20° C. for 24 h. After a short drying period,the test suspension was sprayed to the point of run-off on the grapeseedlings, which were then moved to a growth chamber at 20° C. for 5days, after which time the grape seedling were placed back into asaturated atmosphere at 20° C. for 24 h. Upon removal, visual diseaseratings were made.

Test B

The test suspension was sprayed to the point of run-off on tomatoseedlings. The following day the seedlings were inoculated with a sporesuspension of Phytophthora infestans (the causal agent of tomato lateblight) and incubated in a saturated atmosphere at 20° C. for 24 h, andthen moved to a growth chamber at 20° C. for 5 days, after which timevisual disease ratings were made.

Test C

Tomato seedlings were inoculated with a spore suspension of Phytophthorainfestans (the causal agent of tomato late blight) and incubated in asaturated atmosphere at 20° C. for 17 h. After a short drying period,the test suspension was sprayed to the point of run-off on the tomatoseedlings, which were then moved to a growth chamber at 20° C. for 4days, after which time visual disease ratings were made.

In addition to Tests A-C, the compounds were also sprayed on 2 separatesets of tomato plants, which were inoculated with Botrvtis cinerea orAlternaria solani 24 h after treatment, bluegrass plants, which wereinoculated with Pythium aphanidermatum 24 h after treatment and 3separate sets of wheat plants, which were inoculated with Erysiphegraminis f. sp. tritici, Puccinia recondita or Septoria nodorum 24 hafter treatment. Test compounds did not show noticeable activity againstthese additional pathogens under the test conditions at the applicationrates tested.

Results for Tests A-C are given in Table A. In the table, a rating of100 indicates 100% disease control and a rating of 0 indicates nodisease control (relative to the controls). A dash (-) indicates no testresults.

TABLE A RESULTS OF BIOLOGICAL TESTS Percent Disease Control CompoundTest A Test B Test C  1 100 100 99  2 100 99 99   3** 100 100 99   4**100 100 99  5 96 100 99  6* 95 100 99  7 0 93 59  8 100 100 99  9 99 10099 10 97 100 99 11 99 100 99 12 52 47 0 13 0 95 86 14 25 99 99 15 100100 98 16 99 100 99  17* 100 99 99  18* 100 100 99  19* 100 100 99  20*96 99 99  21* 46 50 7  22* 100 100 99 23 99 100 99 24 99 100 93  25* 100100 99 26 76 83 33 27 100 100 98 28 99 100 94 29 99 100 99  30** 31 5750  31** 84 83 60 32 0 26 0 33 15 9 0 34 0 40 0 * 100 100 96 36 58 57 24 37* 100 100 99 38 0 9 0 39 8 67 0 40 47 100 99 41 0 100 99 42 62 100 9643 0 43 0  44* 100 100 99 45 30 26 0 46 0 99 53 47 0 85 47 48 0 85 0 490 100 96 50 0 100 99 51 99 100 99 52 85 100 67  53* 24 68 26 54 16 73 055 17 26 0 56 99 100 99 57 99 100 99 58 0 99 0  59* 97 100 91 60 100 9594 61 80 77 0 62 73 73 26 63 80 100 98 64 90 99 88 65 46 100 83 66 48 6373  67* 100 100 99 68 96 95 88 69 40 9 0 70 8 24 0 71 — 99 33 72 72 10052 73 27 40 0 74 50 40 0 75 72 24 0 76 72 92 67 77 87 100 99 78 0 0 0 79100 100 66 80 99 100 57 81 93 92 77 82 0 88 26 83 46 92 0 84 67 33 0 8585 70 0 86 83 79 14 87 76 44 0  88* 99 100 99 89 49 73 0 90 66 57 0  91*99 100 91  92* 13 33 9  93* 78 100 99  94* 99 100 99  95* 100 100 95 96* 100 100 99  97* 99 100 95  98* 77 100 99 99 31 33 0 100* 100 100 99101* 100 100 99 102* 100 100 99 103* 100 100 99 104  100 100 99 105* 100100 99 106* 80 85 24 107* 100 100 99 108  0 58 0 109* 100 100 98 110* 97100 99 111* 97 100 97 112* 76 100 68 113* 99 100 99 114* 100 100 99 115*100 100 99 116  46 100 79 117* 93 100 99 118* 0 87 16 119  0 82 0 120 99 88 0 121  83 47 0 122  99 46 0 123  95 68 0 124  8 98 26 125  31 53 0126  100 100 99 127  73 40 0 128* 100 100 99 129* 99 100 99  130** 100100 99 131* 100 100 99 132* 85 100 91 133* 100 100 99 134* 90 100 66135* 100 100 99 136* 99 100 99 137* 100 100 99 138* 93 100 99 139* 87 9887 140* 98 100 57 141* 99 100 99 142* 97 100 98 143* 99 100 99 144* 99100 93 145  17 58 0 146  83 100 53 147* 100 100 95  148** 100 100 99149  99 97 — 150  99 100 — 151  100 99 — 152  91 89 — 153  73 0 — 154*90 100 99 155* 100 100 99 156* 100 100 99 157* 100 100 94 158  96 100 99159  94 100 99 160  68 80 17 161* 100 100 99 162* 100 100 99  163** 99100 98  164** 99 100 99  165** 99 100 99  166** 100 100 98 167  67 64 24 168** 100 100 99 169  100 100 99 170* 99 100 93 171* 99 100 98 172* 9163 0 173* 100 100 99 174* 100 100 99 175  68 100 33 176  68 100 63 177*93 100 99 178* 100 100 99 179* 99 100 98 180  50 100 99 181  80 100 97182  99 100 97 183* 92 92 33 184* 99 95 73 185* 100 100 98 186* 95 10086 187* 99 100 93 188* 99 100 99 189* 100 100 99 190  80 68 17 191  99100 99 192* 99 100 99 193* 100 100 99 194* 94 100 99 195  48 92 80 196*99 100 99 197* 89 100 90 198* 100 100 99 199  91 99 98 200  80 100 90201* 99 100 99 202  95 100 98 203* 99 100 92 204* 99 100 99 205* 99 10099 206* 99 100 99 207  40 83 0 208  79 64 0 209* 99 100 90 210  91 10083 211* 100 100 99 212* 98 100 99 213* 94 100 98 214* 100 100 99 215* 99100 99 216* 100 100 99 217* 95 100 99 218* 73 63 47 219  100 100 99 220 100 100 99 221  100 100 99 222  100 100 100 223  100 100 100 224  0 63 0225  100 100 100 226  83 100 99 227  100 100 100 228  99 100 100  229**100 100 100  230** 100 100 100  231** 100 100 100  232** 100 100 100233* 100 100 100 234* 99 100 100 235* 99 100 100 236* 100 100 100 237*22 47 16 238* 100 100 100 239* 14 0 0 240* 100 100 100 241* 100 100 100242* 99 100 85  243** 99 100 100 244* 98 100 99 245* 99 74 0 246* 99 7940 247* 99 100 88 248* 90 73 26 249* 99 64 0 250* 86 58 0 251* 99 100 99252* 88 91 97 253* 100 100 95 254* 100 100 93 255* 95 100 93 256* 100100 99 257* 17 0 0  258** 100 100 98 259* 100 100 99  260** 100 100 96 261** 100 100 93 262* 79 100 91 263* 99 84 83 264* 99 100 88  265** 100100 98 266* 100 100 100 267  100 100 100 268  100 100 88 269  100 100 0270  99 83 0 271  100 100 72 272  100 100 100 273  100 100 90 274  99100 100  275** 99 100 98  276** 100 100 97 277* 86 100 99 278* 94 100 99279* 100 100 99  280** 92 100 98  281** 100 100 99 282  — — — 283  — — —284  — — — *indicates compounds tested at 40 ppm. **indicates compoundstested at l0 ppm.

What is claimed is:
 1. A compound selected from Formula 1, an N-oxideand salt thereof,

wherein R¹ is

each R⁴ is selected from R^(4a); each R^(4a) is independently C₁-C₂alkyl, trifluoromethyl, Cl, Br, I or methoxy; A is CH₂; W is O; X is

the ring comprising X is saturated; the bond of X¹ or X² which isidentified with “t” is connected to the carbon atom identified with “q”of Formula 1, the bond which is identified with “u” is connected to thecarbon atom identified with “r” of Formula 1, and the bond which isidentified with “v” is connected to G; each R² is independently ethyl,methoxy, cyano or hydroxy; G is

the bond of G shown projecting to the left is bonded to X, and the bondof G shown projecting to the right is bonded to Z¹; each R^(3a) is H; Jis

the bond of J shown projecting to the left is bonded to Z¹; each R⁵ isindependently H, halogen, cyano, hydroxy, amino, nitro, —CHO, —C(═O)OH,—C(═O)NH₂, —NR²⁵R²⁶, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆ haloalkynyl, C₃-C₈ cycloalkyl, C₃-C₈halocycloalkyl, C₄-C₁₀ alkylcycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₆-C₁₄cycloalkylcycloalkyl, C₄-C₁₀ halocycloalkylalkyl, C₅-C₁₀alkylcycloalkylalkyl, C₃-C₈ cycloalkenyl, C₃-C₈ halocycloalkenyl, C₂-C₆alkoxyalkyl, C₄-C₁₀ cycloalkoxyalkyl, C₃-C₈ alkoxyalkoxyalkyl, C₂-C₆alkylthioalkyl, C₂-C₆ alkylsulfinylalkyl, C₂-C₆ alkylsulfonylalkyl,C₂-C₆ alkylaminoalkyl, C₃-C₈ dialkylaminoalkyl, C₂-C₆haloalkylaminoalkyl, C₄-C₁₀ cycloalkylaminoalkyl, C₂-C₆ alkylcarbonyl,C₂-C₆ haloalkylcarbonyl, C₄-C₈ cycloalkylcarbonyl, C₂-C₆ alkoxycarbonyl,C₄-C₈ cycloalkoxycarbonyl, C₅-C₁₀ cycloalkylalkoxycarbonyl, C₂-C₆alkylaminocarbonyl, C₃-C₈ dialkylaminocarbonyl, C₄-C₈cycloalkylaminocarbonyl, C₂-C₆ haloalkoxyalkyl, C₁-C₆ hydroxyalkyl,C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₃-C₈ cycloalkoxy, C₃-C₈halocycloalkoxy, C₄-C₁₀ cycloalkylalkoxy, C₂-C₆ alkenyloxy, C₂-C₆haloalkenyloxy, C₂-C₆ alkynyloxy, C₂-C₆ haloalkynyloxy, C₂-C₆alkoxyalkoxy, C₂-C₆ alkylcarbonyloxy, C₂-C₆ haloalkylcarbonyloxy, C₄-C₈cycloalkylcarbonyloxy, C₃-C₆ alkylcarbonylalkoxy, C₁-C₆ alkylthio, C₁-C₆haloalkylthio, C₃-C₈ cycloalkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆haloalkylsulfinyl, C₁-C₆ alkylsulfonyl, C₁-C₆ haloalkylsulfonyl, C₃-C₈cycloalkylsulfonyl, C₃-C₁₀ trialkylsilyl, C₁-C₆ alkylsulfonylamino,C₁-C₆ haloalkylsulfonylamino or —Z²Q; each R²⁵ is independently H, C₁-C₆alkyl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆haloalkylcarbonyl, C₂-C₆ alkoxycarbonyl or C₂-C₆ haloalkoxycarbonyl;each R²⁶ is independently C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₈cycloalkyl, C₂-C₆ alkylcarbonyl, C₂-C₆ haloalkylcarbonyl, C₂-C₆alkoxycarbonyl, C₂-C₆ haloalkoxycarbonyl or —Z⁴Q; each Q is

each R⁷ is independently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,C₃-C₆ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀alkylcycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆haloalkynyl, C₃-C₆ halocycloalkyl, halogen, hydroxy, amino, cyano,nitro, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl,C₃-C₈ dialkylaminocarbonyl or C₃-C₆ trialkylsilyl; or R⁵ and R⁷ aretaken together with the atoms linking R⁵ and R⁷ to form a 5- to7-membered ring containing ring members selected from carbon andoptionally 1 to 3 heteroatoms selected from up to 1 O, up to 1 S and upto 1 N, and optionally including 1 to 3 ring members selected from thegroup consisting of C(═O), C(═S), S(O), S(O)₂ and SiR¹⁷R¹⁸, the ringoptionally substituted on ring members other than the atoms linking R⁵and R⁷ with up to 4 substituents selected from R⁸; each R⁸ isindependently C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₄-C₁₀ alkylcycloalkyl, C₅-C₁₀alkylcycloalkylalkyl, C₁-C₆ haloalkyl, C₂-C₆ haloalkenyl, C₂-C₆haloalkynyl, C₃-C₆ halocycloalkyl, halogen, hydroxy, amino, cyano,nitro, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, C₁-C₄ alkylthio, C₁-C₄alkylsulfinyl, C₁-C₄ alkylsulfonyl, C₁-C₄ haloalkylthio, C₁-C₄haloalkylsulfinyl, C₁-C₄ haloalkylsulfonyl, C₁-C₄ alkylamino, C₂-C₈dialkylamino, C₃-C₆ cycloalkylamino, C₂-C₄ alkoxyalkyl, C₁-C₄hydroxyalkyl, C₂-C₄ alkylcarbonyl, C₂-C₆ alkoxycarbonyl, C₂-C₆alkylcarbonyloxy, C₂-C₆ alkylcarbonylthio, C₂-C₆ alkylaminocarbonyl,C₃-C₈ dialkylaminocarbonyl or C₃-C₆ trialkylsilyl; Z¹ is a direct bond;each Z² is a direct bond; each Z⁴ is independently C(═O) or SO₂; k is 0,1 or 2; n is 0, 1 or 2; p is 0, 1, or 2; and x is an integer from 0 to5.
 2. A compound of claim 1 or a salt thereof, wherein the compound isselected from the group consisting of:4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]piperidineand its enantiomer,1-[[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-[4-(5-phenyl-3-isoxazolyl)-2-thiazolyl]piperidine,1-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(3aS,9bR),3a,4,5,9b-tetrahydronaphth[2,1-d]isoxazol-3-yl]-2-thiazolyl]-1-piperidinyl]ethanoneand its enantiomer,1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]ethanone andits enantiomer,1-[4-[4-[(5R)-3′,4′-dihydrospiro[isoxazole-5(4H),1′,(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,1-[4-[4-[(5R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazoly]-2-thiazolyl]-1-piperidinyl]ethanoneand its enantiomer,2-[(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]-1H-isoindole-1,3(2H)-dioneand its enantiomer,2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]ethanoneand its enantiomer,2-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4′H),1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]ethanoneand its enantiomer,2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-(3R)-spiro[benzofuran-3(2H),5′(4′H)-isoxazol]-3′-yl-2-thiazolyl]-1-piperidinyl]ethanoneand its enantiomer,1-[4-[4-[(1R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)ethanoneand its enantiomer,2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4′H),1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]ethanoneand its enantiomer,2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(1R)-2,3-dihydrospiro[1H-indene-1,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]ethanoneand its enantiomer,1-[4-[4-[(5R)-5-(2,6-dichlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,1-[4-[4-[(5R)-4,5-dihydro-5-(2-fluorophenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,1-[4-[4-[(5R)-4,5-dihydro-5-(2-methylphenyl)-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,1-[4-[4-[(5R)-5-(2,6-dimethylphenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,1-[4-[4-[(1′R)-3′,4′-dihydrospiro[isoxazole-5(4H),1′(2′H)-naphthalen]-3-yl]-2-thiazolyl]-1-piperidinyl]-2-(3,5-dimethyl-1H-pyrazol-1-yl)ethanoneand its enantiomer,1-[4-[4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,2-[(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-isoxazolyl]benzonitrileand its enantiomer,2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1-[4-[4-[(5R)-4,5-dihydro-5-methyl-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]ethanoneand its enantiomer,1-[4-[4-[(5R)-5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,1-[4-[4-[(5R)-4,5-dihydro-5-phenyl-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer,1-[4-[4-[(4S)-2,3-dihydrospiro[4H-1-benzopyran-4,5′(4′H)-isoxazol]-3′-yl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanoneand its enantiomer, and(5R)-4,5-dihydro-3-[2-[1-[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolyl]-5-phenyl-5-isoxazolecarbonitrileand its enantiomer.
 3. A method for controlling plant diseases caused byOomycete fungal plant pathogens comprising applying to the plant orportion thereof, or to the plant seed, a fungicidally effective amountof a compound or salt of claim
 1. 4. A fungicidal composition comprising(1) a compound or salt of claim 1, and (2) at least one other fungicide.5. A fungicidal composition comprising (1) a fungicidally effectiveamount of a compound or salt of claim 1; and (2) at least one additionalcomponent selected from the group consisting of surfactants, soliddiluents and liquid diluents.
 6. A composition of claim 4 whereincomponent (2) includes at least one compound selected from acibenzolar,aldimorph, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl,benodanil, benomyl, benthiavalicarb, benthiavalicarb-isopropyl,binapacryl, biphenyl, bitertanol, bixafen, blasticidin-S, Bordeauxmixture (tribasic copper sulfate), boscalid/nicobifen, bromuconazole,bupirimate, buthiobate, carboxin, carpropamid, captafol, captan,carbendazim, chloroneb, chlorothalonil,5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine,chlozolinate, clotrimazole, copper oxychloride, copper salts such ascopper sulfate and copper hydroxide, cyazofamid, cyflufenamid,cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet,diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim,dimethirimol,N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazol-4-carboxamide,dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinocap,discostrobin, dithianon, dodemorph, dodine, econazole, edifenphos,enestroburin, epoxiconazole, etaconazole, ethaboxam, ethirimol,ethridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole,fencaramid, fenfuram, fenhexamide, fenoxanil, fenpiclonil, fenpropidin,fenpropimorph, fentin acetate, fentin chloride, fentin hydroxide,ferbam, ferfurazoate, ferimzone, fluazinam, fludioxonil, flumetover,flumorph, fluopicolide, fluopyram, fluoxastrobin, fluquinconazole,fluquinconazole, flusilazole, flusulfamide, flutolanil, flutriafol,folpet, fosetyl-aluminum, fuberidazole, furalaxyl, furametapyr,hexaconazole, hymexazole, guazatine, imazalil, imibenconazole,iminoctadine, iodicarb, ipconazole, iprobenfos, iprodione, iprovalicarb,isoconazole, isoprothiolane, isotianil, kasugamycin, kresoxim-methyl,mancozeb, mandipropamid, maneb, mapanipyrin, mefenoxam, mepronil,meptyldinocap, metalaxyl, metconazole, methasulfocarb, metiram,metominostrobin, mepanipyrim, metiram, metrafenone, miconazole,myclobutanil, naftifine, neo-asozin (ferric methanearsonate), nuarimol,octhilinone, ofurace, orysastrobin, oxadixyl, oxolinic acid,oxpoconazole, oxycarboxin, oxytetracycline, paclobutrazol, penconazole,pencycuron, penthiopyrad, perfurazoate, phosphonic acid, phthalide,picobenzamid, picoxystrobin, piperalin, polyoxin, probenazole,prochloraz, procymidone, propamocarb, propamocarb-hydrochloride,propiconazole, propineb, proquinazid, prothiocarb, prothioconazole,pyraclostrobin, pryazophos, pyribencarb, pyrifenox, pyrimethanil,pyrifenox, pyrolnitrine, pyroquilon, quinconazole, quinoxyfen,quintozene, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur,tebuconazole, techrazene, tecloftalam, tecnazene, terbinafine,tetraconazole, thiabendazole, thifluzamide, thiophanate,thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolyfluanid,triadimefon, triadimenol, triarimol, triazoxide, tricyclazole,tridemorph, triflumizole, trimoprhamide tricyclazole, trifloxystrobin,triforine, triticonazole, uniconazole, validamycin, vinclozolin, zineb,ziram and zoxamide.
 7. A compound or salt of claim 1 wherein: G is G-1;each R⁵ is independently H, cyano, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆alkoxy, C₁-C₆ haloalkoxy, —NR²⁵R²⁶ or Z²Q; each R⁷ is independentlyC₁-C₃ alkyl, C₁-C₃ haloalkyl, halogen, hydroxy, amino, cyano, nitro,C₁-C₂ alkoxy or C₁-C₂ haloalkoxy; or R⁵ and R⁷ are taken together withthe atoms linking R⁵ and R⁷ to form a 5- to 7-membered ring containingas ring members 2 to 7 carbon atoms and optionally 1 to 3 heteroatomsselected from up to 1 O, up to 1 S and up to 1 N, optionally substitutedwith up to 2 substituents selected from R⁸; each R⁸ is independentlyC₁-C₃ alkyl; n is 0; and x is 1 or
 2. 8. A compound or salt of claim 7wherein: R¹ is U-1; each R^(4a) is independently C₁-C₂ alkyl,trifluoromethyl, Cl or Br; and X is X¹.
 9. A compound or salt of claim 8wherein: J is J-29, and the 3-position of J-29 is connected to Z¹ andthe 5-position of J-29 is connected to R⁵; R⁵ is Z²Q; each R⁷ isindependently methyl, F, Cl, Br, hydroxy, cyano or methoxy; and x is 1.